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Abstract 
Background Colorectal cancer is the fourth commonest cancer in the UK, and the second 
commonest cause of cancer-related death. A knowledge of the biology of colorectal liver 
metastases would be invaluable to inform clinical decision making; however, deriving this 
information from the metastatic lesions is not feasible until after resection. We aimed to 
use proteomic and genomic analysis to establish the degree of biological similarity across 
disease sites and identify biomarkers in the primary tumour which predict response to 
neoadjuvant chemotherapy in liver metastases. An identical approach was also used to 
identify predictors of response to neoadjuvant chemoradiotherapy in rectal cancer. 
Methods Fresh tissue from both primary colorectal tumour and liver metastases from 16 
patients was subjected to proteomic analysis using isobaric tagging for relative 
quantification (iTRAQ). Data were analysed with Protein Pilot (Ab Sciex, Framingham, MA, 
USA), with stratification of patients into those showing low or high response to 
chemotherapy permitting the identification of potential predictive biomarkers. These 
markers were subsequently investigated by immunohistochemistry on a tissue microarray 
of 56 patients, in parallel with a series of in vitro studies to investigate the concordance 
between primary and metastatic tumours of those proteins relevant to the activation and 
metabolism of 5-FU, irinotecan and oxaliplatin. The therapeutic potential of the identified 
biomarkers was also investigated by dosing SW480 cells with irinotecan/5FU with or 
without inhibition (using siRNA or a known competitive inhibitor) of the proteins of 
interest. Four of the 16 patients studied were resected synchronously, and tissue from 
these was also used for exome sequencing using the Ion Proton platform. Diagnostic, post-
treatment and resection biopsies from 8 patients with rectal cancer were again subjected 
to iTRAQ with stratification into low or high response to neoadjuvant chemoradiotherapy to 
investigate potential response biomarkers. 
Findings We identified 5766 discrete proteins, of which 2.54% were differentially expressed 
between primary and metastatic tumours. There were 170 potential response biomarkers 
in the primary tumour and 27 in the metastases. Two proteins were common to both tissue 
types and showed consistent dysregulation, including NQO1. Immunostaining of NQ01 in 
metastases revealed lower expression in patients responding to chemotherapy (p=0.041), 
with a significant correlation between primary and metastatic disease sites (r=0.44, 
p=0.001). Knockdown of NQO1 followed by treatment with irinotecan and 5FU reduced the 
IC50 from 100.1µM to 49.8µM and from 200.1µM to 25.0µM respectively. Pre-treating cells 
with dicoumarol prior to incubation in irinotecan and 5FU reduced the IC50 from 100.0µM 
to 50.0µM and from 183.7µM to 49.9µM respectively. Exome sequencing identified 585 
non-synonymous missense SNVs of which 215 (36.8%) were unique to the primary tumour, 
226 (38.6%) unique to the metastasis and 81 (13.8%) present in patient matched pairs. 
Aberrations in the ErbB pathway were identified in paired samples (ratio 0.07, p=5.87x10-7), 
which were validated by Sanger sequencing along with a potential response biomarker in 
the CDAN1 gene. Changes to the phenotype of the rectal tumour with chemoradiotherapy 
were modest, although it is clear that base excision repair (and in particular PARP1) remains 
of interest, and that acid ceramidase is a potential response biomarker and novel 
radiosensitiser. 
Interpretation Proteomic sequencing of matched metastatic colorectal cancer samples is 
feasible with high coverage. The high degree of similarity between the primary and 
secondary tumours suggests that the primary tissue is predictive of the metastatic 
phenotype. NQO1 expression in the primary tumour predicts response to neoadjuvant 
chemotherapy in the liver metastases, and inhibition of this protein at both genetic and 
functional levels improves chemosensitivity.  
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1.1 Epidemiology of colorectal cancer 
The 2011 dataset published by Cancer Research (UK) declares colorectal cancer (CRC) as the 
fourth commonest cancer in the United Kingdom, with around 41600 people diagnosed in 
2011 alone. There is a slight male preponderance for the disease, and it is the third 
commonest cancer in both men (after prostate and lung), and women (after breast and 
lung). 95% of cases occur in those over the age of 50, the incidence of which has increased 
by 6% over the last decade. These figures are representative of disease burden worldwide, 
with 447 000 new cases diagnosed in Europe and 1.36 million worldwide in 2012. 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/). 
Whilst the fourth commonest cancer, colorectal cancer is the second commonest cause of 
cancer related death in the UK. The death rate remains high despite a two-fold increase in 
five year survival over the past 40 years. The UK bowel cancer screening programme has 
been gradually rolled out since 2006, however it is as yet unclear the effect this will have on 
survival rates.  
Dukes Stage at 
Diagnosis 
Percentage of Cases Five-Year Survival 
A 8.7% 93.2% 
B 24.2% 77.0% 
C 23.6% 47.7% 
D 9.2% 6.6% 
Unknown 34.3% 35.4% 
 
Table 1.1 - Percentage of cases and 5 year relative survival (%) by Dukes' stage at 
diagnosis for colorectal cancer patients diagnosed 1996-2002 in England. (Reproduced 
without permission from Cancer Research (UK)). 
The best known predictor of survival is disease stage, with over 93% of patients with Dukes 
A disease surviving 5 years compared to less than 7% of those with Dukes D disease (Table 
1.1). On separating the disease into tumours of the colon and rectum, survival is 
comparable. Most recent figures from Cancer Research (UK) show that 1-year survival for 
men and women with colon cancer is 73.0% and 72.2% respectively, with 5-year survival of 
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54.4% and 55.1%. In those with rectal cancer 1-year survival for men and women is 78.8% 
and 78.8% respectively, and 5-year survival 54.6% and 57.5%.  
1.2 Risk factors for colorectal cancer 
A number of dietary and lifestyle factors have been linked to the development of colorectal 
cancer, including diets rich in unsaturated fats and red meat, excess alcohol and a 
sedentary lifestyle (Potter, 1999; Slattery et al, 2000; Huxley et al 2009). A number of other 
risk factors have been studied, and a recent review attempted to describe the complex 
interplay between energy intake, hormone levels, inflammation and gut flora which may 
lead to colorectal cancer (Slattery and Fitzpatrick, 2009). Smoking is also associated with an 
increased risk of colorectal cancer (Colangelo et al, 2004) as is a preceding diagnosis of 
inflammatory bowel disease (Choi and Zelig, 1994). Isolated risk factors however have been 
difficult to define, confounded by the fact that the majority of tumours arise in individuals 
with poorly defined risk profiles. 
1.3 Genetics of colorectal cancer 
There are a number of identified gene defects known to predispose to colorectal cancer, as 
well as a number of somatic mutations that are present in sporadic tumours. These 
alterations may lead to novel or improved function in oncogenes, or loss of function of 
tumour suppressor genes. It is estimated that approximately 15-30% of colorectal cancers 
have a significant hereditary component, of which 5% have a Mendelian cancer syndrome 
which predisposes to CRC (Lynch and de la Chapelle, 2003; Rustgi, 2007). The majority of 
these are attributable to hereditary nonpolyposis colorectal cancer (HNPCC) and familial 
adenomatous polyposis (FAP), with a number of other genetic alterations associated with 
less common syndromes (Table 1.2). 
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Syndrome Common Features Gene defect(s) 
FAP 
Multiple adenomatous polyps (>100) 
and carcinomas of the colon and 
rectum; duodenal polyps and 
carcinomas; fundic gland polyps in the 
stomach; congenital hypertrophy of 
the retinal pigment epithelium 
APC (>90%) 
Gardner syndrome 
Same as FAP; also, desmoid tumors 
and mandibular osteomas 
APC 
Turcot's syndrome 
Polyposis and colorectal cancer with 
brain tumors (medulloblastomas); 
colorectal cancer and brain tumors 
(glioblastoma) 
APC 
MLH1, PMS2 
Attenuated 
adenomatous 
polyposis coli 
Fewer than 100 polyps, although 
marked variation in polyp number 
(from ~5 to > 1,000 polyps) observed 
in mutation carriers within a single 
family 
APC (precominantly 5' 
mutations) 
Hereditary 
nonpolyposis 
colorectal cancer 
Colorectal cancer without extensive 
polyposis; other cancers include 
endometrial, ovarian and stomach 
cancer, and occasionally urothelial, 
hepatobiliary, and brain tumors 
MSH2 
MLH1 
PMS2 
GTBP, MSH6 
Peutz-Jeghers 
syndrome 
Hamartomatous polyps throughout 
the GI tract; mucocutaneous 
pigmentation; increased risk of GI and 
non-GI cancers 
LKB1, STK11 (30-70%) 
Cowden disease 
Multiple hamartomas involving breast, 
thyroid, skin, central nervous system 
and GI tract; increased risk of breast, 
uterus and thyroid cancers; risk of GI 
cancer unclear 
PTEN (85%) 
Juvenile polyposis 
syndrome 
Multiple hemartomatous/juvinile 
polyps with predominance in colon 
and stomach: variable increase in 
colorectal and stomach cancer risk; 
facial changes 
DPC4 (15 %) 
BMPRIa (25 %) 
PTEN (5 %) 
MYH - associated 
polyposis 
Mutiple adenomatous GI polyps, 
autosomal recessive basis; colon 
MYH 
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polyps often have somatic KRAS 
mutations 
 
Table 1.2 – Genetics of inherited colorectal tumour syndromes. (Reproduced without 
permission from Fearon, 2011). 
Most tumours arise within dysplastic polyps, and therefore an understanding of the 
adenoma-carcinoma sequence is crucial. Most polyps are hyperplastic and less than 5mm in 
diameter, however it is the larger adenomas which have been shown to possess malignant 
potential (Jass, 2007). An adenoma is a benign lesion of glandular epithelium with a 
prevalence of approximately 25% by age 50 and 50% by age 70 (Rex et al, 1993). Only a 
small number of polyps progress to malignancy, often over a period of years to decades; 
polyp surveillance studies have shown that a 1cm polyp has a 10-15% chance of becoming 
malignant within 10 years (Stryker et al, 1987). Adenoma-carcinoma progression was first 
described by Vogelstein in 1990 as a series of genetic alterations responsible for sporadic 
CRC, beginning with mutation in the adenomatous polyposis coli (APC) gene followed by 
mutations in the KRAS and TP53 genes. These mutations are positively selected for during 
carcinogenesis and are intrinsically involved in DNA repair, cell adhesion and proliferation 
(Wood et al, 2007). 
1.3.1 Adenomatous polyposis coli 
The APC tumour suppressor gene encodes for a protein known to regulate cell-adhesion, 
migration and apoptosis (Fearon and Vogelstein, 1990), and is the genetically defective 
gene in FAP as well as some of the less common inherited cancer syndromes. The defect is 
present in over 75% of colorectal cancers, and is widely believed to be an early step in 
sporadic carcinogenesis due to its reported presence across the adenoma-carcinoma 
sequence, including microscopic adenomas with a small number of dysplastic glands 
(Kinzler and Vogelstein, 1996). 
The most well understood downstream effect of APC mutation is disruption of the WNT 
pathway. APC targets β-catenin for proteasomal degradation, and therefore mutation 
results in the nuclear accumulation of β-catenin, increased WNT activity and cellular 
proliferation (Polakis, 2007). 
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1.3.2 KRAS/BRAF 
The RAS family of proteins (KRAS, HRAS and NRAS) are G-proteins which predominantly 
fulfil the roles of molecular switches. KRAS is a proto-oncogene which, following activation 
through the endothelial growth factor receptor (EGFR) pathway, triggers downstream 
signalling through the PI3K/AKT/MTOR and RAF/MEK/ERK pathways resulting in cellular 
proliferation (Fearon, 2011). Up to 40% of colorectal tumours have a mutated version of 
the KRAS gene, most commonly in codons 12 with smaller subsets affecting codon 13 and 
rarely codon 61 (Downward, 2003). The mutation is also found in a number of flat colonic 
epithelial lesions without dysplasia, questioning its role in early carcinogenesis (Pretlow and 
Pretlow, 2005). However disruption of mutant KRAS in advanced CRC has demonstrated 
that inactivation inhibits tumour growth both in vitro and in animal studies, highlighting its 
role in disease progression (Shirasawa et al, 1993). 
BRAF is a downstream target of KRAS, exerting its effect through the MEK/ERK pathways. 
Mutated in approximately 5-10% of colorectal cancers, BRAF mutation appears to be 
independent of KRAS mutation, however mutation in either can result in pathway 
upregulation and activation of relevant downstream transcription factors such as myc 
(Rajagopalan et al, 2002).  
1.3.3 TP53  
TP53 (p53) is a tumour suppressor gene implicated in a wide range of malignancies, most 
likely due to its significant role as a regulator of cell-cycle checkpoints, genomic stability, 
apoptosis and angiogenesis (Vousden and Prives, 2009). Under conditions of DNA damage 
resulting from cellular stress p53 activates DNA repair proteins, arrests growth by holding 
the cell cycle at the G1/S regulation point and initiates apoptosis. Over 50% of all tumours 
have ineffective p53 (Hollstein et al, 1991), thought to be a combination of loss of 
heterogenezity (LOH) of one allelele of 17p and somatic mutation in the other (Fearon and 
Vogelstein, 1990). This pattern is not observed in most adenomas, highlighting this 
mutation as a significant event in the transition from adenoma to carcinoma (Baker et al, 
1990). 
1.3.4 Mismatch repair and microsatellite instability 
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Whilst germline mutations account for a relatively small proportion of tumours they offer a 
unique opportunity to understand the genetic instability which contributes to the 
development of CRC. Mismatch repair genes (MMR), for example MLH1, MSH2, MSH6 and 
PMS2, are responsible for correcting base mismatches and short insertions or deletions 
which normally occur during DNA replication (Grady and Carethers, 2008). Where these 
genes are defective, DNA sequences are not faithfully replicated and microsatellites are 
created  - short sections of repeating DNA 1-6 base pairs long.   
Germ-line mutations in MMR genes are present in only 2-4% of CRC patients, however 15% 
of sporadic colorectal cancers exhibit microsatellite instability (MSI). A key mechanism for 
this is thought to be hypermethylation of the promoter of MLH1 resulting in a loss of 
function (Aaltonen et al, 1993). MSI tumours exhibit a specific phenotype; they tend to be 
poorly differentiated right colonic tumours with high mucinogens and tumour related 
lymphyocytes and are less likely to metastasise than microsatellite stable (MSS) tumours 
(Buecher et al, 2013). These pathological features confer a survival advantage, despite a 
reported resistance to fluorouracil based chemotherapeutic regimens (Ribic et al, 2003).  
Tumours with MSI can be sub-classifed as MSI-Low or MSI-High by the presence of less than 
or more than 30% unstable loci in a panel of 5-10 points respectively (Boland et al, 1998). 
The distinction of MSI-High/Low is associated with further variations in tumour phenotype 
and disease characteristics.  
1.3.5 Chromosomal instability (CIN) 
The chromosomal instability (CIN) phenotype is observed in approximately 70%–85% of 
CRC. It is widely accepted that most MSS tumours follow the CIN mechanism of 
tumourigenesis, however the MSI and CIN phenotypes are not mutually exclusive 
(Lengauer, Kinzler and Vogelstein, 1997). 
The cause of chromosomal instability is not known, although it is believed to be due to 
defects in genes which regulate formation of the mitotic spindle and alignment and 
segregation of chromosomes at mitosis (Grady, 2004). A small number of specific defects 
have been suggested, including alterations in Mad2, BubR1, Bub3 and CENPE proteins as 
well as LOH in chromosome 18q containing the tumour suppressor genes SMAD2, SMAD4, 
and DCC (Barber et al, 2008). APC mutation is also thought to play a role, but its presence in 
many other non-CIN tumour phenotypes suggests that the molecular basis for CIN tumours 
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is more heterogenous than the relationship between MMR genes and microsatellite 
instability (Alberici and Fodde, 2006). 
1.3.6 CpG island methylator phenotype (CIMP) 
DNA methylation is thought to serve the biological function of silencing repetitive elements 
of the genome (Yoder et al, 1997), and the significance of hypermethylation resulting in loss 
of function of MLH1 has already been discussed. The majority of C-phosphate-G sites have 
been lost from the human genome during evolution, however hypermethylation of any 
residual islands, defined as methylation of at least 3 loci from a panel of 5 gene-associated 
CpG islands, results in the silencing of tumour suppressor or other tumour related genes 
and ultimately carcinogenesis (Carragher et al, 2010). The CPG island methylator phenotype 
(CIMP) represents a further subset of colorectal cancers with a particular molecular and 
biological profile. Specifically these tumours have a higher incidence of concurrent 
mutations in KRAS/BRAF but wild type TP53, and are more frequently proximal tumours 
with mucinous and poorly differentiated histopathological features most often presenting 
in older female patients (Issa, 2004). Similarly to MSI, CIMP status of the tumour has been 
used to infer potential response to chemotherapeutics (Shiovitz et al, 2014). 
1.3.7 Summary of colorectal cancer genetics 
Our understanding of colorectal carcinogenesis has progressed significantly since the model 
first proffered by Vogelstein in 1990, and is summarised in Figure 1.1. 
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Figure 1.1 – Suggested genetic model for colorectal cancer. In (a) a number of hereditary 
and sporadic mutations drive the transformation of normal epithelia to an adenomatous 
lesion and latterly carcinoma. In (b) an inherited or acquired defect in DNA mismatch 
repair (MMR) function is the initiator for carcinogenesis. (Adapted from Fearon, 2011). 
The vast majority of colorectal tumours reflect a series of hereditary and somatic mutations 
in key genes i.e APC, KRAS, BRAF and TP53. These mutations are most frequently associated 
with a CIN phenotype and are often acquired in a different order, although the sequence 
may be relevant to tumourogenicity. A subset of tumours initiate through inactivation of 
MMR function, which may be through inherited or, less commonly, somatic mutation, or 
alternatively epigenetic inactivation through hypermethylation (CIMP) leading to MSI-H. 
Further cumulative mutations in the APC/KRAS/BRAF/TP53 genes ultimately lead to 
carcinogenesis. 
1.4 Staging of colorectal cancer 
Given the relative immaturity of the Bowel Cancer Screening Programme, the vast majority 
of patients with colorectal cancer still present symptomatically (Majumdar, Fletcher and 
Evans, 1999). Lesions in the left side of the colon are associated with alteration in bowel 
function, rectal bleeding and tenesmus, whereas lesions in the right side of the colon are 
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associated with abdominal pain and mass, anaemia and systemic symptoms of malignancy 
such as malaise and anorexia. A timely and accurate diagnosis is imperative to establish the 
diagnosis, accurately stage the disease and instigate an appropriate management plan. 
1.4.1 Clinical assessment 
Clinical assessment of the patient includes an understanding of comorbidity relevant to the 
treatment of the disease as well as an assessment of the disease itself, for example the 
tumour may be palpable via the abdomen or on per rectal examination. 
1.4.2 Endoscopic assessment 
Colonoscopy allows the visualisation of the entire colonic mucosa whilst also permitting 
biopsies of any suspicious lesions to be taken as well as delivering therapy, for example 
polypectomy. This is particularly important given the incidence of synchronous tumours 
(5%) and concurrent polyps (28%) which may influence management decisions (Langevin 
and Nivatvongs, 1984). The procedure also permits the marking of lesions with tattoo ink 
for subsequent localisation during surgery and a better understanding of tumour location 
and anatomy. 
1.4.3 Radiological assessment 
Computed tomography (CT) is the most widely used modality for staging local disease, as 
well as the detection and characterisation of both hepatic and extra-hepatic metastases for 
which it has a sensitivity of 60-90% (Ong and Leen, 2007). Modern techniques of multi-
detector helical scanning combined with rapid infusion of contrast allows visualisation of 
the liver in a number of different vascular phases. Combined with multi-slice reconstruction 
this technique has significantly improved lesion characterisation in the liver (Scott et al, 
2001). 
CT scanning is supplemented with magnetic resonance imaging (MRI) in two specific 
situations. In the local staging of rectal cancer, pre-operative high resolution MRI images 
provide information previously not normally available until the final surgical specimen had 
been examined histopathologically. Knowledge of these features in advance of surgery 
affords the opportunity to downstage disease and therefore influence outcome. On T2-
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weighted images taken by a 1.5T system with phased array coils, details of tumour 
morphology and stage, lymph node status and extramural vascular invasion can all be 
observed (Taylor et al, 2011). Perhaps more importantly, close proximity (within 1mm) of 
the tumour to the mesorectal fascia on MRI is a very sensitive predictor of circumferential 
resection margin (CRM) positivity at the time of surgery (MERCURY Study Group, 2006). The 
widespread adoption of treating these patients with so-called ‘threatened margins’ with 
neoadjuvant chemoradiotherapy followed by total mesorectal excision (TME) surgery has 
led to a significant reduction in margin positivity.   Secondly, for indeterminate lesions in 
the liver, further visualisation with MRI (combined with gadolinium contrast) is considered 
the most effective imaging modality for accurate characterisation (Kamel and Bluemke, 
2003). 
Positron emission topography (PET) utilises the increased glucose metabolism in tumour 
cells to uptake the radiotracer 18-fluorodeoxyglucose (FDG). On uptake the tracer is 
phosphorylated, thus becoming metabolically inactive and accumulating in cells. Now 
frequently combined with CT, PET scanning allows for the accurate localisation of small 
disease deposits, for example extra-hepatic abdominal metastases or local disease 
recurrence, on the understanding that metabolic changes in cells precede any anatomical 
variance which may be detected on contrast CT (Arulampalam et al, 2004). This additional 
information has been shown to alter disease management in 29% of patients with 
colorectal liver metastases (Huebner et al, 2000). 
1.4.4 Histopathological assessment 
As previously discussed, endoscopic examination of the colon permits acquisition of tissue 
for histopathological analysis. Given that the digestive tract can be considered as a 
continuum which at all times from mouth to anus is outside the body, biopsies can be taken 
without fear of seeding tumour into adjacent tumour free tissue.  
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Figure 1.2 - Invasive colonic adenocarcinoma penetrating the muscularis mucosa; stained 
with haematoxylin and eosin. Photomicrograph taken at x200 magnification.  
Tissue for analysis is formalin-fixed and paraffin-embedded (FFPE) and slices for 
examination are stained with haematoxylin and eosin (H&E). The histological diagnosis of 
colorectal cancer is based on invasion through the muscularis mucosae into the submucosa 
(Figure 1.2) and further classification into a number of histopathological subtypes, 
including: adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma and 
medullary carcinoma.  
Another important element of the histopathological assessment of colorectal cancer is 
tumour grade; an interpretation of the degree of de-differentation from the morphology of 
the original tissue assigned on a scale of G1-G4. Assignment of tumour grade considers 
nuclear features such as pleomorphism, cellular architecture and mitotic count, with G1-2 
tumours and G3-4 tumours grouped together for simplicity as low and high grade 
respectively. Whilst some tumour types have specific grading systems shown to link closely 
with prognosis, for example the Nottingham index for breast cancer and Gleason score for 
prostate cancer, none has as yet been developed for colorectal adenocarcinoma. 
Biopsy and histopathological assessment of lesions of presumed colorectal origin from 
outside the gastrointestinal tract, for example in the liver, proves more challenging, with 
uncertainty amongst clinicians both of its value and safety. Certainly given accurate 
radiological assessment as previously discussed and the increasing role of serum 
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biomarkers, the role of needle biopsy of colorectal liver metastases to obtain a diagnosis 
would seem unnecessary, however obtaining biological information from the metastatic 
site(s) may provide useful predictive and prognostic information. 
The most significant evidence to challenge the practice of biopsying colorectal liver 
metastases is a case series published by Jones et al (2005) comparing two cohorts of 
patients undergoing surgery for colorectal liver metastases, one of which had pre-operative 
needle biopsies to confirm diagnosis of adenocarcinoma. The incidence of needle-track 
tumour deposits was 19%, and whilst operative morbidity in the two groups were similar, 
the 4-year survival after liver resection was 32.5% in those having pre-operative needle 
biopsy compared to 46.7% in the group who did not (P=0.008). There are a number of other 
similar, albeit smaller, studies highlighted in a recent review (Table 1.3) which also goes on 
to discuss mechanical as well as oncological complications of liver biopsies (Cresswell, 
Welsh and Rees, 2009). Whilst the overall complication rate is thought to be around 5.9% 
(Perrault et al, 1978), the risk of significant haemorrhage is 0.5% (Knauer, 1978). 
Authors Year Design n Findings 
Al-Leswas et al. 2008 Case report 2 2 cases of implantaion 
Jones et al.  2005 Retrospective review 17 
19% seeding rate; poorer longterm 
survival after biopsy 
Rodgers et al. 2003 Retrospective review 7 
16% risk of seeding irrespective of 
route of biopsy 
Metcalf et al.  2004 Case report 1 
Biopsy added nothing to diagnostic 
pathway 
Ohlsson et al. 2002 Case series 5 10% seeding rate 
Scheele & 
Altendorf-
Hofmann 1990 Case report 2 
Seeding following biopsy of 
resectable lesion 
Ferrucci et al. 1979 Case Report 1 
First documented case of tract 
seeding 
 
Table 1.3 – Summary of evidence highlighting complications from percutaneous needle 
biopsy of colorectal liver metastases. (Reproduced without permission from Cresswell, 
Welsh and Rees, 2009). 
1.4.5 Staging systems 
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The first staging system for colorectal cancer was described by Dr Cuthbert Dukes in 1932. 
Applied initially only to rectal cancer, tumours were assigned a classification or Dukes’ stage 
from A-C: Dukes’ stage A cancers were confined to the bowel wall, stage B through the 
bowel wall and stage C where there was lymph node involvement (Dukes, 1932). Duke 
himself later correlated his pathological grading system with prognosis (Dukes and Bussey, 
1958), at which time the subdivision of stages C1 (regional lymph node involvement) and C2 
(apical node involvement) were made. Stage D representing distal disease was later added, 
(Turnbull et al, 1967), and the scoring system informally applied to carcinomas arising in the 
colon. 
With significant improvement in both our understanding of disease biology, but perhaps 
more so the advances in radiological techniques described above, the current standard of 
care is the use of the Union for International Cancer Control/American Joint Committee for 
Cancer TNM classification. This classification is a disease specific extension of the original 
TNM system devised by Denoix et al in 1946 whereby the degree of invasion and tumour 
spread is characterised by a T stage referring to the primary tumour, N stage recording the 
presence and extent of local lymph node invasion, and M stage describing the presence or 
absence of distant metastatic disease. The current version in widespread clinical use is the 
7th edition published in 2010 (Table 1.4). 
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TNM Stage Description 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 
Tumour invades through the muscularis propria into pericolorectal 
tissues 
T4a Tumour penetrates to the surface of the visceral peritoneum 
T4b 
Tumour directly invades or is adherent to other organs or 
structures 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c 
Tumour deposit(s) in the subserosa, mesentery, or non 
peritonealized pericolic or perirectal tissues without regional 
nodeal metastasis 
N2 Metastasis in 4 or more regional lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
M0 No distant metastasis 
M1 Distant metastasis 
M1a 
Metastasis confined to one organ or site (e.g. Liver, lung, ovary, 
non regional node) 
M1b Metastases in more than one organ/site or the peritoneum 
 
Table 1.4 – UICC/AJCC TNM staging of colorectal cancer; 7th edition (2010). Available 
online at https://cancerstaging.org/references-ools/quickreferences/Pages/default.aspx 
Given that it is possible to stage disease on a number of parameters at a number of 
different points along the patient’s journey, a number of prefixes to the TNM system have 
been created to highlight the origin of the information used for staging. These include: c – 
indicating the stage is given by clinical examination of the patient, p – indicating the stage is 
given by histopathological examination of a surgical specimen, y – indicating the stage is 
assessed after chemotherapy and/or radiation therapy (i.e. the patient received 
neoadjuvant treatment), r – for recurrent tumours with a substantial disease-free period, a 
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– determined at autopsy (or post mortem examination) and u – determined by 
ultrasonography. 
As can be seen from the table above there are many potential combinations of Tumour, 
Node and Metastasis stages which the UICC/AJCC have grouped together into stages (Table 
1.5) for the benefit of simplifying treatment decisions (Carrato, 2008). 
Stage Description TNM Stages 
0 No tumour Tis, N0, M0 
I 
Primary tumour into but not 
through muscularis propria, and 
no metastases T1-2, N0, M0 
IIa 
Primary tumour grown through 
to serosa and peritoneal surface 
but no metastases 
T3, N0, M0 
IIb T4a, N0, M0 
IIc T4b, N0, M0 
IIIa 
Any size of primary tumour with 
lymph node metastases 
T1-2, N1-N1c, M0 / T1, N2a, M0 
IIIb 
T3-T4a, N1-N1c, M0 or T2-T3, N2a, 
M0 or T1-T2, N2b, M0 
IIIc 
T4a, N2a, M0 or T3-T4a, N2b, M0 or 
T4b, N1-2, M0 
IVa Presence of distant metastatic 
disease 
Any T, Any N, M1a 
IVb Any T, Any N, M1b 
 
Table 1.5 - UICC/AJCC stage groupings for colorectal cancer; 7th edition (2010). Available 
online at https://cancerstaging.org/references-ools/quickreferences/Pages/default.aspx. 
Other staging systems have been established to further guide treatment or prognosticate. 
The best utilised of these systems is the Jass classification (Table 1.6) which combines some 
of the genetic aberrations previously discussed with a number of macroscopic and 
microscopic pathological correlates and patient features (Jass, 2007). 
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Feature Group 1 Group 2  Group 3 Group 4  Group 5 
MSI Status H S/L S/L S H 
Methylation +++ +++ ++  +/-  +/- 
Ploidy Dip > An Dip > An An > Dip An > Dip An > Dip 
APC  +/-  +/- + +++ ++ 
KRAS - + +++ ++ ++ 
BRAF +++ ++ - - - 
TP53 - + ++ +++ + 
Location R > L R > L L > R L > R R > L 
Gender  F > M F > M M > F M > F M > F 
Precursor SP  SP SP/AD AD  AD 
Serration  +++ +++ +  +/-  +/- 
Mucinous +++ +++ + + ++ 
Dirty Necrosis + + ? +++ + 
Poor 
differentiation 
+++ +++ + + ++ 
Circumscribed +++ + ? ++ ++ 
Tumour budding  +/- + ? +++ + 
Lymphocytes +++ + ? + +++ 
 
Table 1.6 – The Jass classification combines a number of patient, histopathological and 
genetic factors to allocate tumours to a group (1-5). MSI, microsatellite instability; H, 
high; S, stable; L, low; Dip, diploid; An, aneuploid; Serration, serrated morphology; SP, 
serrated polyp; AD, adenoma; Circumscribed, circumscribed invasive margin. Reproduced 
without permission from Jass, 2007. 
Identifying features such as these in classification systems could potentially allow us to gain 
a greater understanding of causation and pathogenesis. At the very least it acknowledges 
that colorectal cancer is a complex and multi-pathway disease. The Jass group is often used 
as a decision tool for those patients with Dukes’ Stage B (or Stage II) disease. A study of 183 
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patients with Dukes’ B disease who were also Jass grouped identified that cancer specific 
mortality was considerably higher in those with Jass group III than I or II. This additional 
prognostic information may facilitate the selection of patients who are most likely to 
benefit from adjuvant chemotherapy (Mander et al, 2006). 
1.5 Treatment of colorectal cancer with surgery 
Surgical resection remains the mainstay of oncological treatment for colorectal cancer. The 
exact oncosurgical strategy to employ and how to incorporate this with other treatment 
modalities has been the subject of much study in recent years. 
1.5.1 Resection of the primary tumour 
The surgical approach to colorectal cancer is dependent upon the site and stage of the 
disease, and in particular is somewhat different for the 37% of tumours present in the 
rectum.  
Small tumours contained within colonic polyps are often removed by polypectomy at the 
time of colonoscopy, however a significant number of patients undergo formal resection of 
the diseased segment of colon along with its arterial supply and accompanying lymphatic 
drainage. For tumours in the right colon a right hemicolectomy is performed. A section of 
bowel from the terminal ileum to transverse colon is excised, with ligation of the right colic 
and ileocolic vessels close to their origins in order to ensure maximum lymphatic clearance. 
For tumours in the transverse colon a more extensive version of this procedure is 
performed, often referred to as an extended right hemicolectomy. For tumours in the left 
colon a section of bowel extending from the sigmoid colon for a variable distance along the 
descending colon, with or without the splenic flexure, is mobilised, and excised following 
division of the inferior mesenteric artery and vein (usually to obtain full mobility of the 
colon). In the elective setting of either scenario an anastomosis is usually performed, 
although this may not be feasible or safe in the emergency setting. The concept of total 
mesocolic excision and its potential oncological advantages are currently being explored. 
The procedure consists of three essential components: dissection between the mesenteric 
plane and the parietal fascia with subsequent removal of the mesentery, a central vascular 
tie to completely remove all lymph nodes in the central (vertical) direction, and resection of 
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an adequate length of bowel to remove involved pericolic lymph nodes in the longitudinal 
direction (West et al, 2009). 
Tumours in the rectum may be amenable to local or trans-anal excision, with a significant 
increase in uptake of a number of variations of this technique in recent years (Atallah and 
Albert, 2013). Formal resection of the diseased segment of bowel however is more 
frequently performed. In brief tumours of the upper third of the rectum are approached in 
a similar manner to the operation for tumours in the left colon as previously described. 
Tumours in the middle and lower thirds of the rectum are now almost universally excised 
by low anterior resection using a technique known as total-mesorectal excision (TME). 
Professor Bill Heald popularised this technique in 1982, recognising that the lateral, deep or 
circumferential margins were much better predictors of local recurrence than distal margin 
(Heald, Husband and Ryall, 1982). The technique of TME was published in 1988 and the 
follow up data in 1998 reported a local recurrence rate of between 3-6%, considerably less 
than the 30% historically quoted (Heald, 1988; Heald et al, 1998). It is now well established 
that involvement of the circumferential resection margin is a good predictor of local 
recurrence, distant metastasis and also survival (Nagtegaal and Quirke, 2008). 
This technique brought about a considerable reduction in the number of abdomino-
perineal excision of rectum (APER) procedures, which involves removal of the entirety of 
the rectum and anal canal. This operation removes the sphincters and results in a 
permanent stoma, and therefore should be avoided if at all oncologically feasible. Rates of 
this operation still remain extremely variable, however are universally reducing as 
combinations of nejoadjuvant chemoradiation, total mesorectal excision, intersphincteric 
proctectomy and colonic-J pouch to anal anastomosis means that sphincter preservation 
can be achieved for most patients (Ludwig, 2007). 
A number of international multi-centre studies have confirmed the oncological equivalence 
of laparoscopic colorectal cancer surgery, two of the most significant being the Colon 
cancer Laparoscopic or Open Resection (CoLOR) trial studying colonic cancer (Veldkamp et 
al, 2005), and the Conventional versus Laparoscopic-Assisted Surgery in Colorectal Cancer 
(CLASSIC) trial for rectal cancer(Bang et al, 2012). Whilst oncological outcomes are 
comparable, laparoscopic surgery offers reduced wound infection rates, less pain and 
narcotic use, less overall morbidity and a shorter hospital stay, at the cost of modest 
increase in operative times (Abraham, Young and Solomon, 2004). 
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1.5.2 Resection of metastatic disease 
Over the past 10-20 years there has been a rapid expansion in potentially curative surgery 
for colorectal metastases, particularly those confined to the liver. This is in part a result of a 
more aggressive approach to neoadjuvant chemotherapy combined with improved surgical 
techniques, bringing an increasing number of patients who were initially thought not to be 
resectable to resection. Those patients who do undergo resection experience a 10 year 
survival of 9-69% (Taylor et al, 2012). 
Prior to this there was a very conservative approach to the management of metastatic 
disease in the liver, the traditional indications for which were 1-3 unilobar metastases 
which were resectable with a generous margin. Patients presenting with liver metastases 
(i.e. those with stage IV disease), those with a rectal primary, multiple diffuse metastases, 
metastases larger than 5cm, a disease free interval of less than 1 year from the diagnosis of 
the primary and high serum carcinoembryonic antigen (CEA) were not considered 
appropriate for curative surgical resection due to poor prognosis (Poston, 2008). The 
approach to surgical resection in the liver is now more of a consideration of both technical 
and oncological feasibility. 
In order to achieve adequate resection in the liver it must be feasible to remove all 
macroscopic disease with negative margins, preserve vascular inflow and outflow and leave 
sufficient future remnant liver (FRL) to ensure adequate hepatic function (Garden et al, 
2006). The volume of FRL sufficient to ensure adequate hepatic function would clearly 
depend upon the functional quality of the remaining liver parenchyma, with those patients 
with cirrhosis, steatosis or, increasingly commonly, drug induced liver injury (DILI), requiring 
a larger liver remnant than those with normal underlying liver parenchyma. Generally 
speaking, 25% of the liver volume (approximately two Couinaud segments) is considered 
adequate. Given the regenerative ability of the liver parenchyma, liver regrowth may allow 
multi-stage resections (Narita et al, 2011). 
Removal of all macroscopic and microscopic disease with negative margins is referred to as 
an R0 resection. Where microscopic disease remains the resection is said to be R1 and 
where macroscopic disease remains the resection is said to be R2. It has been clearly 
demonstrated that those patients with R1 resections have better outcomes than those with 
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R2 (Pawlik et al, 2005), and whilst R0 is considered the optimum standard of care, survival 
in those with R0 and R1 resections is comparable (de Haas, Wicherts and Adam, 2008).   
A number of alternatives to surgical resection exist, all of which centre on the concept of 
tumour ablation. This is now most commonly achieved by radiofrequency ablation (RFA) or 
microwave ablation (MWA) either at open surgery or percutaneously. Given the 
considerable variation in local recurrence and overall survival, the role of ablation in the 
curative setting is unclear. This was highlighted by recent guidelines from the American 
Society of Clinical Oncology (ASCO) who recommend that resection remains the gold 
standard of treatment. As such the use of these ablative techniques is often reserved for 
unfit patients with low volume disease, as an adjunct to formal resection or in the non-
curative setting. 
Guidance from the National Institute for Health and Care Excellence (NICE) pertaining to 
the management of colorectal cancer (CG131) now recommends that surgery for 
metastatic disease in the liver be considered in those patients fit enough for surgery and in 
whom complete resection can be obtained leaving adequate FRL. The guidance goes on to 
suggest that liver resection is relatively contra-indicated in those with a non-treatable or 
recurrent primary tumour, widespread pulmonary and/or metastatic disease, extensive 
nodal disease or metastases in the bone or central nervous system. 
Decision making in the context of extra-hepatic metastases is somewhat more complex, 
although it is no longer a contra-indication to potentially curative surgery. One of the 
largest series of pulmonary metastasectomy published by Pfannschmidt et al (2003) quotes 
a five-year survival of 32.4% with number of metastases and lymph node positivity being 
independently prognostic factors on both multivariate and univariate analysis. The 
Pulmonary Metastasectomy in Colorectal Cancer (PulMICC) trial is a currently recruiting 
feasibility study randomising to open/thoracoscopic surgery or active monitoring (no 
treatment) and will hopefully add further clarity to the role of surgery for metastatic 
colorectal cancer in the thorax. Extra-hepatic abdominal metastases again are no longer a 
contra-indication to surgery at other sites, and resection of these sites is associated with a 
5-year survival of around 25% (Adam et al, 2011). 
1.5.3 Surgical management of synchronous disease 
22 
 
The above described strategies apply to those patients who present with a primary tumour, 
and following a period of disease free survival develop metastastic disease. However, those 
presenting with a resectable primary tumour and synchronous metastatic disease in the 
liver, now thought to be approximately 14.5% of patients due to improvements in our 
ability to detect this radiologically, have a number of surgical options (Manfredi et al, 2006). 
In brief these are: traditional approach (primary first and then liver), reverse approach (liver 
first and then primary) or to synchronously (often referred to as simultaneously) resect 
disease at both sites within a single procedure. All of these approaches would require 
integration with other treatment modalities, in particular peri-operative chemotherapy 
and, in the case of rectal cancer, neoadjuvant radiotherapy. 
It is safe to say the optimal strategy for the management of these patients remains unclear, 
and there is certainly an absence of level 1 evidence. A recent systematic review identified 
18 papers in which 21 comparisons had been performed between at least two of these 
strategies (Lykoudis et al, 2014). A number of other smaller series exist, but for the purpose 
of the published systematic review only those with patient groups greater than 10 were 
included (Table 1.7).  
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Table 1.7 – Summary of recent evidence pertaining to the synchronous management of liver limited metastatic colorectal cancer. Reproduced with 
permission from Lykoudis et al (2014). References: Martin et al; J Am Coll Surg (2003); 197; 233-241, Chua et al; Dis Colon Rectum (2004); 47; 1310-1316, 
Capussotti et al; Ann Surg Oncol (2007); 14; 195-201, Capussotti et al, Ann Surg Oncol (2007); 14; 1143-1150, Reddy et al; Ann Surg Oncol (2007); 14; 
3481-3491, Thelen et al; Int J Colorectal Dis (2007); 14; 3481-3491, Turrini et al; Eur J Surg Oncol (2007); 33; 735-740, Vassiliou et al; World J Gastroenterol 
(2007); 13; 1431-1434, Martin et al; J Am Coll Surg (2009); 208; 842-850, Slupski et al; Can J Surg (2009); 52; E241-E244, Brouquet et al, J Am Coll Surg 
(2010); 210; 934-941, de Haas et al; Br J Surg (2010); 97; 1279-1289, Luo et al; J Gastrointest Surg (2010); 14; 1974-1980, Moug et al; Eur J Surg Oncol 
(2010); 36; 365-370, Mayo et al; J Am Coll Surg (2013); 216; 707-716. 
Reference Year 
Duration of operation (min)* 
Blood loss (ml)* Transfused patients Hospital stay (days)* Morbidity (%) 
In-hospital mortality 
(%) 
Simultaneous 
approach  
Staged approach 
Total 
Colorectal 
surgery 
Liver 
surgery Simultaneous Staged Simultaneous Staged Simultaneous Staged Simultaneous Staged Simultaneous Staged 
Cohort studies 
   Martin et al. 2003 235 411§ n.s. n.s. 
550 
1100§ 31 38 10 18§ 48 68§ 2 2 
   Chua et al. 2004 370 392 n.s. n.s. 600 575 n.s. 10 17§ 53 41 0 0 
   Capussotti et al. 2007 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 36 37 Excluded 
   Thelen et al. 2007 260† n.s. n.s. 2091 n.s. 35 n.s. 20† n.s. 18 n.s. 10 n.s. 
   Turrini et al. 2007 325 n.s. n.s. 256 n.s. n.s. 18 n.s. 21 n.s. 4 n.s. 
   Vassiliou et al. 2007 260† 340†§ n.s. n.s. n.s. n.s. 12† 20†§ n.s. 0 0 
   Martin et al. 2009 180 235 n.s. n.s. 300 350 50 45 10 18§ 56 55 2 2 
   Slupski et al. 2009 250 290§ 90 200 950 1040 n.s. 12 15§ n.s. 0 0 
   de Haas et al. 2010 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 11 25§ 0 1 
   Brouquet et al. 2010 n.s. n.s. n.s. n.s. 300 600§ 16 13 n.s. 19‡ 17‡ n.s. 
   Luo et al. 2010 255 415§ n.s. n.s. 400 650§ n.s. 8 14§ 47 54 2 2 
   Mayo et al. 2013 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 3 3 
   Martin et al. 2003 290 423§ n.s. n.s. 800 1100§ n.s. 12 18§ 60 70§ 4 4 
   Capusotti et al. 2007 330 n.s. n.s. 280 
n.s. 
42 17¶ 14 21§ 33 56§ 3 0 
   Reddy et al. 2007 n.s. n.s. n.s. n.s. n.s. n.s. 9 14§ 44 45 n.s. 
   Martin et al. 2009 202 268 n.s. n.s. 450 750§ n.s. 12 18§ 50 60 0 4 
   de Haas et al. 2010 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 8 31§ 0 0 
   Moug et al. 2010 n.s. n.s. n.s. n.s. 475 425 n.s. 12 20§ 34 59 0 0 
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No significant differences in mortality were found between groups. Statistically significant 
differences were found in: duration of operation, blood loss, transfusion requirements, 
length of hospital stay and morbidity. Five studies favoured synchronous resection in terms 
of cumulative procedure duration and blood loss, however no difference was found in 
either of these variables in 3 and 4 papers respectively. 12 studies examined for length of 
hospital stay, all of which favoured synchronous resection. Five papers favoured the 
synchronous approach in terms of overall morbidity, however 8 papers failed to detect any 
difference. One study found increased transfusion requirements in those undergoing 
synchronous resection.  
The authors conclude that no one strategy is inferior to the others, and that all of them 
should be considered in patients presenting with synchronous colorectal liver metastases. 
The clear contra-indication to this approach would be those patients with a symptomatic 
primary tumour, for example those that are bleeding and requiring transfusion, perforated 
tumours and those obstructing or with an imminent threat of the same. The biggest 
question arising from these studies is whether or not it is possible to identify subgroups of 
patients who would benefit from one particular strategy over another, particularly if 
considering that those patients presenting with synchronous disease may represent a 
distinct biological subtype (Silvestrini et al, 1990).  Unfortunately the evidence is lacking, 
with a complete absence of prospective data and multiple inadequacies in existing cohort 
studies, the most appropriate course of management for these patients should be 
determined on an individual basis by specialty multidisciplinary teams (Abdalla et al, 2013). 
1.6 Treatment of colorectal cancer with radiotherapy  
Radiotherapy is an established adjuvant treatment for the management of colorectal 
cancer. As with all adjuvant treatments, the majority of patients receiving treatment, along 
with all the established risks, inconvenience and side-effects, will not actually benefit. This 
could be either because surgery alone has been curative, or because the disease will 
ultimately recur regardless of additional treatment received. The decision to treat cohorts 
of patients with common cancers with adjuvant therapy therefore stems from the concept 
that altering the outcome in a small proportion of patients will still translate to many 
hundreds or thousands of lives saved. 
1.6.1 Biological effects of radiation 
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Radiation causes ionisation of atoms, which in turn can affect cell, tissue and organ 
function. Effects of radiotherapy can be divided into direct and indirect effects. Direct 
effects occur when, for example, radiation causes ionisation of atoms in DNA molecules, or 
in other molecules essential to the survival and reproduction of the cell. Given these 
components make up a relatively small proportion of the cell, most of the radiation will 
interact with intra-cellular water. The so-called indirect effects of radiation cause 
fragmentation of water into hydrogen and hydroxyl ions, which may recombine as water or 
other chemicals more harmful to the cell such as hydrogen peroxide. 
The sensitivity of cells to radiation is proportional to its rate of replication. Dividing cells 
require correct DNA for the progeny to survive, and direct interaction of radiation with DNA 
may ultimately result in cellular mutation or death. The rapid cell division of a neoplastic 
lesion is exploited in this manner; tumour cells divide rapidly and are therefore prone to the 
effects of radiation. Dormant cells, which tend to be relatively hypoxic, are less sensitive to 
the effects of ionising radiation. 
The ability of the tumour to repair damage imparted by radiotherapy is thought at least in 
part to reflect its resistance and response to treatment. Base excision repair proteins are a 
key mechanism by which small, non-helix-distorting base lesions are repaired (compared to 
the nucleotide excision repair pathway which repairs bulky helix-distorting lesions). Base 
excision repair (BER) mechanisms remove damaged bases that could otherwise cause 
mutations by mispairing or lead to breaks in DNA during replication. Some of the key 
proteins involved in this mechanism include AP endonuclease 1 (APE1) which cleaves an AP 
site for subsequent binding, DNA polymerase β which catalyses short-patch repair (i.e. 
single nucleotide replacement), and DNA ligase III along with its cofactor XRCC1 which 
catalyses the nick-sealing step in short-patch BER. The expression of these proteins has 
been investigated for potential as both biomarkers and therapeutic targets, although as yet 
there is insufficient evidence for incorporation into clinical practice (Vens and Begg, 2010). 
Small bowel epithelia are rapidly dividing cells, and so too are prone to the effects of 
radiation. The risk of so-called radiation enteritis combined with the relative mobility of the 
colon within the abdomen poses difficulty for the use of radiation in colon cancer. As such 
the use of radiation is almost exclusively limited to the treatment of rectal cancer. 
1.6.2 Indications for radiotherapy 
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The most important distinction to be made is between those tumours initially felt to be 
resectable and those where the planned resection margins are threatened by tumour. 
Beyond that, the indications for radiotherapy in rectal cancer can be divided into two broad 
classifications: 
 Reducing the risk of local recurrence  
 Shrinking locally advanced tumours to facilitate successful surgical resection 
1.6.3 Short-course pre-operative radiotherapy (SCPRT) 
Where the disease is already felt to be resectable, radiotherapy can be administered either 
pre- or post-operatively. The main advantage of pre-operative treatment is that pelvic 
anatomy is undisturbed and therefore toxic doses of radiation to the small bowel are less 
likely. Conversely, delivering the treatment post-operatively allows for better 
personalisation of treatment by focusing on those patients with adverse pathological 
features. 
A regimen of irradiation which did not delay definitive surgical treatment became popular, 
and is now referred to as short-course pre-operative radiotherapy (SCPRT). A typical 
regimen is the delivery of 25Gy in five 5Gy fractions over 5 days. This approach was 
supported by a number of early randomised controlled trials (Goldberg et al, 1994; Marsh 
et al, 1994; Cedermark et al, 1995), the largest and most significant of which being the 
Swedish Rectal Cancer Trial which demonstrated improved survival and reduced local 
recurrence rates compared to surgery alone (Swedish Rectal Cancer Trial, 1997). 
To further evaluate the role of SCPRT in the post TME era, the Dutch Colorectal Cancer 
Study Group trial compared SCPRT and TME surgery with TME surgery alone. A total of 
1805 patients were randomised to the two groups, and whilst the overall survival at 2 years 
was comparable, the rate of local recurrence was 2.4% in those receiving SCPRT-TME 
compared to 8.2% in the group receiving TME alone (Kapiteijn et al, 2001). Similarly the 
Medical Research Council CR07 trial compared SCPRT with selective post-operative 
chemoradiotherapy (for those patients with CRM involvement). 1350 patients were 
randomised to the study, the findings of which were a 61% reduction in local recurrence 
and 6% increase in disease free survival at 3 years in those patients undergoing SCPRT 
(Sebag-Montefiore et al, 2009). 
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1.6.4 Long-course neoadjuvant chemoradiotherapy 
An alternative strategy to SCPRT is the use of a longer course of radiation with a lower dose 
per fraction. With long-course radiotherapy, 45-50Gy is delivered over 5-6 weeks at 1.8-
2.0Gy per fraction. Similarly to SCPRT, there is good evidence for improved local control but 
no evidence of an increase in survival benefit. Addition of concurrent chemotherapy has 
been shown to be more effective than radiotherapy alone, with two significant trials 
(EORTC 222921 and FFCD 9203) both attesting to yet further reductions in local recurrence 
with this strategy (Bosset et al, 2006; Gerard et al, 2006). 
Only one trial has compared SCPRT and long-course CRT in patients with resectable disease 
(Bujko et al, 2006). Whilst longer courses of radiotherapy were associated with greater 
tumour down-staging and CRM-negative resections, it was also associated with higher rates 
of radiation toxicity and no improvement in local recurrence or survival. 
Until recently there was doubt as to the optimum timing for long-course CRT, however the 
recent CAO/ARO/AI0 94 trial compared pre-and post operative chemoradiotherapy in the 
context of standardised TME surgery and adjuvant chemotherapy. The study reported 
lower recurrence rates when the radiotherapy is delivered pre-operatively (6% vs. 12%), as 
well as reduced early and late complications (Sauer, 2004). 
1.6.5 Radiotherapy in locally advanced rectal cancer 
Recognition of the importance of CRM involvement in predicting local recurrence has led to 
an increase in the use of MRI to accurately stage rectal cancer. This increasingly 
sophisticated technology is now being used to identify those patients with ‘locally advanced 
disease’, defined in many different ways but for the purposes of this discussion should be 
thought of as being tumour encroaching upon the mesorectal fascia and therefore likely to 
result in a positive CRM given a satisfactorily performed TME resection (MERCURY, 2006). It 
is from within this group of patients where the other indications for radiotherapy arises; 
shrinking tumours to facilitate successful surgical excision. 
Given the difficulties of treating these patients with surgery alone, little evidence exists to 
support this strategy although two trials from the UK have attempted to answer this 
question. A small trial (284 patients) compared SCPRT with surgery alone, with no 
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difference in survival benefit or local recurrence, although the authors did perceive a 
marginal survival benefit in a subgroup analysis of those patients believed by the surgeon to 
have had a curative resection (Marsh et al, 1994). A larger trial with longer follow-up 
compared long-course CRT with surgery alone, favouring long-course CRT for local 
recurrence (hazard ratio 0.68), distant recurrence (hazard ratio 0.66) and disease-free 
survival (hazard ratio 0.76), all of which were statistically significant (Medical Research 
Council Rectal Cancer Working Party, 1996). 
One other potential advantage of neoadjuvant chemoradiotherapy is the potential for 
converting a planned abomino-perineal resection of the rectum into an anterior resection 
as a result of tumour shrinkage, thus performing a sphincter-preserving procedure and 
sparing the patient from a permanent stoma and the morbidity of a significantly more 
invasive operation. However it would seem that the evidence for this notion is anecdotal, 
as a recent systematic review of 10 randomised controlled trials comparing neo-adjuvant 
radiotherapy and surgery with surgery alone failed to find any difference in permanent 
stoma rates between experimental and control arms (Bujko et al, 2006). 
1.6.6 Other uses of radiotherapy  
Thus far, the role of radiotherapy has only been considered in the curative setting. This may 
be assumed to be external beam radiotherapy delivered by a linear accelerator, however 
there are other roles for radiotherapy in patients with rectal cancer. 
The application of direct contact radiotherapy, for example using the Papillon system, has 
been shown to be a safe and effective treatment for early rectal cancers in those patients 
not suitable for definitive surgical treatment. A study of 220 patients with T1-T3 tumours 
less than 3cm in diameter was reported from the Clatterbridge Centre of Oncology. The 
authors report a local control rate of 93% with no significant morbidity in any patient, 
accepting that their population was highly selective and that close follow-up and plans for 
salvage surgery are required (Myint et al, 2007). 
Radiotherapy has also been shown to be advantageous in the palliative setting, be that in 
those not suitable for surgical intervention or those who have experienced disease 
recurrence. Radiotherapy at a total dose of 20-60Gy can provide relief of pain and bleeding 
in 75% of patients for a median duration of 6-9 months (Saltz, 2004). The role of intra-
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operative radiotherapy (IORT) for those patients with T4 disease is still under investigation, 
with the most recent evidence suggesting an improved local recurrence free survival in 
patients with microscopically involved margins at the time of resection. A study of 409 
patients who underwent surgery for locally advanced or recurrent rectal cancer identified 
48 with a microscopically involved CRM. Within this cohort those who received IORT (n=31 
vs. n=17) benefited from a significant difference in cumulative 5-year local recurrence free 
survival (84% vs. 41%; p=0.01) (Alberda et al, 2014). No evidence from randomised trials is 
as yet available and case series remain small, however the results are promising for 
appropriately selected patients. 
1.7 Chemotherapeutic agents used in colorectal cancer 
Before 2000, the only agent available for the treatment of metastatic and advanced 
colorectal cancer was 5-flourouracil (5-FU), which still remains the cornerstone of 
treatment. Indeed it is still an oral pro-drug of 5-FU (capecitabine) which is used as 
monotherapy alongside neoadjuvant radiotherapy in the treatment of locally advanced 
rectal cancer. 
The development of alternative agents however has revolutionised our approach to the 
management of these patients, with combination regimens now considered standard 
therapy. The most commonly used chemotherapeutic agents in colorectal cancer are 5-
fluorouracil and oxaliplatin, which are combined with leucovorin in a regimen known as 
FOLFOX. An alternative strategy is the combination of fluorouracil and irinotecan with 
leucovorin (FOLFIRI), or 5-fluorouracil with oxaliplatin, irinotecan and leucovorin 
(FOLFIRINOX). Our increasing understanding of tumour biology has also led to the 
development of biological agents, the most common being cetuximab, panitumumab and 
bevacizumab. These agents are frequently used in combination with existing 
chemotherapeutic regimens. 
Evidence for the use of specific regimens will be discussed, but first we shall consider the 
mechanism of action of each of these agents individually. 
1.7.1 5-fluorouracil (5-FU) 
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5-FU is a fluropyrimidine anti-metabolite. The drug was designed, synthesized and patented 
in 1957 as an analogue of uracil, a normal component of RNA. The analogue substitutes a 
hydrogen for fluorine atom at the C5 position and is a specific competitive antagonist for 
uracil. Its misincorporation into RNA and DNA arrests RNA synthesis and therefore halts 
tumour growth. 
As well as being incorporated into macromolecules, 5-FU is converted intra-cellularly into a 
number of active metabolites which disrupt biological function: fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP). It is these active metabolites which inhibit thymidylate synthetase 
(TS), a nucleotide synthetic enzyme which is thought to be the main target for 5-FU (Figure 
1.3). The exact downstream effect of this is unclear, although this action is thought to result 
in dinucleotide pool imbalances and increased levels of deoxyuridine triphosphate (dUTP), 
both of which can cause DNA damage (Yoshioka et al, 1987). 
The drug is predominantly catabolised by dihydropyrimidine dehydrogenase (DPYD), which 
converts 5-FU to dihydrofluorouracil (DHFU), with around 80% of this occurring in the liver 
(Diasio and Harris, 1989). 
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Figure 1.3 – 5-Fluorouracil metabolism – 5-fluorouracil (F-FU) is converted to three main 
metabolites: fluorodeoxyuridine monophosphate (F-dUMP), fluorodeoxyuridine 
triphosphate (FUTP) and fluorouridine triphosphate (FUTP). The main mechanism of 5-FU 
activation is conversion to fluorouridine monophosphate (FUMP) by orotate 
phosphoribosyltransferase (OPRT). FUMP is then phosphorylated to fluorouridine 
disphoaphate (FUDP) and again to fluorouridine triphosphate (FUTP). Alternatively, 
thymidine phosphorylase (TP) can activate 5-FU by catalysing the conversion of 5-FU to 
fluorodeoxyuridine (FUDR) which is then phosphorylated by thymidine kinase (TK) to 
FdUMP. FdUMP can be phosphorylated to fluorodeoxyuridine diphosphate (FdUDP) and 
again to fluorodeoxyuridine triphosphate (FdUTP). 80% of 5-FU is catabolised in the liver 
by dihydropyrimidine dehydrogenase (DPYD). Adapated from Longley, Harkin and 
Johnston, 2003. 
Common side-effects include nausea, vomiting, diarrhoea, mucositis, headache, 
myelosuppression, alopecia and photosensitivity. 
1.7.2 Leucovorin 
High intra-cellular levels of the reduced folate, leucovorin (folinic acid), are required for 
optimal binding of FdUMP to TS. Leucovorin is transported into cells via the reduced folate 
transporter, anabolised and polyglutamated. These steps not only increase intra-cellular 
retention but further help stabilise the complex formed with FdUMP and TS, and as such it 
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is widely accepted that co-administration of leucovorin increases 5-FU toxicity both in vitro 
and in vivo (Wright, 1989). 
1.7.3 Capecitabine 
An alternative approach to the delivery of 5-FU has been the design of oral pro-drugs which 
avoid the DPYD mediated catabolism in the liver. Capecitabine is an oral fluoropyrimidine 
which is absorbed via the gastrointestinal tract and converted in the liver to 5’-deoxy-5-
fluorouridine (5’DFUR) by the enzymatic action of carboxylesterase and cytidine deaminase 
(Johnston and Kaye, 2001). 5-DFUR is ultimately converted to 5-FU by thymidine 
phosphorylase (TP) and uridine phosphorylase (UP). The higher abundance of these 
enzymes in tumour tissue is thought to account for the more tumour-specific conversion of 
capecitabine to 5-FU (Schuller et al, 2000). 
1.7.4 Irinotecan 
Irinotecan is a semi-synthetic analogue of the alkaloid camptothecin. Its mechanism of 
action is by direct interaction with topoisomerase I (Top I). The role of Top I is uncoiling 
DNA ready for transcription by inflicting single-strand DNA breaks which ultimately are 
repaired. Irinotecan binds to the DNA/Top I complex and stabilises these breaks, resulting 
in DNA fragmentation and cell death. 
Irinotecan is a pro-drug, which is converted to its active metabolite, SN-38, by human 
carboxylesterases CES1 and CES2. Irinotecan can also undergo CYP3A4 mediated oxidative 
metabolism to form APC and NPC, both of which are inactive however NPC can be further 
hydrolysed by carboxylesterase to release SN-38 (Mathijssen et al, 2001). The biochemistry 
of the drug is outlined in Figure 1.4. 
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Figure 1.4 – The metabolism of irinotecan (CPT-11). Irinotecan is converted to the active 
metabolite SN38 by carboxylesterase (CE), as well as to two other inactive metabolites 
(NPC and APC) by CYP3A4. NPC can subsequently be converted by SN-38 by CE. 
Inactivation to SN38-G is predominantly controlled by UGT1A1, however the inactive 
metabolite can be re-activated to SN38 by β-glucuronidation. Adapted from Mathijssen et 
al, 2001. 
Irinotecan is conjugated by UDP-glucuronosyl-transferases, the most active form of which is 
1A1 (UGT1A1). A common polymorphism in UGT1A1, known as UGT1A1*28, is 
characterised by the presence of an additional TA repeat in the TATA sequence of the 
UGT1A1 promoter. Individuals with this polymorphism are at significantly higher risk of 
developing the most common and severe side effects of irinotecan, diarrhoea and 
neutropenia (Iyer et al, 2002). The glucuronidated product is SN38-G, which can be 
deglucuronidated by intestinal β–glucuronidase (β-Glu) back to the active metabolite SN38. 
1.7.5 Oxaliplatin 
Oxaliplatin is a platinum based chemotherapeutic which was discovered in 1976. Its 
chemical structure features a square planar platinum centre, the bidentate ligand 1,2-
diaminocychlohexane (DACH) and a bidentate oxalate group. 
Its anti-tumour effects are non-targeted, although oxaliplatin undergoes intra-cellular 
transformation into a number of active metabolites all of which contain a DACH ring. These 
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metabolites form inter- and intra-stand cross links in DNA which prevent replication and 
transcription (Graham, Mushin and Kirkpatrick, 2004).  
In a similar way to the patterns of resistance described for radiotherapy, resistance to 
oxaliplatin is thought to stem from the cell’s ability to repair DNA damage. These 
mechanisms include nucleotide-excision repair (NER) and mismatch repair (MMR), however 
the major system responsible for the removal of corrupt DNA bases and repair of DNA 
single strand breaks is the base excision repair (BER) system (Sharma and Dianov, 2007). In 
particular deficiency in the most significant DNA polymerase, polymerase-β, has been 
shown to render cells hypersensitive to oxaliplatin therapy (Yang et al, 2010). 
1.7.6 Biological agents 
In recent years significant advances have been made in developing novel small molecule 
inhibitors of extracellular receptors. Extracellular growth factor receptor (EGFR) is a 
transmembrane glycoprotein which is a member of the ErbB receptor tyrosine kinase 
group, mutations in which are known to result in carcinogenesis (Zhang et al, 2007). 
EGFR is activated by the binding of specific ligands, most commonly epidermal growth 
factor (EGF) and transforming growth factor α (TGFα). Upon binding EGFR undergoes 
transformation to an active homodimer stimulating intrinsic intracellular protein-tyrosine 
kinase activity and a cascade of autophosphorylation resulting in increased signal 
transduction principally through the PI3K/AKT/MTOR and RAS/RAF/MEK/ERK pathways. 
This activation activates a number of cell-cell adhesion, DNA synthesis and cell proliferation 
pathways responsible for carcinogenesis. 
Cetuximab is a chimeric mouse/human monoclonal antibody and panitumumab is a fully 
human monoclonal antibody, both of which target EGFR directly (Figure 1.5). Their use is 
confined to those tumours who express EGFR and who are KRAS wild type, as the key role 
of this gene in subsequent downstream signalling means that these drugs have little or no 
effect if the KRAS gene is mutated (Messersmith and Ahnen, 2008). Specifically a mutated 
KRAS will continue to trigger downstream signal activation even following inhibition of 
EGFR. 
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Figure 1.5 – Binding of a ligand (EGF, TGFα) to EGFR stimulates receptor dimerisation, 
tyrosine kinase activation, EGFR autophosphorylation and ultimately initiates signal 
transduction cascades involved in cell proliferation and survival. Inhibition of EGFR by the 
monoclonal antibody cetuximab inhibits these downstream events. Adapted from 
Kirkpatrick, Graham and Muhsin, 2004. 
An alternative approach to inhibiting this pathway is to use small molecule inhibitors, which 
act on the cytoplasmic side of the receptor to reduce EGFR tyrosine kinase activity. Without 
this activity, EGFR is unable to autophosphorylate, and therefore downstream signalling is 
halted and tumour proliferation reduced. Drugs used in this category include gefitinib, 
erlotinib and lapatanib although none of these are as yet in widespread use for colorectal 
cancer. 
Vascular endothelial growth factor (VEGF) is an important regulator of angiogenic factors 
crucial for tumour growth and metastasis, activation of which is pro-angiogenic. 
Bevacizumab is a human monoclonal antibody which binds directly to VEGF and forms a 
complex which is unable to bind to any other VEGF receptors. This essentially reduces the 
amount of VEGF available resulting in inhibition of angiogenesis (Los, Roodhart and Voest, 
2007). 
1.8 Treatment of colorectal cancer with chemotherapy 
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 Chemotherapy regimens with 5-FU as the cornerstone remain a widely used treatment for 
advanced colorectal cancer, which in the adjuvant setting is thought to confer a 5-10% 
improvement in absolute survival (Haydon, 2003).  
The vast majority of evidence for the use of chemotherapy in colorectal cancer pertains to 
colon cancer only, with its use in rectal cancer inferred and therefore the subject of much 
debate. A number of questions remain, including the optimum regimen, route of 
administration and the potential for combination with other chemotherapeutic or 
biological agents. Uncertainties still exist around optimum patient selection, in particular 
the role of chemotherapy in patients with stage II disease. 
1.8.1 The evidence for 5-FU 
A  number of early trials explored the role of 5-FU in advanced colorectal cancer. The 
quality of these studies was poor, and a meta-analysis performed in 1988 failed to show 
any survival benefit (Buyse, Zeleniuch-Jacquotte and Chalmers, 1988). 
Shortly after this, a large randomised control trial clearly demonstrated a survival benefit 
following 12 months of 5-FU combined with levamisole (an immunomodulator) when 
compared to either agent as monotherapy or observation alone (Laurie et al, 1989). These 
findings were confirmed in a subsequent larger trial of 1296 patients (Moertel et al, 1990), 
which led to the recommendation and subsequent adoption of this regimen as standard 
practice (NIH Consensus Conference, 1990). 
Interest subsequently turned to the combination of 5-FU with leucovorin/folinic acid, with 
one of the most significant trials addressing this being the Quick and Simple and Reliable 
(QUASAR) study. The trial was a two x two design whereby 4927 patients with colorectal 
cancer but without residual disease were randomly assigned to receive fluorouracil with 
high dose or low-dose folinic acid, and either active of placebo levamisole. On an intention 
to treat analysis for all cause mortality, the inclusion of levamisole in chemotherapy 
regimens did not improve survival, and high dose folinic acid conferred no additional 
benefit to low-dose folinic acid (QUASAR Collaborative Group, 2000). Although not 
randomly allocated, those patients receiving a once weekly bolus regimen suffered less 
toxicity with equivalent efficacy to those receiving five consecutive days every 4 weeks 
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(referred to as the ‘Mayo regimen’). As a result of this the weekly regimen of 5-FU with low 
dose folinic acid was widely adopted in the UK. 
1.8.2 Combination regimens 
Over recent years a number of trials have combined 5-FU with other chemotherapy agents. 
The MOSAIC trial of 2246 patients compared 5-FU/Folinic Acid with 5-FU/Folinic 
Acid/Oxaliplatin, and found an increase in 3-year disease free survival from 72.9% to 78.2% 
(Andre et al, 2009). A subgroup analysis within this study also reported a small 
improvement (72.9% vs. 68.3%) in overall survival for stage III but not stage II patients. The 
NSABP-C07 trial similarly reported 3-year disease free survival rates of 71.8% increasing to 
76.1% with the addition of oxalipatin (Kuebler, 2007). Both trials noted the increased 
disease-free survival came at the cost of significant neurosensory toxicity associated with 
the use of oxaliplatin, however this regimen was widely adopted across Europe. 
Few trials have looked at combining irinotecan in the adjuvant setting. The CALGB 89803 
study randomised 1264 patients with completely resected stage III colon cancer to either 5-
FU/Leucovorin or 5FU/Leucovorin/Irinotecan, each regimen being delivered by single 
weekly bolus infusion. Powered for disease free survival and overall survival, no differences 
were found between groups although significant additional toxicity was reported with the 
use of irinotecan (Saltz et al, 2000). Similar findings were seen in the Pan-European Trials in 
Alimentary Cancer (PETACC-3) study, with 2094 patients recruited into a similar trial design 
demonstrating comparable 5-year disease free survival (73.6% vs. 71.3%) (Van Cutsem et al, 
2009). No trials have as yet compared 5-FU/Leucovorin/Oxaliplatin with 5-
FU/Leucovorin/Irinotecan for its efficacy in the adjuvant treatment of stage II-III disease. 
1.8.3 Adjuvant chemotherapy for colorectal liver metastases 
Chemotherapy following resection of colorectal liver metastases (i.e. patients with stage IV 
disease) aims to maximise survivorship by treating occult residual disease (Chong and 
Cunningham, 2005). The role of adjuvant chemotherapy in this setting however remains 
unclear. 
The FFCD AURC 9002 trial randomised 171 patients with complete R0 resection of liver 
metastases to either observation or adjuvant chemotherapy with a 5-FU/Leucovorin 
38 
 
regimen. Whilst the trial failed to recruit to fulfil its primary end-point of overall survival, 
there was a significant increase (33.5% vs. 26.7%) in 5-year disease free survival in the 
chemotherapy group (Portier et al, 2006).The EORTC 0923 trial was a further similarly 
designed trial which again failed to adequately recruit to demonstrate any potential 
difference in overall survival (Mitry et al, 2008). The authors of this trial went on to pool 
their data with the FFCD AURC 9002 trial, reporting a median overall survival of 62.2 
months vs. 47.3 months favouring adjuvant chemotherapy, although this did not reach 
statistical significance. 
The efficacy of combination chemotherapeutic regimens is also unclear. A randomised trial 
of patients having had R0 resection of colorectal liver metastases comparing 5-
FU/Leucovorin with FOLFIRI reported comparable 2-year disease free survival (51% vs. 46%) 
(Ychou et al, 2009).  
Despite an absence of clear trials evidence for its efficacy, many clinicians still opt to 
manage this patient group with adjuvant chemotherapy. Decisions like this must take into 
account the likelihood of disease clearance at the time of surgery, patient preference, 
perceived efficacy and the burden of morbidity associated with treatment. 
1.8.4 Neoadjuvant chemotherapy for colorectal liver metastases 
The role of neo-adjuvant chemotherapy for gastrointestinal cancer was initially defined by 
the MAGIC trial (Cunningham et al, 2006) for oesophago-gastric carcinoma. The potential 
reduction in disease volume may ensure optimum clearance at the resection margin (for 
example in the primary tumour) or greater sparing of the surrounding parenchyma (for 
example in the liver and lung). In addition the chemotherapy will treat those micro-
metastases not detectable on cross-sectional imaging, which may result in longer disease-
free survival. Finally the test of systemic treatment and evaluation of its response provides 
interesting and clinically useful information about the tumour biology, from which 
predictive and prognostic information can be inferred. 
The safety and tolerability of neoadjuvant chemotherapy was defined in a number of early 
phase 2 studies. The successful delivery of 99% of scheduled 5-fluorouracil and 99% of 
scheduled oxaliplatin associated with a 50% post-operative morbidity and 0% mortality 
(Wein, 2003), and the comparable compliance between neoadjuvant FOLFOX and adjuvant 
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FOLFIRI associated with a 97% delivery and no operative mortality (Taieb et al, 2005) attest 
to this. 
The efficacy of neoadjuvant treatment has also been assessed, although available data is 
limited. A large retrospective study of 1471 patients compared neoadjuvant chemotherapy 
(FOLFOX) with surgery alone (Adam et al, 2010). Preoperative chemotherapy did not 
appear to improve overall survival (60% at 5 years in both groups), however adjuvant 
chemotherapy did (65% vs. 55%, p<0.01). Perhaps more concerningly the incidence of 
postoperative complications was significantly higher in those patients who received 
neoadjuvant chemotherapy (37.2% vs. 24.0%, p=0.006). 
The largest trial to investigate this date is the EORTC 40983 study (EPOC trial) which 
randomised 364 patients with up to four resectable colorectal liver metastases to 12 cycles 
of peri-operative FOLFOX (half delivered prior to surgery and half after) or surgery alone 
(Nordlinger et al, 2008). Powered for 3-year progression free survival, 152 patients from 
each arm underwent resection with dropout attributed to disease progression. On an 
intention to treat basis the median overall survival was 61.3 months in the perioperative 
chemotherapy group and 54.3 months in the surgery alone group, with 5-year survival of 
51.2% and 47.8% respectively (p=0.34). For those who underwent resection, 3-year 
progression free survival was 36.2% in the perioperative chemotherapy arm compared to 
28.1% in the surgery arm (HR 0.77, 95% CI 0.60-1.00; p=0.041). This finding combined with 
the non-statistically significant trend towards increased survival has led to the uptake of 
this management strategy in a number of units, however a potential criticism is the 
exclusion of the higher risk population with more than 4 metastases. 
The role of neoadjuvant chemotherapy in the context of non-metastatic disease is even less 
clear. The FOXTROT trial is currently recruiting patients with colonic T3-4 tumours to be 
randomised to receive preoperative oxaliplatin, folinic acid, fluorouracil and panitumumab 
followed by surgery and adjuvant chemotherapy, or surgery and adjuvant chemotherapy 
combined with panitumumab (Foxtrot Collaborative Group, 2012). The feasibility study has 
been completed and the trial remains open. 
1.8.5 Chemotherapy for irresectable disease 
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As our ability to accurately stage disease and our understanding of tumour biology 
improves it is becoming increasingly clear that a significant proportion of patients have 
irresectable disease. Treatment in this setting with the chemotherapeutic regimens already 
discussed must be decided in partnership with the patient taking into account co-morbidity, 
performance status, prognosis and quality of life. Irresectable disease of the primary is 
unlikely to change significantly with systemic treatment, but it has become apparent that a 
proportion of patients with colorectal liver metastases will have such a significant 
treatment effect that their disease may in fact become technically resectable. 
The conversion to resectability in the liver is estimated to be around 6-60%, with variation 
reflecting patient and disease factors, choice of chemotherapeutic regimen, proportion of 
treatment course completed and local unit approach to surgical resection (Poston, 2008). In 
the situation where disease is converted to resectability, the 5 year survival is comparable 
to those patients who underwent resection at the time of presentation – approximately 35-
50% (Adam et al, 2001). It is not surprising that tumour response to chemotherapy 
correlates with resection rate; information which should be borne in mind when managing 
this cohort (Folprecht et al, 2005).  
NICE currently recommends the use of FOLFOX (with cetuximab if appropriate) as first line 
treatment for all patients with unresectable liver-limited metastatic colorectal cancer with 
FOLFIRI reserved for second line treatment. In this setting the efficacy of the two regimens 
is thought to be comparable (Tournigand et al, 2004), although the significant toxicity 
associated with FOLFIRI may limit its usefulness (Innocenti and Ratain, 2004). 
1.8.6 Cetuximab 
Extensive trial derived evidence exists for the incorporation of cetuximab into modern 
chemotherapeutic regimens for selected patients determined by KRAS status. 
In 2009 the CRYSTAL trial randomised 599 patients to each of FOLFIRI and FOLFIRI plus 
cetuximab (Van Cutsem et al, 2009). All patients had unresectable disease and epidermal 
growth factor receptor positive tumours. No difference was seen in overall survival 
between the two groups, however progression-free survival was considerably greater in 
those receiving cetuximab (hazard ratio 0.85; p=0.048). There was a significant interaction 
between treatment group and KRAS mutation for tumour response, but not progression-
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free or overall survival. Resectability rates (irrespective of KRAS status) were 7% for FOLFIRI 
plus cetuximab compared with 3.7% for FOLFIRI alone, with R0 rates of 4.8% vs. 1.7% 
(p=0.002). This increase in tumour response was associated with an increase in skin 
reactions (19.7% vs. 0.2%), infusion-related reactions (2.5% vs. 0%) and diarrhoea (15.7% 
vs. 10.5%). 
The OPUS trial was again confined to patients with epidermal growth factor-expressing 
tumours, however here the combination of cetuximab and FOLFOX was compared to 
FOLFOX alone with treatment continued until disease progression or unacceptable toxicity. 
A total of 337 patients were randomised, with no statistically significant difference in 
response rate (46% vs. 36%; p=0.06). In those with tissue available for KRAS mutation status 
(n=233), subgroup analysis showed that in KRAS wild-type tumours the addition of 
cetuximab to FOLFOX was associated with a significant increase in treatment response (61% 
vs. 37%; p=0.011). In this study cetuximab was generally well tolerated, with no reports of 
significant adverse events (Bokemeyer et al, 2011). 
The EPIC trial was a large trial of 1298 patients with metastatic colorectal cancer who had 
experienced first line failure to 5-fluorouracil and oxaliplatin (Sobrero et al, 2008). Patients 
received either irinotecan monotherapy or irinotecan plus cetuximab. No difference was 
identified in overall survival (for which the trial was powered), with the authors attributing 
this to significant variations in post-trial treatment. Cetuximab did however significantly 
improve both tumour response rate (16.4% vs. 4.2%; p=<0.0001) and progression free 
survival (4.0 vs. 2.6 months; p=<0.0001).  
A smaller group of patients with irresectable colorectal liver metastases were studied in the 
CELIM phase 2 trial (Folprecht et al, 2010). 114 patients were randomised to receive 
cetuximab with either FOLFOX or FOLFIRI. Randomisation between groups was stratified by 
technical resectability and number of metastases as determined by PET scan, as well as 
epidermal growth factor receptor expression status. Patients were assessed every 8 weeks, 
and if the locally treating multidisciplinary team deemed the disease to be potentially 
resectable they were offered surgery. Whilst the trial showed largely comparable response 
rates and toxicity between groups, a retrospective analysis of response by KRAS status 
showed a partial or complete response in 70% of those with wild-type tumours compared 
with 41% with KRAS mutated tumours (OR 3.42; p=0.008). Further review of the 
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retrospective data suggested that resectability rates increased from 32% at baseline to 60% 
following chemotherapy (p<0.0001) 
More recently the UK COIN trial (2012) compared continuous oxaliplatin/capecitabine 
(OxCap) and oxaliplatin/leucovorin/infusional 5-FU (OxFU) with or without cetuximab. The 
trial reported comparable efficacy between OxFU and OxCap, and the addition of 
cetuximab to OxFU resulted in less diarrhoea and longer progression free survival than for 
its combination with OxCap. As a natural progression to the EPOC trial (see Section 1.8.4), 
New EPOC (2014) compared perioperative treatment with chemotherapy (FOLFOX/FOLFIRI) 
with chemotherapy plus cetuximab for KRAS wild-type patients with resectable colorectal 
liver metastases, and was halted after an interim analysis reported significantly shorter 
progression free survival in the chemotherapy plus cetuximab group than in the 
chemotherapy group alone (14.1 months vs. 20.5 months, HR 1.48). The trial authors 
concluded that further translational investigation is needed to explore the molecular basis 
for the unexpected interaction. 
1.8.7 Bevacizumab 
Hurwitz et al (2004) reported the first randomised trial of 813 patients with metastatic 
disease to receive IFL (irinotecan, bolus 5-FU and leucovorin) or IFL plus bevacizumab. 
Patients receiving bevacizumab benefited from increased median survival (20.3 vs. 15.6 
months; p=<0.001) and progression free survival (10.6 vs. 6.2 months; p=<0.001).The GONO 
group have also reported their experience of combining FOLFIRINOX with bevacizumab in 
57 patients with unresectable metastatic disease (Masi et al, 2010). Progression free 
survival at 10 months was 74% (95% CI 62-85), with similar incidences of adverse events to 
those previously reported.  
The bevacizumab expanded access trial (BEAT) is the largest study documenting the success 
of this targeted biological agent in patients with unresectable colorectal liver metastases 
(Van Cutsem et al, 2009). Patients were treated with their physician’s choice of 
chemotherapy plus bevacizumab in a non-randomised fashion. The study was 
predominantly designed to observe safety rather than efficacy, and of the 1914 patients 
assessed the serious adverse events reported included bleeding (3%), gastrointestinal 
perforation (2%), arterial thromboembolism (1%), hypertension (5.3%), proteinuria (1%) 
and wound complications (1%).  The sixty-day mortality was 3%, median progression free 
43 
 
survival 10.8 months and overall survival 22.7 months. Overall resection was performed in 
7.6% of patients and 15.2% of those with disease confined to the liver, the 2-year survival 
for which was 89%. 
In the United States similar findings were reported in the BRiTE study (Grothey et al, 2008). 
A large observational study of 1445 previously untreated patients with metastatic 
colorectal cancer classified patients who experienced disease progression into: no 
treatment post disease progression (n=253), treatment without bevacizumab (n=531) and 
treatment with bevacizumab (n=642). Baseline factors were well balanced between groups, 
with reported overall survival rates of 12.6, 19.9 and 31.8 months respectively. Multivariate 
analyses strongly and independently associated the use of bevacizumab with improved 
survival (HR 0.48; p<0.01), highlighting the role of continued vascular endothelial growth 
factor inhibition in improving survival following the detection of recurrent disease. 
The TREE study randomised patients into three different oxaliplatin/5-fluorouracil regimens 
– mFOLFOX6 (bolus and infusion fluorouracil and leucovorin with oxaliplatin), bFOL (bolus 
fluorouracil and low-dose leucovorin with oxaliplatin) or CapeOX (capecitabine with 
oxaliplatin). A second cohort (referred to as TREE 2) received the above regimens in 
combination with bevacizumab. For all patients the median overall survival was 18.2 
months (95% CI 14.5-21.6) in TREE 1 and 23.7 months (95% CI 21.3-26.8) in TREE 2, 
highlighting that the addition of bevacizumab to fluoropyrimidine based chemotherapy 
regimens as first line treatment can significantly improve overall survival (Hochster et al, 
2008). 
Modest improvements in progression free survival attributed to the addition of 
bevacizumab were also noted in the N016966 phase III randomised trial (9.4 vs. 8.0 months; 
p=0.0023), where FOLFOX was used as the chemotherapeutic backbone (Cassidy et al, 
2008). The smaller BOXER trial has also reported a conversion rate to resectability of 40% in 
a cohort of 46 patients receiving neoadjuvant capecitabine, oxaliplatin and bevacizumab 
(Wong et al, 2010). 
1.9 Asssessment of response to chemoradiotherapy 
There is an extremely variable response to both radiotherapy and chemotherapeutics, 
irrespective of the setting in which the treatment is delivered. Uncertainty also exists as to 
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when this response to treatment should be assessed. Radiation, for example, induces an 
inflammatory reaction such that re-staging the patient immediately after cessation of 
treatment is likely to result in a considerable under-estimate of tumour response. In 
addition, the response to radiotherapy continues for several weeks after the completion of 
treatment. Radiation will initially affect those cells which are actively dividing, however its 
effects will be latent in those cells which were in the resting (G0) part of the cycle when the 
tumour was irradiated. As these cells begin the process of cell division it becomes apparent 
that they will be unable to successfully divide, and therefore upon reaching checkpoints in 
the cell-cycle are signalled to undergo apoptosis. Patients receiving chemotherapy also 
exhibit variation in response to their treatment, and individuals with advanced disease are 
commonly seen to suffer disease progression despite intense combination regimens. 
In clinical practice, the response to neoadjuvant treatment is normally achieved with 
radiological re-staging of the tumour in the manner previously described, i.e. CT scan of the 
chest, abdomen and pelvis as well as MRI scan of the rectum in the case of rectal cancer 
(with close attention to the proximity of the tumour to the mesorectal fascia). Alternatively 
response to treatment can be determined histopathologically following tumour resection. 
1.9.1 Radiological response to treatment 
Standardisation of response reporting first began in the late 1970s as a collaboration 
between the International Union Against Cancer and the World Health Organisation (Miller 
et al, 1981). Given the rapid advances in both technology and medicine, an international 
group consisting of members from the European Organisation for Research and Treatment 
of cancer (EORTC), the United States National Cancer Institute (NCI) and the Canada Clinical 
Trials Group set out to refine these response criteria in 1994. The guidelines published are 
referred to as the Response Evaluation Criteria in Solid Tumours (RECIST) guidelines 
(Therasse et al, 2000).  
At baseline, all lesions are originally categorised as either measurable or nonmeasurable. 
Measurable lesions can be accurately measured in at least one dimension (with the longest 
dimension to be recorded) as ≥20mm with conventional techniques or as ≥10mm with 
spiral CT scan. All measurable lesions up to a maximum of 5 lesions per organ and 10 in 
total are measured with callipers or a rule. These so-called target lesions should be selected 
on the basis of their size (those with the longest diameter) and suitability for repeated 
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measurements. The sum of these longest diameters is calculated and referred to as the 
baseline sum longest diameter. All other lesions are referred to as non-target lesions; 
measurements are not necessary however their presence or absence during treatment and 
follow-up should be noted.  
The same exercise is repeated following treatment, and an assessment of response 
allocated to both the target (those previously identified as such) and non-target lesions. In 
the target lesions: complete response is defined as the disappearance of all lesions, partial 
response is at least a 30% reduction in the sum of the longest diameter when compared to 
the baseline sum longest diameter, progressive disease is at least a 20% increase in the sum 
of the longest diameter and stable disease as neither sufficient shrinkage to qualify for 
progressive disease. In the non-target lesions: complete response is the disappearance of all 
nontarget lesions, incomplete response/stable disease as the persistence of one of more 
non target lesions, and progressive disease as the appearance of one or more new lesions 
and/or unequivocal progression of existing nontarget lesions. 
Following widespread adoption in clinical practice and cancer research, these criteria were 
later modified in 2008 to RECIST v1.1. In brief, the changes made included a reduction in 
the number of target lesions from 10 to 5, and a maximum of two per organ, an inclusion of 
pathological lymph nodes as target lesions (assuming a short axis of ≥15mm), and a change 
to the use of short axis measurements in the sum of lesions for the calculation of tumour 
response. In addition the definition of disease progression was further clarified, in that in 
addition to the previously defined 20% increase in the sum of the target lesions, a 5mm 
absolute increase is also necessary to label the patient as having disease progression 
(Eisenhauer et al, 2008). 
1.9.2 Pathological response to treatment 
The prequel to the majority of tumour regression grade (TRG) scoring systems originated 
from an early paper whereby pathological response to treatment was correlated with 
outcome in oesophageal cancer (Mandard et al, 1994). In this paper, TRG was quantified as 
one of five grades: TRG1 (complete regression) showed absence of residual cancer and 
fibrosis extending through the oesophageal wall; TRG 2 was characterised by the presence 
of rare residual cancer cells scattered through the fibrosis; TRG 3 was characterised by an 
increase in the number of residual cancer cells but fibrosis still predominated; TRG 4 
46 
 
showed residual cancer outgrowing fibrosis; and TRG 5 was characterised by absence of 
regressive changes. On univariate analysis, tumour size, lymph node status, TRG and 
oesophageal wall involved correlated with disease free survival, however after multivariate 
analysis only TRG (at this point dichotomised as 1-3 vs. 4-5) remained a significant predictor 
of disease free survival. 
Shortly after this Dworak, Keilholz and Hoffman (1997) published a grading system 
specifically for the regression of rectal tumours after neoadjuvant chemoradiotherapy, 
grading regression from GR0-GR4 (Table 1.8) after assessing tumour mass, fibrotic change, 
irradiation vasculopathy and peri-tumourous inflammatory reaction. Similarly to the 
original report by Mannard et al, this system was later shown to have prognostic value in 
predicting outcomes in rectal cancer (Losi et al, 2006). 
Tumour Regression 
Grade 
Description 
0 No regression 
1 Dominant tumour mass with obvious fibrosis and/or 
vasculopathy 
2 Dominant fibrotic changes with few tumour cells or groups 
(easy to find) 
3 Very few (difficult to find microscopically) tumour cells in 
fibrotic tissue with or without mucous substance 
4 No tumour cells, only fibrotic mass (total regression) 
 
Table 1.8 - The tumour regression grade proposed by Dworak, Keilholz and Hoffmann 
(1997) extends from 0-4 and includes an assessment of tumour mass as well as the degree 
of fibrosis and/or vasculopathy. Reproduced without permission from Santos et al, 2014. 
The publication from Dworak, Keilholz and Hoffman (1997) was followed by a simplified 3 
point scale known as the Rectal Cancer Regression Grade (RCRG): RCRG1 – the tumour is 
either sterilised or only microscopic foci remain; RCRG2 – marked fibrosis but with 
macroscopic tumour still present; and RCRG3 – little or no fibrosis in the presence of 
abundant macroscopic tumour. RCRG1 and 2 are considered to represent significant 
tumour regression (Wheeler et al, 2002). 
More recently the Royal College of Pathologists have produced a minimum dataset for 
reporting in colorectal cancer. Originally a 3 tier system was utilised, although a 4 tier 
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system is now endorsed based on the classification by Ryan et al (2005). The 4 tier system 
allows classification of tumour regression as: 0 – Full tumour regression, no visible tumour 
cells; 1 – Moderate tumour regression, single cells or scattered groups of cancer cells; 2 – 
Minimal tumour regression - residual cancer outgrown by fibrosis; 3 – No tumour 
regression – residual tumour without signs of destroyed tumour cells; 4 – Minimal or no 
regression (extensive residual tumour). This scoring system has been accepted as the best 
methodology in the 7th edition of the TNM staging system and has been adopted by the 
currently recruiting FOXTROT trial (FOXTROT, 2012). A similar grading system (0-3) has also 
been recommended in the College of American Pathologists guidelines (Washington et al, 
2009).  
Clearly these differing tumour regression grades need to be cross-validated for their 
predictive and prognostic value and reproducibility in different clinical and research 
settings. What is true of all of these systems for assessing tumour regression grade is that 
nodal disease is not considered, however methods of combining these two features are 
currently under investigation (Huebner et al, 2012). 
Except in the palliative setting and in the context of synchronous liver metastases, it is 
unusual for the colonic primary to remain in situ throughout systemic treatment and 
therefore no system for the assessment of tumour regression exists for colon cancer. A 
method of evaluating the response of liver metastases to systemic treatment however is 
clearly needed. 
Two types of scoring system exist in this regard, those which quantify remaining viable 
tumour cells and those similar to the aforementioned strategy of histopathological 
assessment of regression grade. In a study primarily investigating the effects of 
bevacizumab, Ribero et al (2007) reported a scoring system whereby the area of residual 
viable tumour cells within each metastatic nodule was estimated as a percentage of the 
total tumour surface area that included areas of coagulative necrosis, calcification, fibrosis 
and the associated histiocytes, foreign body giant cells and inflammatory cells.  Samples 
were subsequently grouped into 1-24%, 25-49%, 50-74% and 75% and above for the 
purposes of analysis. This scoring system was later used to clearly demonstrate the impact 
of tumour regression on survival following neoadjuvant chemotherapy for colorectal liver 
metastases (Blazer et al, 2008). Cumulative 5-year survival rates were 75% for complete 
response (no residual cancer cells), 56% for major response (1-49% residual cancer cells) 
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and 33% for minor response (50% or more residual cancer cells) (Figure 1.6). Multivariate 
analysis revealed that only surgical margin and pathological response independently 
predicted survival. The same scoring system has also been used by Kishi et al (2010) to 
report the finding that extended pre-operative chemotherapy (more than 9 cycles) 
increases the risk of hepatoxicity without improving the pathological response. 
 
Figure 1.6 – Kaplan-Meir survival curves of patients with colorectal liver metastases 
treated with neoadjuvant chemotherapy, with greatest survival in those with complete 
response (a) followed by major response (b) and minor response (c). Reproduced with 
permission from Blazer et al, 2008. 
Alternatively the original Mandard tumour regression grade (scored 1-5) has also been used 
to assess colorectal liver metastases in studies investigating the effects of neoadjuvant 
chemotherapy (Rubbia-Brandt et al, 2007) and more recently the addition of bevacizumab 
(Klinger et al, 2010). 
Complete pathological response, whilst oncologically desirable, creates a number of 
surgical problems (Grothey et al, 2008). Correlation between radiological and pathological 
response is unclear, and up to 80% of lesions showing complete radiological response 
continue to harbour viable tumour cells (Benoist et al, 2006). The optimum method of 
managing these patients is still under investigation. 
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1.10 Predictive and prognostic markers in colorectal cancer 
The variation in disease and tumour biology coupled with the mode of presentation, 
rapidity of diagnosis and treatment strategy employed perhaps explains some of the 
variation in both response to treatment and outcomes. The link between disease stage and 
outcome has already been discussed however these other factors, and in particular tumour 
biology, have not yet been incorporated into risk stratification and patient selection for 
treatment. 
The ability to predict response to treatment in the clinical setting would obviously be 
extremely beneficial. To identify patients, by either patient or tumour factors, who are 
likely to respond to chemotherapy and/or radiotherapy would allow those individuals to be 
exposed to a prolonged course of treatment in order to maximise efficacy. It may also be 
that the approach to managing adverse reactions and events to treatment could differ in 
those individuals in whom we knew with a degree of certainty would respond to treatment. 
Taking this one step further if the response to particular chemotherapeutic agents could be 
predicted up-front prior to commencement then the regimen could be tailored specifically 
towards the patient – a concept referred to as personalised medicine. 
Conversely to identify those patients who are unlikely to respond to treatment is arguably 
of greater clinical value. In the neoadjuvant setting, for example, failure of a patient with 
rectal cancer to respond to neoadjuvant chemoradiotherapy commits the patient to 
retaining their tumour in situ for approximately 4 months. Whilst not accurately studied, it 
would be reasonable to assume that this confers the risk of tumour growth, dissemination 
and increases the likelihood of tumour complications such as bleeding, perforation or 
obstruction. 
In the adjuvant setting or indeed in those patients with irresectable disease, the ability to 
predict response to chemotherapy would allow for personalised treatment, and an open 
and honest discussion between patient and physician about the appropriateness of 
aggressive and morbid treatment. In the context of those with irresectable disease it would 
also provide information to the patient and multidisciplinary team about the likelihood of 
conversion to resectability. 
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A cancer diagnosis is clearly a significant life event for any individual, which is handled in 
any number of different ways. The amount of clinical and prognostic information that 
people wish to receive is extremely variable, but the option of providing patients with 
accurate information could potentially assist a proportion of them deal with the 
psychological impact of the disease. 
1.10.1 Clinical prognostic scoring systems 
A number of scoring systems are available to assist clinicians classify patients with advanced 
disease by prognosis, although they are implemented with varying degrees of popularity. 
The three most commonly used are the Clinical Risk Score (Fong et al, 1999), Nordlinger 
Prognostic Index (Nordlinger et al, 1996) and Basingstoke Prognostic Index (Rees et al, 
2008). 
Fong’s clinical risk score pertains specifically to the prediction of recurrence after hepatic 
resection for metastatic colorectal cancer. 1001 consecutive patients were analysed with 
seven factors found to be significant and independent predictors of poor long-term 
outcome by multivariate analysis: positive margin, extrahepatic disease, node-positive 
primary, disease-free interval from primary to detection of metastases of less than 12 
months, more than one hepatic tumour, the largest hepatic tumour being greater than 5cm 
and a carcinoembryonic antigen level (CEA) greater than 200ng/ml. If the last five of these 
are used pre-operatively, the sum of the number of criteria met was highly predictive of 
outcome (p=<0.0001). 
A similar approach was taken by Nordlinger, who identified seven adverse risk factors 
associated with poor outcome: extension into serosa of primary tumour, lymphatic spread 
of primary tumour, delay from diagnosis of primary tumour to resection of less than 24 
months, number of liver metastases in preoperative imaging, the size of the largest liver 
metastasis in preoperative imaging greater than or equal to 5cm, preoperatively estimated 
clearance of normal parenchyma resected with liver metastasis less than 1cm, and age 
greater than or equal to 60 years. 
The Basingstoke Predictive Index was validated for use pre-operatively, given the significant 
correlation between pre- and post-operative scores in the 929 consecutive patients 
analysed. Patients are allocated a score based on 7 different risk factors all of which 
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independents predict poor survival: more than three hepatic metastases, lymph node 
positivity of the primary tumour, poor differentiation of the primary tumour, the presence 
of extrahepatic disease, tumour diameter greater than or equal to 5cm, CEA level greater 
than 60ng/ml and positive resection margins. The first 6 of these criteria were used in a 
preoperative scoring system and the last 6 in the postoperative setting (Table 1.9), with 
each criterion multiplied by a weighted constant within a predictive model to give a score 
out of 30. Patients with a score of 0, 10, 20 and 30 on preoperative scoring had 5-year 
survival rates of 66%, 35%, 12% and 2% respectively, with comparable scores using the 
post-operative prediction tool. 
Risk Factor Status Preoperative Postoperative 
Primary tumour lymph node 
status 
Negative 0 0 
Positive 2 2 
Primary tumour differentiation 
Well 0 0 
Moderate 3 2 
Poor 5 4 
Carcinoembryonic antigen level 
<6ng/mL 0 0 
6-60ng/mL 2 1 
>60ng/mL 3 3 
Number of hepatic metastases 
1-3 0 N/A 
>3 3 3 
Largest hepatic tumour diameter 
<5cm 0 0 
5-10cm 2 2 
>10cm 8 7 
Hepatic resection margin 
Negative N/A 0 
Positive N/A 11 
Extrahepatic disease 
No 0 0 
Yes 7 4 
 
Table 1.9 – The Basingstoke Prognostic Index allocates a score (out of 30) based on a 
number of clinicopathological features. Validated for use in both the pre- and post-
operative situations, the score correlates well with outcome. 
1.10.2 Biomarkers 
A biomarker can be defined as a molecular marker that can be obtained by analysis of 
mRNA, DNA, protein or circulating tumour cells (or tumour-derived nucleic acids) to stratify 
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patients for treatment benefit within clinical trials, prognosticate patient outcome or 
predict and/or monitor response to therapy (Sikorski and Yao, 2010). In more simplistic 
terms, it is a molecular marker which can in some way be measured upon which predictive 
or prognostic information can be derived. The measurement can come from blood, urine, 
or other material such as bile, stomach aspirate or stool. Alternatively biological 
information can be directly obtained from the tumour itself. Broadly speaking biomarkers 
can either be prognostic, i.e. provide information regarding patient outcome irrespective of 
treatment received, or predictive i.e. provide information on the likely effectiveness of 
therapy in a patient. Alternatively they can be used for early detection and risk 
stratification, which when applied to the symptomatic and asymptomatic populations are 
referred to as diagnostic and screening biomarkers respectively. 
The previously described benefits of being able to predict response and offer patients 
prognostic information has led to a significant drive to develop novel biomarkers. To 
facilitate this, Cancer Research (UK) developed roadmaps to offer guidance as to how this 
process should be conducted from biomarker discovery, through to assay development, 
clinical correlation and ultimately application in the clinical setting (Figure 1.7). 
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Figure 1.7 – The Cancer Research (UK) roadmap to the discovery, development and validation of a clinically useful biomarker. Available online at 
http://www.cancerresearchuk.org. 
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1.10.3 Biomarkers in colorectal cancer 
The interest and growth in biomarkers means that the ability to personalise treatment for 
the individual patient is becoming increasingly close. The best and most well known 
example of this is the targeting of the use of cetuximab and, to a lesser degree, 
panitumumab for patients with KRAS wild type tumours. This discovery has led to the 
development of an accurate and cost-effective assay to direct these drugs to appropriate 
patients. 
Most biomarkers studies have focussed on our growing understanding of colorectal 
carcinogenesis, and in particular the mutations in KRAS, BRAF, SMAD4, TP53 and APC as 
well as the subsequent downstream pathways previously discussed, as well as markers of 
microsatellite and chromosomal instability, defects in mismatch repair mechanisms and 
identification of the CpG island methylator phenotype. The presence of defects in mismatch 
repair genes (MLH1, MSH2, MSH6, PMS2) and microsatellite instability are commonly 
tested for in the clinical setting in those individuals felt to be at high risk of having Lynch 
syndrome. Outside of this context routine testing has not yet been adopted, although the 
presence of a reliable assay to detect MSI status means it is likely to soon be incorporated 
into clinical practice. To some extent this places the onus on clinicians to update their 
understanding of colorectal carcinogenesis, and how this may impact on their patients. 
Multiple meta-analyses have attempted to assess the value of these factors as prognostic 
biomarkers, and although conceptually sound very few have actually been validated and 
used in clinical practice (Pritchard and Grady, 2011). The incorporation of biomarkers as 
one of multiple, compositive or correlative endpoints in trials is likely to improve the 
evidence base necessary for further evaluation and adoption. Some of the recently 
investigated prognostic markers identified are shown in Table 1.10. 
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Biomarker 
Mutation 
Frequency 
Prognosis Evidence Status 
Microsatellite 
instability (MSI) 
15% Favourable Strong 
Testing available but 
not widely used 
Chromosome 
instability (CIN) 
70% Unfavourable Strong 
No readily available 
test, not in clinical 
use 
18qLOH/SMAD4 
loss 
50% Unfavourable Moderate 
No readily available 
test, not in clinical 
use 
BRAF V600E 
mutations 
10% 
Probably 
unfavourable 
Moderate 
Testing available but 
insufficient evidence 
to use for prognosis 
KRAS codon 
12/13 
mutations 
40% 
Probably 
unfavourable 
in advanced 
disease 
Limited 
Testing widely 
available but 
insufficient evidence 
to use for prognosis 
PIK3CA 
mutations 
20% 
Possibly 
unfavourable 
Limited 
No readily available 
test, not in clinical 
use 
 
Table 1.10 – Prognostic biomarkers identified for colorectal cancer. The table 
demonstrates the frequency with which these biomarkers are identified, the evidence for 
its correlation with prognosis and its uptake into routine clinical practice. Reproduced 
without permission from Pritchard and Grady, 2011. 
Multiple effective agents now exist for the treatment of colorectal cancer, particularly for 
stage III and IV disease. The degree of heterogeneity in response to treatment has 
stimulated interest in predictive biomarkers, a summary of which can be seen in Table 1.11. 
As might be expected, most relate to the incorporation of relatively new targeted therapies 
into existing chemotherapeutic regimens. 
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Biomarker 
Mutation 
Frequency 
Drug Selection Evidence Status 
KRAS codon 
12/13 
mutations 
40% 
Predicts resistance to 
anti-EGFR therapy 
Strong 
Validated, in 
routine clinical 
use 
KRAS codon 
61/177/146 
mutations 
1% 
Probably predicts 
resistance to anti-EGFR 
therapy 
Moderate 
In clinical use, not 
fully validated 
BRAF V600E 
mutations 
10% 
Probably predicts 
resistance to anti-EGFR 
therapy, may predict 
response to BRAF 
inhibitors 
Moderate 
In clinical use, not 
fully validated 
PIK3CA 
mutations 
20% 
May predict resistance 
to anti-EGFR therapy 
Limited 
No readily 
avaliable test, not 
in clinical use 
PTEN loss 30% 
May predict resistance 
to anti-EGFR therapy 
Limited 
No readily 
avaliable test, not 
in clinical use 
Microsatellite 
instability (MSI) 
15% 
May predict adverse 
outcome with 5-FU and 
improved outcome with 
Irinotecan 
Moderate 
Not yet in routine 
clinical use as a 
predictive 
biomarker 
18qLOH/SMAD4 
loss 
50% 
May predict resistance 
to 5-FU 
Moderate 
No readily 
avaliable test, not 
in clinical use 
Topo1 Low 50% 
May predice resistance 
to Irinotecan 
Limited 
No readily 
avaliable test, not 
in clinical use 
 
Table 1.11 – Predictive biomarkers identified for colorectal cancer. The table 
demonstrates the frequency with which these biomarkers are identified, the evidence for 
its correlation with response to treatment and its uptake into routine clinical practice. 
EGFR, epidermal growth factor receptor; 5-FU, 5- fluorouracil; LOH, loss of heterozygosity. 
Reproduced without permission from Pritchard and Grady, 2011. 
Beyond targeted therapies it has been shown that MSI tumours are less likely to respond to 
5-fluoruracil based regimens, and in a minority of patients this may even be detrimental 
(Sargent, 2008). A potential explanation for this is the understanding that an effective MMR 
system is required for the cytotoxic effect of the drug (Jo and Carethers, 2006), however 
the finding of chemoresistance to 5-fluouracil in MSI tumours is not uniform (Liang et al, 
2002). Conversely MSI tumours have been shown to be more response to 
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chemotherapeutic regimens containing irinotecan (Fallik et al, 2003), and therefore it is 
easy to see how following evaluation of this biomarker on a larger scale that routine testing 
would be incorporated into clinical practice, particularly for patient selection for adjuvant 
therapy in stage II-III disease. LOH in 18q has also been shown to be associated with poor 
response to 5-fluorouracil based therapy (Watanabe et al, 2001), with some evidence to 
suggest this may be due to SMAD4 located in the 18q21 deleted region (Boulay et al, 2002).  
The MRC FOCUS trial randomised patients to receive 5-fluorouracil, 5-fluorouracil plus 
oxaliplatin or 5-fluorouracil with irinotecan. Expression of topoisomerase I, the target for 
irinotecan, was established by immunohistochemistry and the study demonstrated 
improved response to irinotecan containing regimens in those patients with high 
expression of the protein (HR 0.98; 95% CI 0.78-1.22) (Braun et al, 2008). Germline 
polymorphisms which may affect pharmacokinetics and pharmacodynamics have also been 
studied, for example dihydropyrimidine dehydrogenase and thymidylate synthetase in the 
metabolism of 5-fluorouracil. Whilst the results appeared promising, there remains 
insufficient evidence at the current time for its adoption into clinical practice (Ezzeldin and 
Diasio, 2008). Conversely there is good evidence for the use of the UGT1A1*28 
polymorphism previously discussed to predict dose related toxicity to irinotecan, so much 
so that a commercial genotyping kit was approved by the Food and Drug Administration in 
2005 to help guide irinotecan dosing (Palomaki et al, 2009). 
Biomarker research is challenging, requiring large scale multi-centre randomised trials with 
good quality clinical material and validated laboratory techniques and reagents. Published 
studies on biomarkers are often confounding and usually retrospective with small sample 
sizes. The lack of methodological standardization involved in the detection of biomarkers is 
perhaps why only the KRAS gene has become used routinely in clinical practice. The 
potential for combining biomarkers in a panel to further increase the sensitivity and 
specificity is currently being explored, for example the adaptive FOCUS4 trial is stratifying 
patients by combination of KRAS/BRAF/PIK3CA and other biomarkers to further investigate 
the role of novel agents.  
The Oncotype DX® Recurrence Score® combines a panel of 7 genes (Ki-67, C-MYC, MYBL2, 
FAP, BGN, INHBA and GADD45B) identified through the evaluation of 761 colon cancer 
related genes in 1851 patients across 4 studies, with 5 housekeeping genes and MSI/MMR 
status to produce personalised prognostic information for patients with Stage II-III disease. 
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The score has been shown to correlate with risk of recurrence (p=0.01), disease free 
survival (p=0.01) and overall survival (p=0.04) using data from the QUASAR study (Kerr et al, 
2009), however to date no prospective evaluation has been performed. Our understanding 
of colorectal cancer genetics has evolved significantly over the past 10 years and will 
continue to evolve over the next 10, and with this increased understanding comes the 
opportunity to investigate biologically plausible biomarkers in a targeted fashion. 
1.11 Summary 
In the United Kingdom, colorectal cancer is the fourth commonest cancer and the second 
commonest cause of cancer related death. Most recent figures from Cancer Research (UK) 
show that 1-year survival for men and women with colon cancer is 73.0% and 72.2% 
respectively, with 5-year survival of 54.4% and 55.1%. In those with rectal cancer 1-year 
survival for men and women is 78.8% and 78.8% respectively, and 5-year survival 54.6% 
and 57.5%. A number of dietary and lifestyle factors have been linked to the development 
of colorectal cancer, including diets rich in unsaturated fats and red meat, excess alcohol 
and a sedentary lifestyle. Smoking and inflammatory bowel disease have also been linked 
to the development of colorectal cancer. 
Over recent years our understanding of the genetics of colorectal carcinogenesis have 
improved significantly. The vast majority of colorectal tumours reflect a series of hereditary 
and somatic mutations in key genes i.e APC, KRAS, BRAF and TP53. These mutations are 
most frequently associated with a CIN phenotype and are often acquired in a different 
order. A subset of tumours initiate through inactivation of MMR function, which may be 
through inherited or, less commonly, somatic mutation, or alternatively epigenetic 
inactivation through hypermethylation (CIMP) leading to MSI-H.  
The evaluation of a patient with colorectal cancer includes clinical, endoscopic, 
histopathological and radiological assessment, the latter normally consisting of CT, PET and 
for rectal tumours or further evaluation of liver metastases, MRI. This information can be 
used to stage the patient and prognosticate outcome. Commonly used staging systems 
include the Dukes’, UICC/AJCC TNM and Jass classifications. Obtaining biological 
information from the liver metastases is not feasible due to seeding of the cutaneous tract 
and worse outcomes, and therefore we are limited to information gathered from the 
primary tumour.  
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Surgery remains the mainstay of treatment for colorectal cancer, which under normal 
circumstances would be formal surgical resection of the primary and metastatic tumours. 
Alternatives exist for the management of liver metastases, in particular radiofrequency 
ablation or microwave ablation. Radiotherapy is frequently used in the treatment of rectal 
cancer most commonly as either SCPRT or long course CRT, the aim of which is to reduce 
the risk of local recurrence and downstage disease in order to reduce the risk of a positive 
CRM at surgical resection. There remains a significant role for chemotherapy in the 
neoadjuvant, adjuvant and unresectable settings with 5-fluoruracil (supplemented with 
leucovorin) remaining the cornerstone of treatment. This is most frequently supplemented 
with oxaliplatin and/or irinotecan, and increasingly bevacizumab or 
cetuximab/panitumumab in those known to be KRAS wild type. 
Response to treatment may be assessed both radiologically and histopathologically, the 
latter being most commonly performed following surgical resection. Radiological 
assessment is performed using the RECIST v1.1 guidelines, and histopathological 
assessment is performed using any of a number of scoring systems which assess the degree 
of necrosis, fibrosis and viable tumour in a specimen.  
Prognostic information is currently derived from clinical and pathological features 
combined into scoring systems, the three most commonly used being the Clinical Risk 
Score, Nordlinger Prognostic Index and Basingstoke Prognostic Index. At present there are 
no reliable prognostic, screening or diagnostic biomarkers in routine clinical use. The sole 
predictive biomarker in clinical use is KRAS status; KRAS mutant tumours do not respond to 
targeted anti-epidermal growth factor receptor treatments such as cetuximab and 
panitumumab. A number of studies have attempted to correlate the previously discussed 
genetic aberrations with response to chemotherapy, and germline polymorphisms which 
may affect pharmacokinetics and pharmacodynamics have also been studied. 
1.12 Aims, hypotheses and study plan 
From the literature it is clear that there are a number of questions which clinicians face on a 
daily basis to which there is as yet no satisfactory scientific explanation or rationale for a 
particular treatment decision. Three of these key questions are: 
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 In patients with rectal cancer is it possible to predict response to neoadjuvant 
chemoradiotherapy? 
 In patients with colorectal liver metastases is it possible to predict response to 
neoadjuvant chemotherapy? 
 Can biological information from the primary tumour be used to predict response to 
treatment in colorectal liver metastases? 
The aim of this thesis is to begin to address these research questions. 
1.12.1 Hypotheses 
These research questions can be used to formulate a number of testable hypotheses 
investigated in this project: 
1. Somatic non-synonymous mutations in the primary tumour correlate with those 
present in the liver metastasis and predict response to treatment. 
2. The phenotype of the primary tumour is biologically similar to the liver metastasis, 
with markers present in the primary tumour which predict the response of the liver 
metastasis to neoadjuvant chemotherapy.  
4. The phenotype of a rectal tumour changes with neoadjuvant chemoradiotherapy, 
and inter-patient variation in these changes predicts response to treatment. 
5. Levels of expression of key proteins involved in the activation and metabolism of 
chemotherapeutics are comparable between primary and metastatic tumours and 
predict response to treatment. 
6. Levels of expression of DNA base excision repair proteins in rectal tumours vary with 
treatment, and inter-patient variation in the expression of these proteins predicts 
response to neoadjuvant chemoradiotherapy. 
1.12.2 Study plan 
To investigate these hypotheses the following study plan was used: 
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1. Establish a research network across multiple sites to facilitate the collection of 
patient matched primary and metastatic tissue, alongside normal liver parenchyma and 
colonic mucosa, focussing on those receiving neoadjuvant chemotherapy.  
2. Establish a research protocol to facilitate the collection of serial temporal biopsies 
from patients with rectal cancer, acquiring tissue prior to chemoradiotherapy, 
immediately following chemoradiotherapy and at the time of surgical resection. 
3. Investigate alternative strategies to the standard mechanisms of tissue collection (i.e. 
liquid nitrogen, dedicated research technician and archiving facilities in a -80oC freezer) 
in order to facilitate 1 and 2. 
4. Subject tumour samples (alongside normal adjacent tissue) from patients undergoing 
synchronous resection to exome sequencing in order to establish the degree of 
biological similarity between primary and metastatic tumours, specifically to identify 
whether the presence of somatic non-synonymous mutations in the primary tumour 
predicts the presence of the same mutations in the liver metastasis. 
5. Perform isobaric tagging for relative quantification (iTRAQ) of patient matched 
primary and metastatic tumours as well as adjacent normal liver parenchyma and 
colonic mucosa on a discovery set of fresh tissue. Data will be analysed to assess the 
degree of biological similarity between primary and metastatic tumours, as well as 
identify potential biomarkers measurable in the primary tumour which will predict the 
response to chemotherapy in the liver metastases. 
6. Validate any potential biomarkers by immunohistochemistry on a larger validation 
tissue set, with samples combined into a tissue micro-array. Any potential mechanisms 
for validated biomarkers will be explored. 
7. Perform isobaric tagging for relative quantification (iTRAQ) of serial rectal cancer 
samples on a discovery set of fresh tissue. Data will be analysed to assess how the 
tumour phenotype changes with treatment, as well as identify potential biomarkers 
which may predict response of the primary tumour to neoadjuvant chemoradiotherapy. 
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8. Validate any potential biomarkers by immunohistochemistry on a larger validation 
tissue set, with samples combined into a tissue micro-array. Any potential mechanisms 
for validated biomarkers will be explored. 
9. Undertake a targeted analysis of the expression and function of key proteins involved 
in the activation and metabolism of oxaliplatin, 5-fluorouracil and irinotecan in patient 
matched primary and metastatic tumour samples. Data will be analysed to assess the 
correlation in expression and function between primary and metastatic tumours as well 
as how this information may predict response to treatment. 
10. Undertake a targeted analysis of the expression of key proteins involved in DNA 
base excision repair in serial rectal cancer samples. Data will be analysed to assess how 
levels of expression vary with treatment and how this information may be used to 
predict response.   
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Chapter 2 
Evaluation of a tissue stabilisation gel (AllprotectTM) to facilitate clinical sampling for 
translational research in surgical trials 
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2.1 Introduction 
2.1.1 Background 
Successful translational research in surgery is dependent upon collaboration between 
scientists and clinicians. Central to this is the acquisition of tissue samples following surgical 
or endoscopic resection. In specialties such as thoracic surgery, neurosurgery and some 
gastrointestinal subspecialties such as hepatopancreaticobiliary, centralisation of services 
within large trusts or university teaching hospitals has facilitated routine collection of tissue 
through biobanks. Higher volume specialties performing oncological resections, such as 
colorectal surgery, have not been centralised. Indeed the majority of colorectal cancer 
resections are still performed in the non-teaching hospital setting, making the harvest and 
storage of fresh tissue problematic because of a lack of specialised facilities, such as a ready 
supply of liquid nitrogen and -80oC storage (Shabihkhani et al, 2014). Consequently, most 
colorectal biobanks contain only formalin-fixed paraffin embedded (FFPE) samples which 
are of limited use for most bioanalytical applications.  
2.1.2 The need for an alternative infrastructure 
In order to facilitate the inclusion of high volume non-teaching hospitals in more 
translational research projects and clinical trials, or for more ad-hoc tissue sampling, an 
alternative method of tissue stabilisation is needed which does not require immediate 
processing and freezing. Indeed, a system that allowed transfer of samples by post or 
courier, without the need for specialist shipping conditions, would also increase the 
potential recruitment of patients for large scale trials and reduce costs associated with on-
site processing. AllprotectTM is a new to the market tissue stabilisation gel which according 
to the manufacturer overcomes the need for liquid nitrogen and -800C storage, allowing 
tissue collection and stabilisation to be performed with limited infrastructure (Qiagen, 
Venlo, Netherlands). As AllprotectTM is a proprietary compound, details of its composition 
are currently unavailable. 
2.1.3 Relevance to this thesis 
Clinical samples used for the analysis which has informed later chapters of this thesis will 
attest to the complex regional infrastructure which was created in order to facilitate the 
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work. On Merseyside all resections of colorectal liver metastases are performed at Aintree 
University Hospital, a teaching hospital with a well developed research infrastructure. The 
hospitals referring patients to this institution however are less well equipped for research, 
and it is these institutions in which the vast majority of the primary tumours of the patients 
recruited to these studies were resected. As such, a regional network was established to 
facilitate the acquisition of patient matched clinical samples and corresponding clinical and 
demographic data. The work described in this chapter was devised in order to facilitate 
other translational work presented later in the thesis. 
2.1.4 Aims and hypotheses 
The aim of this study was to rigorously evaluate the use of AllprotectTM as an alternative to 
liquid nitrogen for the short and long term storage of clinical samples from patients 
undergoing surgical resection of colorectal primary and metastatic tumours. Tissue integrity 
under all storage conditions was assessed across a range of typical biomolecules including 
DNA, mRNA, microRNA and protein. In addition, retention of protein function following 
storage in AllprotectTM was determined by enzyme activity measurements. Specifically, we 
hypothesise that AllprotectTM offers comparable tissue stabilisation to liquid nitrogen for 
downstream translational research. 
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2.2 Methods 
2.2.1 Sample collection 
The study was performed to facilitate an existing translational research project, for which 
NHS Research Ethics Committee and Research and Development approval had already been 
obtained (12/NW/0011). Samples were obtained from patients undergoing primary 
resection for colorectal cancer (n=5). Following delivery of the surgical specimen, the 
proximal staple line was incised and a linear cut was made down the anti-mesenteric 
border being cautious to stop either 1cm away from the tumour or upon approaching the 
mesorectum. Using forceps and a scalpel a peripheral section of tumour was excised. 
Samples were obtained from a second cohort of patients undergoing resection for 
colorectal liver metastases (n=5). Following delivery of the surgical specimen an incision 
was made through the resected surface to the liver metastasis, with care being taken not to 
breach the liver capsule, and peripheral samples of tumour were obtained as previously 
described. All tissue sampling was performed in the operating theatre under aseptic 
conditions. 
2.2.2 Stability study 
Each sample was cut into 10 discrete sections of approximately 4 mm3, 5 of which were 
individually placed into sealed cryodorfs and processed immediately (within 5 minutes of 
specimen delivery) as follows: 1. Snap frozen in liquid nitrogen and transferred to tissue 
archiving freezer (-80oC) – control sample. 2. AllprotectTM at room temperature (190C). 3. 
AllprotectTM in a fridge (80C). 4. AllprotectTM in a standard laboratory freezer (-200C) 5. 
AllprotectTM in a tissue archiving freezer (-800C). Those samples processed in AllprotectTM 
were submerged in a 10:1 ratio by volume as per manufacturer’s instructions; samples snap 
frozen in liquid nitrogen were done so without additives. The remaining 5 sections per 
sample were left exposed to the environment on a theatre trolley until the end of the 
procedure (approximately 1 hour for both primary and metastatic resections) in an effort to 
replicate ‘real world’ tissue sampling in the absence of a designated research technician. 
Once the skin had been closed, the remaining samples were processed in an identical 
manner to that already described. Samples remained under stabilisation conditions for 7 
days prior to proceeding with biomolecule extraction. A schematic outline of the study 
design can be seen in Figure 2.1.  
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Figure 2.1 – A schematic outline of the stability study. The available tissue was divided 
into 10 fragments, 5 of which were stabilised immediately in one of the storage 
conditions shown and the remaining 5 in a similar manner but at the end of the 
procedure. The study was designed to ask two specific questions: can sampling wait until 
the end of the procedure, and what is the optimal storage condition? 
2.2.3 Archiving study 
Further cohorts of patients undergoing resection for primary colorectal cancer (n=5) or liver 
metastases (n=5) were sampled in the same manner and again tissue was divided into 10 
sections. One sample was placed into liquid nitrogen and then transferred to a tissue 
archiving freezer (-80oC) and the remaining 9 samples were submerged in AllprotectTM and 
refrigerated (at 8oC). A single sample was removed following storage for 1, 2, 3, 4, 8, 12, 16, 
20 and 24 weeks, and processed for biomolecule extraction. A schematic outline of the 
study design can be seen in Figure 2.2.  
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Figure 2.2 – A schematic outline of the archiving study. The available tissue was divided 
into 10 fragments, one of which was immediately snap frozen in liquid nitrogen and 
transferred to a -80oC freezer (control sample) and one was archived in AllprotectTM for 
each of the time points shown in the figure. 
2.2.4 Biomolecule extraction 
DNA and RNA extraction was performed using the Qiagen miRNeasy Mini Kit and EZ1 DNA 
Tissue Kit respectively as per manufacturer’s instructions (Qiagen, Venlo, Netherlands). 
Protein extraction was performed by a combination of both mechanical and ultrasonic 
homogenisation in phosphate-buffered saline. Following centrifugation the protein 
concentration of the supernatant was established using a Bradford assay (Bradford, 1976). 
In addition, a section of tissue was taken from each of the samples, fixed in formalin and 
embedded in paraffin. A slide was stained with haemotoxylin and eosin and reviewed by a 
pathologist who was blind to the details of the study. Extracted biomolecules were used to 
perform each of the following assays in triplicate on all samples. 
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2.2.5 DNA assays 
DNA concentration was measured using the NanoDropTM ND-1000 spectrophotometer 
(Thermo Scientific, Waltham, USA) and quality assessed using the Human DNAOK! kit 
(Microzone, Haywards Heath, UK). KRAS mutational analysis was performed using an in-
house pyrosequencing assay capable of detecting all somatic mutations in codons 12, 13 
and 61 of the KRAS gene. The lower limit of detection for the assay is 5% of mutated alleles. 
2.2.6 RNA Assays 
Extracted RNA was initially subjected to quantification and quality control using the 
NanodropTM spectrophotometer and reverse transcription was performed with the RT2 
First Strand Kit (Qiagen, Venlo, Netherlands). Further quality control assays were performed 
using a Bioanalyzer (Agilent, Santa Clara, USA) and the commercially available RT2TM RNA 
QC PCR Array (SABiosciences, Venlo, Netherlands). In order to assess the functional 
integrity of the extracted RNA under different storage conditions, RT-PCR was performed 
on two genes (HMGB1 and CES1) and two microRNAs (mir-122 and let7d) relevant to an on-
going translational project conducted within the Medical Research Council Centre for Drug 
Safety Science. Specific primers were designed for HMGB1, CES1, miR122 and let7d 
(Eurofins Scientific, Luxembourg, Luxembourg) and qPCR performed using the ABI-7900 
(Applied Bioscience, Foster City, USA).  
2.2.7 Protein expression by western blotting 
Western blots for HMGB1 and CES1 as representative proteins were performed on both 
primary colorectal cancer tissue and liver metastases. 10% SDS-PAGE gels were transferred 
to a nitrocellulose membrane and blocked in 10% milk. Following overnight incubation with 
the primary antibody (Abcam: ab18256 {HMGB1} or ab45957 {CES1}) membranes were 
incubated with a LI-COR IRDye 680 LT secondary antibody (Biosciences, Lincoln USA) before 
semi-quanitative analysis using the Oydssey scanner (LI-COR Biosciences, Lincoln USA). 
2.2.8 Protein expression by immunohistochemistry  
In order to assess the effect of AllprotectTM on tissue morphology, and the feasibility of 
fixing tissue previously stabilised in this manner, the expression of HMGB1 in FFPE tissue 
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was established by immunohistochemistry. 4µm sections were de-waxed in xylene and 
rehydrated with ethanol solutions of decreasing concentrations. After blocking with 3% 
hydrogen peroxide in 100% methanol, antigens were retrieved by microwaving for 20 
minutes in 10mM citrate buffer and further blocked with 10% goat serum in 0.1% tris-
buffered saline with tween. Slides were incubated with the primary antibody (Abcam, 
ab18256) for 2 hours, and a 1:200 horseradish peroxidase conjugated secondary antibody 
(Dako UK Ltd, E0432) for 30 minutes. Following incubation with the Vectastain Elite® ABC 
reporter system (Vectorlabs, Burlingame, USA), slides were developed with 
diaminobenzidine tetrahydrochloride (DAB) and counterstained with haematoxylin. Slides 
were reviewed by light microscopy and HMGB1 expression was established using a 
previously reported scoring system (Liu et al, 2012). Two reviewers independently scored 
five fields at 400x magnification with a total cell count not less than 1000. The proportion of 
positive cells allowed classification into one of four categories: 1 (<25%), 2 (25-50%), 3 (51-
75%) or 4 (>75%). The intensity of nuclear staining was also classified: 1 (no 
staining/background of negative controls), 2 (weak staining detectable above background), 
3 (moderate staining) or 4 (intense staining). The index was then calculated by multiplying 
the intensity and percentage scores to give a total score out of 16. 
2.2.9 Protein function by mass spectrometry 
The activity of carboxylesterase was determined with irinotecan as a substrate in order to 
assess protein function. Tissue homogenate (250µg protein) was incubated with 100nM 
irinotecan (Sigma Aldrich, Poole, UK) for 30 minutes prior to termination of the reaction 
using a methanol/acetonitrile solution. The supernatant was subjected to a functional assay 
optimised to quantify the active metabolite, SN-38, by liquid-chromatography mass-
spectrometry (Jones et al, 2013).  
2.2.10 Statistical analysis 
Statistical analysis was based on the comparison of different methods of tissue 
stabilisation/archiving to the current gold standard, i.e. tissue snap frozen in liquid nitrogen 
and transferred to a tissue archiving freezer (-80oC). One-way ANOVA with post-hoc 
Dunnett’s test was used to compare each sample in turn to the reference sample. Analysis 
was performed using Stats Direct 2.7.9 (Stats Direct Ltd, Altrincham, UK). 
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2.3 Results 
2.3.1 Assessment of tissue morphology 
All samples were confidently identified as adenocarcinoma on review of the H&E slide, 
irrespective of the method of tissue stabilisation used or length of time archived in 
AllprotectTM (Figure 2.3). A degree of clear cell change/vacuolation was seen in all samples 
which was slightly more apparent in those samples exposed to AllprotectTM, although this 
did not vary significantly with the length of exposure. Tumour sampling did not compromise 
a complete pathological assessment of the remaining surgical specimen in any of the cases. 
 
Figure 2.3 – Representative micrographs of H&E stained sections of colorectal liver 
metastases showing a) tissue snap frozen in liquid nitrogen and b) tissue stabilised in 
AllprotectTM. Both are clearly identifiable as adenocarcinoma, although contain a degree 
of clear cell change/vacuolation (X). Histological appearances did not change significantly 
with the length of the time the sample was exposed to AllprotectTM. Micrographs were 
taken at 200x magnification. 
2.3.1 Short term (0 - 1 week) maintenance of biomolecule expression and function  
DNA 
Automated extraction of DNA from the snap frozen and AllprotectTM stabilised samples 
yielded comparable quantities (2.1-3.3µg/mg tissue) of high quality DNA with 260:280 
ratios of 1.8 - 1.9 and  260:230 ratios of 2.0 - 2.4. There was no correlation between the 
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spectrophotometric quality ratios and the method of stabilisation. The samples 
immediately stabilised were also comparable to those stabilised after a one hour delay. All 
samples passed the internal quality control check utilised by the EZ1 Advanced (Qiagen, 
Venlo, Netherlands). Extracted DNA was successfully utilised for downstream qPCR analysis 
of KRAS status at codons 12, 13 and 61 with 100% concordance between all samples 
originating from the same biological specimen for all patients and both tissue types (Table 
2.1).  
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Sample Stabilisation Method Processing Concentration 
(ng/µl) 
260/280 260/230 Quality 
Check 
KRAS Codon 12 KRAS 
Codon 
13 
KRAS Codon 61 
1 
Snap frozen (liquid 
nitrogen) 
On specimen 
extraction 257.24 1.82 2.23 
Pass c.35G>A (p.Gly12Asp) 
29.8% 
Wild-
type 
Wild-type 
2 
Allprotect (room 
temperature) 259.57 1.86 2.14 
Pass c.35G>A (p.Gly12Asp) 
39.9% 
Wild-
type 
Wild-type 
3 
Allprotect (80C) 
259.91 1.84 2.22 
Pass c.35G>A (p.Gly12Asp) 
33.3% 
Wild-
type 
Wild-type 
4 
Allprotect (-200C) 
282.32 1.88 2.08 
Pass c.35G>A (p.Gly12Asp) 
10.6% 
Wild-
type 
Wild-type 
5 
Allprotect (-800C) 
281.68 1.87 2.10 
Pass c.35G>A (p.Gly12Asp) 
30.8% 
Wild-
type 
Wild-type 
6 
Snap frozen (liquid 
nitrogen) 
At end of 
procedure 157.3 1.82 2.01 
Pass c.35G>A (p.Gly12Asp) 
11.8% 
Wild-
type 
Wild-type 
7 
Allprotect (room 
temperature) 230.28 1.82 2.12 
Pass c.35G>A (p.Gly12Asp) 
30.1% 
Wild-
type 
Wild-type 
8 
Allprotect (80C) 
301.85 1.86 2.18 
Pass c.35G>A (p.Gly12Asp) 
34% 
Wild-
type 
Wild-type 
9 
Allprotect (-200C) 
256.85 1.86 2.15 
Pass c.35G>A (p.Gly12Asp) 
46.4% 
Wild-
type 
Wild-type 
10 
Allprotect (-800C) 
284.41 1.87 2.31 
Pass c.35G>A (p.Gly12Asp) 
37.2% 
Wild-
type 
Wild-type 
Table 2.1 – Representative results following DNA extraction from patient 2 (primary tumour). Comparable quality control indices are seen highlighting 
the suitability of extracted DNA for downstream qPCR analysis. Comparable results following KRAS genotyping are seen: the patient is KRAS mutant at 
codon 12 but wild type at codons 13 and 61.  
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RNA 
The yield of extracted RNA was again comparable between samples (0.41-0.68µg/mg 
tissue), with 260:280 ratios of 1.9 - 2.1 and RNA Integrity Numbers (RIN) of 7.7 - 8.0. The 
commercially produced RT2TM Quality Control Array, which is based on a series of 
housekeeping genes including ACTB (β-actin) and HPRT1 (hypoxanthine 
phosphoribosyltransferase), confirmed the absence of relevant RNA impurities which would 
adversely affect reverse transcription or PCR, and whilst there was a small amount of 
genomic DNA contamination this did not affect PCR results. A minor degree of inter-patient 
variation can be seen, however cycle threshold (Ct) values did not vary significantly with 
either a) the method of tissue stabilisation implemented, or b) the timing of stabilisation 
being either at specimen extraction or after a one hour delay. Figure 2.4 shows the mean Ct 
values for miR122 in patient 1 (liver metastases). Similar data were seen for let7d and the 
findings were comparable in the primary tumour, as were mRNA levels for HMGB1 and 
CES1 in both primary and metastatic tissue. 
 
Figure 2.4 – Cycle threshold (Ct) values for miR-122 in the colorectal liver metastasis from 
patient 1. All samples are comparable irrespective of the method of tissue stabilisation 
used, and whether the samples were stabilised immediately following specimen 
extraction (samples 1-5) or following a delay of 1 hour (samples 6-10). ANOVA with post-
hoc Dunnett’s test shows that no samples are statistically significant from the current 
gold standard (sample 1) i.e. tissue snap frozen in liquid nitrogen. 
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Protein 
Protein yield was comparable between all samples (20.3-31.4µg/mg tissue). Coomassie 
staining confirmed comparable protein coverage and, whilst considerable inter-individual 
variation was observed, analysis of western blots demonstrated similar densitometry values 
for both HMGB1 and CES 1 in all samples originating from the same biological specimen for 
all patients and both tissue types irrespective of the method of tissue stabilisation used. 
The samples immediately stabilised were also comparable to those stabilised after a one 
hour delay. Representative data for HMGB1 expression in patient 1 (primary tumour) is 
shown in Figure 2.5 (0.79 – 1.16iU; P=0.100 - >0.999). 
 
Figure 2.5 – Western blot and corresponding densitometry of HMGB1 expression in 
primary colorectal cancer samples from patient 1. All samples are comparable 
irrespective of the method of tissue stabilisation used, and whether the samples were 
stabilised immediately following specimen extraction (samples 1-5) or following a delay 
of 1 hour (samples 6-10). ANOVA with post-hoc Dunnett’s test shows that no samples are 
statistically significant from the current gold standard (sample 1) i.e. tissue snap frozen in 
liquid nitrogen. 
Similar findings were observed for CES1 expression, the data from patient 2 (liver 
metastases) being displayed in Figure 2.6 (0.41 - 0.62iU; p=0.559 - >0.999).  
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Figure 2.6 – Western blot and corresponding densitometry of CES1 expression in 
colorectal liver metastasis samples from patient 2. All samples are comparable 
irrespective of the method of tissue stabilisation used, and whether the samples were 
stabilised immediately following specimen extraction (samples 1-5) or following a delay 
of 1 hour (samples 6-10). ANOVA with post-hoc Dunnett’s test shows that no samples are 
statistically significant from the current gold standard (sample 1) i.e. tissue snap frozen in 
liquid nitrogen. 
Mass spectrometry analysis also showed a comparable rate of SN38 production from tissue 
irrespective of tissue stabilisation method or timing. Representative data for the primary 
colorectal tumour of patient 3 (4.01-5.58nm/mg tissue/min; p=0.062 - >0.999) can be seen 
in Figure 2.7, with similar results seen in the liver metastases.  
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Figure 2.7 – Tissue homogenate was incubated with irinotecan and the production of SN-
38 (active metabolite) quantified by liquid-chromatography mass-spectrometry. Data 
shown is from patient 3 (primary colorectal tumour). All samples are comparable 
irrespective of the method of tissue stabilisation used, and whether the samples were 
stabilised immediately following specimen extraction (samples 1-5) or following a delay 
of 1 hour (samples 6-10). ANOVA with post-hoc Dunnett’s test shows that no samples are 
statistically significant from the current gold standard (sample 1) i.e. tissue snap frozen in 
liquid nitrogen. 
Immunohistochemistry of sections of primary tumour again revealed no difference in the 
semi-quantitative scoring of HMGB1 expression. A minor degree of inter-patient variation 
was seen, however for each patient all sections stained adequately and received identical 
scores for both coverage and intensity. Figure 2.8 highlights the comparable staining of 
samples from patient 3 (primary tumour) which scored 3 for coverage (51-74%) and 3 for 
intensity (moderate). Similar results were seen in colorectal liver metastases. 
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Figure 2.8 – Immunohistochemistry for HMGB1 in samples from patient 3 (primary 
colorectal tumour): a) Negative control b) Snap frozen in liquid nitrogen c) AllprotectTM at 
room temperature d) AllprotectTM  at 8oC. All sections were scored 3 for coverage (51-
74%) and 3 for intensity (moderate). Haemotoxylin counterstain, x400 magnification. 
2.3.3 Long term (0 – 24 weeks) maintenance of biomolecule expression and function 
DNA 
There was insufficient material available to perform DNA analysis on these samples due to a 
number of smaller tumours in this cohort. 
RNA 
The yield of extracted RNA was comparable to that observed in the short term study (0.37-
0.61µg/mg tissue). All samples had a 260:280 ratio of 1.9 - 2.1, however the RIN fell below 
7.0 for those samples archived in AllprotectTM for a period of more than 1 week. The RT2TM 
Quality Control Array suggested that RNA impurities began to affect both reverse 
transcription and PCR again after a period of 1 week. Figure 2.9 shows the representative Ct 
values for miR122 in the liver metastasis of patient 4 clearly demonstrating a progressive 
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degradation in RNA, which was statistically significant by week 2 (23.60 vs. 25.07; p=0.049). 
Similar data were seen for let7d as well as mRNA levels for HMGB1 and CES1 in both 
primary and metastatic tissue.  
 
Figure 2.9 – Cycle threshold (Ct) values for miR122 in the liver metastasis from patient 4. 
Ct values increase with time archived in AllprotectTM, and by 2 weeks there is a 
statistically significantly difference from the current ‘gold standard’, i.e. tissue snap 
frozen in liquid nitrogen (0). 
Protein 
Protein stability after longer term storage proved much more variable than RNA, with 
extraction yield ranging from 6.4-30.9 µg/mg tissue and Coomassie staining of 
polyacrylamide gels identifying progressive degradation of samples with time. Whilst a 
degree of inter-individual variation was observed in these samples, western blot analysis of 
HMGB1 showed a marked reduction in protein expression after 2 weeks in AllprotectTM. 
Representative data from patient 1 (primary tumour) is shown in Figure 2.10, which 
demonstrates that the mean (SD) densitometry of 28.9(0.59)iU achieved by snap freezing 
the tissue in liquid nitrogen was no longer comparable to tissue archived in AllprotectTM by 
week 3 (12.43(1.15)iU (p=<0.001), with preservation of expression up until this point. 
Similar findings were observed for the expression of CES1 and in colorectal liver 
metastases, and negligible levels of SN-38 were detected in all samples archived in 
AllprotectTM for periods beyond 2 weeks. 
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Figure 2.10 – Western blot and corresponding densitometry of HMGB1 expression in 
primary colorectal cancer samples (patient 1) archived in AllprotectTM . The densitometric 
panels demonstrate the sharp reduction in protein abundance which occurs between 1 
and 3 weeks, by which time it is statistically significantly different from the current ‘gold 
standard’, i.e. tissue snap frozen in liquid nitrogen (0). 
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2.4 Discussion 
2.4.1 Summary of aims 
The aim of this study was to rigorously evaluate the use of AllprotectTM as an alternative to 
liquid nitrogen for the short and long term storage of clinical samples from patients 
undergoing surgical resection of colorectal primary and metatastatic tumours. Tissue 
integrity under all storage conditions was assessed across a range of typical biomolecules 
including DNA, mRNA, microRNA and protein. In addition, retention of protein function 
following storage in AllprotectTM was determined by enzyme activity measurements. 
2.4.2 Summary of results 
This study has demonstrated that effective tissue stabilisation can be achieved with 
AllprotectTM, and that tissue stabilised in this manner yields high quality DNA, RNA and 
protein suitable for commonly used laboratory techniques. Comparable protein (by 
western blot and immunohistochemistry) and mRNA expression for HMGB1 and CES1 in 
primary colorectal tumour and colorectal liver metastases was observed irrespective of the 
method of tissue stabilisation employed. Beyond that, the demonstration of comparable 
production of SN-38, an active metabolite of irinotecan, suggests that protein function 
(CES1) as well as expression is preserved. miRNA yield was also consistent and all extracted 
DNA was of sufficient quality for downstream PCR. 
Whilst short term tissue stabilisation with AllprotectTM appears to be comparable to liquid 
nitrogen, its role for long term archiving is less clear. Our study suggests that both protein 
function and expression are significantly reduced by week 3, and, although densitometry 
values do not reach statistical significance, visualisation of the western immunoblots 
suggests that protein degradation may occur even earlier than this. RNA integrity also 
begins to reduce after one week, with the RIN of samples rapidly falling below 7.0. These 
findings are confirmed by the RT2 quality control array, and the increasing Ct values seen at 
qPCR for both mRNA and miRNA. In light of this we have adopted a protocol whereby all 
samples are removed from AllprotectTM and transferred to a definitive storage facility on a 
weekly basis. 
2.4.3 Current barriers to translational research 
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Access to good quality clinical material is a fundamental part of translational research 
(LaBaer, 2012). The standard model for acquisition of clinical material requires a dedicated 
individual, for example a research nurse or research fellow, being on hand to sample tissue 
(Magner et al, 2007). This in itself has significant cost implications and frequently precludes 
institutions from being able to contribute their own tissue samples to translational studies 
(Thasler et al, 2013). Following the acquisition of clinical material, the research nurse/fellow 
would routinely place the sample into a sealed container and snap freeze it in liquid 
nitrogen. Again, the availability of liquid nitrogen may be variable and there are safety 
concerns associated with its use. After tissue stabilisation in liquid nitrogen, the final stage 
is the transfer to a -80oC storage facility which, again, is not available in every institution 
(Day and Stacey, 2008).  
2.4.4 Alternative methods of tissue stabilisation 
A number of alternatives to liquid nitrogen have been developed in an attempt to provide 
lower cost and less resource intense strategies for tissue collection. These tissue 
stabilisation products also make the transfer of tissue between institutions significantly 
easier and cheaper. For those institutions with the necessary infrastructure, these 
approaches would also permit more ad hoc tissue sampling; for example, following 
emergency resections out of hours or unexpected diagnoses on invasive investigations. The 
best known tissue stabilisation product is RNALaterTM (Qiagen, Venlo, Netherlands), but it is 
often used as an adjunct to liquid nitrogen in an effort to maximise yield rather than as a 
stabilisation method in its own right (Hatzis et al, 2011). The RNA yield of tissue stabilised in 
RNALaterTM and liquid nitrogen are comparable (Khaustova et al, 2014), as are those of 
RNALaterTM and an alternative product, PaxGeneTM (Qiagen, Venlo, Netherlands) (Weber et 
al, 2010). AllprotectTM offers two key advantages over these existing stabilisation 
techniques - the ability to preserve DNA and protein structure and function as well as RNA, 
and the preservation of tissue morphology (Roos-van Groningen et al, 2004). In our study, 
all samples were clearly identifiable as adenocarcinoma with only a minor degree of 
vacuolation seen in those samples stabilised with AllprotectTM. Only two papers have 
previously investigated the role of AllprotectTM. Mee et al found lower DNA yield but 
comparable quality when compared to liquid nitrogen, QIAampTM (Qiagen, Venlo, 
Netherlands) and AllprepTM (Qiagen, Venlo, Netherlands), as well as comparable quality 
RNA and protein yield (Mee et al, 2011). Conversely, Staff et al were unable to demonstrate 
preserved antigenicity for immunohistochemical analysis following AllprotectTM 
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stabilisation, and report a mean RIN value of 2.1 (95% CI 0.8 – 3.4) for RNA extracted from 5 
patients with benign gynaecological disease (Staff et al, 2013). A significant limitation of 
AllprotectTM is its inability to stabilise DNA, RNA or protein in whole blood or serum, and 
therefore an alternative strategy would need to be found if this material is also required.  
2.4.5 Strengths and limitations of the study 
The experimental design was conceived in such a way as to not only determine the 
feasibility and optimum storage conditions for stabilising tissue in AllprotectTM, but also 
permitted us to ask a further question: Can tissue stabilisation be performed following 
completion of the surgical procedure? In the ‘stability’ study, samples 6-10 were all taken at 
the end of the case, approximately 60 minutes following specimen delivery. The fact that 
we have demonstrated comparable biomolecule extraction in these samples suggests that 
an additional member of the research team need not necessarily be available to perform 
the sampling, and that a member of the surgical team could acquire the tissue at the end of 
the surgical procedure. Whilst this might not be surprising for protein and DNA retrieval, 
studies have documented the potential for rapid degradation of RNA from as early as 15 
minutes following the onset of tissue ischaemia (Von Euler et al, 2005). However Lee et al 
(2013) characterised only a minor reduction in RNA quality which did not affect gene 
expression levels up to 24 hours following surgical resection. Whilst we have demonstrated 
comparable RNA quality and yield we would not advocate deliberate delay in the sampling 
and stabilisation of clinical samples for scientific research, but merely highlight that where 
this is unavoidable due to institutional constraints, adequate clinical samples can be 
obtained in this manner. 
Whilst our study demonstrates that AllprotectTM offers comparable tissue stabilisation to 
liquid nitrogen, the panel of biomolecules and laboratory techniques we have studied is 
narrow. We would therefore advocate that individual research groups validate the use of 
AllprotectTM for their specific biomolecules and applications of interest. The mere addition 
of a compound to a clinical sample will inevitably cause biological and chemical differences 
when compared to samples snap frozen without additive. We have demonstrated no 
significant difference over the panel we have tested and feel therefore that AllprotectTM is 
likely to be appropriate for comparison of tissues acquired by the same sampling protocol, 
however it must be acknowledged that the integration of tissue acquired in this way with 
an existing tissue bank or comparison to tissue stabilised using an alternative approach may 
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not be scientifically meaningful. The same argument could however be made for samples 
acquired across different institutions, all of which will undoubtedly have been sampled, 
stabilised and processed following slightly different protocols.  
2.4.6 Establishing a research infrastructure 
This chapter highlights some of the preliminary work performed in order to provide a 
platform for the remainder of the work contained within this thesis. The collection of 
patient matched primary and metastatic tissue across multiple sites required the creation 
of a suitable infrastructrue. In brief this comprised: 
 Registration of the project through the Integrated Research Application System 
(IRAS) to include the completion of Research Ethics Committee (REC) and NHS 
Research and Development (R&D) proformas 
 Responding to queries on the above and provision of patient information sheets, 
consent forms and notifications to general practitioners 
 Attendance at the local meeting of the REC and obtaining final ethical approval 
 Attempts to place the study on the NIHR portfolio – failed due to technicalities 
surrounding the funding stream (at the time Cancer Research (UK) centre awards 
were ineligible) 
 Liaison with NHS R&D co-ordinating centre and global approval of the study 
 Establishing a sponsor for the study (Countess of Chester Hospital) and local R&D 
approval 
 The recruitment of a local principal investigator at each of the required trusts 
 Following recruitment of a local principal investigator, at each site the following 
was arranged 
o Site visit and meeting 
o Creation of the site specific information form on IRAS 
o Local research and development approval 
o Letter of access 
o Materials transfer agreement 
 After the research sites had been added, the REC responsible for the study was 
updated and an amendment made to include all research sites 
 The completion of ongoing local audit of recruitment figures and research 
engagement at each of the sites 
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The infrastructure has since permitted the centralised collection of patient matched 
primary and metastatic colorectal cancer samples for ongoing translational research in the 
region. The project was also registered at the Liverpool Tissue Bank. 
2.4.7 Conclusion 
This study clearly demonstrates that AllprotectTM is appropriate for widening participation 
in translational research.  A major impediment to the recruitment of sampling sites for 
clinical trials or translational studies is the lack of resources for tissue sampling and storage: 
this often limits studies to major teaching hospitals simply because the required facilities 
are not available in smaller hospitals. Foremost in this is the ability to instantly freeze the 
sample upon collection, prior to transfer or analysis. A method to bypass this bottle-neck 
could dramatically increase both the scale and recruitment rates of translational studies. In 
this study, there was no difference between the quality of biological material extracted 
from tissue samples following storage in AllprotectTM or after snap freezing in liquid 
nitrogen. Storage for up to one week in AllprotectTM also led to no significant deterioration, 
meaning that rapid sample retrieval from sampling sites is not required where it may be 
impractical to accomplish this. After this time period, however, we did detect a significant 
fall in the quality, and thus it would be imprudent to plan long term storage in this medium.  
Across the range of different biomolecules investigated here, there was no evidence that 
AllprotectTM couldn’t play a major role in sample procurement, and this may have profound 
benefits for the recruitment of smaller or less well-resourced centres for translational 
research studies.  
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Chapter 3 
Exome sequencing of synchronously resected primary colorectal tumours and colorectal 
liver metastases to inform oncosurgical management 
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3.1 Introduction 
3.1.1 Genomics of colorectal cancer 
Colorectal cancer (CRC) remains the fourth commonest cancer worldwide and the second 
commonest cause of cancer related death. Like most solid tumours, CRC is a highly complex 
disorder arising from an interplay between a number of genomic alterations, such as point 
mutations, rearrangements, gene fusions or copy number alterations (Fearon, 2011) and 
environmental factors such as diet and lifestyle (Huxley et al, 2009). A failure to identify the 
disease at an early stage of carcinogenesis increases the likelihood of the development of 
metastases, which, despite significant advances both oncologically and surgically, is still 
associated with significantly poorer outcomes (Cancer Research UK, 2014). 
Our understanding of the development of primary colorectal cancer is improving, with 
sequential genetic alterations in APC, KRAS, mismatch repair genes, TP53 and loss of 18q 
heterozygosity of great significance. However, how these cells evolve in the process of 
metastagenesis and the clonal origin and genetic heterogeneity of colorectal liver 
metastases remains unclear. The initial concept of monoclonal evolution of a tumour, 
essentially the clonal expansion of dominant tumour clones, has been challenged. The self-
feeding polyclonal hypothesis proposes that tumour cells enter the systemic circulation via 
the tumour vasculature and colonise at a different site therefore establishing a new 
subpopulation, whereas the mutator phenotype suggests a small population of diverse 
tumour cells may migrate (Navin and Hicks, 2010). Metastases therefore can be expected to 
carry similar mutations to their corresponding primary tumour, but also harbour additional 
mutations acquired after transformation (Siegmund et al, 2009). The accrual of these 
genetic mutations in the metastases results in tumour heterogeneity between sites, 
presenting problems for treating clinicians. These problems are further confounded in the 
case of colorectal liver metastases with the knowledge that transcutaneous needle biopsy 
of the liver lesion is associated with cutaneous seeding and poorer outcomes following 
surgery (Cresswell, Welsh and Rees, 2009). A thorough understanding of genetic 
heterogeneity between tumour sites is vital to the development of novel therapeutic 
agents (Klein, 2009). 
3.1.2 Next generation sequencing technology 
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For many years genomic profiling was conducted using hybridization based micro-array 
technologies or low-throughput Sanger sequencing. The development of next generation 
sequencing (NGS) technology has exponentially increased the rapidity and efficacy with 
which the previously discussed genomic aberrations can be identified and studied.  
There are numerous types of next generation sequencing available. Whole genome 
sequencing uses genomic DNA to identify point mutations, indels, rearrangements and DNA 
copy number changes; information which is generally detected by paired-end mapping 
(Chen et al, 2009). More focussed exome sequencing can be performed on target regions of 
genomic DNA which is capable of identifying point mutations and indels. Epigenome 
sequencing targets genomic DNA to identify sites of DNA methylation and post-
translational histone modifications. This can either be achieved using chromatin-
immunoprecipitation (ChIP)-based methods (Park, 2009) or DNA methylation sequencing 
for example using bisulfite-sequencing (Hansen et al, 2011). Finally, sequencing of RNA 
allows for the examination of gene fusions, alternative splicing events, point mutations and 
indels. 
3.1.3 The ion proton platform 
There are a number of different platforms available for next generation sequencing studies. 
The commonest use either pyosequencing (Roche 454, GS FLX Titanium), reversible dye 
terminators (Illumina HiSeq, Bioscience Heliscope), oligonucleotide chained ligation (Life 
Technologies SOLiD) or native dNTPs and proton detection (Life Technologies Ion Proton). 
The selection of an appropriate platform currently relies on a compromise between read 
length (i.e the number of bases continually read), depth of read (the number of times each 
section of the library will be read), run time (still a matter of days) and cost (which is 
extremely variable). 
In Ion Proton sequencing the library to be sequenced is a collection of DNA inserts of 
~200bp. These are obtained from randomly fragmented genomic DNA of the samples to be 
sequenced.  During sequencing these single stranded inserts function as the template. Such 
sequencing is referred to as "sequencing by synthesis", during which a complementary 
strand is built based on the sequence of an adapter ligated template strand. Sequencing is 
performed on a semiconductor chip containing small beads with clonally amplified 
template DNA in each microwell. DNA polymerase is added with sequentially unmodified A, 
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C, G or T dNTPs. Sequencing is based on the detection of hydrogen ions that are released 
during the polymerization of DNA. If the nucleotide is complementary it is added to the 
strand.  Addition of the nucleotide causes the release of a hydrogen ion, which in turn 
results in decreased pH that triggers an ion sensor in the chip. The series of electrical pulses 
transmitted from the chip to a computer is translated into a DNA sequence. If the 
nucleotide is not complementary, no reaction takes place within that well. The unmodified 
dNTPs are then flushed out of the system and the next added. This process is repeated 125 
times for each base, with no intermediate signal conversion required due to the nucleotide 
incorporation events being measured directly by the electronics. Signal processing and DNA 
assembly is carried out using software inbuilt into the platform. Figure 3.1 is a graphical 
representation of sequencing using the ion torrent platform.  
 
Figure 3.1 – The sequencing by synthesis of the Ion Proton platform. Sequencing is 
performed on a semiconductor chip containing small beads with clonally amplified 
template DNA. DNA polymerase is added with sequentially unmodified A, C, G or T dNTPs 
which are incorporated if complementary, releasing a hydrogen ion which is results in 
decreased pH that triggers an ion sensor in the chip. If the nucleotide is not 
complementary, no reaction takes place within that well. The unmodified dNTPs are then 
flushed out of the system and the next added. Figure taken from the European 
Bioinformatics Institute (with permission) 
http://www.ebi.ac.uk/training/online/course/ebi-next-generation-sequencing-practical-
course/what-next-generation-dna-sequencing/ion-torre 
3.1.4 Aims and hypotheses 
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The aim of this investigation was to compare and contrast the exome of synchronously 
resected primary and metastatic colorectal tumours, specifically to identify those genetic 
aberrations which: 
- Are present in the primary tumour but not in the metastasis  
- Are present in the metastasis but not in the primary tumour  
- Are present in both primary and metastasis (i.e. the primary tumour is 
predictive of the metastatic genotype) 
- May predict response to neoadjuvant therapy 
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3.2 Methods 
3.2.1 Patients and tissue collection 
National Health Service Research Ethics Committee and Research and Development 
approval was obtained for this study. Samples were obtained from four patients 
undergoing synchronous resection of a primary colorectal tumour and liver metastases. 
Following delivery of the colorectal specimen the proximal staple line was incised and a 
linear cut made down the antimesenteric border before excising a peripheral section of 
tumour using forceps and a scalpel. Following delivery of the liver specimen, an incision was 
made through the resected surface to the liver metastasis, with care being taken not to 
breach the liver capsule; a peripheral sample of tumour was obtained. Macroscopically 
normal adjacent colonic mucosa and liver parenchyma were also obtained, with all tissue 
sampling performed in the operating theatre under aseptic conditions followed by 
immediate stabilisation in liquid nitrogen. An additional sample was obtained, formalin 
fixed and paraffin embedded for concurrent histopathological assessment. 
3.2.2 Evaluation of histopathological response 
Given all four patients had undergone neoadjuvant treatment, an assessment of 
histopathological response was made using a scoring system first described by Ribero et al 
(2007), and used for this purpose by Blazer et al (2008). The number of residual viable 
tumour cells within each metastatic nodule was estimated as a percentage of the total 
tumour surface area that included areas of coagulative necrosis, calcification, fibrosis and 
the associated histiocytes, foreign body giant cells and inflammatory cells.  Samples were 
subsequently scored as 1 (1-24%), 2 (25-49%), 3 (50-74%) or 4 (>75%) for the purposes of 
analysis.   
3.2.3 DNA extraction, quality control and library preparation 
DNA was extracted from harvested material using the DNeasy Blood & Tissue Kit as per 
manufacturer’s instructions (Qiagen, Venlo, Netherlands). Library preparation and 
sequencing was performed using Ion TargetSeq™ exome enrichment for the Ion Proton™ 
System (Life Technologies, Carlsbad, USA). Genomic DNA (3.5µg) was fragmented using an 
ion shear enzyme, and the resulting fragmented DNA cleaned up using Agencourt® 
92 
 
AMPure® XP beads (Beckman Coulter, Brea, USA). The size distribution was checked by 
running an aliquot of the sample on 2% E-Gel® (Life Technologies, Carlsbad, USA). Adapter 
ligation was performed using the Ion Plus Fragment Library Kit according to manufacturer’s 
instructions (Life Technologies, Carlsbad, USA). The resulting samples were again cleaned 
using Agencourt® AMPure® XP beads of 300bp in length using a 2% agarose gel and were 
eluted using MinElute columns (Qiagen, Venlo, Netherlands). PCR amplification (10 cycles) 
was subsequently performed to enrich the adaptor-ligated fragments.  
3.2.4 Exome sequencing 
For capture, 500ng of prepared library was concentrated using a vacuum concentrator and 
then hybridized with the Ion TargetSeq™ Exome Probe Pool at 47°C for 66 hours. Hybridized 
library fragments were isolated by magnetic capture using Dynal M-270 streptavidin coated 
beads (Invitrogen, Carlsbad, USA). PCR amplification (8 cycles) was carried out to amplify 
the captured library which was again cleaned using Agencourt® AMPure® XP beads. An 
aliquot of the captured library was run on a High Sensitivity DNA Chip on the Agilent 
Bioanalyser (Agilent, Santa Clara, USA). Real time PCR validation was performed with pre 
and post capture libraries to observe the capture efficiency. The purified, exome-enriched 
library was then used to prepare clonally amplified templated Ion PI™ Ion Sphere™ Particles 
(ISPs) for sequencing on an Ion PI™ Chip to obtain the necessary data coverage. Sequencing 
was performed on the Ion Proton™ sequencer at Genotypic Technology’s Genomics facility 
(Bangalore, India). 
3.2.5 Variant calling and annotation 
Sequenced data was analyzed with Torrent SuiteTM v 3.6 (Life Technologies, Carlsbad, USA). 
Following base calling, raw reads underwent trimming of undesired base calls at the 3' end 
of the read, the adapter sequence, and low quality 3' ends. The resultant data were filtered 
of low quality base calls. The raw reads obtained were then aligned to the reference 
genome (HG19) using the Torrent Mapping Alignment Program for Ion Torrent Data (TMAP) 
software. Variants were then called and detected using Variant Caller v 4.0, an inbuilt plugin 
of Torrent Suite v 3.6. These variants were further annotated using Ion Reporter v 1.6 to 
give location (intronic/exonic/utr), gene name, protein change, function and dbSNP 
identifier (from the dbSNP database 137). 
3.2.6 Somatic variant analysis 
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Data from tumorous and non-tumorous tissue was compared for each patient. The variants 
of each sample were compared by chromosome number and position to identify those 
mutations in the tumour samples which were somatic. The somatic single nucleotide 
variants (SNVs) identified in both primary and metastatic samples were assessed for 
functional consequence and biologically deleterious non-synonymous SNVs were selected.  
The resulting SNVs were compared to identify those present in patient matched primary 
and metastatic paired samples. Those mutations unique to primary tumour and those 
unique to liver metastases were subsequently identified. Further analysis was performed to 
compare and contrast the SNVs present in the responders and non-responders to 
neoadjuvant systemic therapy.  
3.2.7 Ingenuity pathway and network analysis 
Genes identified from these lists of SNVs were subjected to pathway analysis using 
Ingenuity Pathway Analysis (Redwood City, USA). Significant canonical pathways were 
identified with a threshold p value of <0.05 for significance (after correction). If there are n 
genes in a pathway, and f have been identified through sequencing, the p-value is the 
probability of finding f or more genes in a set of n genes randomly selected from the global 
molecular network. 
With the aim of reducing the false discovery rate, the Benjamini-Hochberg multiple test 
correction was used (Benjamini and Hochberg, 1995). In this correction p-values are sorted 
and ranked, the smallest value receiving 1, second 2 and largest N. Each p-value is then 
multiplied by N and divided by its assigned rank to give the adjusted p-values. 
Ingenuity Pathways Analysis computes a score for each network according to the fit of that 
network with the identified genes of interest (referred to as the focus genes).The score is 
derived from a p-value and indicates the probability of the focus genes in a network being 
found together due to random chance. A score of 2 indicates that there is a 1 in 100 chance 
that the focus genes are together in a network due to random chance, therefore scores 
greater than 2 have at least a 99% confidence of not being generated by random chance 
alone. Analysis must also take into account both the number of focus genes identified and 
total known genes in each network. A summary of the bioinformatics workflow can be seen 
in Figure 3.2. 
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Figure 3.2 – Bioinformatics analysis workflow for exome sequencing of synchronously 
resected primary colorectal tumours and colorectal liver metastases. 
3.2.8 Validation of SNVs by Sanger sequencing 
SNVs identified as being of interest during analysis (see Results) were subjected to 
validation by Sanger sequencing on the same tissue set. Following reconfirmation of DNA 
quality by agarose gel electrophoresis, samples were cleaned up with an Ultraclean® PCR 
Clean Up Kit (Mobio, Carlsbad, USA) and quantified using the NanodropTM 
spectrophotometer (Thermo Scientific, Waltham, USA). Targeted forward and reverse 
1
•Base calling followed by trimming of undesired base calls, the adapter 
sequence and low quality 3’ ends using Torrent SuiteTM v3.6
2
•Alignment to reference genome (HG19) using Torrent Mapping Alignment 
Program for Ion Torrent (TMAP)
3
•Variant calling and annotation using Variant Caller v4.0 and Ion Reporter v 
1.6
4
•Identification of somatic, non synonymous, missense, biologically 
deleterious (as per dbSNP 137) single nucleotide variants
5
•Identification of SNVs: unique to primary tumours, unique to liver 
metastases, present in both primary and metastatic tumours, predictive of 
favourable response (at either primary or metastatic sites) and predictive 
of poor response (at either primary or metastatic sites)
6
•Pathway and network analysis  of variant lists using Ingenuity Pathway 
Analysis
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primers were specifically designed and manufactured for each of the SNVs of interest. 
Sanger sequencing was performed using a BigDye® Terminator v3.1 Cycle Sequencing Kit 
(Life Technologies, Carlsbad, USA) and 3130XL Genetic Analyser (Life Technologies, 
Carlsbad, USA), with the resultant FASTA sequence compared with both the reference 
genome and exome sequencing data to confirm the presence of the previously identified 
SNVs. 
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3.3 Results 
3.3.1 Clinical information 
Demographic and clinical information pertaining to the four patients sequenced is displayed 
in Table 3.1.  
Variable Patient 1 Patient 2 Patient 3 Patient 4 
Age at 
diagnosis 
67 70 59 75 
Gender M M F M 
Site of 
primary 
Ascending Sigmoid Sigmoid Sigmoid 
T stage 4 3 3 3 
N stage 0 0 0 2 
Metastatic 
burden 
16 - Bilobar 7 - Bilobar 3 - Bilobar 4 - Unilobar 
Neoadjuvant 
agents 
IrMdG IrMdG Oxaliplatin, 
capecitabine, 
cetuximab 
IrMdG 
Procedure 
performed 
Right 
hemicolectomy 
and multiple 
segmentectomies 
Sigmoid 
colectomy and 
multiple 
segmentectomies 
Sigmoid 
colectomy and 
multiple 
segmentectomies 
Sigmoid 
colectomy and 
left hemi-
hepatectomy 
Pathological 
features 
(primary) 
Adenocarcinoma 
Well 
differentiated 
No 
lymphovascular 
invasion 
Adenocarcinoma 
Moderately 
differentiated 
No 
lymphovascular 
invasion 
Adenocarcinoma 
Moderately 
differentiated 
No 
lymphovascular 
invasion 
Adenocarcinoma 
Poorly 
differentiated 
Lymphoid 
invasion 
No vascular 
invasion 
Pathological 
features 
(liver) 
Adenocarcinoma 
Well 
differentiated 
Adenocarcinoma 
Moderately 
differentiated 
Adenocarcinoma 
Moderately 
differentiated 
Adenocarcinoma 
Poorly 
differentiated 
Tumour 
regression 
grade 
1 1 3 4 
 
Table 3.1 – Demographic and clinical features of the four patients from whom tumours 
were sequenced. IrMdG – Irinotecan and modified de Gramont (5-fluoruracil and folinic 
acid). 
All patients underwent 5-fluorouracil based neoadjuvant chemotherapy followed by 
synchronous resection of a colonic primary and metastatic lesions at a single institution 
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during the course of the study. All resections were R0 with no significant complications. At 
the time of writing, all patients were alive with no evidence of recurrent disease. 
Two patients (1 and 2) were both scored as having a tumour regression grade of 1. For the 
purposes of analysis these patients were regarded as the responders to neoadjuvant 
treatment. Patients 3 and 4 had tumour regression grades of 3 and 4 respectively, and were 
therefore regarded as the non-responders to neoadjuvant treatment. 
3.3.2 Sequencing statistics 
All DNA samples passed the necessary quality control steps with adequate 260:280 and 
260:230. The colonic mucosa from patient 4 was the only sample regarded as being of 
suboptimal quality DNA, although still adequate for sequencing (Table 3.2). 
 
Table 3.2 – Quality control data from samples undergoing exome sequencing with Ion 
Proton. Sample ID column identifies samples as follows: SO_2510 relates to project id; 1-4 
relate to patient number; A-D relate to tissue type (A – colonic mucosa, B – primary 
tumour, C – liver parenchyma, D – liver metastasis). All quality control variables and yield 
were good, with the exception of the colonic mucosa from patient 4. DNA was 
suboptimal but still adequate for sequencing. 
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Having established appropriate quality DNA, samples underwent library preparation 
described above and were sequenced. The total number of reads obtained per sample 
ranged from ~23-54x106 (Table 3.3). 
Patient Sample Number of Reads 
1 Colonic Mucosa 41846478 
Primary Tumour 36382877 
Liver Parenchyma 44525752 
Liver Metastases 50127733 
2 Colonic Mucosa 35296569 
Primary Tumour 46092664 
Liver Parenchyma 39611322 
Liver Metastases 54105628 
3 Colonic Mucosa 47251410 
Primary Tumour 41224669 
Liver Parenchyma 51992117 
Liver Metastases 48375092 
4 Colonic Mucosa 41328946 
Primary Tumour 38052851 
Liver Parenchyma 45159239 
Liver Metastases 22924823 
 
Table 3.3 – Total number of raw reads through Ion Proton exome sequencing. 
Further analysis of the sequencing statistics identified that 62.96 - 83.17% of reads were 
successfully on target areas of the genome, with average base depth per target of 34.68 – 
79.63. The result of this coverage has ensured that a minimum of 96.58% of the target (the 
whole exome) has been sequenced, with 67.61 – 88.33% of targets covered to a depth of at 
least 20X (Table 3.4). 
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Table 3.4 – Sequencing statistics for all samples. Sample ID (column 1) 1-4 relates to 
patient number, and A-D tissue type (A: normal mucosa, B: colorectal primary tumour, C: 
normal liver parenchyma, D: liver metastasis). The report attests to a high number of 
reads successfully on target, a 1x coverage of 96.58 – 98.07% and 20x coverage of 67.61 – 
88.33% of the targeted exome. 
3.3.3 Variant calling and annotation 
The mapped reads described above were subjected to variant calling based on a number of 
quality control criteria designed to optimise the analysis for high frequency variants and 
minimal false positive calls. These include minimum coverage criteria and quality scores for 
the SNV on each strand and a minimum observed allele frequency. The total number of 
variants identified can be seen in Table 3.5.  
Variant 
Category 
Patient 1 Patient 2 Patient 3 Patient 4 
Total 1B 1D 2B 2D 3B 3D 4B 4D 
Synonymous 
Known 463 738 847 945 650 430 637 452 5162 
Synonymous 
Novel 67 61 65 57 36 47 57 56 446 
Synonymous 
Total 530 799 912 1002 686 477 694 508 5608 
Frameshift 
deletion 
Known 42 35 67 66 37 37 56 57 397 
Frameshift 
deletion 
Novel 66 60 85 59 66 58 133 126 653 
Frameshift 
deletion 108 95 152 125 103 95 189 183 1050 
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Total 
Stop loss 
Known 3 0 2 3 3 4 4 4 23 
Stop loss 
Novel 0 0 0 0 0 1 0 0 1 
Stop loss 
Total 3 0 2 3 3 5 4 4 24 
Nonsense 
Known 10 5 19 16 9 9 9 7 84 
Nonsense 
Novel 6 9 5 5 0 9 11 3 48 
Nonsense 
Total 16 14 24 21 9 18 20 10 132 
Missense 
Known 514 754 901 1082 673 528 671 455 5578 
Missense 
Novel 129 150 115 89 80 97 131 126 917 
Missense 
Total 643 904 1016 1171 753 625 802 581 6495 
Non-
Synonymous 
Known 527 759 922 1101 685 541 684 466 5685 
Non-
Synonymous 
Novel 135 159 120 94 80 107 142 129 966 
Non-
Synonymous 
Total 662 918 1042 1195 765 648 826 595 6651 
Somatic 
Known 1693 2288 2973 3414 2072 1714 2134 1449 17737 
Somatic 
Novel 463 458 429 369 321 353 532 517 3442 
Somatic 
Total 2156 2746 3402 3783 2393 2067 2666 1966 21179 
Total 
Variants 26881 28762 28303 29009 28768 29498 27562 23442 222225 
 
Table 3.5 – Total number of high quality variants identified through Ion Proton exome 
sequencing 
Called variants were subjected to the analysis workflow outlined in Section 3.2.6. This 
workflow was designed to remove germline mutations and identify somatic SNVs that are 
non-synonymous, missense and biologically deleterious. It is these SNVs which have been 
used for subsequent bioinformatics analysis, the numbers of which were identified in each 
of the samples can be seen in Table 3.6. A total of 585 unique SNVs were identified. 
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Patient Sample Number of SNVs 
1 Primary Tumour 94 
Liver Metastases 110 
2 Primary Tumour 106 
Liver Metastases 120 
3 Primary Tumour 93 
Liver Metastases 88 
4 Primary Tumour 98 
Liver Metastases 85 
 
Table 3.6 – Total number of somatic, non-synonymous, missense, biologically deleterious 
SNVs identified in each of the tumour samples. 
3.3.4 Variants unique to the primary tumours 
This analysis identified all those eligible SNVs present in one or more of the primary 
tumours but not present in any of the metastases. A total of 215 SNVs were identified 
across 177 genes spanning all autosomes and the X chromosome. The complete list of 
variants can be seen in Appendix 1 – Lists of single nucleotide variants from exome 
sequencing Table 1: Single nucleotide variants exclusive to the primary tumours.  
Ingenuity core analysis of direct and indirect relationships revealed the significant canonical 
pathways in this group to be: α-tocopherol degradation, vitamin C transport, glycine 
biosynthesis III, GDP-L fructose biosynthesis I and TCA cycle II. Statistics for these identified 
pathways can be seen in Table 3.7. 
Pathway p-value Ratio 
α-tocopherol degradation 5.36E-04 2/4 (0.5) 
Vitamin-c transport 7.64E-03 2/14 (0.143) 
Glycine biosynthesis 1.90E-02 1/2 (0.5) 
GDP-L-fucose biosynthesis I 1.90E-02 1/2 (0.5) 
TCA cycle II (eukaryotic) 2.01E-02 2/23 (0.087) 
 
Table 3.7 – Pathway analysis for SNVs unique to the primary tumours. P-value is adjusted 
using Benjamini-Hochberg correction. Ratio identifies the number of focus genes 
identified (numerator) in the pathway (denominator). 
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Further analysis of all (unfiltered) biological pathways identified 5 networks with scores 
greater than 2 pertaining to: connective tissue disorders, drug metabolism, infectious 
diseases, cell cycle and molecular transport. The focus genes and statistics pertinent to 
these networks can be seen in Table 3.8.  
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 26s 
Proteasome,ADAMTS1,Akt,APOB,C5or
f22,CHRNA5,CLDN3,COL15A1,COL6A2,
CTBP2,DROSHA,DUOX2,E2f,ELP2,ERK1
/2,estrogen 
receptor,FGFR3,FSH,GALNT2,GDNF,GL
B1,Hsp70,INF2,KRT18,MUC4,MUC16,N
COR1,NFkB (complex),PABPC1,PI3K 
(complex),PRKRA,PTPRS,TCF3,TNS1,US
PL1 
44 25 Connective Tissue 
Disorders, 
Developmental 
Disorder, Skeletal 
and Muscular 
Disorders 
2 AGTR1,AURKA,CBX5,CDC27,CNN2,CTN
NB1,CYP2C8,CYP2D6,DCLK1,DHTKD1,F
UT11,Histone 
h3,HIVEP3,HNF4A,KIFC1,MAGI1,MSH6
,NFATC2IP,NR1I2,NUPR1,PABPC3,PAK
7,PPP1R2,RAB11FIP5,RB1,RNF123,RPL
19,SDHA,SOX7,SPATS2L,SRRM2,TFAP2
A,TNFRSF14,TNIK,TRAF2 
22 15 Drug Metabolism, 
Small Molecule 
Biochemistry, 
Cellular Assembly 
and Organization 
3 ADD1,CCL5,CCRN4L,CD93,CD300C,CSR
NP1,CX3CR1,CYP4F2,DMTN,EHD1,F2,F
9,FERMT1,FMN2,HSPG2,KCNJ12,KHSR
P,KRT34,LILRA5,MAPK1,MT-
CYB,PHF11,PI3,RELA,SAMHD1,SERPIN
B8,SERPINB10,SQLE,SREK1IP1,TDRD7,
TGM2,TNF,TPMT,TPSD1,ZNF318 
20 14 Infectious Disease, 
Hematological 
System 
Development and 
Function, 
Organismal 
Functions 
4 ABCC5,BMP2K,CDKN1A,CELF1,CHAT,C
OL5A3,COTL1,CSAD,ESR1,ESRRA,FAM1
02A,FKBPL,GPR6,HAMP,HSF1,IFI16,Int
erferon 
alpha,KLF16,KRT13,LOC100996763/N
OTCH2NL,MAZ,MINOS1,MSR1,NDUFS
2,NFYA,PAK2,Pkc(s),PLEKHG2,POU2F1,
PTGS2,RASA4,SEC14L3,SMARCA4,TGM
1,UBALD1 
20 14 Cell Cycle, Nervous 
System 
Development and 
Function, Organ 
Morphology 
5 ABCC3,ACSL3,ADA,AMOTL2,ARPC1B,C
ASP1,DOCK7,EVL,HIST4H4,IL13,IL3RA,
KIF24,KLK10,KMT2C,MLH1,NAA30,NLR
C4,PFKP,PIEZO1,PRDM5,S100A2,SETD
8,SKIV2L,SLC16A1,SLC25A5,SLC2A1,SL
C43A3,SLC5A8,SYVN1,TMSB10/TMSB4
X,TNFRSF10B,TP53,TPT1,WNT10B,YLP
M1 
18 13 Molecular 
Transport, Cell 
Death and Survival, 
Developmental 
Disorder 
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Table 3.8 - Network analysis for SNVs unique to the primary tumours. The score is derived 
from a p-value and indicates the probability of the focus genes in a network being found 
together due to random chance. Focus molecules is the total number of SNVs of interest 
identified in the respective network. 
3.3.5 Variants unique to the liver metastases 
This analysis identified all those eligible SNVs present in one or more of the metastatic 
tumours but not present in any of the primaries. A total of 226 SNVs were identified across 
199 genes spanning all autosomes and the X chromosome. The complete list of variants can 
be seen in Appendix 1 – Lists of single nucleotide variants from exome sequencing Table 2: 
Single nucleotide variants exclusive to the metastatic tumours.  
Ingenuity core analysis of direct and indirect relationships revealed the significant canonical 
pathways in this group to be: AMPK signalling, rennin-angiotensin signalling, role of NANOG 
in mammalian embryonic stem cell pluripotency, basal cell carcinoma signalling and PEDF 
signalling. Statistics for these identified pathways can be seen in Table 3.9. 
Pathway p-value Ratio 
AMPK signalling 5.84E-04 7/132 (0.053) 
Renin-angiotensin signalling 6.36E-03 5/108 (0.046) 
Role of NANOG in mammalian 
embryonic stem cell pleuripotency 
6.61E-03 5/109 (0.046) 
Basal cell carcinoma signalling 6.62E-03 4/69 (0.058) 
PEDF signalling 7.32E-03 4/71 (0.056) 
 
Table 3.9 – Pathway analysis for SNVs unique to the metastatic tumours. P-value is 
adjusted using Benjamini-Hochberg correction. Ratio identifies the number of focus genes 
identified (numerator) in the pathway (denominator). 
Further analysis of all (unfiltered) biological pathways identified 8 networks with scores 
greater than 2 pertaining to: Cancer, respiratory disease, dermatological disease and 
conditions, infectious disease, DNA replication, recombination and repair, endocrine system 
disorders, gastrointestinal disease, metabolic disease, cellular development, 
haematological system development and function, haematopoiesis,  developmental 
disorder, organismal injury and abnormalities, inflammatory response, cellular movement, 
104 
 
cardiac infarction, cell cycle. The focus genes and statistics pertinent to these networks can 
be seen in Table 3.10.  
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 26s 
Proteasome,A4GALT,APOBEC3G,CAL
CA,calpain,caspase,CD1A,CHRNA3,CT
BP2,DSG1,DUOX2,E2f,EP400,FANCA,
FES,GATA3,Hsp27,Hsp90,HSPD1,Inte
rferon 
alpha,KMT2C,KRT14,NOTCH1,P38 
MAPK,p70 S6k,PABPC1,PI3K 
(complex),Pkc(s),POU4F2,RBBP5,SET
D8,STK17A,TH,TLR2,TP53 
39 23 Cancer, Respiratory 
Disease, 
Dermatological 
Diseases and 
Conditions 
2 ACTN2,ASPM,ATXN1,BNIP3L,CLCN4,
CORO1C,DNA2,DNAJC15,DPH6,ELM
OD1,EME1,ERCC2,ERCC5,FLVCR1,GH
R,ING2,ITIH1,KAT5,KCNJ12,MKL2,MP
G,NAV1,NR3C1,NUPR1,PARN,PARP4,
PDLIM2,PLK3,PRUNE2,PTX3,RAG1,RE
LA,SERF1A/SERF1B,SERTAD2,ZC3HA
V1 
24 16 Infectious Disease, 
Respiratory Disease, 
DNA Replication, 
Recombination, and 
Repair 
3 ADRA2A,ADRB3,AHSP,Akt,ALDH3B2,
CDH8,CDH13,CFTR,ERK,ERK1/2,estro
gen receptor,FUT3,Histone 
h3,Histone 
h4,HNF1A,HRAS,IgG,IL36A,INS,IRS,Jn
k,Mapk,MBD1,NFkB 
(complex),NHLRC1,NOD1,NUP98,PA
CSIN2,PAK2,PI3Kγ,PPL,PRKRA,RALGD
S,SYT6,TRPM2 
22 16 Endocrine System 
Disorders, 
Gastrointestinal 
Disease, Metabolic 
Disease 
4 ACTR1A,ASUN,BMP4,C21orf119,CCT
8,CDK8,CDKN1A,COL5A3,E2F1,FAM8
6C1,FRG1,GZMM,HSD17B14,IFI30,K
MT2E,LRBA,LUM,MUC16,NFYA,PARP
1,PTPRCAP,PTPRU,RAB33A,RRN3,SAL
L2,SLC22A16,SMARCA4,TAL1,TBP,TC
F3,TMEFF1,TMEM180,TYR,WNT16,Z
P3 
17 14 Cellular 
Development, 
Hematological 
System 
Development and 
Function, 
Hematopoiesis 
5 ACE,ADORA1,ALG1,BCAS3,CHTOP,CN
N2,CTNNB1,DDX54,DYNLL2,ERG,ESR
1,GPR64,KMT2D,LAMA5,MAGI1,MU
C6,NCOA4,NRCAM,NUP88,NUP214,P
DZK1,PRSS1,PTEN,RANBP2,RBFOX2,R
NF31,RYR3,TACC1,TFF1,TGFBR2,TME
M74,TNRC6A,TRIM65,WNT2,WNT11 
15 12 Cancer, 
Developmental 
Disorder, 
Organismal Injury 
and Abnormalities 
6 ACACB,ADIPOQ,AGTR1,AZU1,CCRL2,
CD300C,CEACAM3,COL4A3,CP,CXCL1
6,DCD,EHD1,EMR2,FCGR1B,GNAQ,H
12 10 Inflammatory 
Response, Cellular 
Movement, Cardiac 
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SP,HSPA1A/HSPA1B,IFNG,ITGB3,LGA
LS9,LILRA5,LRP1B,MAGEA3/MAGEA6
,MARCKSL1,MORC2,MYO9B,PABPC3,
PLA2G5,PTGDR,SACS,Sod,STAR,TGM
2,TNF,VIPR1 
Infarction 
7 ANAPC7,BRCA1,CCNA2,CCNB1,CDC1
6,CDC20,CDC27,CDK2,CEBPD,CHUK,E
RBB3,FOXM1,GADD45A,GRB2,HDAC
1,HNRNPA1,HNRNPH1,HNRNPK,Hsp
90,HSP90AB1,MAD2L1,NCAPG,NCL,
NPM1,PCDHA9,PLEC,PLK1,RB1,RBMX
,Rnr,SBDS,SOD2,SPTAN1,TERT,TNXB 
4 5 Cell Cycle, Cancer, 
Organismal Injury 
and Abnormalities 
8 KCNB1,KCNG4 4 2 Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive 
System Disease 
 
Table 3.10 - Network analysis for SNVs unique to the metastatic tumours. The score is 
derived from a p-value and indicates the probability of the focus genes in a network being 
found together due to random chance. Focus molecules is the total number of SNVs of 
interest identified in the respective network. 
3.3.6 Paired variants 
This analysis identified all those eligible SNVs present in at least one primary and metastatic 
tumour pertaining to the same patient. A total of 81 SNVs were identified across 67 genes 
spanning the X chromosome and all autosomes except 22. The complete list of variants can 
be seen in Appendix 1 – Lists of single nucleotide variants from exome sequencing Table 3: 
Single nucleotide variants present in paired samples.  
Ingenuity core analysis of direct and indirect relationships revealed the significant canonical 
pathways in this group to be: ErbB signalling, germ cell-sertoli cell junction signalling, 
endothelin-1 signalling, antiproliferative role of somatostatin receptor 2, and rening-
angiotensin signalling.  Statistics for these identified pathways can be seen in Table 3.11.  
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Pathway p-value Ratio 
ErbB signalling 5.87E-07 6/85 (0.071) 
Germ cell-sertoli cell junction signalling 1.40E-06 7/156 (0.045) 
Endothelin-1 signalling 2.20E-06 7/167 (0.042) 
Antiproliferative role of somatostatin 
receptor 2 
2.37E-06 5/60 (0.083) 
Renin angiotensin signalling 2.41E-06 6/108 (0.056) 
 
Table 3.11 – Pathway analysis for SNVs present in at least one primary and metastatic 
tumour pertaining to the same patient. P-value is adjusted using Benjamini-Hochberg 
correction. Ratio identifies the number of focus genes identified (numerator) in the 
pathway (denominator). 
The ErbB signalling pathway was identified as the most significant pathway arising from the 
analysis of SNVs meeting these criteria (Figure 3.3). Whilst only 6 (KRAS, MAP2K3, PAK2, 
PIK3C2G, PLCG2, RRAS) of the 85 genes contained SNVs (ratio 0.07), the likelihood of this 
combination of SNVs occurring due to chance alone is <5.87x10-7. The identified genes are 
well known, i.e. KRAS, RRAS and a number of associated downstream kinases. 
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Figure 3.3 – The ErbB signalling pathway was identified as the most statistically significant 
pathway arising from analysis of the SNVs present in at least one primary and metastatic 
tumour pertaining to the same patient. The focus genes in which the SNVs have arisen 
are highlighted in purple. 
Further analysis of all (unfiltered) biological pathways identified 3 networks with scores 
greater than 2 pertaining to: endocrine system disorders, gastrointestinal disease, 
inflammatory disease, cellular development, nervous system development and function, 
tissue development, free radical scavenging, molecular transport and cellular growth and 
proliferation. The focus genes and statistics pertinent to these networks can be seen in 
Table 3.12.  
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ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 A2M,ABLIM,ADCY7,Akt,ARPC1A,ATP9
A,BRAF,C1QTNF9,COL18A1,Cyclin 
A,DUSP3,ERK,ERK1/2,FSH,GNLY,GNRH,
IgG,KRAS,KRT18,LGALS3,Lh,MAP2K3,N
COA1,NFkB 
(complex),PAK2,PDXK,PLCG2,PLIN3,PO
P5,PRKX,PRSS1,PRSS3,PTPRN,TLK1,US
PL1 
23 13 Endocrine System 
Disorders, 
Gastrointestinal 
Disease, 
Inflammatory 
Disease 
2 ACAA1,ACSS2,ANAPC5,CCND1,CDC27,
CDK5RAP2,CINP,CREB1,CTNNB1,DBN1
,DPEP1,EPHB3,ERG,GFRA3,LAMB1,MA
GI1,MAML1,MGEA5,MINK1,MYO5A,N
ME1,NOS1,NRP2,PABPC1,PPARA,RB1,
STARD4,SVIL,TCF7,TUBA4A,UTRN,VEN
TX,WNT2,WNT11,ZMIZ2 
16 10 Cellular 
Development, 
Nervous System 
Development and 
Function, Tissue 
Development 
3 ACTN2,AGTR1,AKAP13,BNIP3L,CYP3A4
,DIABLO,DRD5,EPB41L3,G3BP2,GCH1,
KCNJ12,LTB,MAP3K7,NOD2,NR3C1,NR
IP1,PABPC3,PAWR,PLD1,PPP1R13L,PT
CH1,RELA,RGS2,RIPK2,RRAS,SDHA,SH
H,SNX1,SPTBN1,TADA3,TP53BP2,TRAF
5,TRAF3IP2,WDR26,YWHAH 
12 8 Free Radical 
Scavenging, 
Molecular 
Transport, Cellular 
Growth and 
Proliferation 
 
Table 3.12 - Network analysis for SNVs present in at least one primary and metastatic 
tumour pertaining to the same patient. The score is derived from a p-value and indicates 
the probability of the focus genes in a network being found together due to random 
chance. Focus molecules is the total number of SNVs of interest identified in the 
respective network. 
3.3.7 Predictors of favourable response 
This analysis identified all those eligible SNVs present in one or more of the primary or 
metastatic tumours which exhibited favourable response to neoadjuvant chemotherapy 
(i.e. patient 1 and 2), which were not also present in those exhibiting unfavourable 
response (i.e. patient 3 and 4). A total of 268 SNVs were identified across 228 genes 
spanning all autosomes and the X chromosome. The complete list of variants can be seen in 
Appendix 1 – Lists of single nucleotide variants from exome sequencing Table 4: Single 
nucleotide variants exclusive to the responders. 
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Ingenuity core analysis of direct and indirect relationships revealed the significant canonical 
pathways in this group to be: thyroid cancer signalling, regulation of the epithelial-
mesenchymal transition pathway, ovarian cancer signalling, acute myeloid leukemia 
signalling, and colorectal cancer metastasis signalling.  Statistics for these identified 
pathways can be seen in Table 3.13. 
Pathway p-value Ratio 
Thyroid cancer signalling 7.32E-06 6/39 (0.154) 
Regulation of the epithelial-
mesenchymal transition pathway 
1.55E-05 11/182 (0.06) 
Ovarian cancer signalling 3.21E-05 9/130 (0.069) 
Acute myeloid leukaemia signalling 4.00E-05 7/76 (0.092) 
Colorectal cancer metastasis signalling 1.35E-04 11/231 (0.048) 
 
Table 3.13 – Pathway analysis for SNVs unique to the responding tumours. P-value is 
adjusted using Benjamini-Hochberg correction. Ratio identifies the number of focus genes 
identified (numerator) in the pathway (denominator). 
Further analysis of all (unfiltered) biological pathways identified 7 networks with scores 
greater than 2 pertaining to: cancer, gastrointestinal disease, respiratory disease, 
organismal development, connective tissue disorders, dermatological diseases and 
conditions, cellular assembly and organisation, cellular function and maintenance, drug 
metabolism, cellular movement, haematological system development and function, 
immune cell trafficking, cellular  movement, cell-to-cell signalling and interaction and 
inflammatory response. The focus genes and statistics pertinent to these networks can be 
seen in Table 3.14.  
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 26s 
Proteasome,BRAF,CALCA,CD3,CD1A,C
HRNA3,CHRNA5,CTBP2,Cyclin 
A,DCLK1,EP400,ERK,ERK1/2,GATA3,His
tone h3,Histone 
h4,HSPD1,IFI16,INS,KMT2C,KRAS,LGAL
S3,MBD1,MSH6,MUC16,NOTCH1,PI3K 
(complex),Pka,Pkc(s),SETD8,TCF3,TH,T
LR2,TP53,ZP3 
40 25 Cancer, 
Gastrointestinal 
Disease, Respiratory 
Disease 
2 A2M,Akt,ALDH3B2,APOB,C5orf22,CLD
N3,DSC1,E2f,ELP2,estrogen 
31 21 Organismal 
Development, 
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receptor,GALNT2,GHR,HNF1A,Hsp70,
Hsp90,HSPG2,IgG,Interferon 
alpha,Jnk,KRT14,LDL,LDL-
cholesterol,MAP2K3,Mek,NFkB 
(complex),NOD1,NOS1,NUP98,P38 
MAPK,PLCG2,PLEC,PRKRA,SACS,SYT6,T
GM1 
Connective Tissue 
Disorders, 
Dermatological 
Diseases and 
Conditions 
3 ADD1,AGTR1,APP,ARHGAP17,ATXN1,C
D81,CNN2,CTNNB1,CYP2B6,CYP2C8,C
YP2D6,DNM1,DVL1,EPB41L3,ERG,GNA
Q,HNF4A,IGSF8,ITGB1,LAMA5,MAGI1,
MYO5A,NAA10,NOTCH4,NR1I2,NRCA
M,PABPC3,PAK7,ROCK2,RPL19,RRAS,R
YR3,VANGL2,WNT2,WNT11 
19 15 Cellular Assembly 
and Organization, 
Cellular Function 
and Maintenance, 
Drug Metabolism 
4 Aldose 
Reductase,ATXN10,AZU1,CCND1,CCT8
,CDC27,CEACAM3,CHAT,CP,CXCL16,FC
GR1B,GGT1,GZMM,HSP,IFNG,IL17RB,K
IF26B,MAGEA3/MAGEA6,MARCKSL1,
MYO9B,NQO1,PARP1,Pkc(s),PLA2G5,P
TGDR,SERPINB8,SERPINB10,SLC25A5,S
od,TNF,TNFRSF10B,TYMP,TYR,VIPR1,Y
LPM1 
17 14 Cellular Movement, 
Hematological 
System 
Development and 
Function, Immune 
Cell Trafficking 
5 ABCC5,ACSS2,CD93,CDCA7,COL4A3,C
OL5A3,CPE,CSAD,CX3CR1,ESR1,ESRRA,
FAM102A,FBP1,FERMT1,FMN2,ITGB3,I
TIH1,KRT13,LAMB1,MGEA5,MINOS1,N
AV1,NFYA,PDLIM2,PHKB,PNRC1,POU2
F1,PTX3,RELA,SLC7A2,TGM2,TMEM74,
UBALD1,WNT11,YPEL3 
16 13 Cellular Movement, 
Cell-To-Cell Signaling 
and Interaction, 
Inflammatory 
Response 
6 ABHD2,ACTN2,ACTR1A,ALDH3A1,CDK
N1A,CELF1,CORO1C,DEDD2,DNASE1L3
,E2F1,FOXG1,HNRNPA3,HSF1,IFI30,JM
JD6,LOC100996763/NOTCH2NL,LUM,
MT1L,NDUFS2,NPAT,NR3C1,NRP2,PAK
2,PBRM1,POLA2,RIMS1,RRM1,RRN3,S
ALL2,SMARCA4,SRSF2,SWI-
SNF,TAF1B,TBP,WNT16 
14 12 Cell Cycle, 
Connective Tissue 
Development and 
Function, Cellular 
Assembly and 
Organization 
7 ASPM,ATF3,ATR,AURKA,CASP3,CCND1
,CHUK,CXCL8,DHTKD1,DPH6,EREG,FLV
CR1,Histone 
h3,KAT5,KIF2C,MKL2,MYC,NUPR1,PAR
P1,PLK1,PPP1R2,RAG1,SCN2A,TP53 
9 8 Cancer, DNA 
Replication, 
Recombination, and 
Repair, Cell Cycle 
 
Table 3.14 - Network analysis for SNVs unique to the responding tumours. The score is 
derived from a p-value and indicates the probability of the focus genes in a network being 
found together due to random chance. Focus molecules is the total number of SNVs of 
interest identified in the respective network. 
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3.3.8 Predictors of poor response 
This analysis identified all those eligible SNVs present in one or more of the primary or 
metastatic tumours which exhibited poor response to neoadjuvant chemotherapy (i.e. 
patient 3 and 4), which were not also present in those exhibiting favourable response (i.e. 
patient 1 and 2). A total of 226 SNVs were identified across 187 genes spanning all 
autosomes and the X chromosome. The complete list of variants can be seen in Appendix 1 
– Lists of single nucleotide variants from exome sequencing Table 5: Single nucleotide 
variants exclusive to the non-responders. 
Ingenuity core analysis of direct and indirect relationships revealed the significant canonical 
pathways in this group to be: regulation of cellular mechanics by calpain protease, renal cell 
carcinoma signalling, PEDF signalling, thyroid cancer signalling, and UVC-induced MAPK 
signalling.  Statistics for these identified pathways can be seen in Table 3.15. 
Pathway p-value Ratio 
Regulation of cellular mechanics by 
calpain protease 
2.43E-03 4/55 (0.073) 
Renal cell carcinoma signalling 5.31E-03 4/69 (0.058) 
PEDF signalling 5.87E-03 4/71 (0.056) 
Thyroid cancer signalling 7.18E-03 3/39 (0.077) 
UVC-induced MAPK signalling 8.82E-03 3/42 (0.071) 
 
Table 3.15 – Pathway analysis for SNVs unique to the non-responding tumours. P-value is 
adjusted using Benjamini-Hochberg correction. Ratio identifies the number of focus genes 
identified (numerator) in the pathway (denominator). 
Further analysis of all (unfiltered) biological pathways identified 7 networks with scores 
greater than 2 pertaining to: cancer, endocrine system disorders, organismal injury and 
abnormalities, cellular development, cell-to-cell signalling and interaction, cellular assembly 
and organisation, cell cycle, cellular growth and proliferation, cellular movement, cell 
signalling, haematological disease, lipid metabolism, molecular transport, small molecule 
biochemistry and inflammatory response. The focus genes and statistics pertinent to these 
networks can be seen in Table 3.16.  
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ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 26s 
Proteasome,A4GALT,Akt,APOBEC3G,C
DH8,CFTR,COL18A1,COL6A2,CTBP2,Cy
clin A,estrogen 
receptor,FANCA,FGFR3,GDNF,GLB1,HR
AS,Hsp90,INF2,Interferon 
alpha,Jnk,KMT2E,KRAS,KRT18,MUC4,N
COA1,NCOR1,NFkB 
(complex),PABPC1,PI3K 
(complex),PRKRA,PTPRS,SEC14L3,TCF7
,TNS1,VWF 
46 26 Cancer, Endocrine 
System Disorders, 
Organismal Injury 
and Abnormalities 
2 AIM1,ALG1,BCAS3,BMP2K,BTF3,CNN2,
COTL1,CTNNA3,CTNNB1,DDX54,DNA2,
ERCC2,FASTK,FUT3,GPR6,HAMP,IgG,IL
17RB,MC4R,MINK1,MUC6,MYC,PERP,
PLEKHG2,PLS3,PPL,RANBP2,RASA4,RG
S3,SMARCA4,SNRK,TACSTD2,TFAP2A,T
FF1,ZMIZ2 
16 12 Cellular 
Development, Cell-
To-Cell Signaling and 
Interaction, Cellular 
Assembly and 
Organization 
3 ABLIM,ADAMTS1,ADCY7,ARPC1A,ATP
9A,CCNB1,CDC27,COL15A1,CTDSP2,CY
P4F2,DOCK7,DUSP3,F2,FSH,GNLY,GNR
H,Lh,MAPK1,PDXK,PHF11,PI4K2A,PLIN
3,POP5,PPFIA4,PRKX,PRSS3,PTPRN,RB
1,RBMX,SMAD1,SOX7,STK17A,TGFB1,
TLK1,TPSD1 
16 12 Cell Cycle, Cellular 
Growth and 
Proliferation, Cell-
To-Cell Signaling and 
Interaction 
4 ADCYAP1,ALPPL2,BAI1,C1QTNF9,CCL2
1,CRIP2,CSPG4,DISP1,DROSHA,DUOX2
,E2f,EFNA1,ENO3,ERK,ERK1/2,GMFG,G
PR183,Histone 
h3,HOXC6,HPSE,ITSN1,KMT2B,KMT2C,
KMT2D,LGALS1,NANOG,NHLRC1,PAGR
1,PAK2,PAXIP1,RBBP5,RNF41,SCRIB,TR
PM2,VRK2 
14 11 Cellular Movement, 
Cancer, Cell 
Signaling 
5 ACTN2,AMOTL2,CDK11B,CLCN4,DAPK
3,DNAJC15,EBAG9,GLIPR1,GRIN1,HIST
4H4,KIF24,NR3C1,PARN,PDLIM2,PHLD
A3,PPP1R13L,PRDM5,PRUNE2,SCARA3
,SETD8,SKIV2L,SLC25A5,SLC2A1,SLC43
A3,SON,STOM,SYVN1,TNFRSF14,TNFR
SF10B,TNS4,TP53,TRAF2,TRIM24,WNT
10B,ZC3HAV1 
14 12 Hematological 
Disease, Cancer, 
Organismal Injury 
and Abnormalities 
6 ABCC3,ACAA1,ACACB,ACE,APOA1,APO
A4,APOA5,APOC2,APOC3,CD163,CPT1
A,DIABLO,DSG1,FABP2,HDL,HDL-
cholesterol,Hsp27,IL6R,KCNJ12,KHSRP,
LIPG,LPL,MSR1,MVP,NR1D1,NR1H3,N
R1H4,PLA2G2A,POU4F2,PPARA,PTX3,S
ERPINB10,SREK1IP1,TAC1,TNF 
12 10 Lipid Metabolism, 
Molecular 
Transport, Small 
Molecule 
Biochemistry 
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Table 3.16 - Network analysis for SNVs unique to the non-responding tumours. The score 
is derived from a p-value and indicates the probability of the focus genes in a network 
being found together due to random chance. Focus molecules is the total number of SNVs 
of interest identified in the respective network. 
3.3.9 Selection of SNVs for validation  
The primary purpose of the study was to identify whether biological information from a 
primary tumour is predictive of the metastatic genotype, and if this information could 
potentially be used to predict response to neoadjuvant treatment. To that end, the list of all 
those eligible SNVs present in at least one primary and metastatic tumour pertaining to the 
same patient (i.e. paired) were combined with those SNVs exclusive to either the 
responders or the non-responders. The resulting lists of variants can be seen in Appendix 1 
– Lists of single nucleotide variants from exome sequencing Table 6: Single nucleotide 
variants present in paired samples and exclusive to the responders, and Table 7:  Single 
nucleotide variants present in paired samples and exclusive to the non-responders. 
In order to rationalise the use of resource, the following decisions were made for SNV 
validation: 
1. Those paired predictors of favourable response present in 3 or more samples would 
be validated. 
2. All paired predictors of poor response were only present in 2 samples. As such 
those novel SNVs (as per dbSNP) would be validated. 
3. Given its potential significance to the aim of the study, those SNVs identified in the 
ErBb signalling pathway would be validated. 
The resulting SNVs subjected to Sanger sequencing for validation can therefore be seen in 
Table 3.17. 
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Paired predictors of favourable response (present in 3 or more samples) 
Annotation Gene Chromosome Location 
Substituted 
Amino Acid 
New 
Amino 
Acid 
CDAN1_15_43020983_G/A CDAN1 15 43020983 G A 
LGALS3_14_55604935_C/A LGALS3 14 55604935 C A 
PANK3_5_167988433_T/A PANK3 5 167988433 T A 
CTDSP2_12_58220811_G/T CTDSP2 12 58220811 G T 
Paired predictors of poor response (novel only) 
Annotation Gene Chromosome Location 
Substituted 
Amino Acid 
New 
Amino 
Acid 
ABCA13_7_48390326_G/A ABCA13 7 48390326 G A 
CDC27_17_45214551_G/A CDC27 17 45214551 G A 
ErbB signalling pathway (identified through pathway analysis) 
Annotation Gene Chromosome Location 
Substituted 
Amino Acid 
New 
Amino 
Acid 
KRAS_12_25398284_C/A KRAS 12 25398284 C A 
MAP2K3_17_21207834_C/T MAP2K3 17 21207834 C T 
PAK2_3_196529982_A/G PAK2 3 196529982 A G 
PIK3C2G_12_18650667_A/T PIK3C2G 12 18650667 A T 
PLCG2_16_81888178_C/T PLCG2 16 81888178 C T 
RRAS_19_50140130_G/A RRAS 19 50140130 G A 
 
Table 3.17 – Those SNVs identified for validation with Sanger sequencing 
3.3.9 Sanger sequencing  
Sanger sequencing was attempted for 12 SNVs (above) in 8 samples (primary tumour and 
liver metastases from 4 patients). Eighty-eight of the 96 runs were successful; in 8 samples 
there was failure to detect the amplicon. A summary of the Sanger sequencing results can 
be seen in Table 3.18.  
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Patient 1 Patient 2 Patient 3 Patient 4 
Annotation Count Primary Metastasis Primary Metastasis Primary Metastasis Primary Metastasis 
Paired predictors of favourable response 
CDAN1_15_43020983_G/A 3 G and A G and A G and A G and A G G G G 
LGALS3_14_55604935_C/A 4 C C C C C C C C 
PANK3_5_167988433_T/A 3 Undetermined Undetermined T T T Undetermined T T 
CTDSP2_12_58220811_G/T 3 G G G G G G G G 
Paired predictors of poor response 
ABCA13_7_48390326_G/A 2 G G G G G G G G 
CDC27_17_45214551_G/A 2 G and C G and C G and C G and C G and C G and C G and C G and C 
ErbB signalling pathway 
KRAS_12_25398284_C/A 2 C Undetermined Undetermined C C C C C and A 
MAP2K3_17_21207834_C/T 2 C and T C and T C and T C and T C C C C 
PAK2_3_196529982_A/G 3 A A A A A A A Undetermined 
PIK3C2G_12_18650667_A/T 2 A and T A and T A A and T A A A A 
PLCG2_16_81888178_C/T 2 C and T C and T Undetermined C C C C C 
RRAS_19_50140130_G/A 2 G and A G and A G Undetermined G G G G 
 
Table 3.18 – Summary of the Sanger sequencing for 12 SNVs of interest in 8 samples (matched primary and metastatic tumours from 4 patients). The 
fields displayed in red highlight the location of SNVs identified through Ion Proton sequencing, with the content of the fields representing the identified 
base(s) on Sanger sequencing. Those marked undetermined failed due to inability to detect the amplicon. 
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For those paired predictors of favourable response, only the SNV occurring in the CDAN1 
gene was validated by Sanger sequencing. The table shows the presence of both G and A 
nucleotides in all samples from the responders (patient 1 and 2), including the primary 
tumour from patient 1 which was not seen on exome sequencing. Conversely only the G 
nucleotide is present in the non-responders (patient 3 and 4). The remainder of the Sanger 
sequencing failed to identify any of the substituted nucleotides seen on exome sequencing. 
Where the amplicon was detected, the nucleotide identified was the same in all samples. 
For the paired predictors of poor response, no SNVs were validated. The SNV observed in 
the ABCA13 gene was not identified in any of the samples, whereas in the CDC27 gene a 
substitution from G to C was seen in all samples rather than the expected G to A. 
When considering the ErbB pathway, the SNV: 
 in the KRAS gene was confirmed in 1 of 2 expected samples and no others 
 in the MAP2K3 gene was confirmed in 2 of 2 expected samples and two others 
(from the same  patient) 
 in the PAK2 gene was not confirmed in any sample 
 in the PIK3C2G gene was confirmed in 2 of 2 expected samples and one other 
 in the PLCG2 gene was confirmed in 2 of 2 expected samples and no others 
 in the RRAS gene was confirmed in 2 of 2 expected samples and no others 
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3.4 Discussion 
3.4.1 Summary of aims 
In this study, a comprehensive exome analysis of four synchronously resected patient 
matched primary and metastatic tumours was performed. Analysis of acquired data 
focussed solely on the identified somatic, non-synonymous missense biologically 
deleterious SNVs. The aims were to identify those genetic aberrations that: 
- Are present in the primary tumour but not in the metastasis  
-  Are present in the metastasis but not in the primary tumour  
- Are present in both primary and metastasis (i.e. the primary tumour is predictive of 
the metastatic genotype) 
- May predict response to neoadjuvant therapy 
3.4.2 Summary of results 
Of the 585 unique non-synonymous, missense SNVs identified 215 (36.8%) were unique to 
the primary tumour, 226 (38.6%) unique to the metastasis and 81 (13.8%) present in at 
least one primary and metastatic tumour pertaining to the same patient. The remaining 63 
(10.8%) were neither unique to a tissue type or present in a pair of samples from the same 
patient. Two hundred and sixty-eight (45.8%) predicted favourable response, whilst 226 
(38.6%) predicted poor response. Of those, 43 and 23 respectively were present in patient 
matched samples. The remaining 91 (15.6%) were neither unique to responders or non-
responders. 
Pathway analysis identified putative pathways in those variants unique to the primary 
tumour (α-tocopherol degradation, vitamin C transport, glycine biosynthesis III, GDP-L 
fructose biosynthesis I and TCA cycle II), unique to the metastatic tumour (AMPK signalling, 
rennin-angiotensin signalling, role of NANOG in mammalian embryonic stem cell 
pluripotency, basal cell carcinoma signalling and PEDF signalling), present in at least one 
primary and metastatic tumour pertaining to the same patient (ErbB signalling, germ cell-
sertoli cell junction signalling, endothelin-1 signalling, antiproliferative role of somatostatin 
receptor 2, and rening-angiotensin signalling), unique to the responders (thyroid cancer 
signalling, regulation of the epithelial-mesenchymal transition pathway, ovarian cancer 
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signalling, acute myeloid leukemia signalling, and colorectal cancer metastasis signalling) 
and unique to the non-responders (regulation of cellular mechanics by calpain protease, 
renal cell carcinoma signalling, PEDF signalling, thyroid cancer signalling, and UVC-induced 
MAPK signalling). 
The ErbB signalling pathway was identified as the most significant pathway arising from the 
analysis of SNVs in paired patient samples, with 6 (KRAS, MAP2K3, PAK2, PIK3C2G, PLCG2, 
RRAS) of the 85 pathway genes containing SNVs (Ratio 0.07, p=5.87x10-7). 
Sanger sequencing validated the CDAN1_15_43020983_G/A SNV as a potential predictor of 
favourable response where the primary tumour is predictive of the metastatic genotype. 
For the 6 SNVs of interest in the ErbB pathway, 4 showed absolute concordance between 
the primary and metastatic genotype (those in MAP2K3, PIK3C2G, PLCG2 and RRAS) thus 
validating the results of the Ion Proton exome sequencing. 
3.4.3 Next generation sequencing of colorectal cancer 
For decades our understanding of the genetics of colorectal carcinogenesis has gone 
unchallenged, however a complete catalogue of oncogenic drivers has yet to be 
determined. 
The largest published study to date remains The Cancer Genome Atlas Network (2012) of 
276 colorectal samples subjected to exome sequencing, 97 of which also underwent whole 
genome sequencing. This paper demonstrated that colon and rectal cancers had similar 
patterns of genomic alteration, and that most of the 24 genes found to be significantly 
mutated were known cancer-related genes such as APC, TP53, KRAS, PIK3CA and SMAD4.  
A number of studies, published both before and after, have attempted to improve our 
understanding of the genomic aberrations in colorectal cancer with three main aims: 
identifying clinically actionable targets for personalised therapy, improving pathway-level 
understanding of carcinogenesis, and identifying novel features or mutation types. A 
summary of these papers can be seen in Table 3.19, and a complete list of accompanying 
variants from these papers can be found in Appendix 2 – Genetic variants in colorectal 
cancer identified by next generation sequencing studies.  
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Paper Number of 
Patients 
Comparing Summary 
The Cancer Genome Atlas Network 
Nature, 2012 
276 Tumour and 
normal 
mucosa 
Implicated pathways 
included WNT, RAS-MAPK, 
PI3K, TGF-B, P53, and DNA 
mismatch repair. 
The consensus coding sequences of 
human breast and colorectal cancers 
Science, 2006 
11 Tumour and 
normal 
mucosa 
Sanger sequencing study 
identifying 189 genes, most 
of which not known to be 
implicated in 
carcinogenesis 
Patterns of somatic mutation in 
human cancer genomes 
Nature, 2007 
28 Tumour and 
normal 
mucosa 
44 mutations identified, 
many of which were 
protein kinases 
Somatic mutation profiles of MSI 
and MSS colorectal cancer identified 
by whole exome next generation 
sequencing and bioinformatics 
analysis 
PLOS One, 2010 
2 
(1 MSI-S, 1 
MSI-H) 
Tumour and 
normal 
mucosa 
359 significant mutations 
for the MSI tumour and 45 
for the MSS, all with 
predicted altered protein 
function 
Exome capture sequencing of 
adenoma reveals genetic alterations 
in multiple cellular pathways at the 
early stage of colorectal 
tumorigenesis 
PLOS One, 2013 
1 Tumour, 
adenoma 
and normal 
mucosa 
12 variants were identified 
in the adenoma and 42 in 
the adenocarcinoma 
Chromothripsis is a common 
mechanism driving genomic 
rearrangements in primary and 
metastatic colorectal cancer 
Genome Biology, 2011 
4 Primary 
tumour, 
normal 
mucosa, liver 
metastasis 
and liver 
parenchyma 
24 genes suggesting the 
relevance of 
chromothripsis to 
metastagenesis 
Genomic sequencing of colorectal 
adenocarcinomas identifies a 
recurrent VTI1A-TCF7L2 fusion 
Nature Genetics, 2011 
9 Tumour and 
normal 
mucosa 
Eleven rearrangements 
encode predicted in-frame 
fusion proteins, including a 
fusion of TVI1A and TCF7L2 
found in 3 out of 9 patients 
Exome sequencing reveals frequent 
inactivating mutations in ARID1A, 
ARID1B, ARID2 and ARID4 in 
microsatellite unstable colorectal 
cancer 
International Journal of Cancer, 
2013 
21 Tumour and 
normal 
mucosa 
Analysis focussed to ARID 
genes only which were 
frequently mutated (13-
39%) 
Comprehensive genomic analysis of 
a metastatic colon cancer to the 
lung by whole exome sequencing 
and gene expression analysis 
International Journal of Oncology, 
2014 
1 Metastatic 
lung tumour 
and normal 
lung 
8 of the 71 variants 
identified pertain to the 
‘metastatic colorectal 
cancer signalling’ or 
‘phospholipase C signalling’ 
pathways 
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Table 3.19 – Summary of next generation sequencing papers published on colorectal 
cancer. 
As can be seen, at the time of writing only one paper includes the sequencing of colorectal 
liver metastases: Kloosterman et al (2011) demonstrated that chromothripsis is a 
widespread phenomenon in colorectal primary and metastatic tumours with considerable 
variation between sites, and that in the 24 genes they identified (including 
APC, KRAS, SMAD4 and PIK3CA) considerable variation was seen between primary and 
metastatic tumours. This will no doubt rapidly change, and as the technology grows the 
challenge will increasingly be how to exploit this to better our understanding of the 
mechanisms underlying colorectal carcinogenesis.  
3.4.4 The ErbB receptor tyrosine kinases and pathway 
The epidermal growth factor receptor (EGFR) family consists of 4 members, ErbB1-4. These 
receptors consist of a glycosylated extracellular domain and an intracellular domain with a 
juxtamembrane segment, protein kinase domain and carboxylterminal tail. ErbB1, ErbB3 
and ErbB4 all have 7 biologically occurring ligands (EGF, EPG, TGFα, AR, BTC, HB-EGFEPR), 
whereas Erb2 has none (Roskoski, 2004). 
Downstream signalling of ErbB activation is by 3 integrated pathways: the 
phosphatidylinositol 3-kinase/Akt (PKB) pathway, the Ras/Raf/Mek/ERK pathway and the 
phospholipase C pathway (See Section 1.7.6). Many tumours besides colorectal tumours 
are associated with mutation or increased expression of the gene family, which have a 
number of designations: EGFR/ERBB1/HER1, ERBB2/HER2/NEU, ERBB3/HER3 and 
ERBB4/HER4. These mutations results in aberrant activity of downstream pathways 
(Miettinen et al, 1995). 
Given their importance in a number of cell functions, including regulation of apoptosis, cell 
cycle progression, cytoskeletal rearrangement, differentiation and development (Manning 
et al, 2002), and their biological implication in colorectal cancer (Yao et al, 2013), the ErbB 
Targeted sequencing of cancer 
related genes in colorectal cancer 
using next generation sequencing 
PLOS One, 2013 
60 Tumour and 
normal 
mucosa 
183 genes selected for 
analysis from COSMIC 
database (study designed 
to validate new platform) 
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family and downstream pathways have become a commonly utilised drug target (Table 
3.20). 
Small Molecule 
Inhibitors Manufacturer Target Year Application 
Afatinib/Gilotrif® 
Boehringer 
Ingelheim ErbB1 2013 
First-line treatment of non 
small cel lung cancer with 
exom-19 deletions 
Erlotinib/Tarceva® Genentech/OSI ErbB1 2004 
(i) First-line treatment of 
non small cel lung cancer 
with exom-19 deletions (ii) 
second-line treatment 
following cytotoxic therapy 
and (iii) first-line treatment 
of pancreatic cancer in 
combination with 
gemcitabine 
Gefitinib/Iressa® Astra Zeneca ErbB1 2003 
Second-line treatment of 
non small cell lung cancer 
after cytotoxic therapies 
Lapatinib/Tykerb® Glaxo SmithKline ErbB1/2 2007 
Second-line treatment of 
patients with capecitabine 
for ErbB2 positive breast 
cancer who have 
previously received 
cytotoxic chemotherapy or 
trastuzumab 
Monoclonal Antibodies Manufacturer Target Year Application 
Ado-trastuzumab 
emtansine/Kadcyla® Genentech/OSI ErbB2 2013 
ErbB2 positive metastatic 
breast cancer previously 
treated with trastuzumab 
Cetuximab/Erbitux® ImClone ErbB1 2004 
(i) Wildtype KRAS 
colorectal cancer in 
combination with cytotoxic 
therapies and (ii) head and 
neck cancers in 
combination with radiation 
therapy or cytotoxic 
chemotherapy 
Panitumumab/Vectibix® Genentech/OSI ErbB1 2006 
Second-line treatment for 
metastatic colorectal 
cancer following cytotoxic 
therapies 
Pertuzumab/Omnitarg® Abgenix ErbB2 2012 
ErbB2 positive metastatic 
breast cancer in 
combination with 
trastuzumab and docetaxel 
in patients who have not 
received prior anti-ErbB2 
therapy or chemotherapy 
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for metastatic disease 
Trastuzumab/Herceptin® Genentech ErbB2 1998 
ErbB2 positive breast, 
gastric and gastro-
oesophageal cancer 
 
Table 3.20 – Some of the ErbB inhibitors currently in clinical use (only ones approved by 
the Federal Drug Administration are shown). Adapted from Roskoski, 2004. 
The efficacy of cetuximab in relation to KRAS status, and concordance of the primary and 
metastatic genotype in this regard has been discussed in Section 1.7.6. Given the inter-
relation of the RAS/RAF pathway with other downstream effectors of ErbB signalling, our 
study raises the question of whether the concordance seen in the case of KRAS can be 
extrapolated to other members of the ErbB pathways. As our understanding of the role of 
these genes in treatment response improves, this concordance could be exploited to create 
personalised treatment regimens.  Such a move would have the potential for improved 
treatment efficacy as well as a reduction in unwanted off-target effects.  
3.4.5 The CDAN1 gene 
Codanin 1 (CDAN1) is located at 15q15.2 and codes for a protein which appears to play a 
role in nuclear envelope integrity, possibly through microtubule attachments. Mutation of 
this gene is known to cause the clinical condition congenital dyserythropoietic anaemia 
type I, a rare autosomal recessive disorder resulting in morphological abnormalities of 
erythroblasts, ineffective erythropoiesis, macrocytic anaemia and secondary 
haemochromatosis (Tamary et al, 2005). The genetic variants responsible for this condition 
have been well reported (Dgany et al, 2002), although their potential role in cancer and 
treatment response have not yet been investigated.  
The mechanism of action of the codanin 1 protein remains to be elucidated, however in an 
immunofluorescence study of HeLa cells, Noy-Lotan et al (2009) localised it to 
heterochromatin in interphase cells, found high levels in the S-phase of the cell cycle, and 
noted its phosphorylation and exclusion from condensed chromosomes during mitosis. As 
such they concluded that the protein is cell-cycle regulated and active during the S-phase. 
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Ask et al (2012) suggest that the function of the protein is direct interaction with the 
histone chaperone anti-silencing function 1 (Asf1) complex, sequestering it in the 
cytoplasm, blocking histone delivery and arresting S-phase progression.  
A potential mechanism of action for carcinogenesis and treatment response could 
therefore be hypothesised, however given the paucity of information in the literature it 
would be prudent to first validate the presence of this SNV in a larger cohort of cancer 
samples. 
3.4.6 Study strengths and limitations 
This study represents the first genomic sequencing of synchronously resected patient 
matched primary colorectal tumour and colorectal liver metastases in the literature. As 
such it is complementary to the paper by Kloosterman et al (2011), in which the patients 
were metachronously resected. The significance of this is the exclusion of confounding 
factors introduced by metachronous resection, be that merely the passage of time, other 
neoadjuvant treatments or the stress response to the first operation. 
Given the aims of this study clearly the numbers we have used are inadequate to draw any 
firm conclusions. Our desire to perform exome sequencing is in part related to later 
chapters of this thesis in which we perform a global proteomic analysis on the same (and 
other) tissue sets. Focussing on the non-synonymous missense SNVs has allowed us to 
make potentially more meaningful correlations between the datasets, but in doing so has 
left little regard for the potential for significant findings in both the SNVs not meeting these 
criteria as well as indels.  
We opted to validate the SNVs of interest in the same tissue set but using an alternative 
technology, specifically Sanger sequencing. The preferred alternative would have been 
validation on a larger, different tissue set using either the same or a different platform. The 
precious nature of these difficult to acquire samples meant that this was not feasible, as 
synchronous resections are a relatively recent development in hepatobiliary surgery. The 
incorporation of metachronous resections into the tissue set would have increased 
numbers (and cost) at the expense of losing the novelty and scientific value we have 
achieved with this study. 
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The final limitation is the inherent heterogeneity in the study population. Differences 
existed in terms of patient age, gender, TNM stage, burden and distribution of metastases, 
and the presence of adverse pathological features. It is advantageous that all of the primary 
tumours were confined to the colon (rather than including rectal cancers also), although 
there were primary tumours from both the right and left colon. It is now widely accepted 
that right and left colonic tumours are to be regarded as different biological entities, 
particularly where genomic aberrations are concerned (Zhu, 2013). Given the study partly 
attempted to review SNVs which may account for differences in response to neoadjuvant 
treatment, again there was heterogeneity between patients. All patients received a 5-
fluorouracil based regimen, although one patient received this as capecitabine. The same 
patient (3) was the only patient to receive an EGFR inhibitor. As such the biomarkers 
identified are likely to relate to the cellular response to chemotherapy, rather than the 
mechanism of action of the specific agents involved. Indeed as the tumours have been 
treated with chemotherapy, those cells remaining available for biopsy may represent those 
that are particularly chemoresistant. Intra-tumoural heterogeneity has also already been 
briefly discussed and is a key limitation of this study. Given that all patients had received 
neoadjuvant therapy it is possible that only chemo-resistant cells remained for sampling 
and analysis. This concept is explored further in Section 4.4.4. 
3.4.7 Conclusion 
Approximately one third of mutations identified in this study are present exclusively in the 
primary tumour, one third are present exclusively in the metastases and one third are 
present in tumours at both sites. In this cohort, only 13.8% of mutations were present in 
patient matched samples, i.e. only 13.8% of the metastatic genotype can be predicted by 
the genotype of the primary tumour.  
We have identified a SNV in the CDAN1 gene which has potential to serve as a predictive 
biomarker, with the presence of the SNV in the primary tumour predicting the metastatic 
genotype. Further validation on a micro-array of multiple patient matched samples with 
corresponding response and outcome data would assist with further evaluation. 
SNVs identified in the ErbB pathway appear to be concordant between primary and 
metastatic tumours. As our understanding of the relevance of this pathway (and genetic 
variants within) to response to treatment with chemotherapy and targeted agents grows, 
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treatment decisions may increasingly be made on the basis of other genetic abberations 
beyond the currently used KRAS status. This genotypic information can be acquired from 
the primary tumour given its concordance with the metastatic genotype.  
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Chapter 4 
A global proteomic assessment of patient matched primary and metastatic colorectal 
tumours 
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4.1 Introduction 
4.1.1 Background 
The role of neoadjuvant therapy has already been discussed in some detail (Section 1.8.4). 
In the context of colorectal liver metastases, neoadjuvant chemotherapy is often used to 
downstage borderline resectable patients to facilitate safe and effective surgery with the 
survival benefit we now know that it confers.  
The ability to establish prospectively the likely response to neoadjuvant therapy would be 
of tremendous benefit to clinicians. Those patients who are identifiable as likely to respond 
could be subjected to potentially more effective systemic therapy, whilst conversely those 
less likely to respond could be saved the unnecessary morbidity of systemic treatment and 
the delay to surgical intervention necessary with the use of neoadjuvant treatments. 
Access to the colon and rectum to obtain tumour samples for biological analysis is feasible 
and safe by means of endoscopic assessment. In the context of metastatic disease in the 
liver, studies have shown that pre-operative needle biopsy is associated with seeding of the 
cutaneous tract and a considerable increase in morbidity (Cresswell, Welsh and Rees, 
2009). As such we are limited to the primary tumour for biological information to help us 
guide the treatment of the liver metastases. This is observed in current clinical practice with 
the genotyping of KRAS performed on the archived primary tumour tissue to establish the 
potential benefit of the inclusion of cetuximab alongside other systemic agents. 
4.1.2 Proteomics 
Proteomics is defined as the large scale study of proteins, and in particular their structure 
and function. The term was first coined in 1997 to draw a parallel with the increasing 
interest in genomics (James, 1997). The proteome is the entire set of proteins produced or 
modified by an organism or system which varies with time and distinct requirements of the 
cell or organism (Wilkins et al, 1996). 
The study of proteomics is arguably more complicated than the genomics described in 
Chapter 3. Firstly, an individual’s genome remains more or less constant, however the 
proteome can vary between cells and over time. Secondly, modification of the translated 
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protein, for example by phosphorylation or glycosylation, is common and can have a 
significant impact on protein function. Thirdly, many proteins form complexes with other 
proteins, and only exert their biological effect as part of this complex. Fourthly, protein 
degradation plays a significant part in any attempt at quantification. Finally, as a 
combination of the above factors, reproducibility between experimental runs, with 
alternative equipment and in different laboratories can prove challenging (Peng et al, 
2003). These challenges however represent an opportunity to help us understand the 
complexities of tumour biology, which is critical in helping us develop the most effective 
diagnostic tools and treatment strategies for the future (Ceciliani et al, 2014). 
The investigation of protein expression, structure and protein-protein interactions is all 
feasible. Proteomic data can also be used to enhance gene annotations, with parallel 
genomic studies assisting to further characterise post-translational modifications and 
proteolytic events (Gupta et al, 2007). Monitoring these post-translational modifications is 
critical, as for many cellular events protein abundance does not change rather their 
function is altered by these modifications. A current area of significant method 
development is the advancement of quantitative proteomics, data from which would 
permit a more detailed analysis of cell systems and biological functions (Yin et al, 2013). 
4.1.3 Isobaric tagging for relative (and absolute) quantification 
Isobaric tagging for relative and absolute quantification (iTRAQ) is a quantitative 
proteomics technique designed to determine the absolute or relative amount of proteins 
from a number of different samples within a single experiment. Samples are prepared by 
reducing and alkylating cysteine residues and subjecting them to an overnight tryptic 
digest, whereby proteins are cleaved at the carboxyl side of the amino acids lysine and 
arginine (except when either is followed by proline) to produce peptides. 
Each sample is incubated with a specific isotope labelled molecule which covalently binds 
to the N-terminus and side chains of all peptides within the sample. The iTRAQ tag consists 
of a reporter moiety which is used for quantification during analysis and a balance moiety. 
All tags have the same total mass of 145Da, however the reporter moieties in each tag are 
different in mass. When each tag binds to a peptide that is present in all eight samples, all 
eight iTRAQ labelled peptides should have the same mass. 
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For ease of mass spectrometry, samples first undergo a ‘clean up’ step where the peptides 
are separated into fractions of certain ionic charge by cation exchange. During mass 
spectrometry, the peptides within a particular fraction are separated by mass and ionised 
thus producing parent ion molecules. Each parent ion is represented by a single peak and is 
isolated and directed to a collision chamber where the peptides are bombarded with a 
collision gas causing the tagged peptides to fragment. During fragmentation, the reporter 
and balance moieties are cleaved from each other and from the peptide to which they are 
bound. The peptide itself is also cleaved into fragment ions and these ions are used to 
identify the protein that this peptide represents by cross-referencing with a known 
database. The released reporter molecules, which should be a combination of the eight 
varying masses, are used to quantify the relative abundance of the peptide to which they 
were bound in each of the original samples by calculating the ratios of the reporter 
molecules. The abundance is compared to a common pool of a number of samples, use of 
which across multiple runs allows for efficient and accurate multiplexing (Zieske, 2006). 
Figure 4.1 is a schematic representation of this laboratory technique as applied to the 
experimental design. 
 
Figure 4.1 – Samples are reduced and undergo a tryptic digest before being tagged with 
an isotope labelled molecule. These tags all have the same molecular weight although the 
reporter and balance moieties vary. After a cation exchange cleanup step the samples 
undergo nanoLC-MS/MS. The reporter and balance moieties are cleaved from each other 
and from the peptide to which they are bound, the ratio of which helps determine 
relative abundance. The peptide is also cleaved into fragment ions used to identify the 
protein.   
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4.1.4 Study aim  
The aim of this investigation is to compare the proteomic profile of the primary and 
metastatic tumours, both with each other and with their normal adjacent tissue, to 
establish the degree of similarity and identify potential response biomarkers present in the 
primary tumour which may predict response to neoadjuvant therapy in the liver metastasis.   
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4.2 Methods  
National Health Service Research Ethics Committee and Research and Development 
approval was obtained for this study and informed consent obtained from each of the study 
participants. 
4.2.1 Patient recruitment and tissue collection 
Samples were obtained from consecutive patients undergoing synchronous or staged 
resection of a primary colorectal tumour and liver metastases at any of the institutions 
within the research infrastructure constructed to facilitate this study. 
Following delivery of the colorectal specimen the proximal staple line was incised and a 
linear cut made down the antimesenteric border before excising a peripheral section of 
tumour using forceps and a scalpel. Following delivery of the liver specimen, an incision was 
made through the resected surface to the liver metastasis, with care being taken not to 
breach the liver capsule; a peripheral sample of tumour was obtained as described 
previously. Macroscopically normal adjacent colonic mucosa and liver parenchyma were 
also obtained, with all tissue sampling performed in the operating theatre under aseptic 
conditions followed by immediate stabilisation in liquid nitrogen and transfer to a -80oC 
storage facility. 
4.2.2 Exclusion criteria 
For this study, the exclusion criteria were: 
 Recent (last 12 months) personal history of malignancy at another site 
 Patients under the age of 18 
 Patients without capacity to provide informed consent 
 Patients identified by the multidisciplinary team as being at significant risk of 
emotional distress by additional hospital visits and/or procedures that may be 
required 
4.2.3 Evaluation of histopathological response to treatment 
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Additional tumour samples were obtained for the purposes of formalin fixation and 
embedding in paraffin. All samples were reviewed by a consultant histopathologist to verify 
the diagnosis of adenocarcinoma. 
For those patients who had received neoadjuvant chemotherapy the histopathological 
response to treatment was assessed. The number of residual viable tumour cells within 
each sample was estimated as a percentage of the total tumour surface area that included 
areas of coagulative necrosis, calcification, fibrosis and the associated histiocytes, foreign 
body giant cells and inflammatory cells.  Samples were subsequently scored as tumour 
regression grade 1 (1-24%), 2 (25-49%), 3 (50-74%) or 4 (>75%) for the purposes of analysis.  
This scoring system was first described by Ribero et al (2007), and used for this purpose by 
Blazer et al (2008). 
4.2.4 Sample preparation 
Protein was extracted from sampled tissue by mechanical dissolution and sonication in 
500mM triethylammonium bicarbonate (TEAB) with 0.1% sodium dodecyl sulphate (SDS). 
After centrifugation at 4oC at 2000 g for 15 minutes, the supernatant was removed and 
protein concentration determined by Bradford assay (Bradford, 1976). 
4.2.5 Protein quantification 
Standard protein concentrations of bovine serum albumin (BSA) (Sigma Aldrich) were 
prepared at 0.1, 0.2, 0.4, 0.8, 1.0 and 1.4mg/ml and 20µl placed in triplicate on a 96 well 
plate. Serial dilutions of each sample were made at concentrations of 1:10, 1:20, 1:50 and 
1:100, and 20µl placed in triplicate on the same 96 well plate. Bradford reagent (BioRad) 
was diluted 1:5 with dH2O and 180µl placed in each of the wells and then mixed. 
Absorbance at 570nm was measured using the Dynex MRXe plate reader (Magellan 
Biosciences, Chelmsford, UK), and protein concentration of the sample calculated by 
comparison to the standard curve. 
4.2.6 Creation of a reference pool 
In order to infer relative protein abundance between samples, a reference pool was 
created for each study. For each sample to be quantified 100µg of protein was combined 
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together in a common pool i.e. 100µg of each of normal mucosa, primary tumour, liver 
metastasis and liver parenchyma for each patient in the study. Once the reference pool had 
been created it was re-quantified as above and prepared in an identical fashion to the other 
samples as follows. 
4.2.7 Allocation across and within experimental runs  
iTRAQ reagents are available in 4-plex and 8-plex formats, thus restricting the number of 
samples to 8 per run. Inclusion of the reference pool as a sample further limits each 
experimental run to 7. Given some of the inherent difficulties in reproducibility with 
proteomics discussed in Section 4.1.2, all samples to be analysed were randomly allocated 
across all experimental runs in a stratified fashion thus ensuring even distribution of tissue 
types and patients. In order to facilitate rigorous bioinformatics analysis across sample runs 
the same reference pool was included. Within experimental runs allocation to iTRAQ label 
was performed on a purely random basis. 
4.2.8 iTRAQ labelling 
Labelling with iTRAQ reagents was carried out according to the Applied Biosystems protocol 
for an 8-plex procedure (Life Technologies, Paisley, UK).  In brief, 100μg of protein from 
each sample was reduced with Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) and 
capped with methylmethanethiosulfate (MMTS), before overnight digestion with trypsin 
(Promega, Southampton, UK). Peptides were then labelled with isobaric tags and pooled 
and diluted to 5ml with 10mM potassium dihydrogen phosphate/25% acetonitrile (ACN) 
and acidified to <pH3 with phosphoric acid. 
 
4.2.9 Cation exchange 
 
Samples were fractionated on a Polysulfoethyl A strong cation-exchange column (200 × 
4.6mm, 5m, 300Å; Poly LC, Columbia, MD) at 2ml/minute using a gradient from 10mM 
potassium dihydrogen phosphate/25% ACN (w/v) to 0.5M potassium chloride/10mM 
potassium dihydrogen phosphate/25% ACN (w/w/v) in 75 minutes. Fractions of 2ml were 
collected and dried by centrifugation under vacuum (SpeedVac, Eppendorf UK Ltd, 
Stevenage, UK). Fractions were reconstituted in 1ml of 0.1% trifluoroacetic acid (TFA) and 
were desalted using a mRP Hi Recovery protein column 4.6 x 50mm (Agilent, Berkshire UK) 
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on a Vision Workstation (Applied Biosystems/Life Technologies, Paisley, UK) prior to mass 
spectrometric analysis. 
4.2.10 Mass spectrometry 
Desalted fractions were reconstituted in 40l 0.1% formic acid and 5l aliquots were 
delivered into a Triple TOF 5600 (AB Sciex, Warrington, UK) via an Eksigent NanoUltra 
cHiPLC System (AB Sciex) mounted with a microfluidic trap and analytical column (15 cm × 
75 μm) packed with ChromXP C18−CL 3 μm. A NanoSpray III source was fitted with a 10μm 
inner diameter PicoTip emitter (New Objective, Woburn, USA). The trap column was 
washed with 2% ACN/0.1% formic acid for 10 minutes at 2μL/minute before switching in-
line with the analytical column. A gradient of 2−50% ACN/0.1% formic acid (v/v) over 90 
minutes was applied to the column at a flow rate of 300nl/min. Spectra were acquired 
automatically in positive ion mode using information-dependent acquisition powered by 
Analyst TF 1.5.1. software (AB Sciex). Up to 25 MS/MS spectra were acquired per cycle 
(approximately 10Hz) using a threshold of 100 counts per second and with dynamic 
exclusion for 12 seconds. The rolling collision energy was increased automatically by 
selecting the iTRAQ check box in Analyst, and manually by increasing the collision energy 
intercepts by 5. 
4.2.11 Protein identification and quantification 
Data were searched using ProteinPilot 4.2 and the Paragon algorithm (AB Sciex) against the 
latest version of the SwissProt database, with MMTS as a fixed modification of cysteine 
residues and biological modifications allowed. The data were also searched against a 
reversed decoy database and only proteins lying within a 1% global false discovery rate 
(FDR) were taken forward for analysis. Quantitation of proteins was relative to the common 
pooled sample present in each iTRAQ-MS experiment. iTRAQ data for proteins identified by 
2 or more peptides with at least 90% confidence of correct sequence assignment, or by a 
single peptide with at least 99% confidence were log2 transformed, batch corrected and 
included in subsequent analyses. 
4.2.12 Bioinformatics analysis 
Proteins present in at least 50% of all samples were taken forward for bioinformatics 
analysis. A number of direct two group comparisons were made using Partek® (St Louis, 
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USA) to identify proteins significantly different between the groups. A two-way Analysis of 
Variance (ANOVA) was employed to identify the differential proteins whilst accounting for 
batch effect. With the aim of reducing the false discovery rate, the Benjamini-Hochberg 
multiple test correction was used (Benjamini and Hochberg, 1995). In this correction p 
values are sorted and ranked, the smallest value receiving 1, second 2 and largest N. Each p 
value is then multiplied by N and divided by its assigned rank to give the adjusted p-values. 
Statistical significance was taken as log2 fold change >2 with an adjusted p value of <0.05.  
Those proteins identified as statistically significantly different were subjected to analysis 
with Ingenuity Pathway Analysis (Redwood City, USA). Ingenuity Pathways Analysis 
computes a score for each network according to the fit of that network with the identified 
proteins of interest (referred to as the focus proteins). The score is derived from a p-value 
and indicates the probability of the focus proteins in a network being found together due to 
random chance. A score of 2 indicates that there is a 1 in 100 chance that the focus proteins 
are together in a network due to random chance, therefore scores greater than 2 have at 
least a 99% confidence of not being generated by random chance alone. Analysis must also 
take into account both the number of focus proteins identified and total known proteins in 
each network. Significant canonical pathways were identified with a threshold p value of 
<0.05 (after correction). If there are n proteins in a pathway, and f have been identified 
through iTRAQ, the p-value is the probability of finding f or more proteins in a set of n 
proteins randomly selected from the global molecular network. 
In addition, the lists of single nucleotide variants identified in Chapter 3 will be combined 
with the proteomic dataset to identify those proteins in which SNVs have also been found. 
A summary of the bioinformatics workflow can be seen in Figure 4.2. 
136 
 
 
Figure 4.2 – Bioinformatics analysis workflow for global proteomic assessment of patient 
matched primary and metastatic colorectal tumours. 
 
1
•iTRAQ data for proteins identified by 2 or more peptides with at least 90% 
confidence of correct sequence assignment, or by a single peptide with at 
least 99% confidence
2
•Log 2 transformation and batch correction
3
•Proteins present in at least 50% of the samples
4
•Two group comparisons (using Partek®) of: primary tumour and normal 
colorectal mucosa, metastatic tumour and normal colorectal mucosa, 
metastatic tumour and normal adjacent liver parenchyma, primary and 
metastatic tumour, primary tumour in responders and non-responders and 
metastatic tumour in responders and non-responders 
5
•Statistical analysis using ANOVA, and multiple test correction using 
Benjamini-Hochberg (significance taken as log2 fold change > 2 and 
unadjusted p<0.05)
6
•Pathway and network analysis of protein lists using Ingenuity Pathway 
Analysis
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4.3 Results  
4.3.1 Clinical and demographic data  
Sixteen patients presenting with liver limited stage IV disease were recruited to this study. 
Of these patients, 12 were male and 4 female ranging in age from 59-84 years at the time 
of diagnosis. Eleven patients underwent neoadjuvant chemotherapy, with 5 proceeding 
straight to surgery. Six patients underwent simultaneous resection of disease at both sites, 
with the remainder undergoing staged resections. The distribution of disease across the 
colon ranged from the rectum through to the caecum, with T-stage varying from 2-4 and a 
mixture of node positive and negative disease. Similarly 1-17 liver metastases were 
identified in one or both lobes of the liver and there was variation in tumour grade at both 
sites. All patients with the exception of patient 14 underwent resection at both sites. In this 
particular case the liver metastasis was unresectable due to its proximity to major vascular 
structures. A summary of the clinical and demographic data can be seen in Table 4.1.  
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Patient 
Age at 
Diagnosis Sex 
Neoadjuvant 
Chemotherapy 
Synchronously 
Resected 
Location of 
Primary 
Primary 
Histology 
T 
Stage 
N 
Stage 
Number 
of Mets 
Distribution 
of Mets 
Mets 
Histology 
1 66 M Y N Rectum 
Moderately 
differentiated 3 1 4 Unilobar 
Moderately 
differentiated 
2 73 M N N Sigmoid 
Poorly 
differentiated 3 1 2 Unilobar 
Moderately 
differentiated 
3 64 F Y Y Caecum 
Moderately 
differentiated 2 0 5 Bilobar 
Moderately 
differentiated 
4 84 M N N Rectum 
Moderately 
differentiated 3 1 2 Unilobar 
Moderately 
differentiated 
5 75 F Y N Rectum 
Poorly 
differentiated 3 0 2 Unilobar 
Moderately 
differentiated 
6 76 M N N Sigmoid 
Moderately 
differentiated 3 1 1 Unilobar 
Moderately 
differentiated 
7 73 F N N Sigmoid 
Moderately 
differentiated 4 0 1 Unilobar 
Moderately 
differentiated 
8 81 M N N Sigmoid 
Moderately 
differentiated 4 0 2 Unilobar 
Moderately 
differentiated 
9 79 M Y N Caecum 
Moderately 
differentiated 4 0 3 Bilobar 
Moderately 
differentiated 
10 62 M Y N Caecum 
Moderately 
differentiated 3 1 1 Unilobar 
Moderately 
differentiated 
11 76 M Y N Rectum 
Moderately 
differentiated 3 1 2 Bilobar 
Moderately 
differentiated 
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12 70 M Y Y Sigmoid 
Moderately 
differentiated 3 0 7 Bilobar 
Moderately 
differentiated 
13 67 M Y Y Ascending 
Well 
differentiated 4 0 16 Bilobar 
Well 
differentiated 
14 70 M Y Y Caecum 
Moderately 
differentiated 2 0 1 Unilobar Unavailable 
15 59 F Y Y Sigmoid 
Moderately 
differentiated 3 0 3 Bilobar 
Moderately 
differentiated 
16 75 M Y Y Sigmoid 
Poorly 
differentiated 3 2 4 Unilobar 
Poorly 
differentiated 
 
Table 4.1 – Clinical, demographic and disease characteristics of the 16 patients recruited to this study. Eleven patients underwent neoadjuvant 
chemotherapy, the remainder proceeding straight to surgery. Six patients were simultaneously resected. There was considerable variation in location of 
the primary tumour, disease stage and grade as well as metastatic burden. 
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4.3.2 Response evaluation  
Eleven of the 16 patients recruited underwent neoadjuvant chemotherapy, for which there 
was considerable variation in the regimen. One of these 11 patients did not undergo 
resection of the liver metastasis. As such, response evaluation data is available for 10 
patients (Table 4.2). 
 
Table 4.2 – Details of neoadjuvant chemotherapy agents and response evaluation. Five 
patients were chemonaive and 11 underwent neoadjuvant treatment. One of these 
patients failed to undergo resection of the liver metastasis. Response evaluation data is 
therefore available for 10 patients, 5 of which had a tumour regression grade of 1-2 
(responders) with the remaining 5 having a tumour regression grade of 3-4 (non-
responders). 
Patient 
Neoadjuvant 
Chemotherapy Agents 
Viable 
Tumour (%) 
Tumour 
Regression 
Grade Responder 
1 Y 
Oxaliplatin 
and 
capecitabine 60 3 No 
2 N 
 3 Y IrMdG 60 3 No 
4 N 
 5 Y FOLFOX 20 1 Yes 
6 N 
 7 N 
 8 N 
 9 Y FOLFOX 20 1 Yes 
10 Y IrMdG 90 4 No 
11 Y FOLFOX 40 2 Yes 
12 Y IrMdG 25 2 Yes 
13 Y IrMdG 40 2 Yes 
14 Y 
Irinotecan 
and 
capecitabine 
 
15 Y 
Oxaliplatin, 
capecitabine 
and 
cetuximab 80 4 No 
16 Y IrMdG 80 4 No 
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There was considerable variation (20-80%) in histopathological response to neoadjuvant 
treatment. Five patients had a tumour regression grade of 1-2 and five patients had a 
tumour regression grade of 3-4. For the purposes of analysis these two groups are referred 
to as responders and non-responders respectively. 
4.3.3 Overview of iTRAQ data  
A total of 5766 unique proteins were identified. Of these, 2637 were present in at least half 
of the samples and therefore taken forwards for analysis.   The data were acquired over 12 
experimental runs, with a mean (SD) of 10.2 (3.3) peptides used to identify the proteins of 
origin. This corresponds to a mean (SD) coverage of 21.04% (8.92%) for identified proteins.  
4.3.4 Comparison of primary tumour and normal colorectal mucosa 
This analysis identified all those proteins dysregulated in the primary tumour compared to 
the normal colorectal mucosa. A total of 25 proteins were identified, 6 of which were 
upregulated in the tumour and 19 downregulated (Table 4.3). 
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Accession 
Number Name p Value 
Log2 Fold-Change  
(Primary/Mucosa) 
Q8NHM4 Putative trypsin-6 2.39E-04 -187.923 
P10645 Chromogranin-A 6.22E-05 -11.296 
P07585 Decorin 1.73E-04 -10.715 
Q8WWA0 Intelectin-1 2.00E-04 -6.680 
P22676 Calretinin 6.62E-04 -4.223 
P00403 Cytochrome c oxidase subunit 2 6.86E-05 -4.215 
P00488 Coagulation factor XIII A chain 2.57E-04 -3.765 
P21397 
Amine oxidase [flavin-
containing] A 6.66E-04 -3.351 
P09669 
Cytochrome c oxidase subunit 
6C 3.13E-04 -2.990 
P14406 
Cytochrome c oxidase subunit 
7A2, mitochondrial 1.97E-04 -2.928 
P06576 
ATP synthase subunit beta, 
mitochondrial 6.97E-05 -2.812 
P25705 
ATP synthase subunit alpha, 
mitochondrial 6.28E-05 -2.662 
Q99795 Cell surface A33 antigen 1.41E-04 -2.540 
P48047 
ATP synthase subunit O, 
mitochondrial 2.32E-05 -2.458 
P56470 Galectin-4 1.06E-05 -2.281 
P50224 Sulfotransferase 1A3/1A4 5.97E-04 -2.231 
Q53EL6 
Programmed cell death protein 
4 1.39E-04 -2.158 
P19404 
NADH dehydrogenase 
[ubiquinone] flavoprotein 2, 
mitochondrial 4.19E-04 -2.077 
P31930 
Cytochrome b-c1 complex 
subunit 1, mitochondrial 1.45E-04 -2.075 
Q96D15 Reticulocalbin-3 1.01E-04 2.064 
P06733 Alpha-enolase 2.57E-05 2.108 
P50454 Serpin H1 2.34E-04 2.360 
P80188 
Neutrophil gelatinase-
associated lipocalin 4.48E-04 2.385 
P05109 Protein S100-A8 4.01E-04 2.668 
P06702 Protein S100-A9 1.58E-04 2.780 
 
Table 4.3 – Those proteins differentially expressed between the primary tumour and 
normal colorectal mucosa. 25 proteins were identified, 6 of which were upregulated 
(positive values for fold change) and 19 downregulated (negative values for fold change). 
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Analysing those proteins upregulated separately from those downregulated, Ingenuity core 
analysis of direct and indirect relationships revealed the significant upregulated canonical 
pathways in this group to be: Role of IL-17A in psoriasis, differential regulation of cytokine 
production in intestinal epithelial cells by IL-17A and IL-17F, glycolysis I, gluconeogenesis I 
and IL-17A signalling in fibroblasts. Similarly the downregulated canonical pathways were: 
Mitochondrial dysfunction, oxidative phosphorylation, melatoning degradation II, 
phenylalanine degradation IV and extrinsic prothrombin activation pathway. Statistics for 
these identified pathways can be seen in Table 4.4. 
Upregulated Pathways p-value Ratio 
Role of IL-17A in psoriasis 7.10E-06 2/13 (0.154) 
Differential regulation of cytokine 
production in intestinal epithelial cells 
7.59E-03 1/23 (0.043) 
Glycolysis I 7.91E-03 1/24 (0.042) 
Gluconeogenesis I 8.24E-03 1/25 (0.04) 
IL-17A signalling in fibroblasts 1.15E-02 1/35 (0.029) 
Downregulated Pathways p-value Ratio 
Mitochondrial dysfunction 7.35E-15 9/165 (0.055) 
Oxidative phosphorylation 2.07E-14 8/104 (0.077) 
Melatonin degradation II 3.74E-03 1/4(0.25) 
Phenylalanine degradation IV 1.30E-02 1/14 (0.071) 
Extrinsic prothrombin activation 
pathway 
1.49E-02 1/16 (0.062) 
 
Table 4.4 – Pathway analysis for proteins both upregulated and downregulated in the 
primary tumour when compared to normal adjacent colorectal mucosa. P-value is 
adjusted using Benjamini-Hochberg correction. Ratio identifies the number of focus 
molecules identified (numerator) in the pathway (denominator). 
Further analysis of all (unfiltered) biological pathways identified 1 upregulated network 
with a score greater than 2 pertaining to: cellular movement, haematological system 
development and function and immune cell trafficking. Similarly 5 downregulated networks 
were identified pertaining to: Cellular development, haematological system development 
and function, haematopoiesis, cell morphology, cell death and survival, cell-to-cell signalling 
and interaction, cancer, cellular growth and proliferation and cellular assembly and 
organisation. The focus molecules and statistics pertinent to these networks can be seen in 
Table 4.5.  
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Upregulated Networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 A4GALT,APOC2,CCL11,CTSS,ENO1,GSTA1,
HEXA,HEXB,HIF1A,HLA-
DQ,HSF2,HTR4,HTR7,IL25,IL37,IL1B,LAMA
3,LCN2,LILRA5,lymphotoxin-alpha1-
beta2,MMP8,MMP12,PGF,PLA2G3,PLA2G
5,POPDC2,PROK2,S100A8,S100A9,SERPIN
B9,SERPINH1,SHH,Sod,TAB3,TNF 
13 5 Cellular 
Movement, 
Haematological 
System 
Development 
and Function, 
Immune Cell 
Trafficking 
Downregulated Networks 
1 AGTR1,ATP5A1,ATP5B,C10orf10,CALB2,C
HGA,CHST2,COA3,COX5A,COX6C,CTNNAL
1,CTNNB1,DCD,DCN,estrogen 
receptor,F13A1,HSPE1,IFNE,IL6,IL10,IL13,
LGALS4,LILRA5,MAOA,MKK3/6,MT-
CO2,NID1,PDCD4,PDGFC,SEMA3C,SLC8A1
,STAT1,SURF1,TIMP4,TNF 
26 11 Cellular 
Development, 
Hematological 
System 
Development 
and Function, 
Hematopoiesis 
2 GPA33,KLF4 3 1 Cellular 
Development, 
Hematopoiesis, 
Cell Morphology 
3 ITLN1,LTF 3 1 Cell Death and 
Survival, Cell 
Morphology, 
Cell-To-Cell 
Signaling and 
Interaction 
4 NDUFV2,RBM5 3 1 Cancer, Cellular 
Development, 
Cellular Growth 
and Proliferation 
5 RTN4,UQCRC1 3 1 Cell Death and 
Survival, Cell 
Morphology, 
Cellular Assembly 
and Organization 
 
Table 4.5 - Network analysis for proteins both upregulated and downregulated in the 
primary tumour when compared to normal adjacent colorectal mucosa. The score is 
derived from a p-value and indicates the probability of the focus molecules in a network 
being found together due to random chance. Focus molecules is the total number of 
proteins of interest identified in the respective network. 
4.3.5 Comparison of metastatic tumour and normal colorectal mucosa 
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This analysis identified all those proteins dysregulated in the metastatic tumour compared 
to the normal colorectal mucosa. A total of 53 proteins were identified, 13 of which were 
upregulated in the tumour and 40 downregulated (Table 4.6). 
Accession 
Number Name p Value 
Log2 Fold-Change 
(Metastasis/Mucosa 
Q8NHM4 Putative trypsin-6 2.21E-04 -231.682 
P20774 Mimecan 5.66E-04 -67.140 
Q03135 Caveolin-1 3.51E-04 -20.544 
P10645 Chromogranin-A 2.75E-05 -12.934 
P02511 Alpha-crystallin B chain 1.50E-03 -10.484 
P07585 Decorin 1.63E-04 -10.388 
O60844 
Zymogen granule membrane 
protein 16 7.41E-04 -9.924 
Q8WWA0 Intelectin-1 2.20E-05 -9.843 
P43121 
Cell surface glycoprotein 
MUC18 9.46E-04 -8.682 
Q96BQ1 Protein FAM3D 2.90E-04 -7.850 
A8K7I4 
Calcium-activated chloride 
channel regulator 1 8.23E-04 -5.347 
Q9Y6R7 IgGFc-binding protein 1.35E-03 -4.591 
Q96A26 Protein FAM162A 1.30E-03 -4.281 
Q02952 A-kinase anchor protein 12 1.37E-04 -4.268 
P22676 Calretinin 9.49E-04 -4.166 
Q09666 
Neuroblast differentiation-
associated protein AHNAK 4.27E-05 -4.085 
Q9NR45 Sialic acid synthase 3.98E-04 -3.972 
P00403 
Cytochrome c oxidase 
subunit 2 1.14E-04 -3.839 
O75489 
NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 3, mitochondrial 1.73E-04 -3.469 
P23946 Chymase 2.27E-04 -3.391 
O00159 Myosin-Ic 2.81E-04 -3.185 
P14406 
Cytochrome c oxidase 
subunit 7A2, mitochondrial 7.69E-05 -3.171 
Q9Y639 Neuroplastin 1.24E-04 -3.166 
P09669 
Cytochrome c oxidase 
subunit 6C 1.66E-04 -3.146 
P56470 Galectin-4 2.42E-07 -2.95662 
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Q99795 Cell surface A33 antigen 5.44E-05 -2.950 
P00488 
Coagulation factor XIII A 
chain 1.27E-03 -2.910 
P09936 
Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 1.36E-03 -2.888 
Q99798 
Aconitate hydratase, 
mitochondrial 1.21E-03 -2.602 
P05023 
Sodium/potassium-
transporting ATPase subunit 
alpha-1 6.41E-05 -2.590 
P25705 
ATP synthase subunit alpha, 
mitochondrial 7.71E-05 -2.567 
Q53EL6 
Programmed cell death 
protein 4 1.46E-05 -2.523 
P50224 Sulfotransferase 1A3/1A4 1.43E-04 -2.504 
P06576 
ATP synthase subunit beta, 
mitochondrial 2.10E-04 -2.490 
P19404 
NADH dehydrogenase 
[ubiquinone] flavoprotein 2, 
mitochondrial 6.70E-05 -2.362 
P48047 
ATP synthase subunit O, 
mitochondrial 3.48E-05 -2.344 
O95571 Protein ETHE1, mitochondrial 3.86E-07 -2.202 
P01877 Ig alpha-2 chain C region 2.59E-04 -2.185 
Q14651 Plastin-1 1.21E-04 -2.165 
Q9P2B2 
Prostaglandin F2 receptor 
negative regulator 1.01E-03 -2.098 
P34897 
Serine 
hydroxymethyltransferase, 
mitochondrial 5.92E-05 2.038 
P17096 
High mobility group protein 
HMG-I/HMG-Y 8.96E-04 2.072 
P06733 Alpha-enolase 2.08E-05 2.107 
Q53H82 Beta-lactamase-like protein 2 1.11E-03 2.114 
P50454 Serpin H1 6.50E-04 2.130 
Q96HE7 ERO1-like protein alpha 4.37E-04 2.212 
P08195 
4F2 cell-surface antigen 
heavy chain 1.56E-03 2.398 
Q06787 
Fragile X mental retardation 
1 protein 5.60E-04 2.667 
P13797 Plastin-3 4.66E-05 3.007 
P19971 Thymidine phosphorylase 4.73E-04 3.656 
P40261 Nicotinamide N- 1.21E-03 4.242 
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methyltransferase 
P05181 Cytochrome P450 2E1 1.12E-03 6.000 
P05177 Cytochrome P450 1A2 7.07E-04 32.731 
 
Table 4.6 – Those proteins differentially expressed between the metastatic tumour and 
normal colorectal mucosa. 53 proteins were identified, 13 of which were upregulated 
(positive values for fold change) and 40 downregulated (negative values for fold change). 
Analysing those proteins upregulated separately from those downregulated, Ingenuity core 
analysis of direct and indirect relationships revealed the significant upregulated canonical 
pathways in this group to be: bupronion degradation, acetone degradation I, estrogen 
biosynthesis, nicotine degradation III and melatonin degradation I. Similarly the 
downregulated canonical pathways were: oxidative phosphorylation, mitochondrial 
dysfunction, CMP-N-acetylneuramine biosynthesis I, extrinsic prothrombin activation 
pathway and Parkinson’s signalling. Statistics for these identified pathways can be seen in 
Table 4.7. 
Upregulated Pathways p-value Ratio 
Bupropion degradation 1.34E-04 2/24 (0.083) 
Acetone degradation I 1.41E-04 2/25 (0.08) 
Estrogen biosynthesis 2.95E-04 2/36 (0.056) 
Nicotine degradation III 4.41E-04 2/44 (0.045) 
Melatonin degradation I 5.03E-04 2/47 (0.043) 
Downregulated Pathways p-value Ratio 
Oxidative phosphorylation 3.77E-11 8/104 (0.077) 
Mitochondrial dysfunction 4.46E-11 9/165 (0.055) 
CMP-N-acetylneuraminate biosynthesis I 1.04E-02 1/5 (0.2) 
Extrinsic prothrombin activation pathway 3.30E-02 1/16 (0.062) 
Parkinson’s signalling 3.30E-02 1/16 )0.062) 
 
Table 4.7 – Pathway analysis for proteins both upregulated and downregulated in the 
metastatic tumour when compared to normal adjacent colorectal mucosa. P-value is 
adjusted using Benjamini-Hochberg correction. Ratio identifies the number of focus 
molecules identified (numerator) in the pathway (denominator). 
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Further analysis of all (unfiltered) biological pathways identified 3 upregulated networks 
with a score greater than 2 pertaining to: cellular assembly and organisation, drug 
metabolism, energy production, post-translational modification, protein folding, 
cardiovascular disease, cellular movement, inflammatory disease, and nervous system 
development and function. Similarly 2 downregulated networks were identified pertaining 
to: cardiovascular system development and function, cell-to-cell signalling and interaction, 
tissue development, cellular compromise, tissue morphology and cellular growth and 
proliferation. The focus molecules and statistics pertinent to these networks can be seen in 
Table 4.8.  
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Upregulated Networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 C9orf3,CDK5R1,CTNNB1,CYP1A2,CYP2E1,
DVL3,DYNLL1,ENO1,EPHB2,FAF1,FMR1,G
FER,GLI2,HAS3,Hat,HIF1AN,HMGA1,LTBP
2,mir-24,MYC,NFkB (complex),PI3K 
(complex),PLS3,RAB31,RGS3,SERPINH1,SF
RP1,SHMT2,SLC3A2,SNRK,ST3GAL1,TDG,T
GFB1,TYMP,ZMIZ2 
24 10 Cellular Assembly 
and Organization, 
Drug 
Metabolism, 
Energy 
Production 
2 ERO1L,PDIA2 3 1 Post-
Translational 
Modification, 
Protein Folding, 
Cardiovascular 
Disease 
3 CHI3L1,EIF2AK2,NNMT 3 1 Cellular 
Movement, 
Inflammatory 
Disease, Nervous 
System 
Development 
and Function 
Downregulated Networks 
1 ACO2,AGTR1,Akt,ANXA9,ATP5A1,ATP5B,
CALB2,CAV1,CD44,CDH13,CMA1,COA3,C
OX5A,COX6C,DCN,estrogen 
receptor,F12,FAT1,IL6,IL1B,LGALS4,LILRA
5,MAP1B,MAP3K14,MCAM,MT-
CO2,MYO1C,ORM1,PDCD4,PIK3R2,RPL6,R
PL35A,RPS11,S1PR2,SURF1 
26 13 Cardiovascular 
System 
Development 
and Function, 
Cell-To-Cell 
Signaling and 
Interaction, 
Tissue 
Development 
2 AHNAK,AIM1,AKAP12,APP,ATP1A1,CD81,
CHGA,CLCA1,CLEC4A,CRYAB,CTNNAL1,CT
NNB1,DVL1,ERK1/2,ETHE1,F13A1,FAM16
2A,GPR183,IL13,MAPK8IP1,MN1,MT1L,M
UC5AC,PERP,PLS1,PPP3CA,PTGFRN,RAD2
3A,SEMA3C,SMARCA4,SORT1,STXBP1,TP5
3,tyrosine kinase,UCHL1 
23 12 Cellular 
Compromise, 
Tissue 
Morphology, 
Cellular Growth 
and Proliferation 
 
Table 4.8 - Network analysis for proteins both upregulated and downregulated in the 
metastatic tumour when compared to normal adjacent colorectal mucosa. The score is 
derived from a p-value and indicates the probability of the focus molecules in a network 
being found together due to random chance. Focus molecules is the total number of 
proteins of interest identified in the respective network. 
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4.3.6 Comparison of metastatic tumour and normal adjacent liver parenchyma 
This analysis identified all those proteins dysregulated in the metastatic tumour compared 
to the normal liver parenchyma. A total of 444 proteins were identified, 164 of which were 
upregulated in the tumour and 280 downregulated. The data set can be found in Appendix 
3 – Proteomic comparison of metastatic tumour and normal adjacent liver parenchyma. 
Analysing those proteins upregulated separately from those downregulated, Ingenuity core 
analysis of direct and indirect relationships revealed the significant upregulated canonical 
pathways in this group to be: acute phase response signalling, LXR/RXR activation, FXR/RXR 
activation, complement system and coagulation system. Similarly the downregulated 
canonical pathways were: serotonin degradation, LPS/IL mediated inhibition of RXR, fatty 
acid β-oxidation I, noradrenaline and adrenaline degradation and xenobiotic metabolism 
signalling. Statistics for these identified pathways can be seen in Table 4.9. 
Upregulated Pathways p-value Ratio 
Acute phase response signalling 6.23E-30 29/168 (0.173) 
LXR/RXR activation 2.10E-26 24/121 (0.198) 
FXR/RXR activation 1.56E-24 23/125 (0.184) 
Complement system 2.15E-19 13/32 (0.406) 
Coagulation system 2.22E-13 10/35 (0.286) 
Downregulated Pathways p-value Ratio 
Serotonin degradation 4.85E-27 22/52 (0.423) 
LPS/IL mediated inhibition of RXR 8.04E-27 35/208 (0.168) 
Fatty acid β-oxidation I 2.31E-24 17/29 (0.586) 
Noradrenaline and adrenaline 
degradation 
2.42E-23 17/32 (0.531) 
Xenobiotic metabolism signalling 1.52E-21 33/256 (0.129) 
 
Table 4.9 – Pathway analysis for proteins both upregulated and downregulated in the 
metastatic tumour when compared to normal adjacent colorectal mucosa. P-value is 
adjusted using Benjamini-Hochberg correction. Ratio identifies the number of focus 
molecules identified (numerator) in the pathway (denominator). 
Further analysis of all (unfiltered) biological pathways identified 8 upregulated networks 
with a score greater than 2 pertaining to: cell-to-cell signalling and interaction, 
haematological system development and function, immune cell trafficking, cellular 
movement, cancer, digestive system development and function, developmental disorder, 
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haematological disease, cellular movement, organismal injury and abnormalities, 
dermatological diseases and conditions, hereditary disorder, organismal survival, cellular 
development, embryonic development, organismal development and gene expression. 
Similarly 10 downregulated networks were identified pertaining to: lipid metabolism, small 
molecule biochemistry, vitamin and mineral metabolism, energy production,  molecular 
transport, endocrine system development and function, drug metabolism, nucleic acid 
metabolism, amino acid metabolism, infectious disease, carbohydrate metabolism, cancer, 
organismal injury and abnormalities, reproductive system disease, antimicrobial response, 
metabolic disease, neurological disease and psychological disorders. The focus molecules 
and statistics pertinent to these networks can be seen in Table 4.10.  
Upregulated Networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 Alpha 
Actinin,ANXA1,APOA1,APOA2,APOA4,AP
OB,APOE,APOH,C3,C5,C7,C9,CFB,CLU,Cre
b,EPCAM,Fibrinogen,HDL,HDL-
cholesterol,HPX,ITGAM,ITGB2,KNG1,LCN
2,LDL,LTF,MPO,NFkB 
(complex),PLG,PLTP,PRELP,PRTN3,S100A1
2,TES,TSPAN8 
49 27 Cell-To-Cell 
Signaling and 
Interaction, 
Hematological 
System 
Development 
and Function, 
Immune Cell 
Trafficking 
2 Akt,Ap1,ATP1B3,AZGP1,CAPG,CD9,CFH,C
FL1,CLDN3,COL12A1,DCN,estrogen 
receptor,FSH,GPRC5A,GSTP1,HMGA1,Hsp
90,IgG,Jnk,KRT19,LGALS3,LGALS3BP,MYH
14,PADI4,PDGF BB,PI3K 
(family),POSTN,S100A4,S100A6,SDCBP,SL
C12A2,TF,TFRC,THBS1,VIM 
44 26 Cellular 
Movement, 
Cancer, Digestive 
System 
Development 
and Function 
3 A2M,Alp,ANXA2,CD44,COL1A1,Cyclin 
A,ERK,ERK1/2,F2,FGA,FGB,FGG,FLNA,FN1,
Focal adhesion kinase,GC,Igm,IL12 
(complex),Iti,ITIH1,ITIH2,MVP,MYH11,P38 
MAPK,PI3K 
(complex),Pkc(s),S100A10,SERPINC1,SERP
IND1,SET,SFN,TIMP1,TNC,Vegf,VTN 
37 22 Cellular 
Movement, 
Developmental 
Disorder, 
Hematological 
Disease 
4 ABCC5,CDH17,CHMP4B,CHMP4C,COL1A2
,CTNNB1,EFEMP1,ESR1,FBLN2,FBN1,GJB1
,GTSE1,HIST1H1B,KIFC1,KRT20,LDHB,MA
GI1,NUPR1,PDCD6IP,PKM,PPARG,RAD23A
,S100P,SEMA3C,SLC2A1,SLC2A12,SLC39A
8,TAGLN2,TCF4,TMEM97,TMSB10/TMSB4
X,TP53,UNC5B,VEGFA,VENTX 
18 14 Cellular 
Movement, 
Cancer, 
Organismal Injury 
and 
Abnormalities 
5 ACTC1,AGTR1,AHSG,ANXA3,APCS,ASPN,C
1R,C1S,C4BPA,CDX2,CKAP4,CLDN7,CLIC1,
18 14 Organismal Injury 
and 
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DEPTOR,F5,F11,GLS,HNF1A,IFI44,LAMA4,
LBR,LIPA,MAPK1,MEP1A,MT1X,MUC13,M
X2,PLA1A,SERPINB1,SERPING1,SMAD3,SO
AT2,TCR,UGT1A9 (includes 
others),YWHAZ 
Abnormalities, 
Dermatological 
Diseases and 
Conditions, 
Hereditary 
Disorder 
6 Actin,AGR2,ALDOA,BGN,CDKN1A,CSF2,CX
3CR1,CYP4F3,EPHB2,FFAR2,FSTL3,GSN,HE
XB,HIF1A,HSPH1,LOXL2,Ltbp,LUM,MAPK1
3,mir-
145,NOV,OLFM4,PBRM1,S100A8,S100A9,
S100A11,SERPINH1,SLPI,SMARCA4,SPAG4
,TAGLN,TEC,TGFB1,TGFBI,TGM2 
16 13 Cancer, 
Organismal 
Survival, Cellular 
Movement 
7 AIF1,APOL1,AUTS2,C8A,CABP7,CAV1,CP,D
SG2,EFCAB6,ELAVL1,EMID1,HMOX1,HSP,I
FNG,IGHM,IGLL1/IGLL5,IL6,Interferon 
alpha,MARCKSL1,miR-146a-5p (and other 
miRNAs w/seed 
GAGAACU),MORC2,ORM1,PCOLCE,PGLYR
P2,PIGR,PTMA,RTDR1,SLC2A11,SMC1B,T
HBS2,TNF,TRIL,TRIOBP,TTC28,TTR 
16 13 Cellular 
Development, 
Embryonic 
Development, 
Organismal 
Development 
8 26s 
Proteasome,BCL2,CCND1,CEACAM1,CEAC
AM5,CTNNB1,CXCL8,DICER1,DPEP1,GFI1,I
GHG1,IL2,IL6,IL1A,IRS1,ITGB3,KLK2,MAPT
,MGEA5,MYC,SERPINA1,SERPINA3,SERPI
NF1,SP1,STAT3,TCF,TGFB1,TNF 
8 7 Cellular 
Development, 
Cancer, Gene 
Expression 
Downregulated Networks 
1 ABLIM,AIFM1,ALDH1A1,ALDH3A2,CAT,CR
AT,CYP2E1,CYP3A4,CYP4F2,CYP8B1,DHCR
7,ENO3,FASN,FSH,GOT1,GPT,GSTA2,Histo
ne 
h3,HSD11B1,HSD17B2,IDH1,Jnk,Lh,MGST
1,MTTP,NFkB 
(complex),NQO2,PGRMC1,POR,RNA 
polymerase 
II,Rxr,SLC27A2,SOD2,SULT2A1,TCF 
41 26 Lipid 
Metabolism, 
Small Molecule 
Biochemistry, 
Vitamin and 
Mineral 
Metabolism 
2 AADAC,ACADS,ACADVL,ADH1A,AK4,AKR1
C4,AKR1C1/AKR1C2,BHMT2,CCDC87,CDK
N1A,CYB5A,CYP3A5,DECR1,DYNC1I2,FH,G
LUD1,HADHA,HADHB,HNF1A,LDL-
cholesterol,LOH12CR1,MAT1A,MCCC1,m
ediator,MTORC1,PCK2,SKIV2L2,SREBF1,T
AL1,TFR2,TFRC,TUBB6,TXLNG,UGT2B15,Z
FC3H1 
28 21 Energy 
Production, Lipid 
Metabolism, 
Small Molecule 
Biochemistry 
3 ABCB11,ACAA1,ACAA2,ACOX1,ACSL1,ACS
M2B,ADH1B,APOA5,APOC3,APOM,CPT2,
CPT1A,CYP3A4,CYP4A11,CYP7A1,DDX20,F
ABP2,FABP6,G6PC,GLYATL1,HADH,HMGC
S2,KNG1,mir-21,mir-27,miR-124-3p (and 
other miRNAs w/seed 
17 15 Lipid 
Metabolism, 
Small Molecule 
Biochemistry, 
Molecular 
Transport 
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AAGGCAC),NR1H4,PPARA,Rxr,RXRA,RXRG
,SLC10A2,SUCLG2,TCF7,UGT2B4 
4 ACAT1,ACAT2,ALDH2,ALDH5A1,ALOX15,A
POBEC3B,AQP9,CA2,CSRNP1,DAPK2,ELM
OD1,EPB41L4A-
AS1,FANCC,H6PD,ING2,KYNU,LILRA5,LSS,
NCKIPSD,NPPB,NR3C1,NUPR1,P4HB,PAX3
,PEBP1,PRDX3,RAF1,SAMD4A,SLC25A20,S
RGAP2,TGM2,TNF,UGT2B7,WDR3,YWHA
G 
15 13 Endocrine 
System 
Development 
and Function, 
Lipid 
Metabolism, 
Small Molecule 
Biochemistry 
5 ACADM,AGTR1,ATP5B,CYP1A2,CYP2A6 
(includes 
others),CYP2C8,CYP2C9,CYP7A1,ENO1,ES
RRA,FOXA3,GFER,HNRNPA2B1,HNRNPM,
HSD17B4,mir-
122,MUT,NR1I2,NR1I3,P110,p85 
(pik3r),PIPOX,PPARGC1A,PPIA,RPL6,RPS2,
SDHA,SDHB,SEC14L2,SEMA3B,SULT1A2,T
DGF1,TMPO,TUBA1A,ZNF217 
15 13 Drug 
Metabolism, 
Endocrine 
System 
Development 
and Function, 
Energy 
Production 
6 ACSM3,BDH1,BRD4,CDC45,CDC42EP5,CD
CA7L,CDK4,CES1,DCTPP1,ENO1,ENPP2,EP
AS1,FOSL2,GCDH,GYS2,HAMP,IL17RB,IQG
AP2,LAMP2,MC4R,miR-145-5p (and other 
miRNAs w/seed 
UCCAGUU),MTHFD1,MYC,PBLD,PIM2,PN
N,RGS3,SERINC3,SHMT1,SHMT2,SORD,SO
X5,TMPRSS6,TYMS,UGP2 
13 12 Nucleic Acid 
Metabolism, 
Small Molecule 
Biochemistry, 
Amino Acid 
Metabolism 
7 ABCD3,ABLIM1,ACO1,ADAP1,CRYL1,DAK,
DHX58,DRD3,ERP29,FBP1,FLNA,GATM,IC
K,IFI44,IFIH1,ITGB7,KHK,LBR,MAPK1,MGE
A5,MMP14,MX2,NIPSNAP1,NNT,NREP,OA
SL,PAK1,PECR,PFKM,PGM1,SLC2A3,SOX1
1,TCR,TGFBR2,TUBA1A 
13 13 Infectious 
Disease, 
Carbohydrate 
Metabolism, 
Small Molecule 
Biochemistry 
8 AKR1C3,ALDH6A1,AR,ASGR1,ASS1,CDH1,
COMT,ENTPD5,EPHX1,ESR1,ESR2,FKBP4,F
KBPL,FMN1,FOXA1,GREB1,HSD17B6,Hsp9
0,IDH2,KDM4B,LTBP1,MAOA,MARC2,MG
AT3,NCOA4,NEUROG1,NFATC4,PRKCD,RP
RM,SIAH2,SOD1,SOST,TMEM74,TMOD1,V
AV3 
13 12 Cancer, 
Organismal Injury 
and 
Abnormalities, 
Reproductive 
System Disease 
9 ADH5,AIM2,ARG1,CBS/LOC102724560,CC
NG2,CLEC4M,CSNK2A1,CTH,CYP17A1,DD
B2,ECHDC3,EIF2AK2,EPHX2,FAM213A,GB
P1,HAS1,HEBP1,HRH2,IFI27,IL18RAP,Inter
feron 
alpha,ISG20,MAOB,MAPKAPK2,miR-483-
3p (miRNAs w/seed 
CACUCCU),MKNK1,NF1,OAS1,P38 
MAPK,SMAD4,SP1,TRIB1,UGDH,UNC93B1
,USP18 
12 11 Amino Acid 
Metabolism, 
Small Molecule 
Biochemistry, 
Antimicrobial 
Response 
10 ACTB,APBA2,APOE,APP,ASL,ATP5A1,CCN 10 12 Metabolic 
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D1,CEP55,CES2,DDT,GART,GSTO1,HSD17
B10,HSPA1L,ITM2B,MLH1,MYBL1,PDX1,P
FAS,PFKP,PHGDH,Pp2b,PPAT,PPP3CA,PRD
X6,RFC1,RNF219,SCP2,SLC2A2,SNRK,SNR
NP70,TAGLN2,TMSB15A,TP53,UCHL1 
Disease, 
Neurological 
Disease, 
Psychological 
Disorders 
 
Table 4.10 - Network analysis for proteins both upregulated and downregulated in the 
metastatic tumour when compared to normal adjacent liver parenchyma. The score is 
derived from a p-value and indicates the probability of the focus molecules in a network 
being found together due to random chance. Focus molecules is the total number of 
proteins of interest identified in the respective network. 
4.3.7 Comparison of primary and metastatic tumours 
This analysis identified all those proteins significantly differentially expressed in the 
metastatic tumour compared to the primary tumour.  A total of 67 proteins were identified, 
58 of which were more abundant in the metastatic tumour and 9 were less abundant (Table 
4.11).  
Accession 
Number Name p Value 
Log2 Fold-Change 
(Metastasis/Primary) 
P08311 Cathepsin G 6.05E-03 -5.220 
P48539 Purkinje cell protein 4 1.46E-02 -4.063 
P24158 Myeloblastin 5.40E-03 -3.844 
P84157 
Matrix-remodeling-
associated protein 7 3.21E-02 -2.579 
P25815 Protein S100-P 2.50E-02 -2.505 
P06702 Protein S100-A9 1.05E-03 -2.077 
P05106 Integrin beta-3 3.78E-02 -2.068 
P23142 Fibulin-1 9.89E-03 -2.040 
Q02952 A-kinase anchor protein 12 1.55E-02 -2.037 
P01019 Angiotensinogen 4.10E-02 2.012 
P13671 Complement component C6 4.65E-02 2.032 
P04114 Apolipoprotein B-100 1.28E-02 2.048 
P15153 
Ras-related C3 botulinum 
toxin substrate 2 2.02E-02 2.152 
O14773 Tripeptidyl-peptidase 1 1.69E-02 2.212 
Q9BX68 
Histidine triad nucleotide-
binding protein 2, 
mitochondrial 1.93E-02 2.260 
P42765 3-ketoacyl-CoA thiolase, 4.04E-02 2.292 
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mitochondrial 
P36269 
Gamma-glutamyltransferase 
5 4.61E-03 2.360 
P08571 
Monocyte differentiation 
antigen CD14 1.10E-03 2.364 
P02792 Ferritin light chain 3.17E-02 2.385 
P07858 Cathepsin B 2.86E-03 2.388 
P40261 
Nicotinamide N-
methyltransferase 1.59E-02 2.437 
P19971 Thymidine phosphorylase 4.02E-03 2.438 
P02787 Serotransferrin 1.55E-02 2.469 
P01834 Ig kappa chain C region 1.42E-02 2.477 
P01857 Ig gamma-1 chain C region 3.23E-02 2.482 
P34896 
Serine 
hydroxymethyltransferase, 
cytosolic 2.06E-02 2.494 
P05177 Cytochrome P450 1A2 3.40E-03 2.557 
P21695 
Glycerol-3-phosphate 
dehydrogenase [NAD+], 
cytoplasmic 3.34E-02 2.578 
P08123 Collagen alpha-2(I) chain 3.97E-02 2.743 
P51884 Lumican 3.26E-02 2.779 
Q00796 Sorbitol dehydrogenase 1.43E-02 2.839 
Q8IUX7 
Adipocyte enhancer-binding 
protein 1 5.60E-03 2.872 
P15104 Glutamine synthetase 4.91E-02 2.994 
Q9UJS0 
Calcium-binding 
mitochondrial carrier 
protein Aralar2 1.94E-02 3.037 
Q7Z4W1 L-xylulose reductase 3.03E-02 3.065 
Q4G0N4 
NAD kinase domain-
containing protein 1 6.71E-03 3.146 
Q16719 Kynureninase 3.73E-02 3.158 
P01011 Alpha-1-antichymotrypsin 2.36E-03 3.186 
P22307 
Non-specific lipid-transfer 
protein 3.28E-02 3.235 
P00367 
Glutamate dehydrogenase 
1, mitochondrial 1.95E-02 3.410 
P02749 Beta-2-glycoprotein 1 3.82E-02 3.589 
P28845 
Corticosteroid 11-beta-
dehydrogenase isozyme 1 2.32E-02 3.649 
P28332 Alcohol dehydrogenase 6 1.30E-02 3.674 
P01033 
Metalloproteinase inhibitor 
1 6.73E-03 3.685 
P09467 
Fructose-1,6-bisphosphatase 
1 2.75E-02 3.972 
P35442 Thrombospondin-2 4.00E-03 4.321 
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P02649 Apolipoprotein E 5.18E-03 4.333 
P04196 Histidine-rich glycoprotein 1.27E-02 4.599 
P10620 
Microsomal glutathione S-
transferase 1 4.56E-02 4.652 
P04004 Vitronectin 1.25E-02 4.721 
P32754 
4-hydroxyphenylpyruvate 
dioxygenase 5.36E-03 6.385 
Q06828 Fibromodulin 2.79E-03 6.766 
P11498 
Pyruvate carboxylase, 
mitochondrial 1.17E-02 7.180 
P00167 Cytochrome b5 3.30E-02 7.915 
P05089 Arginase-1 3.85E-02 9.069 
P05181 Cytochrome P450 2E1 3.98E-04 9.526 
P00325 Alcohol dehydrogenase 1B 3.47E-02 12.136 
P33121 
Long-chain-fatty-acid--CoA 
ligase 1 4.67E-02 14.035 
P24752 
Acetyl-CoA 
acetyltransferase, 
mitochondrial 2.70E-02 15.347 
P51888 Prolargin 7.03E-03 17.972 
P05062 
Fructose-bisphosphate 
aldolase B 4.04E-02 22.005 
P50440 
Glycine amidinotransferase, 
mitochondrial 2.12E-02 34.116 
O75891 
Cytosolic 10-
formyltetrahydrofolate 
dehydrogenase 4.02E-02 34.809 
P31513 
Dimethylaniline 
monooxygenase [N-oxide-
forming] 3 2.52E-02 36.361 
P30038 
Delta-1-pyrroline-5-
carboxylate dehydrogenase, 
mitochondrial 2.68E-02 54.551 
P08319 Alcohol dehydrogenase 4 3.35E-02 253.897 
Q06520 Bile salt sulfotransferase 4.40E-03 954.271 
 
Table 4.11 – Those proteins differentially expressed between the metastatic tumour and 
the primary tumour. 67 proteins were identified, 58 of which were upregulated (positive 
values for fold change) and 9 downregulated (negative values for fold change). 
Analysing those proteins upregulated separately from those downregulated, Ingenuity core 
analysis of direct and indirect relationships revealed the significant upregulated canonical 
pathways in this group to be: FXR/RXR activation, ethanol degradation II, LXR/RXR 
activation, LPS/IL-I mediated inhibition of RXR and noradrenaline and adrenaline 
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degradation. Similarly the downregulated canonical pathways were: role of IL-17A in 
psoriasis, glioma invasiveness signalling, agrin interactions at neuromuscular junction, 
macropinocytosis signalling and caveolar-mediated endocytosis signalling. Statistics for 
these identified pathways can be seen in Table 4.12. 
Upregulated Pathways p-value Ratio 
FXR/RXR activation 5.06E-09 8/125 (0.064) 
Ethanol degradation II 3.44E-08 5/30 (0.167) 
LXR/RXR activation 9.91E-08 7/121 (0.058) 
LPS/IL-I mediated inhibition of RXR 2.67E-07 8/208 (0.038) 
Noradrenaline and adrenaline 
degradation 
2.95E-06 4/32 (0.125) 
Downregulated Pathways p-value Ratio 
Role of IL-17A in psoriasis 5.72E-03 1/13 (0.077) 
Glioma invasiveness signalling 2.49E-02 1/57 (0.018) 
Agrin interactions at neuromuscular 
junction 
2.92E-02 1/67 (0.015) 
Macropinocytosis signalling 2.96E-02 1/68 (0.015) 
Caveolar-mediated endocytosis 
signalling 
3.13E-02 1/72 (0.014) 
 
Table 4.12 – Pathway analysis for proteins both upregulated and downregulated in the 
metastatic tumour when compared to the primary tumour. P-value is adjusted using 
Benjamini-Hochberg correction. Ratio identifies the number of focus molecules identified 
(numerator) in the pathway (denominator). 
Further analysis of all (unfiltered) biological pathways identified 3 upregulated networks 
with a score greater than 2 pertaining to: lipid metabolism, small molecule biochemistry, 
vitamin and mineral metabolism, cellular movement, haematological system development 
and function and immune cell trafficking. Similarly, 1 downregulated network was identified 
pertaining to: cell-to-cell signalling and interaction, haematological system development 
and function and immune cell trafficking. The focus molecules and statistics pertinent to 
these networks can be seen in Table 4.13.  
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Upregulated Networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 ABHD2,ACAT1,ACSL1,ADH4,AIM1,AKAP13
,CTNNB1,CTSB,CYB5A,CYP1A2,CYP2E1,DY
NLL1,DYNLL2,GFER,GLA,GLUL,HNF1A,HSD
11B1,HSD17B2,IGHG1,LUM,MGST1,MSX2
,MT1L,NFIC,NR3C1,PGR,PTP4A1,S100P,SE
RPINA5,SMARCA4,TFEB,TNS4,TPP1,VTN 
26 16 Lipid 
Metabolism, 
Small Molecule 
Biochemistry, 
Vitamin and 
Mineral 
Metabolism 
2 ACPP,APOB,APOE,ARG1,CDCA7L,Cg,DHCR
7,EIF2AK2,FBP1,FDFT1,FMOD,FTL,GLIPR1,
HMGCS1,LAMP2,LOC102724788/PRODH,
LSS,MGEA5,MYC,NAP1L1,NNMT,PERP,PF
KM,Pp2b,S100A2,SCP2,SHC1,SHMT1,SNR
K,SULT2A1,TAF5L,TIMP1,TMSB10/TMSB4
X,TP53,TPD52L1 
19 12 Lipid 
Metabolism, 
Small Molecule 
Biochemistry, 
Vitamin and 
Mineral 
Metabolism 
3 ABCC3,AFP,AGT,APOH,C3,CASP3,CD14,CF
B,COL1A2,CYP27A1,FCGR1B,FGA,GMFG,H
MOX1,HSPE1,IL6,IL17D,KYNU,LGALS4,LIL
RA4,LILRA5,MMP8,PRELP,RAC2,S100A10,
SCAVENGER receptor CLASS 
A,SERPINA3,SIRT6,SREBF1,TF,THBS2,TNF,
TNFRSF18,TNIP3,TYMP 
19 11 Cellular 
Movement, 
Hematological 
System 
Development 
and Function, 
Immune Cell 
Trafficking 
Downregulated Networks 
1 AKAP12,BCAN,CCL5,CDKN3,CELSR2,CTSG,
ENPP1,ESR1,FBLN1,Fibrin,FN1,GUSB,HEX
A,IL1B,ITGB3,ITPA,MAPK12,mir-224,miR-
224-5p (miRNAs w/seed AAGUCAC),miR-
24-3p (and other miRNAs w/seed 
GGCUCAG),PCP4,PPIF,PRIM1,PRTN3,S100
A9,S100P,SEMA3A,SERPINH1,SLC39A8,So
d,SQLE,TGFB1,TMEM97,TOP2B,TP53 
21 7 Cell-To-Cell 
Signaling and 
Interaction, 
Hematological 
System 
Development 
and Function, 
Immune Cell 
Trafficking 
 
Table 4.13 - Network analysis for proteins both upregulated and downregulated in the 
metastatic tumour when compared to the primary tumour. The score is derived from a p-
value and indicates the probability of the focus molecules in a network being found 
together due to random chance. Focus molecules is the total number of proteins of 
interest identified in the respective network. 
4.3.8 Predictive biomarkers in the primary tumours 
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Patients from whom matched primary and metastatic tissue had been obtained and 
neoadjuvant chemotherapy had been given(n=10)  were classified as being responders or 
non-responders to chemotherapy on the basis of histopathological assessment (Section 
4.2.3). Proteins differentially expressed between responders and non-responders (log2 fold 
change >2, unadjusted p<0.05) were again identified and subjected to pathway and 
network analysis. 
A total of 170 proteins were differentially expressed between the primary tumours of the 
responders and the primary tumours of the non-responders. 59 proteins were upregulated 
in the responders, and 111 downregulated. Details of these can be seen in Appendix 4 – 
Proteomic comparison of responders and non-responders in the primary tumour. 
Analysing those proteins upregulated separately from those downregulated, Ingenuity core 
analysis of direct and indirect relationships revealed the significant upregulated canonical 
pathways in this group to be: TR/RXR activation, Huntington’s disease signalling, role of 
PI3K/AKT signalling, cell cycle: G1/S checkpoint regulation and IL4 signalling . Similarly the 
downregulated canonical pathways were: mitochondrial dysfunction, fatty acid β-oxidation 
I, oxidative phosphorylation, serotonin degradation and glutaryl-CoA degradation. Statistics 
for these identified pathways can be seen in Table 4.14. 
Upregulated Pathways p-value Ratio 
TR/RXR activation 1.68E-04 4/85 (0.047) 
Huntington’s disease signalling 8.33E-04 5/226 (0.022) 
Role of PI3K/AKT signalling 1.03E-03 3/61 (0.049) 
Cell cycle: G1/S checkpoint regulation 1.13E-03 3/63 (0.048) 
IL-4 signalling 1.73E-03 3/73 (0.041) 
Downregulated Pathways p-value Ratio 
Mitochondrial dysfunction 6.22E-07 9/165 (0.055) 
Fatty acid β-oxidation I 7.23E-07 5/29 (0.172) 
Oxidative phosphorylation 2.89E-06 7/104 (0.067) 
Serotonin degradation 1.42E-05 5/52 (0.096) 
Glutaryl-CoA degradation 3.27E-05 3/11 (0.273) 
 
Table 4.14 – Pathway analysis for proteins both upregulated and downregulated in the 
primary tumours of the responders compared to the primary tumours of the non 
responders. P-value is adjusted using Benjamini-Hochberg correction. Ratio identifies the 
number of focus molecules identified (numerator) in the pathway (denominator). 
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Further analysis of all (unfiltered) biological pathways identified 4 upregulated networks 
with a score greater than 2 pertaining to: cellular movement, haematological system 
development and function, immune cell trafficking, cancer, dermatological diseases and 
conditions, immunological disease, hematological disease, organismal injury and 
abnormalities, cell cycle, lipid metabolism, small molecule biochemistry and vitamin and 
mineral metabolism. Similarly 5 downregulated networks were identified pertaining to: 
cellular assembly and organization, cellular function and maintenance, cell death and 
survival, energy production, lipid metabolism, small molecule biochemistry, cell-to-cell 
signalling and interaction, infectious disease, amino acid metabolism, cell signalling, 
molecular transport, lymphoid tissue structure and development, cancer and organismal 
injury and abnormalities. The focus molecules and statistics pertinent to these networks 
can be seen in Table 4.15.  
Upregulated Networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 ANXA1,AQP9,ATM,CLEC11A,DPY30,ENO3,
ERK1/2,FANCC,FKBP5,Histone 
h3,Hsp90,IDH1,IL36A,KPNA3,LSP1,MAPK1
0,miR-491-5p (and other miRNAs w/seed 
GUGGGGA),MT-
TY,MTOR,MYL1,MYO1E,NFKB1,NFkB 
(complex),P2RY6,PPP1R18,PPP1R16B,RLN
2,SH3GLB2,SLC52A1,SSRP1,TGM2,TOP1,T
PCN1,TPM3,UGT2B7 
20 12 Cellular 
Movement, 
Hematological 
System 
Development 
and Function, 
Immune Cell 
Trafficking 
2 ABHD2,ACAT1,ARFGEF1,ARFGEF2,BCOR,C
DC34,CDCA7L,COTL1,DYNLL1,ENO1,GLIPR
1,HEXB,HLA-DRA,Hla-
Drb,HSD11B1,IRF1,MT1L,MTHFD1,MXD1,
MYC,NFIC,NFKBIA,NR3C1,ODC1,PERP,PRK
AC,PRKACB,PRKAR1A,PSME1,ROCK1,SERP
INE2,SH3KBP1,SKP1,SMARCA4,THY1 
18 11 Cancer, 
Dermatological 
Diseases and 
Conditions, 
Immunological 
Disease 
3 AIMP1,C4BPA,CCT5,CCT6A,CDKN2AIP,CO
L6A3,CTNNB1,CTSD,GNAI2,GNL3,GRB2,G
RIN1,HINT1,HNF1A,HNMT,HSD17B2,ITGA
1,mir-224,miR-224-5p (miRNAs w/seed 
AAGUCAC),miR-24-3p (and other miRNAs 
w/seed 
GGCUCAG),PDE6B,PRIM1,RAD23A,RPL8,R
PL23,RPL26,RPL7A,RPS7,RPS4X,SEMA3C,S
LC2A12,SLC39A8,SP1,TGFB1,TP53 
18 12 Hematological 
Disease, 
Organismal Injury 
and 
Abnormalities, 
Cell Cycle 
4 AP2M1,APOB,BST2,CD74,COL14A1,Cpla2,
CXCL5,CYP27A1,EFEMP1,EIF2S1,HLA-
DRB4,HSPG2,IGFBP2,LDL,LGALS3,LIPG,MC
TS1,MHC Class II 
16 11 Lipid 
Metabolism, 
Small Molecule 
Biochemistry, 
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(complex),NBN,Nr1h,NR1H3,OSCAR,PCK2
,PCSK9,PLA2G4A,PON1,PPA1,PTAFR,PTGS
2,RPLP0,SMC1A,SREBF1,TF,TNF,TRAF1 
Vitamin and 
Mineral 
Metabolism 
Downregulated Networks 
1 AIFM1,ANXA2,ATP1B1,BAX,calpain,caspa
se,CAST,CD3,CLTC,CSK,CYP27A1,DSP,ERK
1/2,ERP29,estrogen 
receptor,Hsp90,IgG,INF2,IRF6,Jnk,KRT7,K
RT17,KRT18,KRT19,MVP,MYH14,NFkB 
(complex),P38 
MAPK,PHB,PHB2,PPP2R1A,PPP2R2A,SERP
INB5,VDAC2,XIAP 
47 24 Cellular Assembly 
and Organization, 
Cellular Function 
and 
Maintenance, 
Cell Death and 
Survival 
2 ACAA2,ACADS,ACADVL,ACP1,ATM,CCNA2
,CDKN2AIP,CHMP4C,CNOT1,COPG2,CTTN
,E4F1,ETHE1,FDPS,GRB2,GSR,HADH,HIST1
H4A,HSD17B4,KIF24,LPIN1,MAT1A,PDCD
6IP,PLEC,RGS6,RPL13,RPL23,RPL26,RPL7A
,RPS7,RXRG,SREBF1,SYK,TP53,TUFM 
25 16 Energy 
Production, Lipid 
Metabolism, 
Small Molecule 
Biochemistry 
3 ABLIM,ADCY7,AKR1B10,AKT1,ARPC1A,AT
P9A,CASK,CRYL1,DUSP3,ETV5,FANCC,FH,F
SH,GNLY,GNRH,LAD1,Lh,MAPK1,MMP2,
MYO6,MYRF,NQO1,NR3C1,PDXK,PKP2,PK
P3,PLIN3,PPIH,PRKX,PRPF4B,PTPRN,RAB5
A,S100A14,TLK1,VCL 
17 12 Cell-To-Cell 
Signaling and 
Interaction, 
Infectious 
Disease, Amino 
Acid Metabolism 
4 ABCC3,ACAA1,ACOX1,ALDH2,APOB,CHST
2,EHD1,EPB41L1,ERMAP,G0S2,HDAC10,Hi
stone 
h3,Hsp90,IL13,KDM5B,KLHDC10,LIMCH1,
LONP1,MKK3/6,MT-CO2,MT-
CYB,NID1,PDIA3,PDIA4,PLXNC1,PPARA,R
NA polymerase 
II,SLC8A1,SORT1,SPTA1,SWAP70,SYNPO,T
AF10,TNF,TPM3 
15 10 Cell Signaling, 
Molecular 
Transport, Small 
Molecule 
Biochemistry 
5 AQP3,BCL6,CCND1,CCR6,CD72,EPB41L2,F
CGRT,FES,FOLR1,FUT7,HNF1A,HNF1B,HN
MT,HNRNPA2B1,KIF20A,KLK1,PBLD,PBX1,
PCBP1,PLD2,SEL1L,SKIV2L,SPI1,STOM,SUL
T1A1,SYVN1,TARS,TLE1,TNFRSF14,TUBA3
C/TUBA3D,UGT2B17,UQCRC2,USP5,UTRN
,VIL1 
12 10 Lymphoid Tissue 
Structure and 
Development, 
Cancer, 
Organismal Injury 
and 
Abnormalities 
 
Table 4.15 – Network analysis for proteins both upregulated and downregulated in the 
primary tumours of the responders compared to the primary tumours of the non 
responders. The score is derived from a p-value and indicates the probability of the focus 
molecules in a network being found together due to random chance. Focus molecules is 
the total number of proteins of interest identified in the respective network. 
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4.3.9 Predictive biomarkers in the metastatic tumours 
A total of 27 proteins were differentially expressed between the metastatic tumours of the 
responders and the metastatic tumours of the non-responders. 17 proteins were 
upregulated in the responders, and 10 downregulated. Details of these can be seen in Table 
4.16. 
Accession 
Number Name p Value 
Log2 Fold-Change 
(Responders/Non-
Responders) 
P01719 Ig lambda chain V-V region DEL 2.27E-02 -78.793 
P13760 HLA class II histocompatibility 
antigen, DRB1-4 beta chain 
4.63E-03 -67.649 
Q7L5L3 Glycerophosphodiester 
phosphodiesterase domain-
containing protein 3 
2.56E-03 -15.402 
P15559 NAD(P)H dehydrogenase 
[quinone] 1 
4.09E-02 -3.767 
Q9Y6D6 Brefeldin A-inhibited guanine 
nucleotide-exchange protein 1 
4.24E-02 -3.112 
O76003 Glutaredoxin-3 2.77E-02 -2.284 
P02745 Complement C1q 
subcomponent subunit A 
1.84E-02 -2.271 
Q29865 HLA class I histocompatibility 
antigen, Cw-18 alpha chain 
1.64E-02 -2.239 
P15311 Ezrin 2.85E-02 -2.132 
Q99439 Calponin-2 3.85E-02 -2.060 
Q99735 Microsomal glutathione S-
transferase 2 
3.69E-02 2.034 
P51570 Galactokinase 6.66E-03 2.210 
Q9Y2S2 Lambda-crystallin homolog 3.12E-02 2.358 
P43155 Carnitine O-acetyltransferase 2.42E-02 2.365 
O14773 Tripeptidyl-peptidase 1 2.50E-02 3.401 
Q14508 WAP four-disulfide core 
domain protein 2 
3.12E-02 3.850 
P04040 Catalase 4.62E-02 4.088 
P01880 Ig delta chain C region 4.16E-02 4.671 
Q02252 Methylmalonate-semialdehyde 
dehydrogenase [acylating], 
mitochondrial 
4.81E-02 4.898 
Q08257 Quinone oxidoreductase 2.95E-02 6.470 
Q02318 Sterol 26-hydroxylase, 
mitochondrial 
3.47E-02 13.663 
P05089 Arginase-1 4.61E-02 32.760 
P51888 Prolargin 4.08E-02 61.579 
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P80404 4-aminobutyrate 
aminotransferase, 
mitochondrial 
3.90E-02 66.207 
P07099 Epoxide hydrolase 1 4.46E-02 100.906 
O75891 Cytosolic 10-
formyltetrahydrofolate 
dehydrogenase 
2.07E-02 397.163 
Q08AH3 Acyl-coenzyme A synthetase 
ACSM2A, mitochondrial 
4.51E-02 56001.100 
 
Table 4.16 – Those proteins differentially expressed between the metastatic tumours of 
the responders and non-responders. 27 proteins were identified, 17 of which were 
upregulated (positive values for fold change) and 10 downregulated (negative values for 
fold change). 
Analysing those proteins upregulated separately from those downregulated, Ingenuity core 
analysis of direct and indirect relationships revealed the significant upregulated canonical 
pathways in this group to be:  β-alanine degradation I, valine degradation I, LPS/IL-1 
mediated inhibition of RXR, xenobiotic metabolism signalling and D-glucuronate 
degradation I. Similarly the downregulated canonical pathways were: antigen presentation 
pathway, allograft rejection signalling, OX40 signalling pathway, communication between 
innate and adaptive immune cells and crosstalk between dendritic cells and natural killer 
cells. Statistics for these identified pathways can be seen in Table 4.17. 
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Upregulated Pathways p-value Ratio 
β-alanine degradation I 7.30E-07 2/2 (1) 
Valine degradation I 1.11E-04 2/18 (0.111) 
LPS/IL-1 mediated inhibition of RXR 7.46E-04 3/208 (0.014) 
Xenobiotic metabolism signalling 1.36E-03 3/256 (0.012) 
D-glucuronate degradation I 2.64E-03 1/3 (0.333) 
Downregulated Pathways p-value Ratio 
Antigen presentation pathway 1.44E-04 2/37 (0.054) 
Allograft rejection signalling 2.44E-04 2/48 (0.042) 
OX40 signalling pathway 3.09E-04 2/54 (0.037) 
Communication between innate and 
adaptive immune cells 
7.12E-04 2/82 (0.024) 
Crosstalk between dendritic cells and 
natural killer cells 
8.38E-04 2/89 (0.022) 
 
Table 4.17 – Pathway analysis for proteins both upregulated and downregulated in the 
metastatic tumours of the responders compared to the metastatic tumours of the non 
responders. P-value is adjusted using Benjamini-Hochberg correction. Ratio identifies the 
number of focus molecules identified (numerator) in the pathway (denominator). 
Further analysis of all (unfiltered) biological pathways identified 5 upregulated networks 
with a score greater than 2 pertaining to: infectious disease,  organismal injury and 
abnormalities, neurological disease, cell-to-cell signalling and interaction, tissue 
development, increased levels of potassium, DNA replication, recombination and repair, 
drug metabolism, cancer, cellular assembly and organization, developmental disorder, 
hereditary disorder, lipid metabolism, molecular transport and small molecule 
biochemistry. Similarly 1 downregulated network was identified pertaining to: cell death 
and survival, cell cycle, and cell-to-cell signalling and interaction. The focus molecules and 
statistics pertinent to these networks can be seen in Table 4.18.  
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Upregulated Networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 ABCC3,ALDH6A1,APLN,ARG1,C3,CAT,C
FB,CYP27A1,EPHX1,ESR1,FCGR1B,FGA,
FMN1,FOXA1,GMFG,GREB1,HSPE1,IL6,
IL17D,LGALS4,LILRA4,LILRA5,PRELP,PR
SS23,RPRM,S100A10,SCAVENGER 
receptor CLASS 
A,SIRT6,Sod,TM4SF1,TMEM74,TNF,TN
FAIP2,TNFRSF18,TNIP3 
13 7 Infectious Disease, 
Organismal Injury 
and Abnormalities, 
Neurological Disease 
2 CRYL1,MAPK1 3 1 Cell-To-Cell Signaling 
and Interaction, 
Tissue Development, 
Increased Levels of 
Potassium 
3 CRYZ,REXO4 3 1 DNA Replication, 
Recombination, and 
Repair, Drug 
Metabolism, Cancer 
4 TFEB,TPP1 3 1 Cellular Assembly 
and Organization, 
Developmental 
Disorder, Hereditary 
Disorder 
5 CRAT,CTNNB1,TCF 3 1 Lipid Metabolism, 
Molecular 
Transport, Small 
Molecule 
Biochemistry 
Downregulated Networks 
1 ARFGEF1,C1QA,CDKN1A,CEACAM3,CN
N2,CTNNB1,CXCL16,EZR,FCGR1B,Ferrit
in,GLRX3,HLA-C,HLA-
DRB4,HSP,IFNG,IL17RB,KIR,KIR2DL1/KI
R2DL3,KIR2DS4 (includes 
others),LAIR1,MAGEA3/MAGEA6,MAR
CKSL1,NQO1,PLA2G5,PRKAR2A,PTGDR
,SEMA3C,SERPINA5,SOAT1,Sod,TNF,TY
MP,U1 snRNP,ULBP1,VIPR1 
21 8 Cell Death and 
Survival, Cell 
Cycle, Cell-To-Cell 
Signaling and 
Interaction 
 
Table 4.18 – Network analysis for proteins both upregulated and downregulated in the 
metastatic tumours of the responders compared to the metastatic tumours of the non 
responders. The score is derived from a p-value and indicates the probability of the focus 
molecules in a network being found together due to random chance. Focus molecules is 
the total number of proteins of interest identified in the respective network. 
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4.3.10 Predictive biomarkers common to primary and metastatic tumours 
170 proteins in the primary tumours were significantly differentially expressed between 
responders and non-responders. In the metastases 22 proteins were identified. 5 proteins 
were common to both primary and metastatic tissues, none of which were significantly 
differentially expressed between the two tissue types (Figure 4.3). 
 
Figure 4.3 – Venn diagram of predictive biomarkers identified in the primary tumour 
(170), metastatic tumour (27) and common to both (5). 
The 5 proteins identified as predictors of response alongside the P value and log2 fold 
change for both tissue types are shown in Table 4.19. Of these 5, 2 proteins were 
upregulated in the primary tumour but downregulated in the metastasis and 1 was 
downregulated in the primary tumour but upregulated in the metastasis. Only 2 proteins 
had consistent dysregulation between primary and metastatic tissue: NAD(P)H 
dehydrogenase [quinone 1] and lambda-crystallin homolog were both downregulated in 
the primary and metastatic tumours of those patients responding to neoadjuvant 
chemotherapy. 
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Accession 
Number Name 
Primary Metastasis 
p Value 
Log2 Fold 
Change p Value 
Log2 Fold 
Change 
P13760 
HLA class II 
histocompatibility 
antigen, DRB1-4 beta 
chain 5.91E-03 88.035 4.63E-03 -67.649 
P15559 
NAD(P)H 
dehydrogenase 
[quinone] 1 2.64E-04 -9.918 4.09E-02 -3.767 
Q02318 
Sterol 26-
hydroxylase, 
mitochondrial 6.70E-03 -2.114 3.47E-02 13.663 
Q9Y2S2 
Lambda-crystallin 
homolog 3.25E-03 -2.085 3.25E-03 -2.085 
Q9Y6D6 
Brefeldin A-inhibited 
guanine nucleotide-
exchange protein 1 7.37E-03 4.595 4.24E-02 -3.112 
 
Table 4.19 – Summary of predictive biomarkers common to both primary and metastatic 
tumours. 
4.3.11 Phenotypic anchoring of exome sequencing 
Of the 5766 proteins identified through iTRAQ, SNVs were identified in the protein coding 
region of 2627. For 3 of these proteins the SNV was present in 14 samples, for 10 it was 
present in 10 samples, 9 present in 9, 3 present in 7, 8 present in 6, 16 present in 5, 
92present in 4, 93 present in 9, 498 present in 2 and 1895 present in 1. 
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4.4 Discussion 
4.4.1 Summary of aims 
In this study a comprehensive proteomic analysis of paired primary and metastatic samples 
from 16 patients was performed. The aim of this investigation was to compare the 
proteomic profile of the primary and metastatic tumours, both with each other and with 
their normal adjacent tissue, to establish the degree of similarity and identify potential 
response biomarkers present in the primary tumour which may predict response to 
neoadjuvant therapy in the liver metastasis.   
4.4.2 Summary of results 
Matched primary and metastatic tissue from 16 patients was subjected to iTRAQ. Eleven 
patients had undergone neoadjuvant chemotherapy, 10 of which achieved resection. Five 
of these patients had a tumour regression grade of 1-2 and the remaining 5 had a tumour 
regression grade of 3-4. A total of 5766 proteins were identified, of which 2637 were taken 
forwards for bioinformatics analysis. A summary of the proteomic data is shown in Table 
4.20.  
 
Table 4.20 - Summary proteomic data for the 2-group comparisons showing the total 
number of dysregulated proteins as well as those up/downregulated. 
Comparing primary tumour with normal colon, 25 proteins were significantly differentially 
expressed (6 upregulated and 19 downregulated) and for metastatic tumour compared 
with normal colon there were 53 (13 upregulated and 40 downregulated). Comparison of 
the metastatic tumour with liver parenchyma identified 444 proteins differentially 
Comparison Total 
Dysregulated 
Upregulated Downregulated 
Primary Tumour / Colonic Mucosa 25 6 19 
Metastatic Tumour / Colonic Mucosa 53 13 40 
Metastastic Tumour / Liver Parenchyma 444 164 280 
Metastatic Tumour / Primary Tumour 67 58 9 
Responders / Non Responders (Primary) 170 59 111 
Responders / Non Responders (Metastasis) 27 17 10 
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expressed, 164 of which were upregulated and 280 downregulated. Only 67 of the 2637 
(2.54%) proteins studied were significantly different between primary and metastatic 
tissue, with 58 upregulated in the metastatic tumour and 9 downregulated. One hundred 
and seventy proteins were identified in the primary tumour which were significantly 
differentially expressed between responders and non-responders with 59 upregulated and 
111 downregulated in the responders. In the metastases there were 27 (17 upregulated 
and 10 downregulated). Five proteins were common to both tissue types, only two of which 
showed consistent dysregulation between responders and non-responders (NAD(P)H 
dehydrogenase [quinone 1] and lambda-crystallin homolog). Of the 5766 proteins identified 
by iTRAQ, SNVs were previously identified in the protein coding region of 2627. Further 
bioinformatics analysis of these comparator groups revealed putative pathways and 
networks involved in carcinogenesis. 
4.4.3 iTRAQ for evaluation of tumour biology 
Proteomic studies using techniques such as iTRAQ offer a significant advantage over 
genomic approaches to similar questions. The level of transcription of a gene only gives an 
estimate of its level of translation into a protein, as an mRNA produced in abundance may 
be degraded rapidly or translated inefficiently. Other proteomics approaches may help to 
investigate post-translational modification of proteins, investigate alternative splicing, 
evaluate the formation of protein complexes and account for protein degradation by 
providing quantitative data, although the technique we have adopted for this study is 
currently unable to provide such insight.  
A number of studies have attempted to use iTRAQ to further our understanding of tumour 
biology. Lin et al (2014) characterised the profile of the human colon adenocarcinoma cell 
line HCT-116 with its metastatic derivative E1. A total of 547 proteins were identified with 
31 differentially expressed including translationally controlled tumour protein 1, A-kinase 
anchor protein 12 and Drebrin (DBN1). Western blotting subsequently validated these 
findings.   
In 2014, Liu et al characterised the cancer stroma expression profile of muscle-invasive 
bladder cancer.  30 clinical samples of 3 different metastatic risk groups were profiled to 
identify differentially expressed proteins. A total of 1049 differentially expressed proteins 
were identified by paired comparisons (high risk vs. median risk, low risk and normal; 
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median risk vs. low risk and normal, low risk vs. normal group), with 510, 549 and 548 
proteins significantly altered respectively. On pathway analysis the differentially expressed 
proteins were mainly located in the focal adhesion pathway, systemic lupus erythematosus 
pathway and ECM-receptor interaction pathway. This group also identified several 
candidate biomarkers (EXOC4, MYH10 and MMP-9) of invasion.  
Wang et al (2012) compared the proteome of ovarian cancer tissues and normal ovarian 
epithelium. One thousand two hundred and fifty-nine unique proteins were identified, with 
205 differentially expressed between ovarian cancer and normal ovarian tissue. A number 
of these proteins were validated by western blotting, RT-PCR or immunohistochemistry. 
Similarly pancreatic adenocarcinoma tissues of varying histological differentiation were 
sequenced by Wang et al in 2013. A total of 1623 proteins were identified of which 15 were 
differentially expressed.  Myoferlin was validated initially by western blotting and latterly 
by immunohistochemistry in a further 154 samples. The authors conclude that iTRAQ 
identified this protein as correlating with histological expression, and evaluation against 
corresponding clinical data suggests its expression is an independent prognostic factor for 
survival.  
Similarly to this study, Leong et al (2012) attempted to identify predictors of response to 
chemotherapy in breast cancer. To focus their assessment on apoptosis, iTRAQ of enriched 
mitochondria and endoplasmic reticulum cells was performed leading to the identification 
of several differentially abundant proteins in breast cancer cells treated with doxorubicin. 
Pathway analysis suggested cellular assembly and organization, molecular transport, 
oxidative stress, cell motility, cell death, and cancer were key pathways upregulated with 
treatment. In another in vitro study, Nishimura et al (2014) investigated four human 
tumour derived cell lines: cisplatin-sensitive UM-SCC-23, UM-SCC-23-CDDPR with acquired 
cisplatin resistance, naturally cisplatin-resistant UM-SCC-81B, and UM-SCC-23/WR with 
acquired 5-fluorouracil resistance. In total, 13 multiple drug resistance proteins were 
identified with a further 7 specifically associated with resistance to cisplatin.  
Perhaps of most clinical interest is a translational study reported by Rehman et al in 2012. 
Pooled serum samples were analysed from 4 groups of patients characterised as benign 
prostatic hyperplasia, localised cancer, apparently localised cancer but with biochemical 
suggestion of spread and advanced disease.  Only 122 proteins were identified, although 25 
were differentially abundant in those with progressive disease.  The authors reported 
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eukaryotic translation elongation factor 1 alpha 1 (eEF1A1) as significantly upregulated in 
osteoblasts adjacent to metastatic tumour cells compared with osteoblasts in control bone 
(p = 0.035). This study highlights the potential use of iTRAQ in identifying serum biomarkers 
rather than those dependent upon the evaluation of tumour tissue. 
What is apparent from these studies is that the level of protein coverage we have obtained 
with our samples is significantly higher than has been obtained in tumour derived cell lines 
or serum/tissue from cancer patients. The implication of this is that a greater degree of 
coverage will assist in formulating a better understanding of tumour biology and an 
increased likelihood of identifying relevant biomarkers. Similar study designs have not been 
reported. 
4.4.4 Tumour heterogeneity 
One of the largest challenges facing the delivery of tumour biomarkers to clinical practice is 
the issue of tumour heterogeneity. Whilst inter-individual variation is to be expected, intra-
tumour heterogeneity has also been shown in a number of studies, for example in 
metastasis-initiating cells in pancreatic cancer (Campbell et al, 2010). Carcinogenesis is an 
evolutionary process of naturally selected cells which have acquired a selective advantage, 
which may also explain drug resistance during systemic therapy (Gerlinger and Swanton, 
2010). Whilst most tumours are thought to arise from a monoclonal population, its 
expansion combined with the acquisition of further mutations creates subclones and 
heterogeneity. Phylogenetic trees constructed from sequencing data are increasingly being 
used to demonstrate the relationships between subclones (Campbell et al, 2008). A recent 
study from Gerlinger et al (2002) used this phylogenetic approach to analyse next 
generation sequencing data and report the branched evolutional tumour growth in a renal 
cell carcinoma and its associated metastatic sites, with 63-69% of all somatic mutations not 
detectable across every tumour region. 
This heterogeneity clearly has significant implications for biomarker studies such as this 
which rely on a single tumour biopsy sample to be representative of the whole tumour 
phenotype (Poste, 2011). Despite this it remains clear that some mutations are common 
between tumours and across tumour sites, located in the so-called ‘trunk’ of the 
phylogenetic tree, and it is perhaps these which offer the most potential to serve as reliable 
clinical biomarkers. It may be that the analysis of circulating tumour cells or DNA allows for 
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more comprehensive, accurate and translatable biomarker studies, although this is based 
on the assumption that cancer cells are shed into the circulation in a manner proportional 
to their clonal frequency.  
A small number of studies comparing the genotype of primary and metastatic colorectal 
tumours have already been discussed in Chapter 3, and the concordance of KRAS status 
between primary and metastatic tumours is now widely accepted (Paligioannis et al, 2014). 
With respect to global proteomic studies, none have compared the phenotype of the 
primary and metastatic lesions of any tumour type. Some groups have however attempted 
to correlate specific proteins of interest, for example in 2013, Laird et al characterised the 
correlation of Ki67, p53 and VEGF between primary renal cell carcinomas, renal vein 
thrombus and metastasis. Similarly Gao et al (2013) compared the protein expression of 
VEGF, HIF-1α, Met, P53, TGF-β1, Cox-2 and TNF-α by immunohistochemistry in eleven 
patients who had received resection of lung cancers and distant metastases, finding no 
statistical significance between primary cancers and matched metastases for the expression 
of these selected biomarkers. 
Our data suggests a high degree of biological similarity (97.46%) between the primary and 
secondary tumours, which will require further analysis and validation. Combined with this 
evidence in the literature, it may be feasible that despite the issues of tumour 
heterogeneity and clonal selection, the phenotype of the primary tumour is sufficiently 
similar to the metastasis to derive useful biological information in order to inform 
treatment strategy. 
4.4.5 NAD(P)H dehydrogenase [quinone 1]  
NQO1 encodes the cytosolic flavoenzyme NAD(P)H dehydrogenase [quinone 1], which is 
involved in the 2-electron reduction of a broad range of substrates including quinones to 
hydroquinones (Sarbia et al, 2003). This 2-electron reduction of the quinone to 
hydroquinone prevents the generation of semiquinone free radicals and reactive oxygen 
species, thus protecting cells from oxidative damage (Rauth, Goldberg and Misra, 1996). 
NQO1 also acts as an antioxidant enzyme which is of significant importance during the 
detoxification of environmental carcinogens (Ross et al, 2000). 
173 
 
The importance of NQO1 activity in carcinogenesis was demonstrated by a study which 
reported that the effects of chemical carcinogens on skin cells were more likely to result in 
skin cancer in NQO1 knockout mice than their wild type control group (Long et al, 2001). 
Other studies have shown that NQO1 expression increases with disease progression in 
colorectal cancer (Mikami et al, 1998). In 2006 a case-control study conducted by Beglieter 
et al demonstrated an association between NQO1 polymorphism and the development of 
colorectal cancer. Within this study serum blood samples were taken from 298 patients 
with colon cancer and 349 healthy control subjects. They were able to demonstrate that 
polymorphisms of the NQO1 gene which lead to a loss of function were statistically higher 
in patients with colorectal cancer. Contradictory to this, a case-control study by Hart et al 
(2000) investigated serum blood samples for polymorphic mutation of NQO1 in 323 
patients with colorectal cancer and 205 healthy volunteers, failing to demonstrate any 
association with colorectal cancer risk.   
NQO1 has been of specific interest for the design of many new chemotherapeutic agents 
due to its high levels of expression in many tumours (Winski et al, 2001). Its  involvement in 
the bioactivation of quinones such as β-lapachone and 17-AAG has highlighted its potential 
use as a predictive biomarker when considering cancer treatment with these therapies. 
Testing for the NQO1*2 polymorphism, which leads to null NQO1 individuals, provides an 
indicator of poor response to quinones thus suggesting the avoidance of these therapies 
(Siegel, Yan and Ross, 2012). 
Our study has suggested that low NQO1 levels are associated with favourable response to 
chemotherapy, and that levels in the primary tumour may be predictive of the metastatic 
phenotype. NQO1 loss and the resultant loss of cyto-protection has already been linked to 
carcinogenesis, although given the agents used in our study are not quinones the currently 
suggested mechanism of 2-electron reduction may not be relevant. Further evaluation is 
needed both to establish the role of NQO1 as a predictive biomarker and also as a 
therapeutic target. 
4.4.6 Lambda-crystallin homolog 
Lambda-crystallin homolog was identified during bioinformatic analysis as a potential 
biomarker. Specifically levels appeared to be reduced in the responders to neoadjuvant 
chemotherapy, and expression between primary and metastasis not significantly different. 
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The protein is a cytosolic enzyme known to have greatest expression in the liver and kidney 
(Chen et al, 2003). The corresponding CRYL-1 gene is located at 13q12.11, and codes for an 
enzyme which catalyzes the dehydrogenation of L-gulonate into dehydro-L-gulonate in the 
uronate cycle. The enzyme requires NAD(H) as a cofactor, and is inhibited by inorganic 
phosphate (Bando et al, 2006). Very little information exists on this protein in the literature, 
with the overwhelming majority of references focusing on the structural role of this protein 
in the rabbit lens (Mulders et al, 1998). The only discernable reference to malignancy was 
the incidental finding of downregulation in 58% of 60 hepatocellular carcinomas in a 
Chinese population (Chen et al, 2003). With little understood about its exact role beyond an 
enzyme in the uronate cycle, it would be challenging to explore the functional potential of 
this biomarker. Investigation in a larger tissue set to confirm these findings before 
embarking upon further work would therefore be prudent. 
4.4.7 Study strengths and limitations 
This study represents the first attempt to characterise the proteome of primary and 
metastatic colorectal tumours with a view to establishing biological similarity and 
identifying novel predictive biomarkers. 
The relative merits and difficulties of a proteomic approach to these questions have already 
been discussed, but it should be remembered that a number of factors can contribute to 
difficulties in reproducibility between experimental runs, with alternative equipment and in 
different laboratories (Peng et al, 2003). 
As with most clinical studies there is inherent heterogeneity in the study population. 
Differences exist in terms of patient age, gender, TNM stage, location of the primary 
tumour, burden and distribution of metastases and the presence of adverse pathological 
features. Ten of the 16 patients were metachronously resected, 5 of which received 
neoadjuvant chemotherapy prior to resection of the liver metastases. In this cohort, 
considerable variation should be expected between the chemonaive primary tumour and 
chemotherapy treated liver metastases. Furthermore the differences in neoadjuvant 
therapies received limit the conclusions we can draw to issues of sensitivity to treatment 
rather than allowing us to explore mechanisms per se. That said, all patients received a 5-
fluorouracil based regimen. 
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The study we have designed and performed utilises biological material obtained from 
patients at the time of resection. If the intent is to look for up-front predictive biomarkers 
of response it would be necessary to assay the levels in the diagnostic biopsy. By the very 
nature of these biopsies there is little biological material available, and therefore obtaining 
them from clinical institutions (i.e. outside of the context of a clinical trial) is not feasible. 
To address this, in vitro studies to demonstrate that observed changes in protein expression 
are likely to be a biological feature of the tumour rather than a treatment effect would be 
necessary. Direct comparison of the proteome of those tumours which are chemonaive 
with those tumours treated with neoadjuvant chemotherapy may also assist with 
identifying which protein changes are induced by chemotherapy and which are biological 
features of the tumour i.e. present pre-treatment and expressed in the diagnostic samples. 
The analyses were constructed in such a way that a protein could feature in a list of 
dysregulated proteins even if the relationship was identified in a single sample. For 
example, the analysis of primary tumour and colonic mucosa was performed by compiling 
pooled lists of proteins dysregulated in one or more sample in one tissue type with respect 
to the other. Whilst statistical attempts were made to reduce the false discovery rate, this 
approach does risk over-fitting of the data. An alternative approach of quantifying the 
number of sample pairs in which the dysregulation was observed could have helped 
minimise that risk and provide further insight into the extent of the differences between 
the proteomes.  
The yield of our mass spectrometry in terms of confidently identified and accurately 
mapped proteins is excellent, and considerably more (often many fold) than many other 
oncology based proteomic studies. The tissue resources we have collected are high value 
and the research questions are novel.  
4.4.8 Conclusion 
This study has evaluated the biological similarity of primary and metastatic tumours, and 
found that only 2.54% of proteins quantified are significantly differentially expressed 
between primary and metastatic tissues. As such, it may be feasible to utilise biological 
information from the primary tumour to predict the phenotype of the metastasis.  
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Bioinformatic analysis of proteins significantly differentially expressed between tissue types 
identified putative pathways of carcinogenesis. Of the two biomarkers identified, NQO1 
shows both biological plausibility and a part-understood role in cancer making it a suitable 
candidate for further validation and exploration of relevant mechanisms.  
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Chapter 5 
A global proteomic assessment of serial rectal tumour biopsies  
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5.1 Introduction 
5.1.1 Background 
The role of neoadjuvant therapy has already been discussed in some detail (Section 1.8.4). 
Patients with rectal cancer who have threatened margins on initial MRI are frequently 
subjected to long-course neoadjuvant chemoradiotherapy in an attempt to downstage 
disease and reduce the risk of a positive margin at resection.  
The ability to establish prospectively the likely response to neoadjuvant therapy would be 
of tremendous benefit to clinicians. Those patients who are identifiable as likely to respond 
could be subjected to potentially more aggressive systemic therapy, whilst conversely those 
less likely to respond could be saved the unnecessary morbidity of systemic treatment and 
the delay to surgical intervention necessary with the use of neoadjuvant treatments. 
One final quandary still remains with the neoadjuvant treatment of rectal cancer with 
chemoradiotherapy, which is the continued downstaging seen for many weeks following 
cessation of treatment. One potential explanation for this is the fact that radiation only has 
its desired effect on actively dividing cells, not those with slow cell turnover or that remain 
in the G0 (rest) phase. The treatment effect is dependent on the amount and type of 
radiation reaching the cell and the speed of cell growth, and as such it may take several 
days or weeks for the treatment effect to manifest (Willet et al, 1995). 
5.1.2 Proteomics and iTRAQ 
Proteomic assessment of tumours and the technique of iTRAQ have already been discussed 
in Sections 4.1.2 and 4.1.3 respectively. This investigation applies the previously described 
approach to the study design shown in Figure 5.1.  
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Figure 5.1 – Samples are reduced and undergo a tryptic digest before being tagged with 
an isotope labelled molecule. These tags all have the same molecular weight although the 
reporter and balance moieties vary. After a cation exchange cleanup step the samples 
undergo nanoLC-MS/MS. The reporter and balance moieties are cleaved from each other 
and from the peptide to which they are bound, the ratio of which helps determine 
relative abundance. The peptide is also cleaved into fragment ions used to identify the 
protein.   
5.1.3 Aims  
The aim of this investigation is to compare the proteomic profile of serial rectal cancer 
biopsies taken at diagnosis, immediately after long course neoadjuvant chemoradiotherapy 
and at resection, to establish how this profile changes with treatment and identify potential 
response biomarkers that are detectable and measurable on the initial diagnostic biopsy. 
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5.2 Methods  
National Health Service Research Ethics Committee and Research and Development 
approval was obtained for this study and informed consent obtained from each of the study 
participants. 
5.2.1 Patient recruitment and tissue collection  
Patients recently having received a diagnosis of rectal cancer and who had been identified 
by the multidisciplinary team as requiring long course chemoradiotherapy were 
approached for inclusion in the study. Those agreeing to participate in the study were 
invited back to the endoscopy unit at the Countess of Chester Hospital for a repeat limited 
flexible sigmoidoscopy and biopsy. Three ‘double bites’ of a standard endoscopic forcep 
(approximately 3mm3 tissue in total) of peripheral tumour was biopsied, with deliberate 
attempts to avoid the area of necrotic tissue in the centre of the tumour.  
Patients were contacted one week after cessation of their chemoradiotherapy and invited 
to return for a further limited flexible sigmoidoscopy and biopsy. On the day of resection, a 
sample of tumour and normal adjacent mucosa were obtained. Following delivery of the 
colorectal specimen the proximal staple line was incised and a linear cut made down the 
antimesenteric border before excising a peripheral section of tumour using forceps and a 
scalpel. All samples were placed in individually labelled cryodorfs, snap frozen in liquid 
nitrogen and transferred to a -80oC storage facility. 
5.2.2 Exclusion criteria 
For this study the exclusion criteria were: 
 Recent (last 12 months) personal history of malignancy at another site 
 Patients under the age of 18 
 Patients without capacity to provide informed consent 
 Patients identified by the multidisciplinary team as being at significant risk of 
emotional distress by additional hospital visits and/or procedures that may be 
required 
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5.2.3 Evaluation of histopathological response to treatment 
Additional tumour samples were obtained for the purposes of formalin fixation and 
embedding in paraffin. All samples were reviewed by a consultant histopathologist to verify 
the diagnosis of adenocarcinoma. Histopathological response was assessed in the resection 
specimens and recorded as described in Section 4.2.3. 
5.2.4 Evaluation of radiological response to treatment 
The radiological response to treatment was also assessed and noted. Pre-treatment and 10 
week post-treatment MRI scans were reviewed by a consultant radiologist, and response 
determined in line with the RECIST v1.1 guidelines (Eisenhauer et al, 2009). In brief, this 
comprises an initial assessment of tumour burden and documentation of target and non-
target lesions, followed by an allocation to one of four response groups as follows:  
 Complete response – Disappearance of all target lesions. Any pathological lymph 
nodes must have reduction in short axis to <10mm. 
 Partial response – At least a 30% decrease in the sum of diameters of target lesions, 
taking as reference the baseline sum diameters. 
 Progressive disease – At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study. 
 Stable disease – Neither sufficient shrinkage to qualify for partial response nor 
sufficient increase to qualify for progressive disease, taking as reference the 
smallest sum diameters on study. 
5.2.5 Sample preparation 
Sample preparation was performed as described in Section 4.2.4. 
5.2.6 Protein quantification 
Protein quantification was performed as described in Section 4.2.5. 
5.2.7 Creation of a reference pool 
In order to infer relative protein abundance between samples, a reference pool was 
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created as described in Section 4.2.6. For each time point from every patient, 100µg of 
protein was added to the reference pool.  Once the reference pool had been created it was  
re-quantified and prepared in an identical fashion to the other samples as follows. 
5.2.8 Allocation across and within experimental runs  
Allocation across and within experimental runs was performed as described in Section 
4.2.7. 
5.2.9 iTRAQ labelling 
iTRAQ labelling was performed as described in Section 4.2.8. 
5.2.10 Cation exchange 
Cation exchange was performed as described in Section 4.2.9. 
5.2.11 Mass spectrometry 
Mass spectrometry was performed as described in Section 4.2.10. 
5.2.12 Protein identification and quantification 
Protein identification and quantification was performed as described in Section 4.2.11. 
5.2.13 Bioinformatics analysis 
Bioinformatics analysis was performed as described in Section 4.2.12.  Proteins 
differentially expressed (log2 fold change >1.5, unadjusted p<0.05) were identified and 
subjected to pathway and network analysis. A summary of the bioinformatics analysis can 
be seen in Figure 5.2. 
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Figure 5.2 – Bioinformatics analysis workflow for global proteomic assessment of serial 
rectal tumour biopsies. 
 
 
 
 
1
•iTRAQ data for proteins identified by 2 or more peptides with at least 90% 
confidence of correct sequence assignment, or by a single peptide with at 
least 99% confidence
2
•Log 2 transformation and batch correction
3
•Proteins present in at least 50% of the samples
4
•Two group comparisons (using Partek®) of rectal tumours: post 
chemoradiotherapy and at diagnosis, at resection and post 
chemoradiotherapy, at resection and at diagnosis, and in the diagnostic 
samples of the responders and non-responders 
5
•Statistical analysis using ANOVA, and multiple test correction using 
Benjamini-Hochberg (significance taken as log2 fold change > 2 and 
unadjusted p<0.05)
6
•Pathway and network analysis of protein lists using Ingenuity Pathway 
Analysis
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5.3 Results  
5.3.1 Clinical and demographic data  
Eight patients were recruited to this study, all of which were male with an age range of 50-
78 years at the time of diagnosis. Dukes’ Stage of the tumours ranged from B-D with 
variation in T (2-4), N (0-1) and M (0-1) stage seen. Patients received oral capecitabine plus 
either 45Gy in 25 fractions or 50.4Gy in 28 fractions at the discretion of the treating 
radiation oncologist. Following this, participants underwent formal excision of the rectum 
in a manner appropriate for both the patient and the tumour (Table 5.1). 
5.3.2 Response evaluation  
Response evaluation can be seen in Table 5.2. For the purposes of analysis, responders 
were those with a histopathological tumour regression grade of 1-2 (n=4) and non 
responders those with a tumour regression grade of 3-4 (n=4). Given the small numbers of 
patients recruited, radiological response was noted but not used for analysis. 
Patient Number 
Radiological 
Response 
Viable 
Tumour (%) 
Tumour 
Regression Grade Responder 
1 PR 5 1 Yes 
2 SD 10 1 Yes 
3 SD 55 3 No 
4 PR 40 2 Yes 
5 SD 60 3 No 
6 PR 45 2 Yes 
7 PD 55 3 No 
8 PD 75 4 No 
 
Table 5.2 – Response evaluation for patients having serial rectal cancer biopsies. The 
percentage viable tumour is displayed along with corresponding tumour regression grade 
(TRG). Those patients with TRG 1-2 were considered responders (patients 1, 2, 4 and 6) 
and patients with TRG 3-4 were considered non-responders (patients 3, 5, 7 and 8).  
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Table 5.1 – Clinical and demographic data for patients having serial rectal cancer biopsies. 8 patients were studied, all of which were male ranging in age 
from 50-78 and Dukes’ stage B-D. Two different neoadjuvant chemotherapeutic regimens were used alongside a number of different surgical 
interventions for formal resection of the rectal tumour. 
Patient Sex Age at 
Diagnosis 
Dukes' 
Stage 
Nodes 
Harvested 
Nodes 
Involved 
T 
Stage 
N 
Stage 
M 
Stage 
Histology Neoadjuvant 
Treatment 
Procedure 
1 M 77 C2 1 1 3 1 0 Moderately 
differentiated 
Capecitabine plus 
45Gy in 25 
fractions 
Open low 
anterior resection 
2 M 50 B 9 0 2 0 0 Moderately 
differentiated 
Capecitabine plus 
50.4Gy in 28 
fractions 
Laparoscopic low 
anterior resection 
3 M 77 C1 36 1 3 1 0 Moderately 
differentiated 
Capecitabine plus 
45Gy in 25 
fractions 
Open low 
anterior resection 
4 M 77 B 10 0 3 0 0 Moderately 
differentiated 
Capecitabine plus 
50.4Gy in 28 
fractions 
Ultra-low 
Hartmann's 
5 M 63 D 20 2 3 1 1 Moderately 
differentiated 
Capecitabine plus 
50.4Gy in 28 
fractions 
Laparoscopic low 
anterior resection 
6 M 71 B 2 0 4 0 0 Moderately 
differentiated 
Capecitabine plus 
50.4Gy in 28 
fractions 
Laparoscopic low 
anterior resection 
7 M 57 B 21 0 3 0 0 Moderately 
differentiated 
Capecitabine plus 
50.4Gy in 28 
fractions 
Laparoscopic low 
anterior resection 
8 M 78 B 17 0 3 0 0 Moderately 
differentiated 
Capecitabine plus 
45Gy in 25 
fractions 
APER 
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5.3.3 Overview of iTRAQ data.  
A total of 3359 unique proteins were identified, all of which were present in at least half of 
the samples and therefore taken forwards for analysis. The data were acquired over 3 
experimental runs, with a mean (SD) of 7 (21.2) peptides used to identify the proteins of 
origin. This corresponds to a mean (SD) coverage of 15.18% (15.72%) for identified proteins.  
5.3.4 Comparison of rectal tumours post chemoradiotherapy with diagnostic samples 
A total of 18 proteins were differentially expressed in the tumours after chemoradiotherapy 
compared with the initial diagnostic samples. Of these proteins, 2 were downregulated and 
16 upregulated (Table 5.3). 
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Accession 
Number Name P Value 
Log2 Fold-Change (Post 
chemoradiotherapy/diagnostic) 
P12109 Collagen alpha-1(VI) 
chain 
1.34E-02 -1.953 
P12429 Annexin A3 9.71E-03 -1.757 
Q1KMD3 Heterogeneous nuclear 
ribonucleoprotein U-
like protein 2 
3.76E-02 1.521 
P51648 Fatty aldehyde 
dehydrogenase 
1.11E-02 1.525 
Q13162 Peroxiredoxin-4 1.84E-02 1.572 
Q96PD5 N-acetylmuramoyl-L-
alanine amidase 
3.04E-02 1.686 
P02652 Apolipoprotein A-II 1.02E-02 1.758 
Q9BY50 Signal peptidase 
complex catalytic 
subunit SEC11C 
1.69E-02 1.760 
Q9Y6R7 IgGFc-binding protein 3.22E-03 1.761 
P01023 Alpha-2-macroglobulin 1.54E-02 1.783 
P01859 Ig gamma-2 chain C 
region 
2.67E-02 1.801 
Q8NBS9 Thioredoxin domain-
containing protein 5 
1.17E-02 1.823 
P01591 Immunoglobulin J chain 2.57E-02 1.861 
O75795 UDP-
glucuronosyltransferase 
2B17 
3.03E-02 1.946 
P02765 Alpha-2-HS-
glycoprotein 
2.18E-02 2.105 
P01275 Glucagon 2.77E-04 2.381 
P04114 Apolipoprotein B-100 1.75E-02 2.429 
P10645 Chromogranin-A 6.10E-03 3.357 
 
Table 5.3 – Those proteins differentially expressed between rectal tumours post 
chemoradiotherapy and diagnostic samples. 18 proteins were identified, 2 of which were 
downregulated (negative values for fold change) and 16 upregulated (positive values for 
fold change). 
Analysing those proteins upregulated separately from those downregulated, Ingenuity core 
analysis of direct and indirect relationships revealed the significant upregulated canonical 
pathways in this group to be: LXR/RXR activation, FXR/RXR activation, acute phase response 
signalling, serotonin degradation and phenylethylamine degradation I. Similarly the 
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downregulated canonical pathways were: hepatic fibrosis/hepatic stellate cell activation. 
Statistics for these identified pathways can be seen in Table 5.4. 
Upregulated Pathways p-value Ratio 
LXR/RXR activation 1.24E-04 3/121 (0.025) 
FXR/RXR activation 1.37E-04 3/125 (0.024) 
Acute phase response signalling 3.27E-04 3/168 (0.018) 
Serotonin degradation 8.27E-04 2/52 (0.038) 
Phenylethylamine degradation I 3.30E-03 1/4 (0.25) 
Downregulated Pathways p-value Ratio 
Hepatic fibrosis/hepatic stellate cell 
activation 
2.15E-02 1/196 (0.005) 
  
Table 5.4 – Pathway analysis for proteins both upregulated and downregulated in the 
rectal tumours post chemoradiotherapy compared to the diagnostic samples. P-value is 
adjusted using Benjamini-Hochberg correction. Ratio identifies the number of focus 
molecules identified (numerator) in the pathway (denominator). 
Further analysis of all (unfiltered) biological pathways identified 5 upregulated networks 
with a score greater than 2 pertaining to: lipid metabolism, molecular transport, small 
molecule biochemistry, cancer, cell-to-cell signalling and interaction, cell-mediated immune 
response, cellular function and maintenance, cellular growth and proliferation, 
haematological system development and function, cell death and survival, cell cycle, cell 
morphology, cardiovascular system development and function, carbohydrate metabolism 
and post-translational modification. Similarly 2 downregulated networks were identified 
pertaining to: cancer, organismal injury and abnormalities, reproductive system disease, 
hereditary disorder, skeletal and muscular disorders and connective tissue disorders. The 
focus molecules and statistics pertinent to these networks can be seen in Table 5.5.  
Upregulated Networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 26s 
Proteasome,A2M,ABCC2,AHSG,ALDH3A2,
APOA2,APOB,AQP3,CCND1,CDC73,CHGA,
CTNNA2,CTNNB1,EPCAM,GCG,GPLD1,HN
F1A,HSD17B2,KIF20A,LRP,MAML1,MTTP,
PCDH11Y,PKM,PSMD14,RAD23A,RB1CC1,
SLCO1B1,SNRK,SP4,TMSB15A,TSPAN8,UG
T2B17,VENTX,ZMIZ2 
18 8 Lipid 
Metabolism, 
Molecular 
Transport, Small 
Molecule 
Biochemistry 
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2 CD40,IGHG2 3 1 Cancer, Cell-To-
Cell Signaling and 
Interaction, Cell-
mediated 
Immune 
Response 
3 miR-146a-5p (and other miRNAs w/seed 
GAGAACU),PGLYRP2 
3 1 Cellular Function 
and 
Maintenance, 
Cellular Growth 
and Proliferation, 
Hematological 
System 
Development 
and Function 
4 BLM,HNRNPUL2,MDC1 3 1 Cell Death and 
Survival, Cell 
Cycle, Cell 
Morphology 
5 MGEA5,PRDX4,SRXN1 3 1 Cardiovascular 
System 
Development 
and Function, 
Carbohydrate 
Metabolism, 
Post-
Translational 
Modification 
Downregulated Networks 
1 ANXA3,CLDN7 3 1 Cancer, 
Organismal Injury 
and 
Abnormalities, 
Reproductive 
System Disease 
2 CHI3L1,COL6A1,COL6A2,COL6A3,estrogen 
receptor,HR,SPDEF 
3 1 Hereditary 
Disorder, Skeletal 
and Muscular 
Disorders, 
Connective 
Tissue Disorders 
 
Table 5.5 – Network analysis for proteins both upregulated and downregulated in the 
rectal tumours post chemoradiotherapy compared to the diagnostic samples. The score is 
derived from a p-value and indicates the probability of the focus molecules in a network 
being found together due to random chance. Focus molecules is the total number of 
proteins of interest identified in the respective network. 
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5.3.5 Comparison of rectal tumours at resection with post chemoradiotherapy samples 
A total of 39 proteins were differentially expressed in the tumours at resection compared 
with the samples taken immediately following completion of chemoradiotherapy. Of these 
proteins, 30 were downregulated and 9 upregulated (Table 5.6). 
Accession 
Number Name P Value 
Log2 Fold-Change 
(Resection/Post 
chemoradiotherapy) 
P10645 Chromogranin-A 1.12E-02 -3.430 
P04114 Apolipoprotein B-100 2.22E-02 -2.630 
P01275 Glucagon 4.03E-04 -2.562 
P12532 Creatine kinase U-type, 
mitochondrial 
3.62E-02 -2.427 
O75795 UDP-glucuronosyltransferase 
2B17 
2.21E-02 -2.293 
Q9Y5M8 Signal recognition particle 
receptor subunit beta 
3.61E-02 -2.226 
Q9Y6R7 IgGFc-binding protein 1.62E-03 -2.095 
P01833 Polymeric immunoglobulin 
receptor 
3.21E-02 -2.078 
P01591 Immunoglobulin J chain 2.99E-02 -1.992 
Q07654 Trefoil factor 3 9.92E-03 -1.952 
P21397 Amine oxidase [flavin-
containing] A 
4.66E-02 -1.882 
P17931 Galectin-3 3.48E-02 -1.830 
Q16836 Hydroxyacyl-coenzyme A 
dehydrogenase, 
mitochondrial 
1.91E-02 -1.787 
P00966 Argininosuccinate synthase 2.71E-02 -1.757 
Q96EY8 Cob(I)yrinic acid a,c-diamide 
adenosyltransferase, 
mitochondrial 
9.12E-03 -1.726 
Q8NBS9 Thioredoxin domain-
containing protein 5 
3.23E-02 -1.725 
P31930 Cytochrome b-c1 complex 
subunit 1, mitochondrial 
3.25E-02 -1.714 
P38117 Electron transfer flavoprotein 
subunit beta 
2.28E-02 -1.691 
P19075 Tetraspanin-8 3.31E-02 -1.686 
O75874 Isocitrate dehydrogenase 
[NADP] cytoplasmic 
3.49E-02 -1.682 
P80303 Nucleobindin-2 4.17E-02 -1.661 
Q96FQ6 Protein S100-A16 1.44E-02 -1.648 
Q9HAT2 Sialate O-acetylesterase 9.52E-03 -1.626 
P17980 26S protease regulatory 2.19E-02 -1.624 
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subunit 6A 
Q1KMD3 Heterogeneous nuclear 
ribonucleoprotein U-like 
protein 2 
3.93E-02 -1.614 
P51648 Fatty aldehyde 
dehydrogenase 
1.33E-02 -1.596 
P15880 40S ribosomal protein S2 4.52E-02 -1.583 
Q13510 Acid ceramidase 1.35E-02 -1.568 
O96000 NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 10 
2.29E-03 -1.538 
P30049 ATP synthase subunit delta, 
mitochondrial 
1.15E-03 -1.537 
Q16658 Fascin 7.94E-03 1.628 
P61106 Ras-related protein Rab-14 2.03E-02 1.706 
Q9H4M9 EH domain-containing 
protein 1 
2.25E-02 1.769 
P08572 Collagen alpha-2(IV) chain 4.48E-02 2.006 
P12429 Annexin A3 6.90E-03 2.009 
P98160 Basement membrane-
specific heparan sulfate 
proteoglycan core protein 
2.73E-02 2.021 
P12109 Collagen alpha-1(VI) chain 1.45E-02 2.136 
P13674 Prolyl 4-hydroxylase subunit 
alpha-1 
9.64E-03 2.569 
P24821 Tenascin 3.63E-02 3.329 
 
Table 5.6 – Those proteins differentially expressed between rectal tumours at resection 
and immediately following completion of chemoradiotherapy. 39 proteins were 
identified, 30 of which were downregulated (negative values for fold change) and 9 
upregulated (positive values for fold change). 
Analysing those proteins upregulated separately from those downregulated, Ingenuity core 
analysis of direct and indirect relationships revealed the significant upregulated canonical 
pathways in this group to be: hepatic fibrosis/stellate cell activation, inhibition of 
angiogenesis by TSP1, inhibition of matrix metalloproteases, crosstalk between dendritic 
cells and natural killer cells and dendritic cell maturation. Similarly the downregulated 
canonical pathways were: serotonin degradation, mitochondrial dysfunction, phenylalanine 
degradation IV, tryptophan degradation and putrescine degradation. Statistics for these 
identified pathways can be seen in Table 5.7. 
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Upregulated Pathways p-value Ratio 
Hepatic fibrosis/hepatic stellate cell 
activation 
3.98E-03 2/196 (0.01) 
Inhibition of angiogenesis by TSP1 1.58E-02 1/32 (0.031) 
Inhibition of matrix metalloproteases 1.87E-02 1/38 (0.026) 
Crosstalk between dendritic cells and 
natural killer cells 
4.33E-02 1/89 (0.011) 
Dendritic cell maturation 8.08E-02 1/169 (0.006) 
Downregulated Pathways p-value Ratio 
Serotonin degradation 7.71E-05 3/52 (0.058) 
Mitochondrial dysfunction 1.31E-05 4/165 (0.024) 
Phenylalanine degradation IV 2.22E-04 2/14 (0.143) 
Tryptophan degradation 2.92E-04 2/16 (0.125) 
Putrescine degradation 2.92E-04 2/16 (0.125) 
  
Table 5.7 – Pathway analysis for proteins both upregulated and downregulated in the 
rectal tumours at resection compared to immediately following completion of 
chemoradiotherapy. P-value is adjusted using Benjamini-Hochberg correction. Ratio 
identifies the number of focus molecules identified (numerator) in the pathway 
(denominator). 
Further analysis of all (unfiltered) biological pathways identified 2 upregulated networks 
with a score greater than 2 pertaining to: organismal injury and abnormalities, connective 
tissue disorders, dermatological diseases and conditions, cancer and reproductive system 
disease. Similarly 1 downregulated network was identified pertaining to: tissue 
development, cell death and survival and dermatological diseases and conditions. The focus 
molecules and statistics pertinent to these networks can be seen in Table 5.8.  
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Upregulated Networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 AFP,BGN,CDH11,CLDN4,COL4A1,COL4A2,
COL5A1,COL6A1,COL6A2,COL6A3,COL7A1
,EHD1,estrogen 
receptor,FGA,FSCN1,HEXA,HEXB,HIF1A,H
SPG2,KRT7,KRT15,LAMC2,LOXL2,LTBP2,m
ir-
31,MMP12,NOV,P4HA1,SPAG4,TGFB1,TN
C,TNF,TYMP,WISP1,WNT5B 
17 7 Organismal Injury 
and 
Abnormalities, 
Connective 
Tissue Disorders, 
Dermatological 
Diseases and 
Conditions 
2 ANXA3,CLDN7 3 1 Cancer, 
Organismal Injury 
and 
Abnormalities, 
Reproductive 
System Disease 
Downregulated Networks 
1 AIM1,AJAP1,Akt,ALDH3A2,CDH1,CHGA,C
NN2,CRAT,CTNNB1,CXCL8,DEFA5,DPEP1,
EDN3,F13A1,GAD1,GCG,GPX2,HSD17B2,I
DH1,IHH,IL4,KLK3,LGALS3,MAOA,MUC6,P
CCA,PIGR,QPCT,RCN1,SLC26A2,TCF,TFF3,
TOB2,TSPAN8,UGT2B17 
20 9 Tissue 
Development, 
Cell Death and 
Survival, 
Dermatological 
Diseases and 
Conditions 
 
Table 5.8 – Network analysis for proteins both upregulated and downregulated in the 
rectal tumours at resection compared to immediately following completion of 
chemoradiotherapy. The score is derived from a p-value and indicates the probability of 
the focus molecules in a network being found together due to random chance. Focus 
molecules is the total number of proteins of interest identified in the respective network. 
5.3.6 Comparison of rectal tumours at resection with diagnostic samples 
A total of 29 proteins were differentially expressed in the tumours at resection compared 
with the samples taken at diagnosis. Of these proteins, 10 were downregulated and 19 
upregulated (Table 5.9). 
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Accession 
Number Name P Value 
Log2 Fold-Change 
(Resection/Diagnostic) 
O95881 Thioredoxin domain-
containing protein 12 
3.98E-02 -2.779 
P16444 Dipeptidase 1 3.35E-02 -2.740 
Q13228 Selenium-binding protein 1 2.03E-02 -2.013 
P05783 Keratin, type I cytoskeletal 
18 
3.44E-02 -1.835 
Q9BY42 UPF0549 protein C20orf43 2.97E-02 -1.732 
P09874 Poly [ADP-ribose] 
polymerase 1 
5.82E-03 -1.599 
O96008 Mitochondrial import 
receptor subunit TOM40 
homolog 
8.41E-03 -1.566 
Q9NX63 Coiled-coil-helix-coiled-
coil-helix domain-
containing protein 3, 
mitochondrial 
4.29E-02 -1.548 
P11940 Polyadenylate-binding 
protein 1 
4.44E-02 -1.530 
P05455 Lupus La protein 3.78E-02 -1.525 
P07099 Epoxide hydrolase 1 4.17E-02 1.504 
O14773 Tripeptidyl-peptidase 1 1.17E-02 1.590 
Q99536 Synaptic vesicle membrane 
protein VAT-1 homolog 
2.76E-02 1.644 
Q92930 Ras-related protein Rab-8B 1.03E-02 1.690 
Q9H4M9 EH domain-containing 
protein 1 
1.24E-02 1.714 
Q9UJ70 N-acetyl-D-glucosamine 
kinase 
1.59E-02 1.737 
P08758 Annexin A5 2.30E-02 1.770 
P53004 Biliverdin reductase A 1.61E-02 1.842 
P04271 Protein S100-B 4.74E-02 1.882 
P02765 Alpha-2-HS-glycoprotein 3.26E-02 1.896 
Q9BUF5 Tubulin beta-6 chain 4.44E-02 2.002 
P01824 Ig heavy chain V-II region 
WAH 
1.80E-02 2.073 
P13674 Prolyl 4-hydroxylase 
subunit alpha-1 
1.06E-02 2.141 
B9A064 Immunoglobulin lambda-
like polypeptide 5 
2.80E-02 2.249 
P01860 Ig gamma-3 chain C region 4.99E-02 2.271 
P08603 Complement factor H 4.15E-02 2.310 
P01008 Antithrombin-III 2.61E-02 2.317 
P01834 Ig kappa chain C region 4.25E-02 2.731 
P10909 Clusterin 4.97E-02 4.945 
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Table 5.9 – Those proteins differentially expressed between rectal tumours at resection 
and at diagnosis. 29 proteins were identified, 10 of which were downregulated (negative 
values for fold change) and 19 upregulated (positive values for fold change). 
Analysing those proteins upregulated separately from those downregulated, Ingenuity core 
analysis of direct and indirect relationships revealed the significant upregulated canonical 
pathways in this group to be: primary immunodeficiency signalling, haematopoiesis from 
pluripotent stem cells, haem degradation, N-acetylglucosamine degradation II and CMP-N-
acetylneuraminate biosynthesis I. Similarly the downregulated canonical pathways were: 
glutathione redox reactions II, BER pathway, DNA double-strand break repair by non-
homologous end joining, leukotriene biosynthesis and granzyme B signalling. Statistics for 
these identified pathways can be seen in Table 5.10. 
Upregulated Pathways p-value Ratio 
Primary immunodeficiency signalling 1.21E-05 3/46 (0.065) 
Haematopoiesis from pluripotent stem 
cells 
8.59E-04 2/44 (0.045) 
Haem degradation 3.96E-03 1/4 (0.25) 
N-acetylglucosamine degradation II 3.96E-03 1/4 (0.25) 
CMP-N-acetylneuraminate biosynthesis I 4.95E-03 1/5 (0.2) 
Downregulated Pathways p-value Ratio 
Glutathione redox reactions II 1.49E-03 1/3 (0.333) 
BER pathway 5.94E-03 1/12 (0.083) 
DNA double-strand break repair by non-
homologous end joining 
6.93E-03 1/14 (0.071) 
Leukotriene biosynthesis 6.93E-03 1/14 (0.071) 
Granzyme B signalling 7.91E-03 1/16 (0.062) 
  
Table 5.10 – Pathway analysis for proteins both upregulated and downregulated in the 
rectal tumours at resection compared to at diagnosis. P-value is adjusted using 
Benjamini-Hochberg correction. Ratio identifies the number of focus molecules identified 
(numerator) in the pathway (denominator). 
The base excision repair (BER) signalling pathway was identified as being highly significant, 
with this data set suggesting downregulation induced by chemoradiotherapy (Figure 5.3). 
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Figure 5.3 – The base excision repair (BER) signalling pathway was identified as being 
highly significant, with this data set suggesting downregulation induced by 
chemoradiotherapy. Only one of the 12 focus molecules was identified – PARP1 
(highlighted in purple). 
Further analysis of all (unfiltered) biological pathways identified 6 upregulated networks 
with a score greater than 2 pertaining to: cell death and survival, tissue morphology, 
cellular development, gastrointestinal disease, hepatic system disease, organismal injury 
and abnormalities, cell-to-cell signalling and interaction, cellular assembly and organization, 
cellular function and maintenance, cancer, carbohydrate metabolism, endocrine system 
disorders, cell morphology,  developmental disorder and hereditary disorder. Similarly 3 
downregulated networks were identified pertaining to: cancer, organismal injury and 
abnormalities, reproductive system disease, cell death and survival, energy production, 
nucleic acid metabolism, cardiovascular system development and function, endocrine 
system disorders and gastrointestinal disease. The focus molecules and statistics pertinent 
to these networks can be seen in Table 5.11.  
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Upregulated Networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 ANXA5,BMP2,BMP4,CDC25B,CDC25C,CDK
N1A,CHRNA3,CLU,GDF15,HMGB1,HRAS,I
D1,IL1R1,JAG1,LTF,NFkB 
(complex),NUMBL,NUP98,PLAA,PP2A,PYC
ARD,RASSF5,RBPJ,REL,RNF34,S100B,SERP
INB2,SNW1,SOD2,TCP1,TFRC,TNFSF13,US
P11,VHL,XRCC5 
5 3 Cell Death and 
Survival, Tissue 
Morphology, 
Cellular 
Development 
2 BLVRA,IL13 3 1 Gastrointestinal 
Disease, Hepatic 
System Disease, 
Organismal Injury 
and 
Abnormalities 
3 miR-30a-3p (and other miRNAs w/seed 
UUUCAGU),RAB8B 
3 1 Cell-To-Cell 
Signaling and 
Interaction, 
Cellular Assembly 
and Organization, 
Cellular Function 
and Maintenance 
4 AHSG,HNF1A 3 1 Cancer, 
Carbohydrate 
Metabolism, 
Endocrine 
System Disorders 
5 CD24,NAGK 3 1 Cell Morphology, 
Cellular Function 
and 
Maintenance, 
Carbohydrate 
Metabolism 
6 TFEB,TPP1 3 1 Cellular Assembly 
and Organization, 
Developmental 
Disorder, 
Hereditary 
Disorder 
Downregulated Networks 
1 APH1B,BRCA1,CASP3,CSTF1,EMILIN2,KRT
18,MIR585,mir-95,mir-128,mir-182,mir-
183,mir-188,mir-191,mir-193,mir-
224,mir-320,mir-330,mir-486,mir-
500,miR-125b-5p (and other miRNAs 
w/seed CCCUGAG),miR-17-3p (and other 
miRNAs w/seed CUGCAGU),miR-330-3p 
(and other miRNAs w/seed 
CAAAGCA),miR-378a-3p (and other 
miRNAs w/seed CUGGACU),miR-486-5p 
12 5 Cancer, 
Organismal Injury 
and 
Abnormalities, 
Reproductive 
System Disease 
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(and other miRNAs w/seed 
CCUGUAC),miR-501-5p (miRNAs w/seed 
AUCCUUU),PABPC1,PARP1,PARP2,PEBP4,
PINK1,PPT1,SSB,TEP1,TOMM40,TP53 
2 CHCHD3,CHCHD6 3 1 Cell Death and 
Survival, Energy 
Production, 
Nucleic Acid 
Metabolism 
3 CTNNB1,DPEP1,MGEA5,TCF 3 1 Cardiovascular 
System 
Development 
and Function, 
Endocrine 
System 
Disorders, 
Gastrointestinal 
Disease 
 
Table 5.11 - Network analysis for proteins both upregulated and downregulated in the 
rectal tumours at resection compared to at diagnosis. The score is derived from a p-value 
and indicates the probability of the focus molecules in a network being found together 
due to random chance. Focus molecules is the total number of proteins of interest 
identified in the respective network. 
5.3.7 Predictive biomarkers in the diagnostic samples 
A total of 8 proteins were differentially expressed between the initial diagnostic samples of 
the responders and non-responders. Of these proteins, 3 were downregulated and 5 
upregulated (Table 5.12). 
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Accession 
Number Name P Value 
Log2 Fold-Change 
(Responders/Non-
responders) 
Q9NZM1 Myoferlin 4.35E-02 -1.633 
Q13510 Acid ceramidase 1.17E-02 -1.526 
P09525 Annexin A4 1.93E-02 -1.524 
P41219 Peripherin 2.13E-02 1.583 
P12109 Collagen alpha-1(VI) chain 3.61E-02 1.800 
P80748 Ig lambda chain V-III region LOI 4.82E-02 1.866 
P07602 Proactivator polypeptide 5.90E-04 1.943 
P01860 Ig gamma-3 chain C region 2.74E-02 2.549 
 
Table 5.12 – Those proteins differentially expressed between the primary tumours of the 
responders and non-responders. 8 proteins were identified, 3 of which were 
downregulated (negative values for fold change) and 5 upregulated (positive values for 
fold change). 
Analysing those proteins upregulated separately from those downregulated, Ingenuity core 
analysis of direct and indirect relationships revealed the significant upregulated canonical 
pathways in this group to be: hepatic fibrosis/stellate cell activation, inhibition of 
angiogenesis by TSP1, inhibition of matrix metalloproteases, crosstalk between dendritic 
cells and natural killer cells and dendritic cell maturation. Similarly the downregulated 
canonical pathways were: serotonin degradation, mitochondrial dysfunction, phenylalanine 
degradation IV, tryptophan degradation and putrescine degradation. Statistics for these 
identified pathways can be seen in Table 5.13. 
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Upregulated Pathways p-value Ratio 
Lipid antigen presentation by CD1 5.28E-03 1/24 (0.042) 
Autoimmune thyroid disease signalling 9.23E-03 1/42 (0.024) 
Haematopoiesis from pleuripotent stem 
cells 
9.67E-03 1/44(0.024) 
Primary immunodeficiency signalling 1.01E-02 1/46 (0.022) 
Allograft rejection signalling 1.05E-02 1/48 (0.021) 
Downregulated Pathways p-value Ratio 
Ceramide degradation 9.92E-04 1/6 (0.167) 
Sphingosine and sphingosine-1-
phosphate metabolism 
1.32E-03 1/8 (0.125) 
Sphingosine-1-phosphate signalling 1.78E-02 1/108 (0.009) 
  
Table 5.13 – Pathway analysis for proteins both upregulated and downregulated in the 
primary tumours of the responders compared to the primary tumours of the non-
responders. P-value is adjusted using Benjamini-Hochberg correction. Ratio identifies the 
number of focus molecules identified (numerator) in the pathway (denominator). 
The ceramide degradation pathway was identified as being the most significantly 
downregulated pathway in those tumours responding to chemoradiotherapy (Figure 5.4). 
This is based on the significantly lower levels of acid ceramidase identified in the diagnostic 
samples. 
 
Figure 5.4 – The ceramide degradation pathway was identified as being the most 
significantly downregulated pathway in the diagnostic samples of those primary tumours 
responding to chemoradiotherapy. Only 1 of the 6 focus molecules was identified – acid 
ceramidase (highlighted in purple). 
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Further analysis of all (unfiltered) biological pathways identified 4 upregulated networks 
with a score greater than 2 pertaining to: cancer, cell cycle, cell morphology and 
haematological disease, hereditary disorder, immunological disease, lipid metabolism, 
small molecule biochemistry, molecular transport, skeletal and muscular disorders and 
connective tissue disorders. Similarly 2 downregulated networks were identified pertaining 
to: cancer, cell cycle, cell death and survival, cardiovascular system development and 
function, tissue morphology and cell death and survival. The focus molecules and statistics 
pertinent to these networks can be seen in Table 5.14.  
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Upregulated Networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 CCND1,PRPH 3 1 Cancer, Cell 
Cycle, Cell 
Morphology 
2 CD40,FCGR2C,IGHG3 3 1 Hematological 
Disease, 
Hereditary 
Disorder, 
Immunological 
Disease 
3 CDKN1A,GBA,mir-19,PSAP,TFEB 3 1 Lipid 
Metabolism, 
Small Molecule 
Biochemistry, 
Molecular 
Transport 
4 CHI3L1,COL6A1,COL6A2,COL6A3,estrogen 
receptor,HR,SPDEF 
3 1 Hereditary 
Disorder, Skeletal 
and Muscular 
Disorders, 
Connective 
Tissue Disorders 
Downregulated Networks 
1 ANXA4,PLAA,TP53 3 1 Cancer, Cell 
Cycle, Cell Death 
and Survival 
2 FANCC,KDR,MYOF,SYVN1,TGFBR2 3 1 Cardiovascular 
System 
Development 
and Function, 
Tissue 
Morphology, Cell 
Death and 
Survival 
 
Table 5.14 – Network analysis for proteins both upregulated and downregulated in the 
primary tumours of the responders compared to the primary tumours of the non-
responders. The score is derived from a p-value and indicates the probability of the focus 
molecules in a network being found together due to random chance. Focus molecules is 
the total number of proteins of interest identified in the respective network. 
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5.4 Discussion 
5.4.1 Summary of aims 
In this study a comprehensive proteomic analysis of serial rectal cancer biopsies from 8 
patients was performed. The aim of this investigation was to compare the proteomic profile 
of serial rectal cancer biopsies taken at diagnosis, immediately after long course 
neoadjuvant chemoradiotherapy and at resection, to establish how this profile changes 
with treatment and identify potential response biomarkers which are detectable and 
measurable on the initial diagnostic biopsy. 
5.4.2 Summary of results 
Serial rectal cancer biopsies were obtained at 3 time points (diagnosis, post 
chemoradiotherapy and resection) from 8 patients which were dichotomised by 
histopathological response into responders and non-responders. 3359 proteins were 
identified, all of which were subjected to bioinformatics analysis. A summary of the 
proteomic data is shown in Table 5.15. 
 
Table 5.15 - Summary proteomic data for the 2-group comparisons showing the total 
number of dysregulated proteins as well as those up/downregulated. 
When comparing the post chemoradiotherapy samples with the diagnostic biopsies 18 
proteins were significantly dysregulated, 2 of which were downregulated and 16 
upregulated. Comparing the samples at resection with post chemoradiotherapy samples 
identified 39 proteins dysregulated, 30 of which were downregulated and 9 upregulated. 
Similarly a comparison of the resection and diagnostic samples identified 29 proteins, 10 of 
which were downregulated and 19 upregulated. The base excision repair pathway was the 
most significantly downregulated pathway in this analysis as a result of a reduction in 
Comparison Total 
Dysregulated 
Upregulated Downregulated 
Post chemoradiotherapy / Diagnosis 18 16 2 
Resection / Post chemoradiotherapy 39 9 30 
Resection / Diagnosis 29 19 10 
Responder /  Non-responder (Diagnosis) 8 5 3 
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PARP1 abundance with treatment. Eight candidate biomarkers were identified in the 
primary tumours which appeared to predict response to chemoradiotherapy, 3 of which 
were downregulated and 5 upregulated. The most statistically significantly downregulated 
pathway was ceramide degradation as a result of low expression of acid ceramidase in 
those patients responding favourably to chemoradiotherapy. Again, further bioinformatic 
analysis of these comparator groups revealed putative pathways and networks involved in 
carcinogenesis. 
5.4.3 iTRAQ for evaluation of tumour biology 
The use of iTRAQ for the evaluation of tumour biology has previously been discussed 
(Section 4.4.3). Again this study reports protein coverage greater than that commonly seen 
in the literature and a novel study design. No other studies have attempted to characterise 
how the phenotype of any tumour changes with treatment. 
5.4.4 Base excision repair 
Base excision repair proteins are a key mechanism by which small, non-helix-distorting base 
lesions are repaired (compared to the nucleotide excision repair pathway which repairs 
bulky helix-distorting lesions). Base excision repair (BER) mechanisms remove damaged 
bases that could otherwise cause mutations by mispairing or lead to breaks in DNA during 
replication. Some of the key proteins involved in this mechanism include AP endonuclease 1 
(APE1) which cleaves an AP site for subsequent binding, DNA polymerase β which catalyses 
short-patch repair (i.e. single nucleotide replacement), and DNA ligase III along with its 
cofactor XRCC1 which catalyses the nick-sealing step in short-patch BER. The expression of 
these proteins has been investigated for potential as both biomarkers and therapeutic 
targets, although as yet there is insufficient evidence for incorporation into clinical practice 
(Vens and Begg, 2010). 
The BER pathway was one of the most significantly downregulated pathways identified 
between the initial diagnostic samples and resection, and was identified due to the 
decreased abundance in poly(ADP-ribose) polymerase (PARP1) at resection. PARP1 
modifies nuclear proteins by poly ADP-ribosylation and is therefore relevant to 
differentiation, proliferation and tumour transformation, predominantly by repairing single 
stranded DNA breaks. Failure to repair these breaks, for example in the case of absent 
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PARP1, leads to an increase in the frequency of double-strand DNA breaks which are 
subsequently repaired by homologous recombination. Cells lacking PARP1 therefore exhibit 
a compensatory hyper-recombinagenic phenotype (Schultz et al, 2003). Interestingly the 
BRCA1 and BRCA2 genes are required for the adequate function of the homologous 
recombination pathway. BRCA mutated tumours are therefore highly sensitive to PARP1 
loss (Farmer et al, 2005). 
This knowledge has led investigators to consider the potential for PARP1 inhibition as a 
radiosensitiser. In an in vitro study of Ewing sarcoma cell lines, Lee et al (2013) 
demonstrated that inhibiting PARP1 with shRNA amplified both the level and duration of 
DNA damage caused by radiotherapy which ultimately resulted in increased apoptosis and 
cell death. Wang et al (2012) considered the effects of PARP1 inhibition with an inhibitor 
currently in phase 1 clinical trials (MK-4827) in lung and breast cancer xenografts, 
demonstrating improved chemosensitivity irrespective of p53 status. 
Only one pre-clinical study is reported for colorectal cancer. Shelton et al (2013) 
investigated the radiosensitisation of ABT-888, an orally available inhibitor of PARP1, 
compared to and in combination with other chemotherapeutics (5-FU, irinotecan, 
oxaliplatin). In the HCT116 and HT26 colorectal tumour derived cell lines ABT-888 
radiosensitised at higher levels than the chemotherapeutics and acted synergistically with 
these when assessed by clonogenic assays. 
When considering the findings from this investigation in light of the literature it is clear that 
the role of PARP-1 requires further investigation both as a biomarker and potential 
chemosensitiser for rectal cancer. What remains unclear is why we may be observing a 
reduction in abundance following chemoradiotherapy in our samples. 
5.4.5 Acid ceramidase 
Acid ceramidase is a sphingolipid - a group of biomolecules known to be responsible for 
important signalling functions in the control of cell growth and differentiation (Garcia-
Barros et al, 2014). Importantly, a recent study from Mahdy et al (2009) has convincingly 
demonstrated that downregulation of the corresponding gene with siRNA in a prostate 
cancer cell line confers radiosensitivity. This in vitro study in PPC-1 cells assessed radiation 
response by clonogenic and cytotoxic assays, and also demonstrated that upregulation of 
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acid ceramidase decreased sensitivity to radiation and created cross-resistance to 
chemotherapy. The small molecule acid ceramidase inhibitor, LCL385, was also sufficient to 
sensitize PPC-1 cells to radiation. These data support our finding of low levels of acid 
ceramidase in those tumours responding to radiotherapy, with our data suggesting the 
potential for its use as an up-front predictive biomarker of response. Further evaluation in a 
larger patient cohort is clearly required however. 
Carmofur, in common to the widely used radiosensitiser capecitabine, is a fluorouracil 
analogue currently in widespread clinical use in the US in the adjuvant setting for colorectal 
cancer. In addition to its presumed primary mode of action as a thymidylate synthetase 
inhibitor it has also independently been shown to inhibit acid ceramidase in the human 
tumour derived cell lines SW403 (colorectal) and LNCaP (prostate), a property not shared 
by fluorouracil or capecitabine (Realini et al, 2013). In light of our study, further work is 
needed to compare the radiosensitisation of capecitabine (thymidylate synthase inhibition) 
and carmofur (thymidylate synthase and acid ceramidase inhibition). 
5.4.6 Study strengths and limitations 
The relative merits and difficulties of a proteomic approach to these questions have already 
been discussed (Peng et al, 2003). As with most clinical studies there is inherent 
heterogeneity in the study population; differences exist in terms of patient age, TNM stage 
and tumour grade as well as the total dose of radiation received. That said, all patients 
received oral capecitabine as a radiosensitiser. 
One of the clear strengths of the study (in contrast with that described in Chapter 4) is the 
utilisation of fresh tissue taken prior to treatment to prospectively identify novel response 
biomarkers. In addition, the yield of our mass spectrometry in terms of confidently 
identified and accurately mapped proteins is excellent, and considerably more (often many 
fold) than many other oncology based proteomic studies. The tissue resources we have 
collected are high value and the research questions are novel.  
Given the aims of this study the numbers we have used are inadequate to draw any firm 
conclusions. This combined with the heterogeneity in the study sample, and the issue of 
tumour heterogeneity previously discussed (Section 4.4.4) mandates a degree of caution in 
the interpretation of the results and validity of any conclusions. 
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5.4.7 Conclusion 
This study has evaluated the changes to the phenotype of a rectal tumour with 
chemoradiotherapy. Whilst the changes we have seen are modest in absolute figures, it is 
clear that base excision repair (and in particular PARP1) remains of interest in both 
carcinogenesis and treatment response. We have also identified acid ceramidase as a 
potential response biomarker, which complements existing understanding of its role in 
radiosensitisation.  
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Chapter 6  
Targeted analysis of candidate biomarkers in the primary tumour for predicting response 
to neoadjuvant chemotherapy in colorectal liver metastases 
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6.1 Introduction 
6.1.1 Background 
Previous chapters in this thesis have described a global approach to both genomic and 
proteomic analysis of patient matched primary and metastatic colorectal tumours. The 
biological similarity of the tumours has been discussed at both a genomic and proteomic 
level, and the issues surrounding the problems of tumour heterogeneity and clonal 
selection on biomarker studies such as this have also been explored.  Further necessary 
targeted work has been identified to explore these findings in more detail. 
6.1.2 Pharmacology of chemotherapeutics 
The bioinformatics analyses described have identified a number of potential pathways and 
networks involved in metastagenesis and treatment response. Accepting that for all 
patients the cornerstone of neoadjuvant therapy received has been 5-FU, the treatments 
have been heterogenous and as such any conclusions drawn relate to chemosensitivity of 
the tumour rather than a precise understanding of the mechanism of action of the 
chemotherapeutic agents received. The global proteomic study failed to confidently 
identify, in sufficient samples to make any meaningful interpretation, those proteins most 
relevant to the metabolism and biological effect of: 
 5-FU – dihydropyrimidine dehydrogenase (DPYD), thymidylate synthase (TS), 
orotate phosphoribosyl transferase (OPRT)  
 Irinotecan – carboxylesterase 1 (CES1), carboxylesterase 2 (CES2), topoisomerase I 
(TOP I), UDP glucuronyltransferase 1A1 (UGT1A1) and cytochrome P450 3A4 
(CYP3A4) 
 Oxaliplatin – DNA polymerase β (DNAPOL β) 
Therefore, a more targeted approach to their investigation is required.  
As yet the focus has purely been on protein expression, however the potential for post-
translational modification affecting protein function is well understood. To characterise the 
similarity in protein function (in addition to expression) between primary and metastatic 
tumours would provide further insight into the potential for using biomarkers from the 
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primary tumour to target therapy in the liver metastases. A mass-spectrometry assay of 
irinotecan conversion to SN-38 by action of human CES1 and CES2 has already been 
described (Section 2.2.9), however such an assay does not exist for 5-FU. It is however well-
established that MSI-H tumours are less likely to respond to 5-fluoruracil-based regimens, 
and in a minority of patients, treatment may even be detrimental (Sargent, 2008). As such, 
establishing MSI status in these patients may provide further useful insight. In addition, 
given the increasing use of EGFR inhibitors evaluating the concordance of KRAS and BRAF 
status in our patients would also add to the existing body of knowledge in this regard. 
6.1.3 Biomarker validation (NQO1) 
The bioinformatics analysis of patient-matched primary and metastatic tumours identified 5 
potential response biomarkers, two of which were similarly dysregulated in the primary and 
metastatic tumours and one of these (NQO1) appeared biologically plausible and worthy of 
further investigation. 
The original discovery tissue set was the 16 patients from which fresh tissue was obtained. 
Validation of the iTRAQ findings on the same samples by another laboratory technique, for 
example western blotting, would be necessary before any further work could be 
undertaken. Beyond that the next step would be validation in a larger tissue set to further 
evaluate the potential for the use of this protein as a predictive biomarker. In addition the 
nature of the dysregulation, i.e. reduced abundance in the responders, raises the question 
about the potential for this protein to be used as a therapeutic target.  
6.1.4 Aims and hypotheses 
The aim of this investigation was to further explore the potential for utilising biological 
information from the primary tumour to inform and predict response to treatment for the 
liver metastases using a targeted approach of previously-identified markers of interest. 
Specifically we hypothesise that: 
1. Expression of those proteins known to be relevant to the activation and metabolism of 
chemotherapeutics (DPYD, TS, OPRT, CES1, CES2, TOP I, UGT1A1, CYP3A4 and DNAPOL β) in 
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the primary tumour correlate with expression in the liver metastases and predict response 
to treatment. 
2. Activity of CES1/CES2 (and therefore conversion of irinotecan to SN-38) in the primary 
tumour correlates with CES1/CES2 activity in the metastasis and predicts response to 
treatment. 
3. MSI status in the primary tumour predicts status in the metastasis (and therefore likely 
response to 5-FU). 
4. KRAS and BRAF status in the primary tumour predicts status in the metastasis (and 
therefore likely response to EGFR inhibitors). 
5. NQO1 expression by western blot confirms the validity of the iTRAQ data. 
6. Immunohistochemical analysis of NQO1 expression in a larger patient cohort confirms its 
status as a predictive biomarker to (5FU based) neoadjuvant chemotherapy. 
7. Inhibition of NQO1 in an in vitro model (by siRNA and/or use of a known competitive 
inhibitor) improves chemosensitivity. 
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6.2 Methods 
6.2.1 Western blotting of proteins relevant to the activation and metabolism of 
chemotherapeutics 
Fresh frozen samples of 16 patients undergoing synchronous or staged resection of 
metastatic colorectal cancer were collected as previously described (Section 4.2.1). Those 
samples with sufficient remaining material were used for this study. Protein extraction was 
performed by a combination of both mechanical and ultrasonic homogenisation in 
phosphate-buffered saline.  
Following centrifugation the protein concentration of the supernatant was established 
using a Bradford assay (Bradford, 1976). Standard protein concentrations of bovine serum 
albumin (BSA) (Sigma Aldrich) were prepared at 0.1, 0.2, 0.4, 0.8, 1.0 and 1.4mg/ml and 
20µl placed in triplicate on a 96 well plate. Serial dilutions of each sample were made at 
concentrations of 1:10, 1:20, 1:50 and 1:100, and 20µl placed in triplicate on the same 96 
well plate. Bradford reagent (BioRad) was diluted 1:5 with dH2O and 180µl placed in each of 
the wells and then mixed. Absorbance at 570nm was measured using the Dynex MRXe 
plate reader (Magellan Biosciences, Chelmsford, UK), and protein concentration of the 
sample calculated by comparison to the standard curve. 
Samples containing 20µg total protein were prepared with 2X Laemmli buffer (BioRad), 
boiled at 100oC for 10 minutes and run on 10% SDS-PAGE gels at 110V for 1 hour. A rainbow 
molecular marker (Sigma Aldrich, Poole, UK) was used to assist with the analysis of the 
molecular weight of protein samples.  
After electrophoresis, membranes were washed in transfer buffer (1 x running buffer with 
20% methanol) and transferred to a Hybond nitrocellulose membrane (GE Lifescience) 
within a blotting sandwich in a transfer unit containing transfer buffer at 230A for 1 hour. 
Membranes were washed briefly in 1x TBST (20mM Tris-Cl pH 7.6, 150mM NaCl, 0.1% 
Tween 20) and the quality of transfer assessed with Ponceau S stain. The stain was 
removed with TBST and the membrane blocked overnight in 10% Marvel milk in TBST with 
constant agitation.  
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The optimum conditions for antibody incubation were determined by experimentation, 
with the final conditions used shown in Table 5.1. All primary antibodies were diluted in 2% 
Marvel milk with TBST and incubated overnight with constant agitation in a cold room (4oC). 
Primary 
Antibody 
Manufacturer Reference Dilution Secondary 
Antibody 
Molecular 
Weight (kDA) 
TS Abcam ab3145 1:100 Mouse 35 
DPYD Abcam ab54797 1 1:1000 Mouse 111 
OPRT Abcam ab155763 1:2500 Rabbit 55 
CES1 Abcam ab64867 1 1:1000 Rabbit 58 
CES2 Abcam ab64867 1 1:1000 Rabbit 58 
TOP I Abcam ab109374 1 1:2500 Rabbit 91 
UGT1A1 Abcam ab170858 1:2500 Rabbit 55 
CYP3A4 Sigma 1400064 1:2500 Mouse 50 
DNA POL β Kind gift from 
Dr J Parsons 
N/A 1:2500 Rabbit 33 
β-Actin Abcam ab6726 1:5000 Mouse 42 
 
Table 6.1 – Antibody incubation conditions for the proteins of interest with respect to the 
activation and metabolism of chemotherapeutics. 
After incubation, membranes were washed with TBST for 3 x 10 minutes and then 
incubated with the appropriate LI-COR IRDye 680 LT secondary antibody (Biosciences, 
Lincoln USA) as shown in Table 6.1. The incubation was performed at a concentration of 
1/20000 at room temperature for 1 hour with constant agitation in a light-tight box. Semi-
quantitative analysis was performed using the Odyssey scanner (LI-COR Biosciences, Lincoln 
USA), with the same intensity adjustments used for all membranes being blotted for the 
same protein. Densitometry measurements were taken at the time of first scanning. 
To permit inter-gel comparisons the same reference sample was included on all blots which 
were performed and analysed in triplicate with β-actin used as a loading control. Data were 
normalised to the reference sample. 
6.2.2 CES1/CES2 activity assessment by mass spectrometry 
The activity of CES1/CES2 was determined with irinotecan as a substrate in order to assess 
protein function. Tissue homogenate (250µg protein) from all patients with sufficient 
remaining primary and metastatic tumour was incubated with 200nM irinotecan (Sigma 
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Aldrich, Poole, UK) in dH20 at 37oC on a bench top rocker for 30 minutes. Given the high 
abundance of CES1 and CES2 in the liver and the significance of this to irinotecan activation 
(Jones et al, 2013), matched liver parenchyma was also studied. The reaction was 
terminated by protein precipitation following the addition of the same volume of a 50% 
acetonitrile / 50% methanol and 0.005% formic acid solution. This solution also contained 
the internal standard – 80nM camptothecin (Sigma Aldrich, Poole, UK), chosen due to its 
structural similarity to the analytes of interest and ready availability. The terminated 
reaction was centrifuged at 14000rpm for 20 minutes at 4oC. 300μl of supernatant was then 
filtered through a Millipore Multiscreen Solvinert 96 well filter plate, which had been pre-
wetted using 100μl of water. Samples were collected in a clean 96 well plate, after which 
100μL was transferred to a 200μl Chromacol glass autosampler vial and sealed with a cap. 
20 μL was injected onto the LC-MS/MS system, the final concentration of which was 100nM 
irinotecan and 40nM camptothecin.  
Two sets of parallel controls were prepared, one containing no tissue homogenate and one 
without irinotecan. A series of standard controls containing irinotecan, SN-38 (Sigma 
Aldrich, Poole, UK) and camptothecin were also prepared as shown in Table 6.2. 
Standard 
Control 
SN38 (nM) Irinotecan (nM) Camptothecin (nM) 
0 0 0 40 
20 20 20 40 
50 50 50 40 
100 100 100 40 
200 200 200 40 
400 400 400 40 
 
Table 6.2 – Preparation of standard controls for mass spectrometry analysis of irinotecan 
conversion to SN-38 by human CES1/CES2. 
The standard controls, control samples and protein samples underwent high pressure liquid 
chromatography mass spectrometry analysis to quantify the active metabolite, SN-38 
(Jones et al, 2013). The assay used has previously been developed and validated in line with 
the US Department of Health & Human Services Food and Drug Administration guidelines, 
as outlined in Bioanalytical Method Validation; Guidance for Industry (FDA, 2001).  
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Sample separation was performed on a Dionex HPLC stack using an Ultimate 3000 system 
and an Altima c18 (150 x 2.1mm, 5μM) column. A dual-buffer technique of an aqueous 
buffer A (LC-MS grade H20 with 0.25% formic acid) and organic buffer B (LC-MS grade 
acetonitrile with 0.25% formic acid) was used with a run time of 15 minutes. The elution 
time of SN38 was 5.5 minutes with a clearly detectable peak and m/z of 393.2. Conditions 
for optimal detection of SN-38 were based on existing literature (Chen et al, 2012) and a 
multiple reaction monitoring (MRM) method implemented. All samples were run in 
triplicate. The concentration of SN-38 in the samples was calculated by reference to the 
standard curve, normalised to the internal standard by peak area ratio and a rate of 
production (nmol/µg protein/minute) calculated.  
6.2.3 Microsatellite instability analysis and KRAS/BRAF pyrosequencing  
DNA extraction was performed using the Qiagen EZ1 DNA Tissue Kit as per manufacturer’s 
instructions (Qiagen, Venlo, Netherlands). DNA concentration was measured using the 
NanoDropTM ND-1000 spectrophotometer (Thermo Scientific, Waltham, USA) and quality 
assessed using the Human DNAOK! kit (Microzone, Haywards Heath, UK). KRAS mutational 
analysis was performed on the PyroMark Q96 ID (Qiagen, Venlo, Netherlands) using an in-
house pyrosequencing assay capable of detecting all somatic mutations in codons 12, 13 
and 61 of the KRAS gene with a lower limit of detection of 5% mutated alleles. BRAF 
mutational analysis for codons 600 and 601 with a lower limit of detection of 10% mutated 
alleles was similarly performed. The MSI Analysis System v1.2 (Promega) was used, with 
samples subsequently run on the Applied Biosystems 3130XL genetic analyser and data 
analysed using GeneMapper® (Life Technologies). 
6.2.4 Validation of iTRAQ data 
Western blotting for NQO1 was performed on all samples with sufficient remaining 
material. A mouse monoclonal antibody for NQO1 (Abcam, ab28947) was used at a dilution 
of 1:500. An anti-mouse LI-COR IRDye 680 LT secondary antibody (Biosciences, Lincoln USA) 
was used to detect a protein with a molecular weight of 30kDa. All conditions were 
otherwise as described in Section 6.2.1. Densitometry values were normalised to a common 
sample to allow inter-gel comparisons and the correlation between densitometry on 
western blotting and protein expression by iTRAQ was established. 
6.2.5 Tissue micro-array construction 
216 
 
Archived samples of formalin-fixed paraffin embedded patient matched primary and 
metastatic  colorectal cancer tissues were obtained from the contributing research sites 
within the Merseyside and Cheshire cancer network (n=56). Where available, normal 
adjacent colonic mucosa and liver parenchyma were also obtained. Blocks and 
corresponding haematoxylin and eosin (H&E) stained slides were reviewed and marked by a 
consultant pathologist in order to identify representative areas of both tumour and normal 
tissue. The H&E slides of the liver metastases of those patients who had received 
neoadjuvant chemotherapy were also reviewed and scored for histopathological response 
to treatment as previously described (Blazer et al, 2008). 
The method of tissue micro-array (TMA) construction is described in full elsewhere 
(Kononen et al, 1998). TMAs were constructed using a tissue microarrayer (Beecher 
Instruments Inc) with 0.6mm cores retrieved from donor blocks and transferred into the 
recipient master paraffin block in triplicate. Triplicate samples of breast and tonsillar tissue 
were also transferred to each TMA to act as controls. Samples of primary tumour, normal 
colon, normal liver and colorectal liver metastases were randomised over four TMAs which 
were produced in duplicate to ensure sufficient material for immunohistochemical staining. 
To allow inter-array comparisons, a sample set consisting of all four sample types from a 
single patient were placed on each of the 4 TMAs.  TMAs were incubated at 37°C overnight, 
placed on ice and then 5µm sections were cut on a rocking microtome. Sections were then 
placed onto coated glass slides. 
6.2.6 Immunohistochemical analysis of NQO1 
To establish optimal conditions three dilutions of the primary antibody were used on a 
series of test slides with concentrations centred around that suggested by the 
manufacturer (1/100, 1/500, 1/1000). Appropriate positive controls (breast tumour and 
colonic mucosa) identified using Protein Atlas (www.proteinatlas.org) were included 
alongside these samples. Antibody diluent only and a mouse IgG1 isotype control (Abcam, 
ab91353) were used as negative controls to assess for background staining.  
Sections were de-waxed in xylene and rehydrated with ethanol solutions of decreasing 
concentrations. After blocking with 3% hydrogen peroxide in 100% methanol, antigens 
were retrieved by microwaving for 20 minutes in 10mM citrate buffer and further blocked 
with 10% goat serum in 0.1% TRIS-buffered saline with tween. Slides were incubated with 
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the primary antibody for 2 hours (Abcam, ab28947) followed by a 1:200 horseradish 
peroxidase conjugated secondary antibody for 30 minutes (Dako UK Ltd, E0433). Following 
incubation with the Vectastain Elite® ABC reporter system (Vectorlabs, Burlingame, USA), 
slides were developed with diaminobenzidine tetrahydrochloride (DAB) and counterstained 
with haematoxylin. The optimisation slides and positive/negative controls were reviewed 
by a consultant histopathologist who confirmed the appropriateness of the staining and 
advised the optimum concentration to be used (1/1000). The control slides can be seen in 
Figure 6.1.  
 
Figure 6.1 – Antibody optimisation of NQO1 demonstrating the optimal concentration of 
antibody (1/1000) in the positive controls (left) and negative controls (right) of colonic 
mucosa (A) and breast cancer (B). 
After optimisation, sections of the TMAs were taken and stained in triplicate using the 
previously described methodology. Stained sections of the TMA were initially reviewed by 
light microscopy, and slides then scanned using the Aperio Scanscope (Leica Biosystems). 
Semi-quantification of protein expression was performed using Tissue Studio v.2.0 
(Definiens AG, Munich, Germany). Prior to quantification the system required 
programming. In brief this consisted of nuclear and cell membrane identification to enable 
the recognition of cells, followed by setting the intensity thresholds for negative and 
positive (weak, moderate and intense) staining.  Minor adjustments were made until 
concordance with a 10% sample similarly scored by eye had been achieved and then the 
TMA slides were scored (Figure 6.2).  
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Figure 6.2 - Images from a randomly selected core produced by Tissue Studio v.2.0 
(Definiens AG, Munich, Germany), an immunohistochemical scoring package.  The stained 
core as it appears under the light microscope is shown in (A), with the brown regions 
representing antibody binding and oxidation of DAB by horseradish peroxidase. Cellular 
identification and localisation is shown in (B), with the nuclei appearing blue and 
cytoplasm green. The degree of antibody staining is shown in (C) and can be seen to 
similarly correspond with the appearances on the micrograph (A). Areas shaded white 
have no antibody staining, yellow have weak antibody binding, orange have moderate 
antibody staining and brown have intense antibody staining (all considered positive). 
The data generated by Tissue Studio allowed a scoring system to be implemented based on 
that previously used by Yang et al (2014). A score was allocated for the proportion of 
positively stained cells as follows: 1 (<25%), 2 (25-50%), 3 (51-75%) or 4 (>75%).  
6.2.7 Cell culture of the SW480 cell line and dose response analysis 
The SW480 cell line is an immortal colorectal tumour derived cell line originating from a 
Dukes B adenocaricnoma of the colon. The cells were provided as a kind gift from the 
Department of Molecular and Clinical Cancer Medicine, University of Liverpool.  
Cells were maintained in Dulbecco’s Modified Eagle Medium (Sigma), 10% foetal bovine 
serum (Sigma) and 1% Penicillin/Streptomycin (Sigma). Cells were kept incubated at 37oC 
and their morphology/confluence observed every 3-4 days at which time the media was 
changed (Figure 6.3). Upon establishing confluence, cells were trypsinised with 0.25% 
trypsin-EDTA (Sigma), filtered through a sterile needle and syringe, passaged in a 1:20 ratio 
and subcultured in the same media. Where the experimental intent was to establish cell 
viability, cells were cultured in 96-well plates at 5000 cells/well. Where sufficient material 
was needed for western blot analysis, 12-well plates were seeded with 3x105 cells/well.  
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Figure 6.3 – Morphology of the SW480 cell line used for this investigation. Micrograph 
taken at x400 magnification. 
Initially, the toxic effect of irinotecan and 5-FU on the cell lines was determined. A 160mM 
stock concentration of each of the drugs was made by dissolving 4.2mg of 5FU (MW 
130.10Da) in 200µl of dimethyl sulfoxide (DMSO) and 5.0mg of irinotecan (MW 623.14Da) 
in 50µl DMSO. A series of 7 1:2 dilutions were then performed with DMSO. 7.5µl of each of 
these solutions combined with 1493µl of media produced solutions of 800 µM, 400µM, 
200µM, 100µM, 50µM, 25µM, 12.5µM and 6.25µM each with 0.5% DMSO. The control 
sample (0.5% DMSO) was prepared by diluting 25µl of DMSO in 4975µl of media. Wells 
were dosed in triplicate with 100µl of each of the prepared solutions with the control 
samples and media-only controls also placed in triplicate on the same 96 well plate. Cells 
were incubated at 37oC for 72 hours before assessing cell viability. The experiment was 
repeated in triplicate for both irinotecan and 5FU. 
An MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt]  assay was used to assess cell viability. The assay utilises MTS 
tetrazolium which is reduced into a formazan-coloured product by viable cells. The 
solubility of the product reduces the need for detergents, and the rapid colour change and 
ease of storage make it desirable for studies such as this (Buttke et al, 1993). 20µL MTS 
reagent (Promega) was introduced to all wells and the plates incubated for 2 hours at 37°C. 
A microplate reader (Multiskan, Thermo Labsystems, Ventaa, Finland) was used to measure 
optical density at 490nm. Cell viability was expressed as a percentage of control cells.  
6.2.8 Effect of chemotherapy on NQO1 expression 
The experiment described in 6.2.7 was repeated in 12 well plates. Following a 72 hour 
incubation period at 37°C, cells were lysed with 50µL of radioimmunoprecipitation assay 
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(RIPA) buffer and incubated at room temperature for 5 minutes.  Cells were scraped from 
the wells and the lysate centrifuged at 15,000 RPM for 15 minutes at 4oC. The resulting 
supernatant was quantified using the Bradford assay and underwent western blotting for 
NQO1 as previously described.  
6.2.9 siRNA transfection of NQO1 
A set of four human NQO1 siGENOME siRNAs (Thermoscientific) each targeting different 
coding regions of the gene was obtained and reconstituted according to manufacturer’s 
instructions. Twelve well plates with each well containing 3 X 105 cells in 1ml media were 
seeded and incubated overnight prior to transfection with one of the four siRNAs.  
Lipofectamine® RNAimax (Invitrogen) and opti-MEM® (Life technologies) were combined 
with the siRNA as per manufacturer’s instructions and incubated for 10 minutes prior to 
application of 15µl to the 85µl of media already placed in the wells. Each siRNA was used at 
two different concentrations (1.25pM and 2.5pM) and placed in triplicate. As a negative 
control, a non-targeting scrambled human siRNA was used to transfect the cells.  
Following a 48 hour incubation period at 37°C, cells were lysed with 50µL of RIPA buffer and 
incubated at room temperature for 5 minutes.  Cells were scraped from the wells and the 
lysate centrifuged at 15,000 RPM for 15 minutes at 4oC. The resulting supernatant was 
quantified using the Bradford assay and underwent western blotting for NQO1 as 
previously described. The blot was examined to identify the siRNA (and concentration) 
conferring the best knockdown of NQO1 (Figure 6.4) 
 
Figure 6.4 – Western blot for NQO1 in transfected S480 cells. From the left: DMSO treated 
cells were used as a control, and the transfection process (scrambled siRNA) had no effect 
on NQO1 expression. All 4 siRNAs (A-D) offered good knockdown of NQO1 at both 
concentrations. The optimum knockdown was achieved with siRNA-A at a concentration 
of 2.5pM. 
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As can be seen, the transfection process (scrambled siRNA) had no effect on NQO1 
expression. All 4 siRNAs (A-D) offered good knockdown of NQO1 at both concentrations. 
The optimum knockdown was achieved with siRNA-A at a concentration of 2.5pM. 
Transfecting the cells with this siRNA alone produced no reduction in cell viability at 72 
hours, and therefore this was used for subsequent experimental work.  
6.2.10 Effect of NQO1 knockdown on chemosensitivity 
The experiment described in section 6.2.7 was repeated in NQO1 knocked down cells 
following siRNA transfection as previously described. 96 well plates were seeded, incubated 
overnight and transfected in triplicate for each drug dose to be used. After a 48 hour 
incubation period, the media was removed and cells dosed in triplicate with irinotecan at 
concentrations of 800µM, 400µM, 200µM, 100µM, 50µM, 25µM, 12.5µM or 6.25µM. 
Scrambled siRNA followed by irinotecan dosing was used as the control arm. Further sets of 
0.5% DMSO and media only controls were included. Cells were incubated for 72 hours at 
37°C before assessing cell viability with an MTS assay as previously described. The 
experiment was repeated using 5-FU, and each plate was run in triplicate. A plate plan for 
this experiment is shown in Figure 6.5. 
 
Figure 6.5 – Wells highlighted in red were transfected with siRNA to knockdown NQO1 
and then incubated with irinotecan or 5FU over a range of concentrations. Wells 
highlighted in blue were transfected with a scrambled siRNA and then similarly treated. 
Wells highlighted in green were incubated in 0.5% DMSO (vehicle control) and wells 
highlighted in yellow were incubated in media only. 
6.2.11 Evaluating dicoumarol as an inhibitor of NQO1 and chemosensitiser 
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Dicoumarol, a coumarin currently in clinical use, has been shown to competitively inhibit 
the action of NQO1 (Tsvetkov et al, 2005). Dicoumarol competes with NAD(P)H for the 
binding of NQO1, thus inhibiting the transfer of electrons from NAD(P)H to the FAD 
cofactor and ultimately preventing the substrate from being reduced (Asher et al, 2006).  
The effects of dicoumarol on SW480 cells 
Firstly the effect of dicoumarol on SW480 cells was established. A 1mM stock concentration 
was made by dissolving 3.6mg of dicoumarol (MW 336.3) in 10ml NaOH and performing a 
series of dilutions as previously described to produce 500µM, 250µM, 100µM, 50µM, 25µM 
and 10µM solutions of dicoumarol in 0.5% NaOH. A control sample (0.5% NaOH) was 
prepared by diluting 25µl of NaOH in 4975µl of media and a media only control also used. 
Wells were dosed in triplicate with 100µl of each of the prepared solutions with the control 
samples also placed in triplicate on the same 96 well plate. Cells were incubated at 37oC for 
4 hours (the intended duration of pre-treating for future studies) before assessing cell 
viability using the MTS assay as previously described. The experiment was repeated in 
triplicate. 
Establishing the optimum concentration of dicoumarol  
A 96 well plate was seeded and incubated overnight before pre-treating triplicate wells 
with each of the dicoumarol concentrations described above. After 4 hours the media was 
removed and the cells dosed with 100µM irinotecan (the closest dose to the IC50). The 
control wells were incubated with 0.5% NaOH for 4 hours (vehicle control for dicoumarol) 
followed by irinotecan. Plates were incubated at 37oC for 72 hours before assessing cell 
viability using the MTS assay as previously described. The experiment was repeated in 
triplicate and again for 5FU at a concentration of 200µM (the closest dose to the IC50). The 
maximal effective concentration (lowest concentration to exert the full biological effect) 
was identified and used for the remainder of the experiments. 
Attributing the effects of dicoumarol to NQO1 activity  
The optimum scientific strategy would be the correlation of any biological effect seen by 
the addition of dicoumarol with cellular NQO1 activity. However, without access to a well-
validated activity assay for NQO1 we adopted an alternative strategy. Given the well 
established knock down already demonstrated with siRNA it would perhaps be reasonable 
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to assume that if dicoumarol were exerting its biological effect through NQO1 inhibition, 
then the addition of dicoumarol to cells in which NQO1 had already been knocked down 
would not result in any further effect than that already achieved with siRNA. This would 
provide at least some circumstantial evidence to confirm that dicoumarol is exerting its 
biological effect through NQO1 inhibition and not another pathway or mechanism.  
A 96 well plate was seeded and incubated overnight before transfecting 6 wells for each 
dose of chemotherapy to be used. After transfection, half of those cells were pre-treated 
with dicoumarol at a dose of 100µM (as previously determined), and the media changed in 
the remainder. After 4 hours all media was removed and the transfected wells, transfected 
and dicoumarol pre-treated wells, and a parallel set of wells which had not been 
transfected or treated were dosed with irinotecan at the range of concentrations previously 
described. The control samples were transfected with scrambled siRNA, incubated for 4 
hours in 0.5% NaOH (vehicle control for dicoumarol) and then incubated for 72 hours in 
0.5% DMSO (vehicle control for irinotecan). A further set of 0.5% DMSO only controls were 
also included. Plates were incubated at 37oC for 72 hours before assessing cell viability 
using the MTS assay. The experiment was repeated using 5-FU, and each plate was run in 
triplicate. A plate plan for this experiment is shown in Figure 6.6. 
 
Figure 6.6 - Wells highlighted in red were transfected with siRNA to knockdown NQO1, 
pre-treated with dicoumarol and then incubated with the irinotecan or 5FU over a range 
of concentrations. Wells highlighted in green were transfected but not pre-treated with 
dicoumarol and wells highlighted in blue were not transfected nor pre-treated.  Wells 
highlighted in yellow were transfected with scrambled siRNA and then pre-treated with 
0.5% NaOH and incubated in 0.5% DMSO, and those highlighted in purple were incubated 
in 0.5% DMSO only.   
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Effect of NQO1 inhibition on chemosensitivity by pre-treating cells with dicoumarol 
The experiment described in section 6.2.7 was repeated in cells pre-treated with 
dicoumarol as previously described. 96 well plates were seeded, incubated overnight and 
pre-treated with 100µM dicoumarol in triplicate for each drug concentration to be used. A 
parallel set of wells within the same plate were not pre-treated with dicoumarol. After a 4 
hour incubation period, the media was removed and cells dosed in triplicate with irinotecan 
at concentrations of 800µM, 400µM, 200µM, 100µM, 50µM, 25µM, 12.5µM or 6.25µM. 
Pre-treatment with 0.5% NaOH followed by incubation with 0.5% DMSO (the vehicle 
control for irinotecan), and 0.5% DMSO only wells were used as controls. Cells were 
incubated for 72 hours at 37°C before assessing cell viability with an MTS assay as 
previously described. The experiment was repeated using 5-FU, and each plate was run in 
triplicate. A plate plan for this experiment is shown in Figure 6.7. 
 
Figure 6.7 – Wells highlighted in red were pre-treated with dicoumarol and then 
incubated with irinotecan or 5FU over a range of concentrations. Wells highlighted in blue 
were not pre-treated but treated with chemotherapy only. Wells highlighted in green 
were pre-treated with 0.5% NaOH and then incubated in 0.5% DMSO (vehicle control) and 
wells highlighted in yellow were not pre-treated but incubated in 0.5% DMSO only. 
6.2.12 Statistical analysis 
Protein expression in primary and metastatic tumours by western blotting was compared 
using Spearman’s rank correlation co-efficient. SN38 production was compared between 
primary and metastatic tumours using the student’s paired t-test, and between all three 
groups (primary, metastasis and liver parenchyma) using one-way ANOVA. Correlation 
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between densitometry on immunoblot and iTRAQ expression was established using 
Pearson’s rank correlation co-efficient. 
With respect to the immunohistochemistry, key clinicopathological variables were 
compared between groups using ANOVA for continuous data and the X2 test for categorical 
data. Spearman’s rank correlation coefficient was used to assess for correlation in the 
percentage of positively stained cells in the primary and metastatic tumours, with a two-
way test for significance. The X2 test was used to compare the positively stained cells in the 
responders and non-responders. 
For the in vitro work data were normalised to the experimental control and experimental 
arms compared using the student’s un-paired t-test. Where multiple testing across doses 
was used, the Bonferroni correction was applied. 
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6.3 Results 
6.3.1 Western blotting of proteins relevant to the activation and metabolism of 
chemotherapeutics 
For this investigation samples were available from 12 patients: 1, 2, 3, 5, 7, 9, 10, 11, 12, 13, 
15 and 16. After optimisation of the laboratory technique, western blotting demonstrated a 
band at the expected molecular weight for each target protein. Wide variation was seen in 
protein expression both in different tissue types and also across individuals. Given the small 
number of patients for whom samples were available and the heterogeneity between 
chemotherapeutic regimens received, correlation between expression and treatment 
response would not have been scientifically meaningful. The expression between primary 
and metastatic tumours however was compared.  
Proteins relevant to 5-FU 
Western blots for TS, DPYD and OPRT are shown in Figures 6.8, 6.9 and 6.10 respectively. 
 
Figure 6.8 - Western blots for thymidylate synthase (TS) in patient matched colonic 
mucosa (C), primary tumour (P), metastatic tumour (M) and liver parenchyma (L). 
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Figure 6.9 - Western blots for dihydropyrimidine dehydrogenage (DPYD) in patient 
matched colonic mucosa (C), primary tumour (P), metastatic tumour (M) and liver 
parenchyma (L). 
 
Figure 6.10 - Western blots for orotate phosphoribosyltransferase (OPRT) in patient 
matched colonic mucosa (C), primary tumour (P), metastatic tumour (M) and liver 
parenchyma (L). 
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Densitometry values were normalised to a common sample included on all gels to allow 
inter-gel comparisons and the correlation between primary and metastatic tumour samples 
were compared using Spearman’s rank test (Table 6.3). Whilst a positive correlation was 
seen for all proteins, this did not reach statistical significance. 
 
Table 6.3 – Median densitometry values for thymidylate synthase (TS), dihydropyrimidine 
dehydrogenase (DPYD) and orotate phosphorisobysltransferase (OPRT) expression in 
patient matched primary and metastatic tumours. Correlation co-efficients (with 
Spearman’s rank test) showed positive correlations although these did not reach 
statistical significance. 
Proteins relevant to irinotecan 
Western blots for CES1, CES2, TOP I, UGT1A1 and CYP3A4 are shown in Figures 6.11, 6.12, 
6.13, 6.14 and 6.15 respectively. 
 
Protein Median (IQR) 
primary tumour 
densitometry 
Mean (SD) 
metastatic tumour 
densitometry 
Correlation 
co-efficient 
p value 
TS 830.05 
(630.89 – 1245.12) 
597.04 
(509.60 – 1798.08) 
0.64 0.054 
DPYD 5.52 
(4.56 – 7.11) 
11.21 
(7.82 – 17.34) 
0.63 0.054 
OPRT 17.50 
(10.31 – 24.10) 
32.40 
(24.67 – 39.75) 
0.05 0.882 
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Figure 6.11 - Western blots for human carboxylesterase 1 (CES1) in patient matched 
colonic mucosa (C), primary tumour (P), metastatic tumour (M) and liver parenchyma (L). 
 
Figure 6.12 - Western blots for human carboxylesterase 2 (CES2) in patient matched 
colonic mucosa (C), primary tumour (P), metastatic tumour (M) and liver parenchyma (L). 
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Figure 6.13 - Western blots for human topoisomerase I (TOP I) in patient matched colonic 
mucosa (C), primary tumour (P), metastatic tumour (M) and liver parenchyma (L). 
 
Figure 6.14 - Western blots for UDP glucuronosyltransferase 1A1 (UGT1A1) in patient 
matched colonic mucosa (C), primary tumour (P), metastatic tumour (M) and liver 
parenchyma (L). 
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Figure 6.15 - Western blots for cytochrome P450 3A4 (CYP3A4) in patient matched colonic 
mucosa (C), primary tumour (P), metastatic tumour (M) and liver parenchyma (L). 
Densitometry values were normalised to a common sample included on all gels to allow 
inter-gel comparisons and the correlation between primary and metastatic tumour samples 
were compared using Spearman’s rank test (Table 6.4). A positive correlation was seen for 
all proteins, reaching statistical significance for TOP I (r=0.79; P=0.009).  
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Table 6.4 – Median densitometry values for carboxylesterase 1 (CES1), carboxylesterase 2 
(CES2), topoisomerase I (TOP I), UDP glucuronosyltransferase 1A1 (UGT1A1) and 
cytochrome P450 3A4 (CYP3A4) expression in patient matched primary and metastatic 
tumours. Correlation co-efficients (with Spearman’s rank test) showed positive 
correlations, reaching statistical significance in the case of TOP I. 
Proteins relevant to oxaliplatin 
Western blots for DNA POL β are shown in Figure 6.16. 
 
 
Protein Median (IQR) 
primary tumour 
densitometry 
Mean (SD) 
metastatic tumour 
densitometry 
Correlation 
co-efficient 
p value 
CES1 4.28 
(1.59 - 7.30) 
15.23 
(6.47 – 37.75) 
0.41 0.248 
CES2 363.04 
(219.33 – 498.44 
518.55 
(255.42 – 837.22) 
0.50 0.144 
TOP I 7.89 
(5.05 – 12.80) 
8.50 
(5.38 – 17.75) 
0.79 0.009 
UGT1A1 2.54 
(1.89 – 4.45) 
29.20 
(4.51 – 55.57) 
0.09 0.811 
CYP3A4 520.23 
(465.13 – 645.98) 
543.80 
(356.28 – 1288.73) 
0.26 0.470 
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Figure 6.16 - Western blots for DNA polymerase β (DNA POL β) in patient matched colonic 
mucosa (C), primary tumour (P), metastatic tumour (M) and liver parenchyma (L). 
Densitometry values were normalised to a common sample included on all gels to allow 
inter-gel comparisons and the correlation between primary and metastatic tumour samples 
were compared using Spearman’s rank test. The median (IQR) densitometry values in the 
primary and metastatic tumours were 4.21 (1.47 – 5.01) and 4.52 (3.07 – 8.32) respectively. 
Spearman rank correlation was 0.58 (p=0.088).  
6.3.2 CES1/CES2 activity assessment by mass spectrometry 
Patient matched primary tumour, liver metastasis and liver parenchyma were available for 
patients 1, 2, 3, 5, 7, 9, 10, 11, 12, 13, 15 and 16. SN-38 production in these samples ranged 
from 0.77-5.36 nmol/µg protein/minute (Figure 6.17). 
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Figure 6.17 - CES1/CES2 activity was measured by SN38 production in patient matched 
primary tumour, liver metastasis and liver parenchyma. Mean (SD) data are presented for 
each tissue type for the patients studied. 
When considering the variation in SN38 production across tissue types, the mean (SD) rate 
was 2.80 (0.13) nmol/µg protein/minute in the primary tumours, 3.13 (0.11) nmol/µg 
protein/minute in the metastatic tumours, and 3.73 (0.08) nmol/µg protein/minute in the 
liver parenchymal samples (Figure 6.18). Comparison across groups with one-way ANOVA 
showed a statistically significant difference (p=0.001). 
 
Figure 6.18 – Mean, SD and 95% confidence interval for SN-38 production in the primary 
tumours, liver metastases and liver parenchyma. Analysis with ANOVA showed significant 
differences between groups (p=0.001). 
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Having identified significant differences between tissue types, patients were analysed on an 
individual basis both across all three tissue types (using ANOVA) and in light of the specific 
hypothesis the rate of production was compared between the primary and metastatic 
tumours (using student’s paired t-test). Of the 12 patients studied, there were significant 
differences between tissue types in all except two. When comparing primary and 
metastatic tumours, significant differences were seen in all except four (Table 6.5). As such 
the activity of carboxylesterase in the primary tumour does not predict that in the 
metastasis, and neither correlate well with activity in the liver parenchyma. 
Sample 
Mean (SD) 
Primary 
Mean (SD) 
Metastasis 
Mean (SD) 
Liver 
All Groups 
(ANOVA) 
Primary vs. Mets 
(Paired t-test) 
1 1.82 (0.14) 3.11 (0.06) 3.66 (0.12) 0.006 0.003 
2 4.08 (0.23) 3.60 (0.13) 4.82 (0.08) 0.018 0.051 
3 2.76 (0.11) 2.70 (0.08) 3.26 (0.05) 0.003 0.055 
5 4.13 (0.11) 4.93 (0.22) 5.37 (0.07) 0.003 0.024 
7 2.79 (0.06) 3.56 (0.12) 3.95 (0.07) 0.004 0.001 
9 4.02 (0.14) 2.81 (0.12) 3.27 (0.08) 0.002 0.000 
10 2.65 (0.27) 2.87 (0.09) 3.34 (0.07) 0.052 0.112 
11 0.82 (0.10) 0.77 (0.09) 2.84 (0.17) 0.001 0.029 
12 4.10 (0.10) 4.23 (0.11) 4.61 (0.11) 0.039 0.175 
13 2.34 (0.07) 4.01 (0.08) 4.24 (0.06) 0.002 0.001 
15 2.16 (0.09) 2.27 (0.12) 2.62 (0.06) 0.061 0.228 
16 1.95 (0.10) 2.76 (0.08) 2.83 (0.05) 0.003 0.000 
 
Table 6.5 – SN-38 production in patient matched primary tumour, liver metastasis and 
liver parenchyma (nmol/µg protein/minute). Of the 12 patients studied there were 
significant differences between tissue types (by ANOVA) in all except two (highlighted in 
red). When specifically comparing the primary and metastatic tumours, significant 
differences (by student’s paired t-test) were seen in all except four (also highlighted in 
red). 
6.3.3 KRAS/BRAF pyrosequencing and microsatellite instability analysis 
With the exception of patient 14, sufficient material was available for analysis of primary 
and metastatic tumours from all patients. Corresponding colonic mucosa and liver 
parenchyma was also sequenced where available. Five patients (3, 6, 10, 12, and 16) had 
mutations in KRAS codon 12, with 100% concordance between primary and metastatic 
236 
 
tumours and the mutations not present in the normal adjacent colonic mucosa from which 
the tumour had arisen. No mutations were detected in KRAS codon 13 or 61. One patient 
(13) had BRAF mutations in codons 600 and 601 and again this mutation was present in 
both primary and metastatic tumour. All patients were microsatellite-stable except patient 
16 who was microsatellite instability low (MSI-L) in the colonic mucosa, primary tumour, 
liver metastasis and liver parenchyma. Results and mutational frequencies can be seen in 
Table 6.6. 
Patient Tissue 
KRAS Codon 
12 
KRAS 
Codon 13  
KRAS 
Codon 61 
BRAF Codon 
600 and 601 MSI Status 
1 
Colon WT WT WT WT Stable 
Primary WT WT WT WT Stable 
Metastasis WT WT WT WT Stable 
2 
Primary WT WT WT WT Stable 
Metastasis WT WT WT WT Stable 
3 
Primary 
c.35G>T 
(p.Gly12Val) 
25% WT WT WT Stable 
Metastasis 
c.35G>T 
(p.Gly12Val) 
25% WT WT WT Stable 
4 
Primary WT WT WT WT Stable 
Metastasis WT WT WT WT Stable 
Liver WT WT WT WT Stable 
5 
Colon WT WT WT WT Stable 
Primary WT WT WT WT Stable 
Metastasis WT WT WT WT Stable 
Liver WT WT WT WT Stable 
6 
Colon WT WT WT WT Stable 
Primary 
c.35G>C 
(p.Gly12Ala) 
20% WT WT WT Stable 
Metastasis 
c.35G>C 
(p.Gly12Ala) 
20% WT WT WT Stable 
Liver WT WT WT WT Stable 
7 
Colon WT WT WT WT Stable 
Primary WT WT WT WT Stable 
Metastasis WT WT WT WT Stable 
Liver WT WT WT WT Stable 
8 
Primary WT WT WT WT Stable 
Metastasis WT WT WT WT Stable 
Liver WT WT WT WT Stable 
9 Colon WT WT WT WT Stable 
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Primary WT WT WT WT Stable 
Metastasis WT WT WT WT Stable 
Liver WT WT WT WT Stable 
10 
Colon WT WT WT WT Stable 
Primary 
c.34G>T 
(p.Gly12Cys) 
35% WT WT WT Stable 
Metastasis 
c.34G>T 
(p.Gly12Cys) 
20% WT WT WT Stable 
Liver WT WT WT WT Stable 
11 
Colon WT WT WT WT Stable 
Primary WT WT WT WT Stable 
Metastasis WT WT WT WT Stable 
Liver WT WT WT WT Stable 
12 
Colon WT WT WT WT Stable 
Primary 
c.35G>A 
(p.Gly12Asp) 
20% WT WT WT Stable 
Metastasis 
c.35G>A 
(p.Gly12Asp) 
30% WT WT WT Stable 
Liver WT WT WT WT Stable 
13 
Colon WT WT WT WT Stable 
Primary WT WT WT 
c.1799T>A 
(p.Val600Glu) 
23% Stable 
Metastasis WT WT WT 
c.1799T>A 
(p.Val600Glu) 
44% Stable 
Liver WT WT WT WT Stable 
15 
Colon WT WT WT WT Stable 
Primary WT WT WT WT Stable 
Metastasis WT WT WT WT Stable 
Liver WT WT WT WT Stable 
16 
Colon WT WT WT WT MSI-Low 
Primary 
c.35G>T 
(p.Gly12Val) 
50% WT WT WT MSI-Low 
Metastasis 
c.35G>T 
(p.Gly12Val) 
50% WT WT WT MSI-Low 
Liver WT WT WT WT MSI-Low 
Table 6.6 – KRAS (codon 12, 13 and 61), BRAF (codon 600 and 601) and microsatellite 
instability analysis for 16 patients undergoing resection at both sites for liver limited 
stage IV colorectal cancer. Five patients had KRAS codon 12 mutation, one patient had 
BRAF 600/601 mutation and one patient was MSI-Low. WT = wild type. 
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With respect to KRAS/BRAF mutation, as only patient received cetuximab (Table 4.2) it is 
not possible to make any further comment on patient selection or treatment response. 
Although all patients undergoing neoadjuvant chemotherapy received 5-FU, only one 
patient had microsatellite instability and therefore again no comment on patient selection 
or treatment response can be made. 
 6.3.4 Validation of iTRAQ data 
Data acquired by iTRAQ were validated by western immunoblotting for NQO1. Evaluation 
of protein expression was directly comparable (Figure 6.19), with a Pearson correlation co-
efficient of 0.59 (95% CI 0.47 – 0.69; p=0.003). 
 
Figure 6.19 – Comparison of protein quantification by western blotting (densitometry iu) 
and iTRAQ (abundance) for NQO1 demonstrates a high statistically significant 
relationship (r=0.59; p=0.003). 
6.3.5 Immunohistochemical analysis of NQO1 
 A tissue micro-array of 56 patient matched primary and metastatic tumour samples was 
assembled. Where available, normal colonic mucosa and liver parenchyma were also 
included. Of the 56 patients, 37 had received neoadjuvant treatment and 19 were chemo-
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naive. As discussed in previous chapters, there was again considerable variation in the 
agents and regimens received. Of the 37 patients, 14 (37.8%) had a tumour regression 
grade of I-II (the responders), and 23 (62.2%) had a tumour regression grade of III-IV. Key 
clinical and pathological characteristics between these groups were compared (Table 6.7). 
 
Table 6.7 – Key clinical and pathological variables in the chemo-naive, responders and 
non-responders. Continuous data was assessed for significance using ANOVA* and 
categorical data using the X2 test#. Only T stage was considerably different between 
groups, with a greater proportion of T4 tumours in the chemo-naive group. 
Continuous data was assessed for significance using ANOVA and categorical data using the 
X2 test. Only T stage was considerably different between groups, with a greater proportion 
of T4 tumours in the chemo-naive group (42.1% vs 7.1% in the responders and 4.3% in the 
non-responders, P=0.017). This discrepancy is most likely to be explained by the ‘straight to 
surgery’ approach usually taken with T4 tumours given their tendency to be symptomatic 
and at high risk of obstruction and perforation. 
Variable Responders 
Non-
responders 
Chemo-naive P value 
Median age (range) 66.1 (49-80) 61.8 (37-77) 67.2 0.363* 
Sex (%) 
Male 10 (71.4) 17 (73.9) 13 (68.4) 
0.926# 
Female 4 (28.6) 6 (26.1) 6 (31.6) 
Simultaneous resection (%) 3 (21.4) 2 (8.7) 2 (10.5) 0.617# 
Location of 
primary (%) 
Rectum 5 (35.7) 6 (26.1) 3 (15.8) 
0.506# Left 8 (57.1) 11 (47.8) 11 (57.9) 
Right 1 (7.1) 6 (26.1) 5 (26.3) 
T stage 
1 0 (0.0) 0 (0.0) 0 (0.0) 
0.017# 
 
2 4 (28.6) 8 (34.8) 5 (26.3) 
3 9 (64.3) 14 (60.9) 6 (31.6) 
4 1 (7.1) 1 (4.3) 8 (42.1) 
N stage 
0 4 (28.6) 11 (47.8) 12 (63.2) 
0.118# 1 5 (35.7) 10 (43.5 5 (26.3) 
2 5 (35.7) (35.7) 2 (10.5) 
Differentiation 
Poor 1 (7.1) 0 (0.0) 1 (5.3) 
0.444# Moderate 8 (57.1) 15 (65.2) 15 (78.9) 
Well 5 (35.7) 8 (34.8) 3 (15.8) 
Mean (SD) number of 
metastases 
2.2 (1.2) 2.4 (1.9) 3.0 (4.3) 0.756* 
Total patients 14 23 19 N/A 
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The percentage of positive cells stained was calculated as previously described. To establish 
the correlation between primary and metastatic tumour expression, the raw data were 
plotted as x and y variables (Figure 6.20). 
 
Figure 6.20 – Correlation between the percentage of cells staining positively for NQO1 in 
the primary tumour and metastatic tumour. Using Spearman’s rank correlation 
coefficient, r=0.44 (95% CI 0.20 – 0.64, p=0.001). 
Given the skewed appearance towards high expression, correlation was assessed 
statistically using Spearman’s rank correlation coefficient. A moderate positive association 
reaching statistical significance was seen: r=0.44 (95% CI 0.20 – 0.64, p=0.001). 
NQO1 expression in the responders and non-responders grouped by percentage of 
positively stained cells (Section 6.2.6) can be seen in Table 6.8. X2 test applied to the 
primary tumour scores was not significant (p=0.470) however analysis of the metastases 
showed that NQO1 staining is considerably higher in the non-responders compared to the 
responders (p=0.041). 
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Cell Staining 
Primary Metastasis 
Responders 
Non 
responders 
Responders 
Non 
responders 
1 (<25%) 1 1 2 0 
2 (25-50%) 3 3 7 6 
3 (51-75%)   10 19 5 12 
4 (>75%) 0 0 0 5 
 
Table 6.8 - NQO1 expression in the responders and non-responders grouped by 
percentage of positively stained cells. No statistically significant difference was observed 
in the primary tumours (p=0.470) however in the metastases, NQO1 staining is 
considerably higher in the non-responders compared to the responders (p=0.041, X2 test). 
6.3.6 Cell culture of the SW480 cell line and dose response analysis  
Dose-response data for irinotecan in the SW480 cell line is shown in Figure 6.21. 
 
Figure 6.21 – Dose response analysis for irinotecan in the SW480 cell line. Cells were 
incubated for 72 hours and cell viability assessed using the MTS assay and presented as a 
mean (95% CI) percentage of the control (0.5% DMSO). The IC50 is 90.2µM. 
As can be seen, doses up to ~50µM have little toxic effect, after which a sharp reduction in 
cell viability is seen. At 800µM, less than 20% of cells were viable at 72 hours. The IC50 
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(concentration of drug required to render 50% of cells non-viable) under these 
experimental conditions is 90.2µM. 
Dose-response data for 5-FU in the SW480 cell line is shown in Figure 6.22. 
 
Figure 6.22 – Dose response analysis for 5-FU in the SW480 cell line. Cells were incubated 
for 72 hours and cell viability assessed using the MTS assay and presented as a mean 
(95% CI) percentage of the control (0.5% DMSO). The IC50 is 202.2µM. 
As can be seen, doses up to ~100µM have little toxic effect, after which a sharp reduction in 
cell viability is seen. At 800µM, less than 20% of cells were viable at 72 hours. The IC50 
(concentration of drug required to render 50% of cells non-viable) under these 
experimental conditions is 202.2µM. 
6.3.7 Effect of chemotherapy on NQO1 expression 
To establish the effect of the chemotherapy agents on NQO1 expression, western blots 
were performed on cell lysates following incubation with the drug for 72 hours. The blot 
and corresponding densitometry values for irinotecan can be seen in Figure 6.23.  The 
effect was negligible, did not reach statistical significance and was similarly observed 
following incubation with 5-FU. 
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Figure 6.23 – The effect of incubation with irinotecan on NQO1 expression was minimal. 
No samples were significantly different from the control value (0.5% DMSO). 
6.3.8 Effect of NQO1 knockdown on chemosensitivity 
The effect of NQO1 knockdown by siRNA transfection on chemosensitivity to irinotecan can 
be seen in Figure 6.24. 
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Figure 6.24 – Dose response analysis for irinotecan in the SW480 cell line with and 
without knockdown of NQO1 by siRNA transfection. Cells were incubated for 72 hours 
and cell viability assessed using the MTS assay and presented as a mean (95% CI) 
percentage of the control (0.5% DMSO). The IC50 is 100.1µM with the scrambled siRNA 
transfection, and 49.8µM following NQO1 knockdown. Statistical significance was 
achieved as follows: *p<0.05, **p<0.01, ***p<0.001. 
An increase in chemosensitivity was seen following knockdown of NQO1 when compared to 
the scramble siRNA transfection, reaching statistical significance at 25µM (p=0.038), 50µM 
(p=0.002), 100µM (p=<0.001), 200µM (p=0.004) and 400µM (p=0.001) doses of irinotecan. 
The IC50 is 100.1µM with the scrambled siRNA transfection, and 49.8µM following NQO1 
knockdown. 
The effect of NQO1 knockdown by siRNA transfection on chemosensitivity to 5-FU can be 
seen in Figure 6.25. 
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Figure 6.25 – Dose response analysis for 5-FU in the SW480 cell line with and without 
knockdown of NQO1 by siRNA transfection. Cells were incubated for 72 hours and cell 
viability assessed using the MTS assay and presented as a mean (95% CI) percentage of 
the control (0.5% DMSO). The IC50 is 200.1µM with the scrambled siRNA transfection, 
and 25.0µM following NQO1 knockdown. Statistical significance was achieved as follows: 
*p<0.05, **p<0.01, ***p<0.001. 
An increase in chemosensitivity was seen following knockdown of NQO1 when compared to 
the scramble siRNA transfection, reaching statistical significance at 25µM (p=<0.001), 50µM 
(p=0.007), 100µM (p=0.010) and 200µM (p=0.044) doses of 5-FU. The IC50 is 200.1µM with 
the scrambled siRNA transfection, and 25.0µM following NQO1 knockdown. 
6.3.9 Evaluating dicoumarol as an inhibitor of NQO1 and chemosensitiser 
The effect of dicoumarol on SW480 cell viability 
The effect of dicoumarol alone on cell viability can be seen in Figure 6.26. The effects are 
negligible, with no significant difference between doses.  
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Figure 6.26 - Dose response analysis for dicoumarol in the SW480 cell line.  Cells were 
incubated for 4 hours and cell viability assessed using the MTS assay and presented as a 
mean (95% CI) percentage of the control (media only). 
Establishing the optimum concentration of dicoumarol  
The maximal effective concentration for dicoumarol was calculated by pre-treating cells for 
4 hours prior to incubation in irinotecan for 72 hours (Figure 6.27).  
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Figure 6.27 – The effect of pre-treating cells with dicoumarol prior to incubation with 
100µM irinotecan. Cell viability is expressed as a percentage of control (0.5% NaOH only 
followed by irinotecan). The maximum effect was achieved at a dicoumarol dose of 
100µM.  
In these experimental conditions, the maximal effective concentration was ~100µM, and 
therefore this dose was used for subsequent investigations. Similar data were also seen 
following incubation with 5-FU. 
Attributing the effects of dicoumarol to NQO1 activity 
Treatment with dicoumarol following siRNA knockdown of NQO1 was performed to 
establish whether dicoumarol may be exerting its pharmacological effect via another 
pathway. 
The results for irinotecan dosing can be seen in Figure 6.28. When comparing the NQO1 
knockdown with irinotecan only, similar data to that previously described are seen. 
Negligible differences are seen between the ‘knockdown’ and ‘knockdown and dicoumarol’ 
experimental arms, and analysis with the student’s un-paired t-test showed no significant 
difference at any data points. As such, dicoumarol does not appear to have any effect on 
chemosensitivity in cells not-expressing NQO1. Similar data were also seen following 5-FU 
incubation. 
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Figure 6.28 - Dose response analysis for irinotecan in the SW480 cell line firstly showing 
the effect of NQO1 knockdown by siRNA transfection, and secondly the absence of any 
additional biological effect following dicoumarol pre-treatment in those cells not 
expressing NQO1. Cells were incubated for 72 hours and cell viability assessed using the 
MTS assay and presented as a mean (95% CI) percentage of the control (scrambled siRNA 
transfection, pre-treatment with 0.5% NaOH and incubation in 0.5% DMSO).  
Effect of NQO1 inhibition on chemosensitivity by pre-treating cells with dicoumarol 
To establish the effect of NQO1 inhibition with dicoumarol on chemosensitivity, cells were 
pre-treated with 100µM dicoumarol prior to being dosed with irinotecan. Results are 
shown in Figure 6.29. 
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Figure 6.29 – Dose response analysis for irinotecan in the SW480 cell line with and 
without pre-treatment with dicoumarol. Cells were incubated for 72 hours and cell 
viability assessed using the MTS assay and presented as a mean (95% CI) percentage of 
the control (0.5% NaOH followed by 0.5% DMSO). The IC50 is 100.0µM for irinotecan 
alone, and 50.0µM following NQO1 inhibition with dicoumarol. Statistical significance 
was achieved as follows: *p<0.05, **p<0.01, ***p<0.001. 
An increase in chemosensitivity was seen following inhibition of NQO1 with dicoumarol 
compared to the control, reaching statistical significance at 12.5µM (p=0.013), 25µM 
(p=0.005), and 50µM (p=0.002) doses of irinotecan. The IC50 is 100.0µM for irinotecan 
alone, and 50.0µM following NQO1 inhibition with dicoumarol. The experiment was 
repeated with 5-FU, with the results shown in Figure 6.30. 
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Figure 6.30 – Dose response analysis for 5-FU in the SW480 cell line with and without pre-
treatment with dicoumarol. Cells were incubated for 72 hours and cell viability assessed 
using the MTS assay and presented as a mean (95% CI) percentage of the control (0.5% 
NaOH followed by 0.5% DMSO). The IC50 is 183.7µM for 5-FU alone, and 49.9µM 
following NQO1 inhibition with dicoumarol. Statistical significance was achieved as 
follows: *p<0.05, **p<0.01, ***p<0.001. 
An increase in chemosensitivity was seen following inhibition of NQO1 with dicoumarol 
compared to the control, reaching statistical significance at 25µM (p=0.008), 50µM 
(p=0.002), 100µM (p=0.003) and 200µM (p=0.030) doses of 5-FU. The IC50 is 183.7µM for 
5-FU alone, and 49.9µM following NQO1 inhibition with dicoumarol. 
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6.4 Discussion 
6.4.1 Summary of aims 
The aim of this investigation was to further explore the potential for utilising biological 
information from the primary tumour to inform and predict response to treatment for the 
liver metastases using a targeted approach of previously identified markers of interest. 
Specific hypotheses were formulated relating to protein expression and activity levels of 
proteins relevant to the activation and metabolism of chemotherapeutics as well as the 
concordance between primary and metastatic tumours of KRAS, BRAF and MSI status. 
The main objective of this investigation, however, was to validate the findings of the 
proteomic work previously undertaken and progress our understanding of the role of NQO1 
as a predictive biomarker of treatment response. This entailed a direct comparison of the 
iTRAQ data by western blotting and validation of these findings in a larger tissue set. The 
finding that NQO1 levels are reduced in those tumours responding to chemotherapy also 
prompted the investigation of its role as a potential drug target. 
6.4.2 Summary of results – patient matched clinical samples 
Western blotting for the proteins of interest with respect to the activation and metabolism 
of key chemotherapeutics (TS, DPYD, OPRT, CES1, CES2, TOPI, UGT1A1, CYP3A4 and DNA 
POL β) all showed a positive correlation in expression between primary and metastatic 
tumours, although this only reached statistical significance for TOP I (p=0.009). Given the 
variation in neoadjuvant treatment regimens received by these patients no response 
analysis was considered feasible.  
Mass spectrometry analysis of CES1/CES2 activity (by irinotecan conversion to SN-38) 
showed significant differences across primary tumour, metastatic tumour and liver 
parenchyma (p=0.001). When analyses were made for individual patients, all except 2 had 
statistically significant differences in the CES1/CES2 activity in the primary tumour, 
metastatic tumour and liver parenchyma. When interrogating the data pertaining to the 
primary and metastatic tumour only, all patients except 4 had statistically significant 
differences between protein activity levels at the two disease sites. As such the activity of 
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carboxylesterase in the primary tumour does not predict that in the metastasis, and neither 
correlate well with activity in the liver parenchyma. 
Pyrosequencing for KRAS and BRAF mutations identified the KRAS codon 12 mutation in 5 
patients with 100% concordance between primary and metastatic tumours and no 
mutation similarly detected in the adjacent normal colonic mucosa. No mutations were 
seen in codons 13 or 61. One patient had BRAF mutation in both codons (600 and 601) 
again with concordance between primary and metastatic tumours. One patient had 
microsatellite instability, which was detected in the colonic mucosa as well as the primary 
and metastatic tumours. Given the low numbers of mutations detected and the 
heterogeneity in the neoadjuvant treatment regimens received, no analysis of correlation 
with response was feasible. 
Western blotting for NQO1 was used to validate the iTRAQ proteomic data reported in 
Chapter 4. Correlation of protein expression by western blotting densitometry and iTRAQ 
abundance data showed a statistically significant positive correlation (r=0.59, p=0.003). 
Having confirmed the validity of the original proteomic data the investigation was 
expanded to validate these findings in a larger tissue set.  
Of the 56 patients for whom patient matched primary and metastatic FFPE blocks were 
available, 37 received neoadjuvant treatment. Fourteen of these patients responded to 
chemotherapy (TRG1-2), 23 did not (TRG3-4). Comparing clinicopathological features 
between groups revealed a higher proportion of T4 tumours in the chemonaive group 
(p=0.017), most likely reflecting a clinical preference for prompt surgery in this patient 
cohort. No other potentially confounding variables were different between groups. A 
statistically significant positive correlation between immunohistochemical protein 
expression in the primary and metastatic tumours was seen (r=0.44, p=0.001). NQO1 
expression in the primary tumour was not statistically significantly different between 
responders and non-responders (p=0.470), however expression in the metastases was 
considerably lower in those patients responding to chemotherapy (p=0.041), mirroring the 
conclusion of the proteomic data. 
6.4.3 Summary of results – in vitro model of colorectal cancer 
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Under the experimental conditions studied, the IC50 for irinotecan and 5-FU in the SW480 
cell line was 90.2µM and 202.2µM respectively. Western blotting for NQO1 after treating 
cells with chemotherapy demonstrated no effect on protein expression. Knockdown of 
NQO1 with siRNA had no direct effect on cell viability. Knockdown of NQO1 followed by 
treatment with irinotecan reduced the IC50 from 100.1µM to 49.8µM, with statistically 
significant differences at doses between 25-400µM. Similarly with respect to 5-FU, NQO1 
knockdown reduced the IC50 from 200.1µM to 25.0µM, with statistically significant 
differences at doses between 25-200µM. 
Dosing cells with dicoumarol alone had no effect on cell viability. When cells were pre-
treated with dicoumarol over a range of doses prior to incubation with a chemotherapeutic, 
a reduction in cell viability was seen which reached its maximal effectiveness at ~100µM. 
Cells in which NQO1 had been knocked down with siRNA experienced no further reduction 
in viability by the addition of dicoumarol, suggesting this drug is acting by inhibition of 
NQO1 rather than through an alternative pathway. Pre-treating cells with dicoumarol prior 
to incubation in irinotecan reduced the IC50 from 100.0µM to 50.0µM, with statistically 
significant differences at irinotecan doses between 12.5-50µM.  Similarly with respect to 5-
FU, inhibition of NQO1 with dicoumarol reduced the IC50 from 183.7µM to 49.9µM, with 
statistically significant differences at 5FU doses between 25-200µM. 
6.4.4 NQO1 as a chemosensitiser 
The role of the NQO1 protein as a biomarker has already been discussed in Section 4.4.5. 
Two polymorphisms of NQO1 however have been well defined and characterised. The 
NQO1*2 polymorphism is a C609T substitution (on 16q) resulting in a proline to serine 
substitution at amino acid 187. The resulting protein is inactive, and therefore homozygotes 
(up to 40% of the population) are NQO1 null with heterozygotes demonstrating reduced 
activity (Traver et al, 1992). The less common (0.05%) NQO1*3 polymorphism is a C465T 
substitution resulting in an arginine to tryptophan amino acid change. This variant however 
is similar to the wildtype and is catalytically active but with major differences in the rate of 
metabolism of quinone substrates (Pan et al, 1995). Given that NQO1 activity and protein 
expression could potentially be rapidly induced by a host of dietary and other factors, 
genotyping patients for the NQO1*2 polymorphism may be more clinically beneficial than 
immunostaining if it were to be further considered as a predictive biomarker. 
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The in vitro data from this study confirms the likelihood that the NQO1 expression levels 
seen in the proteomic study are determined by the phenotype of the tumour rather than 
an effect of treatment with chemotherapy. Furthermore, the immunohistochemical 
analysis suggests that the primary tumour is predictive of the metastatic phenotype and 
confirms the findings of reduced expression in chemo-responsive metastases. Knockdown 
of this protein alone (with siRNA or dicoumarol) had no effect on cell viability, and 
therefore its potential therapeutic role is as a chemosensitiser rather than a cytotoxic.  
In common with many other cytoprotective proteins, NQO1 is transcriptionally regulated 
through the Keap1-Nrf2 pathway. Under normal conditions Nrf2 (nuclear factor (erythroid-
derived 2)) is sequestered in the cytoplasm physically bound to Keap1 (Kelch-like ECH-
associated protein 1). Inducers of the pathway, which may be endogenous or exogenous, 
interact with cysteine residues of Keap1 rendering it unable to target Nrf2 for degradation. 
Consequently Nrf2 is stabilised and subsequently translocates to the nucleus (Figure 6.31). 
Here it dimerises with a number of transcription factors and the heterodimer binds to the 
antioxidant response elements (ARE) of a number of genes thus activating transcription 
(Bataille and Manautou, 2012). 
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Figure 6.31 - Nrf2 is bound to Keap1 until pathway activation causes its stabilisation. Nrf2 
subsequently translocates to the nucleus where it dimerises with a number of 
transcription factors and the heterodimer binds to the antioxidant response elements of 
a number of genes thus activating transcription. Adapted from Bataille and Manautou 
(2012). 
NQO1 is a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. 
The cytosolic enzyme catalyses the beneficial two-electron reduction of quinines to 
hydroquinones, reducing the formation of reactive oxygen species (Lind et al, 1990). This 
mechanism of action explains the reductive activation of chemotherapeutic quinines such 
as mitomycins and aziridinyl-benzoquinones, but not those studied in this investigation 
(Siegel et al, 1990). The hydroquinones derived from these agents are more chemically 
reactive and produce reactive species which kill malignant cells, and therefore if acting 
through this or a similar mechanism we would expect to see high levels of NQO1 in patients 
responding to chemotherapy. 
So if inhibition of NQO1 is not directly increasing the efficacy of the chemotherapeutic 
agent by biochemical modulation, it may be inhibiting the cytoprotective features of the 
cells and rendering them more susceptible to chemotherapy through a mechanism other 
than its enzymatic activity. NQO1 appears to exert cytoprotective effects through another 
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mechanism, by regulating the proteasomal degradation of specific proteins. NQO1 has been 
shown to regulate the ubiquitin-independent 20S proteasomal degradation of p73α (Asher 
et al, 2005), p33 (Garate et al, 2008) and perhaps of most relevance p53. In 2001, Asher et 
al reported that NQO1 inhibits the degradation of p53 in HCT-116 cells, and exposure to an 
inhibitor of NQO1 enhances p53 proteasomal degradation. This degradation appears to be 
most prominent under conditions of oxidative stress, and independent of both Mdm-2 and 
ubiquitin (Gong et al, 2007). 
We report low levels of NQO1 in chemoresponsive tumours, both in clinical samples and 
following manipulation in in vitro studies, potentially therefore associated with enhanced 
degradation of p53. Whilst some studies have reported that p53 is necessary for efficient 
execution of the death programme following treatment with chemotherapeutics and that 
increased expression causes chemosensitivity by promoting apoptosis (Lowe et al, 1993), 
others have suggested that p53 inhibition actually improves response to chemotherapy. If 
apoptosis is suppressed, a frequent finding in tumour cells, the residual functions of p53 
(growth arrest at cell cycle checkpoints and modulation of DNA repair) may contribute to 
cells surviving anticancer treatment (Xu, Mymryk and Cairncross, 2005). Browder et al 
(2000) treated p53-null and p53-WT mouse xenografts with a chemotherapeutic regimen, 
demonstrating increased efficacy in the p53-null mice and concluding that p53 is playing a 
protective role. A similar protective role is observed in the epithelium of the small intestine 
following γ irradiation, where p53 is suggested to allow cells to reside in a growth arrested 
state thus reducing the risk of a mitotic catastrophe (Gudkov and Komarova, 2003). 
Whether or not the observed effects of NQO1 inhibition are a result of its catalytic activity, 
p53 stabilisation, regulation of the proteasomal degradation of another protein or an 
entirely different mechanism has not been answered by this investigation and should be 
the subject of further study. 
6.4.5 Topoisomerase I 
A large randomised control trial comparing 5FU with 5FU and irinotecan demonstrated that 
high expression of TOP I measured by immunohistochemistry correlated with 
responsiveness to treatment (HR 0.98; 95% CI 0.78 – 1.22) (Braun et al, 2008). A similar trial 
from Dutch Colorectal Cancer Group however failed to replicate these findings, with no 
association seen between TOP I expression and response to irinotecan (Koopman et al, 
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2007).  The concordance we have found between expression at different disease sites is 
novel, and contradictory to the evidence presented by Boonsong et al (2002) who found no 
concordance between the expression in primary tumour and lymph node metastases. 
There is clearly conflicting evidence both in terms of concordance of expression across 
disease sites and the potential for its use as a biomarker, however it is clear that TOP I is 
worthy of further investigation. 
6.4.6 Strengths and limitations of the study 
Undertaking investigations on clinical samples has brought the known challenges of small 
numbers and a diverse patient population, resulting in difficulty drawing accurate scientific 
conclusions. The issues surrounding the relevance of tumour heterogeneity and clonal 
selection on biomarker studies such as these have already been discussed in previous 
chapters.  
The in vitro cancer model used shares the same advantages and disadvantages of all in vitro 
experimental models. The complexities of an organism are simplified to basic functions, 
allowing the investigator to focus on and manipulate a small number of conditions (Vignais, 
2010). In this study, for example, it has allowed the manipulation of a single protein’s 
expression using siRNA which would prove challenging in alternative models of cancer. 
Conversely, investigators must be wary about their conclusions and the potential difficulties 
in extrapolating data back to the intact organism. This is particularly true for drug-based 
studies such as these where issues of drug formulation and delivery, pharmacokinetics and 
toxicity have not been studied (De Clercq, 2005). 
The strengths of this study, and in particular the work examining NQO1, is that it has arisen 
from, validates and builds on the iTRAQ proteomic data described in Chapter 4. NQO1 was 
identified through an unbiased shotgun proteomic screen and has now been validated in a 
larger tissue set as a predictive biomarker of chemoresponsiveness. Moreover, 
investigations into its potential use as a novel drug target have begun. The quality of the 
western blot for NQO1 protein and the well-demonstrated knockdown achieved with siRNA 
lead us to a degree of confidence in these findings. 
6.4.7 Future work 
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With respect to the analysis of patient matched tissues for expression of proteins involved 
in the activation and metabolism of chemotherapeutics, very little can be conclusively 
stated given the small number of patients studied and also the heterogeneity of the 
treatment regimens received by the patients. To address the hypothesis of whether protein 
expression in the primary tumour predicts the metastatic phenotype, a sensible next step 
would be immunostaining the TMA constructed within this study for these proteins. To 
answer questions related to the potential use of these proteins as response biomarkers, a 
more homogenous population would need to be defined and studied. Given the difficulty in 
acquiring primary and metastatic tissue which was encountered for this study, the most 
efficient way to accomplish this is likely to be its incorporation as a translational arm in a 
clinical trial. 
Similarly with regards to protein activity, a larger and more homogenous population is 
required. The mass spectrometry assay used for this study is reliant upon tissue 
homogenate, and therefore a method of extracting protein from FFPE blocks which is 
suitable for other proteomic studies besides immunohistochemistry is required. This work 
has already commenced with a comparison of two techniques, one reported by Scicchitano 
et al (2009) and the commercially available Qproteome FFPE tissue kit (Qiagen, Venlo, 
Netherlands). 
Cancer Research UK published a roadmap to assist clinicians and scientists in bringing 
biomarker studies to a clinically useful endpoint. As such, the next steps to further evaluate 
NQO1 as a predictive biomarker would be: 
 Developing and refining a reproducible assay 
 Defining biomarker distribution in the target population and subsequently 
validating the assay 
 Studying the relationship between the biomarker and clinical outcome 
retrospectively 
 Defining the relationship of the biomarker to clinical outcome in a prospective 
analysis of a retrospective tissue collection  
 Validating the correlation between the biomarker and clinical outcome as a primary 
or secondary endpoint in a prospective study 
 Undertaking a clinical trial where the biomarker defines randomisation 
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To some extent this study has addressed many of these issues, although to drive this work 
forwards there would be need for the early development of an alternative strategy for 
assaying the protein or exploring the option for genotyping. As previously discussed, 
incorporating this work as a translational arm into a prospective clinical trial would address 
many of the problems encountered in this study. 
The work presented in this thesis confidently identifies NQO1 as a therapeutic target, 
although the evidence for the use of dicoumarol as a competitive inhibitor is somewhat 
lacking. This is largely a result of difficulties encountered in attributing the effect of 
dicoumarol to NQO1 inhibition. As previously discussed the approach taken with the 
complementary siRNA inhibition provides some circumstantial evidence, although this is 
insufficient. Since the commencement of this project, Mitosciences® (Oregon, USA) 
released a series of microplate kits which are essentially a sandwich-ELISA for 
immunocapture of the protein combined with a measurement of substrate/product 
turnover to generate specific activity data. One of these plates is for NQO1, the activity of 
which is determined following the simultaneous reduction of menadione (with NADH as a 
cofactor) and WST1 (a cell proliferation reagent) which leads to increased absorbance at 
440nm. This would be the essential next step in determining whether dicoumarol is 
exerting the observed effects via this pathway, although it would be unhelpful unless the 
cytoprotective effects we are inhibiting are related to the enzymatic activity of the protein. 
Other in vitro work which would potentially be of interest would be the co-incubation of 
dicoumarol with the chemotherapeutic rather than the pre-treatment approach opted for 
in this study, and repeating the investigation in a p53-deficient cell line. 
Beyond establishing reduced NQO1 activity, to further evaluate the chemosensitising 
effects of NQO1 inhibition it would be necessary to transfer to an in vivo model. A simple 
xenograft model would provide useful scientific information and allow tumour 
measurements to be compared into two animal cohorts: chemotherapeutic drug(s) vs. 
chemotherapeutic drug(s) and dicoumarol. To properly test the hypothesis in the 
metastatic setting however the most suitable model would be surgical orthotopic 
implantation, reported to reliably produce liver metastases in 100% of mice after 11 
passages (Sun et al, 1999). 
6.4.8 Conclusion 
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We have convincingly demonstrated concordance between the primary and metastatic 
tumour for Topoisomerase I expression. KRAS, BRAF and MSI status also appear concordant 
although numbers of mutations detected in this regard were small. 
Western blotting for NQO1 validated the proteomic data set and the conclusions drawn in 
Chapter 4. Immunohistochemical analysis has demonstrated that with respect to NQO1 the 
primary tumour is predictive of the metastatic phenotype. Furthermore, NQO1 expression 
in the metastatic tumour is lower in those patients responding favourably to neoadjuvant 
chemotherapy. 
In vitro work has suggested that this finding is a biological feature of the tumour rather 
than a phenomenon seen as a result of treatment with chemotherapeutics. Knockdown of 
this protein alone had no effect on cell viability, and therefore the potential therapeutic 
role of NQO1 is as a chemosensitiser rather than a cytotoxic. Indeed knockdown of NQO1 
with siRNA considerably improved chemosensitivity to both irinotecan and 5-FU in an in 
vitro model. 
Dicoumarol, a known inhibitor of NQO1, has shown potential for its use in this regard. Pre-
treatment of cells with dicoumarol again improved chemosensitivity to both irinotecan and 
5-FU in the same in vitro model, although evidence to suggest it is exerting the observed 
effect through NQO1 inhibition is circumstantial. 
Further evaluation of these findings in a larger and more homogenous population, for 
example in the context of a clinical trial, is necessary. Attributing the effects of dicoumarol 
to NQO1 inhibition is also necessary prior to any further translational work, the next step 
for which would be transfer to an in vivo model. 
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Chapter 7 
Concluding Discussion 
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7.1 Summary of aims and experimental design 
The starting point for the thesis was the identification of three key questions faced by 
clinicians treating patients with colorectal cancer on a daily basis, which as yet have no 
satisfactory scientific explanation or rationale for the selection of one particular course of 
action. These questions are:  
 In patients with rectal cancer is it possible to predict response to neoadjuvant 
chemoradiotherapy? 
 In patients with colorectal liver metastases is it possible to predict response to 
neoadjuvant chemotherapy? 
 Can biological information from the primary tumour be used to predict response to 
treatment in colorectal liver metastases? 
In order to investigate these research questions, the following study plan was 
implemented: 
1. Establish a research network across multiple sites to facilitate the collection of 
patient matched primary and metastatic tissue, as well as serial biopsies of rectal 
tumours. Establish a research protocol and a satisfactory means of tissue collection.  
2. Subject tumour samples (alongside normal adjacent tissue) from patients 
undergoing synchronous resection to exome sequencing, in order to establish the 
degree of biological similarity between primary and metastatic tumours, and 
specifically to identify whether the presence of somatic non-synonymous mutations 
in the primary tumour predicts the presence of the same mutations in the liver 
metastasis. 
3. Perform an unbiased assessment of the proteome of patient-matched primary and 
metastatic tumours, as well as adjacent normal liver parenchyma and colonic 
mucosa on a discovery set of fresh tissue. Analyse data to assess the degree of 
biological similarity between primary and metastatic tumours, as well as identify 
potential biomarkers measurable in the primary tumour which may predict the 
response to chemotherapy in the liver metastases. 
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4. Validate any potential biomarkers by immunohistochemistry on a larger validation 
tissue set, with samples combined into a tissue micro-array. Explore any potential 
mechanisms for validated biomarkers. 
5. Perform an unbiased assessment of the proteome of serial rectal cancer samples on 
a discovery set of fresh tissue. Analyse data to assess how the tumour phenotype 
changes with treatment, as well as identify potential biomarkers which may predict 
response of the primary tumour to neoadjuvant chemoradiotherapy. 
6. Validate any potential biomarkers by immunohistochemistry on a larger validation 
tissue set, with samples combined into a tissue micro-array. Explore any potential 
mechanisms for validated biomarkers. 
7. Undertake a targeted analysis of the expression and function of key proteins 
involved in the activation and metabolism of oxaliplatin, 5-fluorouracil and 
irinotecan in patient matched primary and metastatic tumour samples. Analyse 
data to assess the correlation in expression and function between primary and 
metastatic tumours and establish how this information may predict response to 
treatment. 
8. Undertake a targeted analysis of the expression of key proteins involved in DNA 
base excision repair in serial rectal cancer samples. Data will be analysed to assess 
how levels of expression vary with treatment and how this information may be 
used to predict response.   
The experimental plan was followed and completed with the exception of steps 6 and 8, 
the further evaluation of biomarkers and DNA base excision repair proteins in rectal cancer. 
These steps were purely omitted due to time constraints and remain valid lines of enquiry 
to address the research questions described above. Given the small numbers of samples 
collected, response analysis was not feasible for step 7.  
7.2 Summary of results 
Chapter 2 evaluated the use of a novel tissue stabilisation gel, AllprotectTM. The study 
demonstrated that effective tissue stabilisation was achieved with AllprotectTM, and that 
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tissue stabilised in this manner yields high quality DNA, RNA and protein suitable for 
commonly used laboratory techniques. Comparable protein (by western blot and 
immunohistochemistry) and mRNA expression for HMGB1 and CES1 in primary colorectal 
tumour and colorectal liver metastases was observed irrespective of the method of tissue 
stabilisation employed. Beyond that, the demonstration of comparable production of SN-
38, an active metabolite of irinotecan, suggested that protein function (CES1) as well as 
expression is preserved. miRNA yield was also consistent and all extracted DNA was of 
sufficient quality for downstream PCR. 
Whilst short term tissue stabilisation with AllprotectTM appeared to be comparable to liquid 
nitrogen, its role for long term archiving was less clear. Our study suggested that both 
protein function and expression were significantly reduced by week 3, and, although 
densitometry values did not reach statistical significance, visualisation of the western 
immunoblots suggested that protein degradation may occur even earlier than this. RNA 
integrity also began to reduce after one week, with the RIN of samples rapidly falling below 
7.0. These findings were confirmed by the RT2 quality control array, and the increasing Ct 
values seen by qPCR for both mRNA and miRNA.  
Chapter 3 reported the exome sequencing of 4 simultaneously resected primary and 
metastatic tumours alongside normal colonic mucosa and liver parenchyma. Of the 585 
unique non-synonymous, missense SNVs identified, 215 (36.8%) were unique to the 
primary tumour, 226 (38.6%) unique to the metastasis, and 81 (13.8%) present in at least 
one primary and metastatic tumour pertaining to the same patient. The remaining 63 
(10.8%) were neither unique to a tissue type nor present in a pair of samples from the same 
patient. 268 (45.8%) predicted favourable response, whilst 226 (38.6%) predicted poor 
response. Of those, 43 and 23 respectively were present in patient-matched samples. The 
remaining 91 (15.6%) were neither unique to responders nor non-responders. 
The ErbB signalling pathway was identified as the most significant pathway arising from the 
analysis of SNVs in paired patient samples, with 6 (KRAS, MAP2K3, PAK2, PIK3C2G, PLCG2, 
RRAS) of the 85 pathway genes containing SNVs (Ratio 0.07, p=5.87x10-7). Sanger 
sequencing validated the CDAN1_15_43020983_G/A SNV as a potential predictor of 
favourable response, where the primary tumour is predictive of the metastatic genotype. 
For the 6 SNVs of interest in the ErbB pathway, 4 showed absolute concordance between 
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the primary and metastatic genotype (those in MAP2K3, PIK3C2G, PLCG2 and RRAS) thus 
validating the results of the Ion Proton exome sequencing. 
Chapter 4 reported the results of the isobaric tagging for relative quantification in patient 
matched primary and metastatic tissues. Of the 16 patients sampled, 11 had undergone 
neoadjuvant chemotherapy 10 of which achieved resection. Five of these patients had a 
tumour regression grade of 1-2 and the remaining 5 had a tumour regression grade of 3-4. 
A total of 5766 proteins were identified, of which 2637 were taken forwards for 
bioinformatics analysis. Comparing primary tumour with normal colon, 25 proteins were 
significantly differentially expressed (6 upregulated and 19 downregulated) and for 
metastatic tumour compared with normal colon there were 53 differentially expressed (13 
upregulated and 40 downregulated). Comparison of the metastatic tumour with liver 
parenchyma identified 444 proteins differentially expressed, 164 of which were 
upregulated and 280 downregulated. Only 67 of the 2637 (2.54%) proteins studied were 
significantly different between primary and metastatic tissue, with 58 upregulated in the 
metastatic tumour and 9 downregulated. One hundred and seventy proteins were 
identified in the primary tumour which were significantly differentially expressed between 
responders and non-responders with 59 upregulated and 111 downregulated in the 
responders. In the metastases, there were 27 differentially expressed (17 upregulated and 
10 downregulated). Five proteins were common to both tissue types, only two of which 
showed consistent dysregulation between responders and non-responders (NAD(P)H 
dehydrogenase [quinone 1] and lambda-crystallin homolog). Of the 5766 proteins identified 
by iTRAQ, SNVs were previously identified in the protein coding region of 2627.  
Chapter 5 reported the results of the isobaric tagging for relative quantification in serial 
rectal cancer biopsies. A total of 3359 proteins were identified all of which were subjected 
to bioinformatics analysis. When comparing the post chemoradiotherapy samples with the 
diagnostic biopsies 18 proteins were significantly dysregulated, 2 of which were 
downregulated and 16 upregulated. Comparing the samples at resection with post 
chemoradiotherapy samples identified 39 proteins dysregulated, 30 of which were 
downregulated and 9 upregulated. Similarly a comparison of the resection and diagnostic 
samples identified 29 proteins, 10 of which were downregulated and 19 upregulated. The 
base excision repair pathway was the most significantly downregulated pathway in this 
analysis as a result of a reduction in PARP1 abundance with treatment. Eight candidate 
biomarkers were identified in the primary tumours which appeared to predict response to 
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chemoradiotherapy, 3 of which were downregulated and 5 upregulated. The most 
statistically significantly downregulated pathway was ceramide degradation as a result of 
low expression of acid ceramidase in those patients responding favourably to 
chemoradiotherapy.  
Chapter 6 reported the targeted analysis of previously identified biomarkers of interest.  
Western blotting of those proteins relevant to the activation and metabolism of key 
chemotherapeutics (TS, DPYD, OPRT, CES1, CES2, TOPI, UGT1A1, CYP3A4 and DNA POL β) 
all showed a positive correlation in expression between primary and metastatic tumours, 
although this only reached statistical significance for TOP I (P=0.009). Mass spectrometry 
analysis of CES1/CES2 activity (by irinotecan conversion to SN-38) showed significant 
differences across primary tumour, metastatic tumour and liver parenchyma (p=0.001). All 
patients except 4 had statistically significant differences between protein activity levels at 
the primary and metastatic disease sites. 
Pyrosequencing for KRAS and BRAF mutations identified the KRAS codon 12 mutation in 5 
patients with 100% concordance between primary and metastatic tumours and no 
mutation similarly detected in the adjacent normal colonic mucosa. No mutations were 
seen in codons 13 or 61. One patient had BRAF mutation in both codons (600 and 601) 
again with concordance between primary and metastatic tumours. One patient had 
microsatellite instability, which was detected in the colonic mucosa as well as the primary 
and metastatic tumours.  
Western blotting for NQO1 was used to validate the iTRAQ proteomic data reported in 
Chapter 4. Correlation of protein expression by western blotting densitometry and iTRAQ 
abundance data showed a statistically significant positive correlation (r=0.59, p=0.003), and 
therefore the findings were investigated by immunohistochemistry. Of the 56 patients for 
whom patient matched primary and metastatic FFPE blocks were available, 37 received 
neoadjuvant treatment. Fourteen of these patients responded to chemotherapy (TRG1-2), 
23 did not (TRG3-4). Comparing clinicopathological features between groups revealed a 
higher proportion of T4 tumours in the chemo-naive group (p=0.017), most likely reflecting 
a clinical preference for prompt surgery in this patient cohort. No other potentially 
confounding variables were different between groups. A statistically significant positive 
correlation between immunohistochemical protein expression in the primary and 
metastatic tumours was seen (r=0.44, p=0.001). NQO1 expression in the primary tumour 
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was not statistically significantly different between responders and non-responders 
(p=0.470), however expression in the metastases was considerably lower in those patients 
responding to chemotherapy (p=0.041), mirroring the conclusion of the proteomic data. 
Functional investigation of these findings in an in vitro model demonstrated that treating 
cells with chemotherapy had no effect on protein expression, and that knockdown of NQO1 
with siRNA had no direct effect on cell viability. Knockdown of NQO1 followed by treatment 
with irinotecan reduced the IC50 from 100.1µM to 49.8µM, with statistically significant 
differences at doses between 25-400µM. Similarly with respect to 5-FU, NQO1 knockdown 
reduced the IC50 from 200.1µM to 25.0µM, with statistically significant differences at doses 
between 25-200µM. Dosing cells with dicoumarol alone had no effect on cell viability. 
When cells were pre-treated with dicoumarol over a range of doses prior to incubation with 
a chemotherapeutic, a reduction in cell viability was seen which reached its maximal 
effectiveness at ~100µM. Cells in which NQO1 had been knocked down with siRNA 
experienced no further reduction in viability by the addition of dicoumarol, suggesting this 
drug is acting by inhibition of NQO1 rather than through an alternative pathway. Pre-
treating cells with dicoumarol prior to incubation in irinotecan reduced the IC50 from 
100.0µM to 50.0µM, with statistically significant differences at irinotecan doses between 
12.5-50µM.  Similarly with respect to 5-FU, inhibition of NQO1 with dicoumarol reduced the 
IC50 from 183.7µM to 49.9µM, with statistically significant differences at 5FU doses 
between 25-200µM. 
7.3 Advances in the literature 
Since the commencement of this thesis the only significant developments in the literature 
have been the publication of 3 papers in 2014 reporting next generation sequencing of 
patient matched primary and metastatic colorectal tumours. This reflects the significant 
increase in the availability of this technology coupled with the associated reduction in cost. 
Xie et al (2014) performed whole genome sequencing of patient matched primary and 
metastatic colorectal tumours. Comparing the data to germline DNA they characterised 
somatic alterations including single nucleotide variants, insertions and deletions, copy 
number aberrations and structural alterations. The focus of the analysis was to identify 
those novel mutations in the metastasis which may be drivers of disease progression, as 
both patients were chemo-naive and simultaneously resected. In both patients clones and 
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subclones of mutational clusters were identified. In one patient 75% of the mutations in the 
primary tumour were present in the metastasis, whereas the other patient had 95% of 
mutations also present in the metastasis. Having attempted to model clonal evolution, the 
authors conclude that this discrepancy occurred as a result of temporal differences in 
metastatic dissemination with respect to the evolution of the founding clone at the primary 
site. The proportion of somatic SNVs shared between primary tumour and liver metastasis 
were 68.4% and 52.8%, compared to 13.8% in our study. The authors focus their discussion 
on the concordance of TP53, APC and KRAS and highlight aberrations in FBXW7, DCLK1, 
FAT2 and PHF6 as being functional and exclusive to the metastases. 
Brannon et al (2014) performed targeted sequencing of 230 key genes in 69 matched 
primary and metastatic tumours, alongside whole genome sequencing of 4 patients. 
Overall, 434 distinct non-synonymous somatic mutations were identified, with 79% 
concordance between primary and metastatic tumour. The analysis differs to the one we 
performed in that indels were also included. The authors focus their discussion on the 
absolute concordance of APC, KRAS, NRAS and BRAF mutations in their samples, concluding 
that these early carcinogenic mutations persist through tumour evolution. The authors 
attempted to correlate mutational concordance with key clinicopathological features but 
found no such association. The whole genome sequencing in this study was used to validate 
the concordance demonstrated by the capture-based assay used (IMPACT), and as such the 
two concordant samples were also concordant on whole genome sequencing (80% and 
83%)and vice versa for the non-concordant samples (38% and 25%). 
Lee et al (2014) performed exome sequencing of 15 patient matched micro-satellite stable 
primary and metastatic tumours. In total, 1079 and 4366 mutations were identified in the 
primary and metastatic tumours respectively. 60.8% of those mutations in the primary 
tumour were non-synonymous compared to 54.9% in the metastases. Whilst the data is 
available in supplementary information, the authors merely state that the findings were 
consistent with previous observations (Greenman et al, 2007) and not significantly different 
between primary and metastatic samples. No analysis is provided to justify this conclusion, 
and the remainder of the paper focuses on the parallel somatic copy-number alteration 
(SCNA) analyses. 
Our data are complementary to these publications, and the finding of concordance in the 
SNVs within the ErbB family remains novel. The discrepancy in the proportion of mutations 
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concordant between primary and metastatic tumours may possibly be explained by the 
biopsy of clones/subclones within a tumour, but also the inclusion of other genetic 
aberrations (for example indels) included in the reported figures. 
7.4 Study limitations and further work 
The limitations of specific investigations and experimental techniques have been discussed 
throughout the thesis, however there are two key themes. Firstly the acquisition of fresh 
material from patient matched primary and metastatic tumours, as well as serial rectal 
tumour samples, was conducted prospectively within the study resulting in small numbers. 
Given the nature of the disease and the complexities involved in its management, there 
was also considerable heterogeneity both in clinicopathological features and treatment 
received.  Secondly, whilst most tumours are thought to arise from a monoclonal 
population, its expansion combined with the acquisition of further mutations creates 
subclones and tumour heterogeneity. This heterogeneity clearly has significant implications 
for biomarker studies such as this which rely on a single tumour biopsy sample to be 
representative of the whole tumour (Poste, 2011). The first limitation could be addressed 
by incorporating this work as a translational arm in a clinical trial. The second is more 
challenging to address, and even though alternative (but non-translatable) strategies such 
as laser capture microdissection or the acquisition of circulating tumour cells may remove 
stromal contamination, they still fail to address this crucial problem (Curran et al, 2000). 
The exome sequencing study has generated two lines of enquiry. The potential role of the 
SNV identified in the CDAN1 gene should be explored by characterisation in a larger 
dataset, in parallel with an analysis of the ErbB pathway genes. The co-analysis of the 
exome and proteome datasets performed thus far has been rudimentary, and further 
integration would require super-specialist bioinformatic support. 
By their very nature, studies which include sequencing of any form, proteomic or genomic, 
generate large amounts of data. In order to handle such volumes of data it is necessary to 
approach the analysis with a clear series of questions. The disadvantage of this approach is 
the potential to overlook key findings in the data. In this study for example the numerous 
pathway and network analyses are likely to provide key insights into carcinogenesis, disease 
progression and treatment response, however it has been necessary to select only a small 
number of findings from these preliminary studies for further analysis. Revisiting these 
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pathway and network analyses in conjunction with a literature review would very likely 
generate a number of research questions worthy of further work.  
Evaluation of the base excision repair proteins relevant to radiotherapy response (PARP1, 
APE1, DNAPOL β and XRCC1) and the potential for the use of acid ceramidase as a 
biomarker and/or chemosensitiser requires further work and validation, although this 
proved unfeasible within the time constraints of this study. The next steps in the further 
evaluation of NQO1 as a biomarker have been recently highlighted in a roadmap by Cancer 
Research UK. Prior to exploring its role as a drug target in an in vivo model, further in vitro 
work to establish whether the effects seen by inhibiting NQO1 relate to its enzymatic 
activity, protein stabilisation function or another mechanism are necessary. 
7.5 Review of hypotheses 
A number of testable hypotheses were generated at the commencement of the thesis. 
1. Somatic non-synonymous mutations in the primary tumour correlate with those present 
in the liver metastasis and predict response to treatment. 
Disproved – only 13.8% of single nucleotide variants identified were concordant between 
primary and metastatic tumours in the small number of samples we studied.  
2. The phenotype of the primary tumour is biologically similar to the liver metastasis, with 
markers present in the primary tumour which predict the response of the liver metastasis 
to neoadjuvant chemotherapy.  
Proved - Only 67 of the 2637 (2.54%) proteins studied were significantly different between 
primary and metastatic tissue. NQO1 and lambda-crystallin homolog appeared to predict 
response to treatment. NQO1 levels in the primary tumour predict the metastatic 
phenotype, and low protein abundance in the metastatic tumour is associated with 
favourable treatment response. Inhibiting the protein (with siRNA or a competitive 
inhibitor) improved chemosensitivity in an in vitro model. 
3. The phenotype of a rectal tumour changes with neoadjuvant chemoradiotherapy, and 
inter-patient variation in these changes predicts response to treatment. 
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Partially Proved – Only minor changes in tumour phenotype were detected with 
neoadjuvant chemoradiotherapy.  The most statistically significantly downregulated 
pathway in those patients responding favourably to chemoradiotherapy was ceramide 
degradation as a result of low expression of acid ceramidase. 
4. Levels of expression of key proteins involved in the activation and metabolism of 
chemotherapeutics are comparable between primary and metastatic tumours and predict 
response to treatment. 
Partially Proved – All proteins studied had a positive correlation although this was only 
statistically significant for Topoisomerase I. 
5. Levels of expression of DNA base excision repair proteins in rectal tumours vary with 
treatment, and inter-patient variation in the expression of these proteins predicts response 
to neoadjuvant chemoradiotherapy. 
Inconclusive – This hypothesis was incompletely tested due to time constraints. iTRAQ data 
of serial rectal cancer samples did however suggest that base excision repair (and in 
particular PARP1) remains of interest in both carcinogenesis and treatment response. 
7.6 Conclusions 
This thesis has generated a number of lines of enquiry and ideas for further work as well as 
providing sufficient evidence to conclude the following: 
 AllprotectTM confers comparable tissue stabilisation to liquid nitrogen for up to 1 
week for the extraction and downstream laboratory analysis of DNA, RNA and 
protein. 
 Approximately one third of single nucleotide mutations identified are present 
exclusively in the primary tumour, one third are present exclusively in the 
metastases and one third are present in tumours at both sites. In our data, only 
13.8% of mutations were present in patient matched samples. 
 A SNV in the CDAN1 gene has potential to serve as a predictive biomarker, with the 
presence of the SNV in the primary tumour predicting the metastatic genotype. 
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 SNVs across the ErbB pathway appear to be concordant between primary and 
metastatic tumours, and not limited to KRAS alone. 
 Only 2.54% of proteins are significantly differentially expressed between primary 
and metastatic tumours. As such, it may be feasible to utilise biological information 
from the primary tumour to predict the phenotype of the metastasis. 
 Phenotypic changes induced by chemoradiotherapy in rectal cancers are modest. 
Base excision repair (and in particular PARP1) remains of interest in both 
carcinogenesis and treatment response, and acid ceramidase is a potential novel 
response biomarker. 
 Topoisomerase I expression in the primary tumour correlates significantly with 
expression in colorectal liver metastases. A positive correlation was also seen in 
other proteins responsible for the activation and metabolism of 
chemotherapeutics, as well as KRAS, BRAF and MSI status. 
 NQO1 expression in the primary tumour is predictive of the metastatic phenotype, 
and expression in the metastatic tumour is lower in those patients responding 
favourably to neoadjuvant chemotherapy. 
 Inhibition of NQO1 with siRNA is not directly therapeutic but enhances the cytotoxic 
effect of irinotecan and 5-FU. The NQO1 inhibitor dicoumarol has similar potential, 
although requires further evaluation. 
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Table 1 – Single nucleotide variants exclusive to the primary tumours 
 
Annotation Gene Chromosome Location 
Substituted 
Amino Acid 
New Amino 
Acid 
ABCC3_17_48761053_G/A ABCC3 17 48761053 G A 
ACAD11_3_132338346_T/G ACAD11 3 132338346 T G 
ACADL_2_211060050_T/G ACADL 2 211060050 T G 
ADAMTS1_21_28212761_G/A ADAMTS1 21 28212761 G A 
ADD1_4_2916762_C/G ADD1 4 2916762 C G 
AGXT_2_241808314_C/T AGXT 2 241808314 C T 
ALPP_2_233243586_C/T ALPP 2 233243586 C T 
APOB_2_21250914_G/A APOB 2 21250914 G A 
ARHGEF19_1_16532498_G/A ARHGEF19 1 16532498 G A 
BAIAP3_16_1394822_C/T BAIAP3 16 1394822 C T 
BMP2K_4_79832411_A/G BMP2K 4 79832411 A G 
C18orf25_18_43796346_G/C C18orf25 18 43796346 G C 
C2orf43_2_20974689_C/T C2orf43 2 20974689 C T 
C5orf22_5_31532534_G/C C5orf22 5 31532534 G C 
CACNA1H_16_1254369_C/T CACNA1H 16 1254369 C T 
CACNA1H_16_1268376_G/A CACNA1H 16 1268376 G A 
CADM4_19_44130960_A/G CADM4 19 44130960 A G 
CCDC136_7_128454762_G/A CCDC136 7 128454762 G A 
CCDC78_16_774760_T/C CCDC78 16 774760 T C 
CCRN4L_4_139966431_C/T CCRN4L 4 139966431 C T 
CCT6B_17_33269648_C/G CCT6B 17 33269648 C G 
CD93_20_23065209_G/A CD93 20 23065209 G A 
CDC27_17_45214615_G/C CDC27 17 45214615 G C 
CDC27_17_45214617_G/C CDC27 17 45214617 G C 
CEP135_4_56819375_A/G CEP135 4 56819375 A G 
CHAT_10_50835687_C/T CHAT 10 50835687 C T 
CHRNA5_15_78880752_G/A CHRNA5 15 78880752 G A 
CHRND_2_233398698_C/T CHRND 2 233398698 C T 
CHST15_10_125769672_G/A CHST15 10 125769672 G A 
CLCNKA_1_16356501_G/A CLCNKA 1 16356501 G A 
CLCNKB_1_16371067_G/T CLCNKB 1 16371067 G T 
CLDN3_7_73183979_G/A CLDN3 7 73183979 G A 
CNGA4_11_6265242_G/C CNGA4 11 6265242 G C 
CNN2_19_1036211_C/T CNN2 19 1036211 C T 
CNN2_19_1037715_T/C CNN2 19 1037715 T C 
CNN2_19_1037716_G/A CNN2 19 1037716 G A 
CNN2_19_1037718_G/T CNN2 19 1037718 G T 
COL15A1_9_101778346_C/G COL15A1 9 101778346 C G 
COL5A3_19_10085054_G/A COL5A3 19 10085054 G A 
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COL6A2_21_47551942_G/A COL6A2 21 47551942 G A 
CPAMD8_19_17025292_G/A CPAMD8 19 17025292 G A 
CTBP2_10_126681824_G/A CTBP2 10 126681824 G A 
CTBP2_10_126681831_C/G CTBP2 10 126681831 C G 
CTBP2_10_126681838_C/G CTBP2 10 126681838 C G 
CTBP2_10_126681848_T/A CTBP2 10 126681848 T A 
CTBP2_10_126683099_G/A CTBP2 10 126683099 G A 
CTBP2_10_126683111_C/T CTBP2 10 126683111 C T 
CTBP2_10_126683132_A/T CTBP2 10 126683132 A T 
CTBP2_10_126683243_C/T CTBP2 10 126683243 C T 
CTBP2_10_126683244_C/G CTBP2 10 126683244 C G 
CTBP2_10_126686629_G/A CTBP2 10 126686629 G A 
CTBP2_10_126691552_T/G CTBP2 10 126691552 T G 
CTDSP2_12_58217770_G/C CTDSP2 12 58217770 G C 
CX3CR1_3_39307162_G/A CX3CR1 3 39307162 G A 
CYP2C8_10_96818119_G/C CYP2C8 10 96818119 G C 
CYP2D6_22_42526694_G/A CYP2D6 22 42526694 G A 
CYP4F12_19_15784377_C/T CYP4F12 19 15784377 C T 
CYP4F2_19_15989696_G/C CYP4F2 19 15989696 G C 
D2HGDH_2_242690675_G/A D2HGDH 2 242690675 G A 
DCLK1_13_36686139_G/C DCLK1 13 36686139 G C 
DHTKD1_10_12143122_C/T DHTKD1 10 12143122 C T 
DIS3L2_2_233127938_C/G DIS3L2 2 233127938 C G 
DLAT_11_111916647_G/A DLAT 11 111916647 G A 
DNAH17_17_76456017_C/G DNAH17 17 76456017 C G 
DOCK7_1_62993881_T/C DOCK7 1 62993881 T C 
DROSHA_5_31508739_C/T DROSHA 5 31508739 C T 
DUOX2_15_45393014_G/C DUOX2 15 45393014 G C 
EFCAB8_20_31480028_A/T EFCAB8 20 31480028 A T 
EHBP1_2_63176139_A/C EHBP1 2 63176139 A C 
ELP2_18_33736498_C/T ELP2 18 33736498 C T 
ESRRA_11_64083320_T/C ESRRA 11 64083320 T C 
ESRRA_11_64083328_C/T ESRRA 11 64083328 C T 
ESRRA_11_64083331_C/T ESRRA 11 64083331 C T 
EXTL3_8_28575417_T/C EXTL3 8 28575417 T C 
FAM70B_13_114504663_G/A FAM70B 13 114504663 G A 
FAM8A1_6_17606159_C/A FAM8A1 6 17606159 C A 
FCGBP_19_40376675_G/A FCGBP 19 40376675 G A 
FERMT1_20_6088265_G/A FERMT1 20 6088265 G A 
FGFR3_4_1806629_C/T FGFR3 4 1806629 C T 
FMN2_1_240370985_C/T FMN2 1 240370985 C T 
FOXN4_12_109725707_G/A FOXN4 12 109725707 G A 
FRG1_4_190876196_G/A FRG1 4 190876196 G A 
FRG1_4_190883039_T/C FRG1 4 190883039 T C 
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GALNT2_1_230391032_G/A GALNT2 1 230391032 G A 
GDNF_5_37816112_G/A GDNF 5 37816112 G A 
GGT2_22_21576218_G/A GGT2 22 21576218 G A 
GLB1_3_33138549_G/A GLB1 3 33138549 G A 
GLIS2_16_4385158_A/G GLIS2 16 4385158 A G 
GLOD4_17_685752_G/A GLOD4 17 685752 G A 
GSTT1_22_24379402_T/G GSTT1 22 24379402 T G 
HEXDC_17_80391684_A/G HEXDC 17 80391684 A G 
HMCN1_1_186101539_A/G HMCN1 1 186101539 A G 
HMCN2_9_133294224_C/T HMCN2 9 133294224 C T 
HSPG2_1_22179244_C/T HSPG2 1 22179244 C T 
IFI16_1_159024668_A/T IFI16 1 159024668 A T 
IL3RA_X_1471083_C/G IL3RA X 1471083 C G 
INF2_14_105180785_C/T INF2 14 105180785 C T 
INPP5B_1_38329999_C/G INPP5B 1 38329999 C G 
IQSEC3_12_247544_C/T IQSEC3 12 247544 C T 
IRX4_5_1878325_C/T IRX4 5 1878325 C T 
IRX6_16_55362942_T/C IRX6 16 55362942 T C 
KCNH8_3_19574945_A/G KCNH8 3 19574945 A G 
KCNJ12_17_21319523_C/T KCNJ12 17 21319523 C T 
KCNJ12_17_21319786_G/A KCNJ12 17 21319786 G A 
KIAA1958_9_115422069_G/A KIAA1958 9 115422069 G A 
KIF24_9_34254413_G/C KIF24 9 34254413 G C 
KIF26B_1_245848798_C/T KIF26B 1 245848798 C T 
KLHL33_14_20897676_T/C KLHL33 14 20897676 T C 
KLK10_19_51519365_C/G KLK10 19 51519365 C G 
KRT18_12_53343225_C/T KRT18 12 53343225 C T 
KRT18_12_53343231_G/C KRT18 12 53343231 G C 
KRT32_17_39616430_G/T KRT32 17 39616430 G T 
KRT40_17_39135089_G/A KRT40 17 39135089 G A 
KRT40_17_39137154_C/G KRT40 17 39137154 C G 
LYPD2_8_143833856_C/T LYPD2 8 143833856 C T 
MATN2_8_98943447_G/C MATN2 8 98943447 G C 
MLL3_7_151935866_G/A MLL3 7 151935866 G A 
MLL3_7_151935871_C/A MLL3 7 151935871 C A 
MPPED1_22_43831057_G/T MPPED1 22 43831057 G T 
MSH6_2_48027136_A/G MSH6 2 48027136 A G 
MSR1_8_16026181_T/C MSR1 8 16026181 T C 
MTCH2_11_47640398_T/C MTCH2 11 47640398 T C 
MTCH2_11_47660334_C/T MTCH2 11 47660334 C T 
MUC16_19_8999530_C/T MUC16 19 8999530 C T 
MUC4_3_195495916_G/C MUC4 3 195495916 G C 
MYH3_17_10542257_A/G MYH3 17 10542257 A G 
MYOM3_1_24409191_C/T MYOM3 1 24409191 C T 
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NAGLU_17_40696233_C/G NAGLU 17 40696233 C G 
NCOR1_17_16097825_T/G NCOR1 17 16097825 T G 
NCOR1_17_16097870_C/A NCOR1 17 16097870 C A 
NDUFS2_1_161183191_C/G NDUFS2 1 161183191 C G 
NOTCH2NL_1_145281408_C/T NOTCH2NL 1 145281408 C T 
NPBWR1_8_53852871_A/T NPBWR1 8 53852871 A T 
NPEPPS_17_45669359_T/G NPEPPS 17 45669359 T G 
PABPC1_8_101719138_C/T PABPC1 8 101719138 C T 
PABPC1_8_101719201_A/G PABPC1 8 101719201 A G 
PABPC1_8_101725003_C/A PABPC1 8 101725003 C A 
PABPC1_8_101727714_G/A PABPC1 8 101727714 G A 
PABPC1_8_101727716_C/T PABPC1 8 101727716 C T 
PABPC3_13_25671195_A/G PABPC3 13 25671195 A G 
PAK2_3_196509577_C/G PAK2 3 196509577 C G 
PANK3_5_167986134_T/C PANK3 5 167986134 T C 
PCDHB4_5_140502343_C/T PCDHB4 5 140502343 C T 
PCDHB4_5_140502344_C/T PCDHB4 5 140502344 C T 
PCDHGB6_5_140788491_T/G PCDHGB6 5 140788491 T G 
PHF11_13_50095041_A/G PHF11 13 50095041 A G 
PHKB_16_47732476_C/T PHKB 16 47732476 C T 
PIEZO1_16_88787673_G/A PIEZO1 16 88787673 G A 
PIEZO1_16_88791458_G/A PIEZO1 16 88791458 G A 
PIEZO2_18_10731428_C/T PIEZO2 18 10731428 C T 
PLEKHG2_19_39913519_C/G PLEKHG2 19 39913519 C G 
PLVAP_19_17471595_T/G PLVAP 19 17471595 T G 
POU2F1_1_167343528_G/A POU2F1 1 167343528 G A 
PPP1R2_3_195269788_T/C PPP1R2 3 195269788 T C 
PRDM7_16_90126993_A/G PRDM7 16 90126993 A G 
PRKRA_2_179300979_A/T PRKRA 2 179300979 A T 
PSMD9_12_122353796_A/G PSMD9 12 122353796 A G 
PTPRS_19_5258067_C/T PTPRS 19 5258067 C T 
RAB26_16_2203334_G/A RAB26 16 2203334 G A 
RASA4_7_102235769_T/C RASA4 7 102235769 T C 
RC3H1_1_173952595_C/T RC3H1 1 173952595 C T 
RNF123_3_49759490_G/A RNF123 3 49759490 G A 
RPL19_17_37360846_C/T RPL19 17 37360846 C T 
RPL19_17_37360863_A/T RPL19 17 37360863 A T 
RSPH4A_6_116950734_G/A RSPH4A 6 116950734 G A 
SBNO1_12_123805023_C/A SBNO1 12 123805023 C A 
SDHA_5_236649_C/T SDHA 5 236649 C T 
SDHA_5_236676_G/A SDHA 5 236676 G A 
SDHA_5_236678_G/A SDHA 5 236678 G A 
SDK2_17_71426656_G/T SDK2 17 71426656 G T 
SEC14L3_22_30864610_A/G SEC14L3 22 30864610 A G 
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SERPINB10_18_61582751_T/G SERPINB10 18 61582751 T G 
SERPINB10_18_61600384_C/T SERPINB10 18 61600384 C T 
SERPINB8_18_61654463_A/G SERPINB8 18 61654463 A G 
SETD8_12_123892186_T/C SETD8 12 123892186 T C 
SKIV2L_6_31931747_G/A SKIV2L 6 31931747 G A 
SLC15A1_13_99337138_A/G SLC15A1 13 99337138 A G 
SLC25A5_X_118604030_T/C SLC25A5 X 118604030 T C 
SLC25A5_X_118604399_C/G SLC25A5 X 118604399 C G 
SLC25A5_X_118604428_T/C SLC25A5 X 118604428 T C 
SLC2A1_1_43393457_T/C SLC2A1 1 43393457 T C 
SLC44A4_6_31846741_C/A SLC44A4 6 31846741 C A 
SLC46A3_13_29292117_C/T SLC46A3 13 29292117 C T 
SLC6A7_5_149578877_C/T SLC6A7 5 149578877 C T 
SMPD4_2_130930380_A/G SMPD4 2 130930380 A G 
SOX7_8_10683685_A/G SOX7 8 10683685 A G 
SPNS1_16_28990588_G/A SPNS1 16 28990588 G A 
SREK1IP1_5_64020269_T/C SREK1IP1 5 64020269 T C 
STAB2_12_104048454_C/A STAB2 12 104048454 C A 
SYT8_11_1857751_C/G SYT8 11 1857751 C G 
TAS2R46_12_11214025_A/T TAS2R46 12 11214025 A T 
TAS2R46_12_11214080_G/A TAS2R46 12 11214080 G A 
TCF3_19_1650228_A/G TCF3 19 1650228 A G 
TEKT4_2_95541427_G/T TEKT4 2 95541427 G T 
TEKT4_2_95541447_C/T TEKT4 2 95541447 C T 
TFAP2A_6_10410556_C/T TFAP2A 6 10410556 C T 
TGM1_14_24729863_G/A TGM1 14 24729863 G A 
TIAM2_6_155561796_C/T TIAM2 6 155561796 C T 
TNFRSF14_1_2488153_A/G TNFRSF14 1 2488153 A G 
TNS1_2_218713282_G/A TNS1 2 218713282 G A 
TPSD1_16_1306986_C/T TPSD1 16 1306986 C T 
TPTE_21_10943003_C/T TPTE 21 10943003 C T 
TSPAN32_11_2325427_T/C TSPAN32 11 2325427 T C 
TSTA3_8_144697051_T/C TSTA3 8 144697051 T C 
TXNRD2_22_19907099_C/A TXNRD2 22 19907099 C A 
USP40_2_234394477_A/G USP40 2 234394477 A G 
WDR33_2_128525866_A/G WDR33 2 128525866 A G 
WDR72_15_53907948_G/A WDR72 15 53907948 G A 
WNT10B_12_49364239_C/T WNT10B 12 49364239 C T 
YLPM1_14_75248652_C/G YLPM1 14 75248652 C G 
ZNF404_19_44377669_G/A ZNF404 19 44377669 G A 
ZNF527_19_37879853_C/T ZNF527 19 37879853 C T 
ZNF544_19_58774094_C/T ZNF544 19 58774094 C T 
ZNF717_3_75790880_A/G ZNF717 3 75790880 A G 
ZNF730_19_23329194_A/G ZNF730 19 23329194 A G 
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Table 2 – Single nucleotide variants exclusive to the metastatic tumours 
 
Annotation Gene Chromosome Location 
Substituted 
Amino Acid 
New Amino 
Acid 
A4GALT_22_43089654_C/T A4GALT 22 43089654 C T 
ABCA9_17_67017930_T/C ABCA9 17 67017930 T C 
ABCB5_7_20762646_G/T ABCB5 7 20762646 G T 
ABCC9_12_22017410_C/T ABCC9 12 22017410 C T 
ACACB_12_109650663_A/G ACACB 12 109650663 A G 
ACE_17_61568577_C/T ACE 17 61568577 C T 
ACTN2_1_236902618_G/A ACTN2 1 236902618 G A 
ACTR1A_10_104241913_C/T ACTR1A 10 104241913 C T 
ADNP2_18_77895325_T/G ADNP2 18 77895325 T G 
AK2_1_33478931_G/C AK2 1 33478931 G C 
ALDH3B2_11_67433662_C/T ALDH3B2 11 67433662 C T 
ALG1_16_5128817_G/A ALG1 16 5128817 G A 
ALPPL2_2_233271669_C/T ALPPL2 2 233271669 C T 
AMY2A_1_104163266_G/A AMY2A 1 104163266 G A 
ANKK1_11_113269792_C/A ANKK1 11 113269792 C A 
ANKRD36_2_97860487_T/C ANKRD36 2 97860487 T C 
APOBEC3G_22_39482396_C/A APOBEC3G 22 39482396 C A 
ARHGEF19_1_16534255_C/G ARHGEF19 1 16534255 C G 
ARSD_X_2836002_C/T ARSD X 2836002 C T 
ASPM_1_197070442_G/T ASPM 1 197070442 G T 
ASPM_1_197070697_T/C ASPM 1 197070697 T C 
ATP11A_13_113530199_G/A ATP11A 13 113530199 G A 
ATP13A4_3_193209178_T/C ATP13A4 3 193209178 T C 
ATP6V0D2_8_87151837_A/T ATP6V0D2 8 87151837 A T 
ATXN1_6_16306751_G/A ATXN1 6 16306751 G A 
AZU1_19_830841_G/A AZU1 19 830841 G A 
BCHE_3_165491184_A/C BCHE 3 165491184 A C 
BMP3_4_81967150_G/A BMP3 4 81967150 G A 
BPI_20_36954670_G/A BPI 20 36954670 G A 
C16orf96_16_4625938_A/T C16orf96 16 4625938 A T 
C3orf39_3_43121884_G/C C3orf39 3 43121884 G C 
CACNA1B_9_140777306_C/G CACNA1B 9 140777306 C G 
CALCA_11_14991511_A/G CALCA 11 14991511 A G 
CCBL2_1_89448608_G/A CCBL2 1 89448608 G A 
CCDC138_2_109408208_G/A CCDC138 2 109408208 G A 
CCT8_21_30439894_C/A CCT8 21 30439894 C A 
CD1A_1_158226621_G/T CD1A 1 158226621 G T 
CDC27_17_45214523_A/C CDC27 17 45214523 A C 
CDC27_17_45214531_G/A CDC27 17 45214531 G A 
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CDC27_17_45214606_G/T CDC27 17 45214606 G T 
CDC27_17_45214623_G/A CDC27 17 45214623 G A 
CDC27_17_45214690_G/A CDC27 17 45214690 G A 
CDC27_17_45219296_G/C CDC27 17 45219296 G C 
CDC27_17_45219332_T/G CDC27 17 45219332 T G 
CDC27_17_45247298_A/G CDC27 17 45247298 A G 
CDH8_16_61859047_T/C CDH8 16 61859047 T C 
CELA1_12_51740416_C/G CELA1 12 51740416 C G 
CFTR_7_117188750_C/T CFTR 7 117188750 C T 
CHRNA3_15_78894026_C/T CHRNA3 15 78894026 C T 
CHRNE_17_4806020_G/A CHRNE 17 4806020 G A 
CLCN4_X_10176599_T/C CLCN4 X 10176599 T C 
CLEC18C_16_70211379_C/T CLEC18C 16 70211379 C T 
CNGB1_16_57996933_C/A CNGB1 16 57996933 C A 
CNN2_19_1037756_G/A CNN2 19 1037756 G A 
CNN2_19_1037766_G/A CNN2 19 1037766 G A 
COL24A1_1_86512536_C/T COL24A1 1 86512536 C T 
COL4A3_2_228135631_C/T COL4A3 2 228135631 C T 
COL5A3_19_10071347_C/T COL5A3 19 10071347 C T 
CORO1C_12_109094907_A/G CORO1C 12 109094907 A G 
COSM45060_17_7577581_A/G COSM45060 17 7577581 A G 
CP_3_148916235_T/A CP 3 148916235 T A 
CTBP2_10_126691979_C/G CTBP2 10 126691979 C G 
CTDSP2_12_58217770_G/T CTDSP2 12 58217770 G T 
CYP21A2_6_32006387_A/T CYP21A2 6 32006387 A T 
DISP1_1_223116472_G/A DISP1 1 223116472 G A 
DNA2_10_70191724_C/G DNA2 10 70191724 C G 
DNAH9_17_11651057_A/G DNAH9 17 11651057 A G 
DSG1_18_28909921_G/T DSG1 18 28909921 G T 
DUOX2_15_45392075_G/A DUOX2 15 45392075 G A 
EME1_17_48457758_C/G EME1 17 48457758 C G 
EMR2_19_14875388_G/A EMR2 19 14875388 G A 
ENOX2_X_129837156_G/A ENOX2 X 129837156 G A 
EP400_12_132445675_G/A EP400 12 132445675 G A 
EPPK1_8_144944226_G/A EPPK1 8 144944226 G A 
ESPNL_2_239039981_A/G ESPNL 2 239039981 A G 
FAM126A_7_23016393_C/G FAM126A 7 23016393 C G 
FAM136A_2_70524515_T/A FAM136A 2 70524515 T A 
FAM136A_2_70524576_C/G FAM136A 2 70524576 C G 
FAM136A_2_70524606_G/A FAM136A 2 70524606 G A 
FAM65C_20_49209710_C/T FAM65C 20 49209710 C T 
FANCA_16_89857935_G/A FANCA 16 89857935 G A 
FCRLB_1_161697072_G/C FCRLB 1 161697072 G C 
FES_15_91433090_A/G FES 15 91433090 A G 
FLVCR1_1_213068595_C/T FLVCR1 1 213068595 C T 
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FNDC1_6_159655103_T/G FNDC1 6 159655103 T G 
FRG1_4_190876293_C/A FRG1 4 190876293 C A 
FRG1_4_190878563_C/A FRG1 4 190878563 C A 
FRG1_4_190878569_T/C FRG1 4 190878569 T C 
FUT3_19_5843784_A/T FUT3 19 5843784 A T 
GATA3_10_8100641_G/A GATA3 10 8100641 G A 
GHR_5_42719239_A/C GHR 5 42719239 A C 
GNAQ_9_80537112_T/A GNAQ 9 80537112 T A 
GPATCH2_1_217604654_T/C GPATCH2 1 217604654 T C 
GPRC6A_6_117130544_A/C GPRC6A 6 117130544 A C 
GXYLT1_12_42499825_A/C GXYLT1 12 42499825 A C 
GZMM_19_548612_G/A GZMM 19 548612 G A 
HIP1R_12_123345509_G/T HIP1R 12 123345509 G T 
HMGXB3_5_149390148_G/A HMGXB3 5 149390148 G A 
HNF1A_12_121435427_G/A HNF1A 12 121435427 G A 
HRAS_11_533880_G/A HRAS 11 533880 G A 
HSD17B11_4_88278497_C/T HSD17B11 4 88278497 C T 
HSPD1_2_198363406_C/T HSPD1 2 198363406 C T 
IFI30_19_18285944_G/A IFI30 19 18285944 G A 
INS_11_2181060_T/G INS 11 2181060 T G 
ITIH1_3_52820981_A/T ITIH1 3 52820981 A T 
ITSN2_2_24435599_G/A ITSN2 2 24435599 G A 
KCNB1_20_47991468_G/A KCNB1 20 47991468 G A 
KCNG4_16_84256410_C/T KCNG4 16 84256410 C T 
KCNH6_17_61615545_A/G KCNH6 17 61615545 A G 
KCNJ12_17_21319230_G/C KCNJ12 17 21319230 G C 
KCNJ16_17_68128332_G/A KCNJ16 17 68128332 G A 
KCNK13_14_90651135_G/T KCNK13 14 90651135 G T 
KCNV1_8_110984553_G/A KCNV1 8 110984553 G A 
KIAA0141_5_141309824_G/A KIAA0141 5 141309824 G A 
KIAA0753_17_6513329_G/A KIAA0753 17 6513329 G A 
KIF19_17_72340981_G/A KIF19 17 72340981 G A 
KRT14_17_39742807_C/T KRT14 17 39742807 C T 
KRT36_17_39643340_T/G KRT36 17 39643340 T G 
LAMA5_20_60889385_G/T LAMA5 20 60889385 G T 
LDHAL6B_15_59500180_C/G LDHAL6B 15 59500180 C G 
LRP1B_2_141459344_C/T LRP1B 2 141459344 C T 
LRRC17_7_102574920_G/C LRRC17 7 102574920 G C 
MASP2_1_11090916_C/A MASP2 1 11090916 C A 
MBD1_18_47800179_G/C MBD1 18 47800179 G C 
MGAT2_14_50089014_A/C MGAT2 14 50089014 A C 
MKL2_16_14341144_A/G MKL2 16 14341144 A G 
MLL2_12_49430947_T/C MLL2 12 49430947 T C 
MLL3_7_151927021_C/A MLL3 7 151927021 C A 
MLL3_7_151927067_T/C MLL3 7 151927067 T C 
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MLL3_7_151935910_C/T MLL3 7 151935910 C T 
MLL5_7_104717522_A/G MLL5 7 104717522 A G 
MLPH_2_238449007_T/C MLPH 2 238449007 T C 
MOGAT1_2_223559089_T/C MOGAT1 2 223559089 T C 
MTCH2_11_47663951_A/G MTCH2 11 47663951 A G 
MTCH2_11_47663986_C/T MTCH2 11 47663986 C T 
MTCH2_11_47663996_C/T MTCH2 11 47663996 C T 
MTMR11_1_149906167_T/G MTMR11 1 149906167 T G 
MUC16_19_9002597_C/T MUC16 19 9002597 C T 
MUC6_11_1027811_C/T MUC6 11 1027811 C T 
MYH4_17_10355371_C/T MYH4 17 10355371 C T 
MYO1H_12_109872909_C/T MYO1H 12 109872909 C T 
MYO9B_19_17213218_G/A MYO9B 19 17213218 G A 
MZT2B_2_130948087_C/T MZT2B 2 130948087 C T 
NAV1_1_201754444_G/C NAV1 1 201754444 G C 
NHLRC1_6_18122258_C/T NHLRC1 6 18122258 C T 
NIN_14_51202311_G/C NIN 14 51202311 G C 
NOD1_7_30492237_C/T NOD1 7 30492237 C T 
NOTCH1_9_139412350_G/A NOTCH1 9 139412350 G A 
NUP88_17_5289554_T/C NUP88 17 5289554 T C 
NUP98_11_3744435_C/G NUP98 11 3744435 C G 
OGDHL_10_50950976_G/A OGDHL 10 50950976 G A 
OLFM1_9_138011540_T/C OLFM1 9 138011540 T C 
OR51G1_11_4945199_C/T OR51G1 11 4945199 C T 
PABPC1_8_101730043_G/C PABPC1 8 101730043 G C 
PABPC1_8_101730064_G/A PABPC1 8 101730064 G A 
PABPC1_8_101730110_A/C PABPC1 8 101730110 A C 
PABPC3_13_25670868_G/A PABPC3 13 25670868 G A 
PABPC3_13_25670877_G/A PABPC3 13 25670877 G A 
PABPC3_13_25670955_C/T PABPC3 13 25670955 C T 
PAK2_3_196529902_G/C PAK2 3 196529902 G C 
PARN_16_14576574_A/C PARN 16 14576574 A C 
PARP4_13_25016762_G/A PARP4 13 25016762 G A 
PCDHA9_5_140228164_C/A PCDHA9 5 140228164 C A 
PEX6_6_42935117_G/A PEX6 6 42935117 G A 
PIK3C2G_12_18649057_C/T PIK3C2G 12 18649057 C T 
PLEC_8_144995494_C/T PLEC 8 144995494 C T 
POTED_21_14987871_G/T POTED 21 14987871 G T 
POU4F2_4_147561758_C/T POU4F2 4 147561758 C T 
PPIAL4G_1_143767544_T/A PPIAL4G 1 143767544 T A 
PPIAL4G_1_143767547_G/A PPIAL4G 1 143767547 G A 
PPL_16_4935985_C/G PPL 16 4935985 C G 
PPP1R9A_7_94540527_G/A PPP1R9A 7 94540527 G A 
PRKRA_2_179309165_G/A PRKRA 2 179309165 G A 
PRR23C_3_138762854_G/T PRR23C 3 138762854 G T 
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PRSS1_7_142458451_A/T PRSS1 7 142458451 A T 
PRUNE2_9_79320847_G/C PRUNE2 9 79320847 G C 
PSAPL1_4_7435721_C/T PSAPL1 4 7435721 C T 
RAB40B_17_80615774_T/G RAB40B 17 80615774 T G 
RAG1_11_36597313_A/G RAG1 11 36597313 A G 
RANBP2_2_109382348_T/C RANBP2 2 109382348 T C 
RBBP5_1_205068225_T/C RBBP5 1 205068225 T C 
RBMX_X_135958704_G/C RBMX X 135958704 G C 
RRN3_16_15162102_G/A RRN3 16 15162102 G A 
RRP7A_22_42912136_G/T RRP7A 22 42912136 G T 
RYR3_15_33954652_C/T RYR3 15 33954652 C T 
SACS_13_23905771_C/A SACS 13 23905771 C A 
SALL2_14_21991626_C/G SALL2 14 21991626 C G 
SETD8_12_123889492_A/C SETD8 12 123889492 A C 
SIGLEC11_19_50463982_T/G SIGLEC11 19 50463982 T G 
SLC25A5_X_118603958_G/A SLC25A5 X 118603958 G A 
SLC25A5_X_118604006_A/G SLC25A5 X 118604006 A G 
SLC25A5_X_118604467_C/T SLC25A5 X 118604467 C T 
SLC25A5_X_118605017_C/T SLC25A5 X 118605017 C T 
SLC35E2_1_1666175_C/T SLC35E2 1 1666175 C T 
SLC39A12_10_18270341_A/G SLC39A12 10 18270341 A G 
SNCAIP_5_121761114_C/T SNCAIP 5 121761114 C T 
SRMS_20_62174830_C/T SRMS 20 62174830 C T 
SRPK3_X_153047251_A/G SRPK3 X 153047251 A G 
STK17A_7_43659260_T/C STK17A 7 43659260 T C 
SYT6_1_114641758_A/G SYT6 1 114641758 A G 
TBX10_11_67402362_T/G TBX10 11 67402362 T G 
TGM4_3_44929287_G/C TGM4 3 44929287 G C 
TH_11_2190951_C/T TH 11 2190951 C T 
TIMM23_10_51620361_G/C TIMM23 10 51620361 G C 
TLR2_4_154625951_C/A TLR2 4 154625951 C A 
TMEM41B_11_9308058_A/G TMEM41B 11 9308058 A G 
TMEM74_8_109796955_G/A TMEM74 8 109796955 G A 
TMPRSS13_11_117789345_G/C TMPRSS13 11 117789345 G C 
TNRC6A_16_24834859_T/C TNRC6A 16 24834859 T C 
TNXB_6_32010272_T/A TNXB 6 32010272 T A 
TP53_17_7577139_G/A TP53 17 7577139 G A 
TP53_17_7579472_G/C TP53 17 7579472 G C 
TPD52L3_9_6328947_T/C TPD52L3 9 6328947 T C 
TROAP_12_49724370_G/A TROAP 12 49724370 G A 
TRPM2_21_45825813_G/C TRPM2 21 45825813 G C 
TYR_11_89017961_G/A TYR 11 89017961 G A 
USP32_17_58285542_G/A USP32 17 58285542 G A 
VWA3B_2_98928429_C/G VWA3B 2 98928429 C G 
WNT16_7_120969745_G/T WNT16 7 120969745 G T 
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WWC3_X_10090689_G/T WWC3 X 10090689 G T 
ZBTB9_6_33423004_C/G ZBTB9 6 33423004 C G 
ZCWPW1_7_100017260_T/C ZCWPW1 7 100017260 T C 
ZNF717_3_75790837_C/A ZNF717 3 75790837 C A 
ZNF813_19_53995266_C/T ZNF813 19 53995266 C T 
ZNF880_19_52888071_G/T ZNF880 19 52888071 G T 
ZP3_7_76071228_A/G ZP3 7 76071228 A G 
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Table 3 – Single nucleotide variants present in paired samples 
 
Annotation Gene Chromosome Location 
Substituted 
Amino Acid 
New Amino 
Acid 
A2M_12_9262564_G/T A2M 12 9262564 G T 
ABCA13_7_48390326_G/A ABCA13 7 48390326 G A 
ABCA7_19_1045173_G/A ABCA7 19 1045173 G A 
ACAA1_3_38167095_A/G ACAA1 3 38167095 A G 
ACTN2_1_236911005_G/A ACTN2 1 236911005 G A 
ADCY2_5_7789872_C/A ADCY2 5 7789872 C A 
AK2_1_33478888_C/T AK2 1 33478888 C T 
AK2_1_33478900_T/A AK2 1 33478900 T A 
BRAF_7_140453136_A/T BRAF 7 140453136 A T 
C1orf109_1_38151996_A/C C1orf109 1 38151996 A C 
C1QTNF9_13_24895805_G/A C1QTNF9 13 24895805 G A 
CDAN1_15_43020983_G/A CDAN1 15 43020983 G A 
CDC27_17_45214551_G/A CDC27 17 45214551 G A 
CDC27_17_45214648_G/C CDC27 17 45214648 G C 
CDC27_17_45214654_C/T CDC27 17 45214654 C T 
CDC27_17_45247317_A/G CDC27 17 45247317 A G 
CDC27_17_45247338_T/G CDC27 17 45247338 T G 
CDC27_17_45258951_A/G CDC27 17 45258951 A G 
CDC27_17_45258954_A/G CDC27 17 45258954 A G 
COL18A1_21_46911188_C/G COL18A1 21 46911188 C G 
CTDSP2_12_58217698_G/T CTDSP2 12 58217698 G T 
CTDSP2_12_58220784_A/T CTDSP2 12 58220784 A T 
CTDSP2_12_58220811_G/T CTDSP2 12 58220811 G T 
DRD5_4_9784542_A/C DRD5 4 9784542 A C 
EPB41L3_18_5398020_C/G EPB41L3 18 5398020 C G 
KCNJ12_17_21319285_C/T KCNJ12 17 21319285 C T 
KRAS_12_25398284_C/A KRAS 12 25398284 C A 
KRAS_12_25398284_C/T KRAS 12 25398284 C T 
KRT18_12_53343209_G/A KRT18 12 53343209 G A 
KRT32_17_39619115_G/A KRT32 17 39619115 G A 
KRT40_17_39137387_C/T KRT40 17 39137387 C T 
LAMB1_7_107594098_C/A LAMB1 7 107594098 C A 
LGALS3_14_55604935_C/A LGALS3 14 55604935 C A 
MAP2K3_17_21207834_C/T MAP2K3 17 21207834 C T 
MDGA2_14_47770622_G/A MDGA2 14 47770622 G A 
MEOX2_7_15725874_C/G MEOX2 7 15725874 C G 
MINK1_17_4797305_G/A MINK1 17 4797305 G A 
MTCH2_11_47660294_C/T MTCH2 11 47660294 C T 
MTCH2_11_47660295_A/G MTCH2 11 47660295 A G 
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MTCH2_11_47663948_C/T MTCH2 11 47663948 C T 
MYO5A_15_52664445_C/T MYO5A 15 52664445 C T 
NCOA1_2_24888632_G/A NCOA1 2 24888632 G A 
NOS1_12_117669907_G/A NOS1 12 117669907 G A 
NRP2_2_206610510_G/A NRP2 2 206610510 G A 
PABPC1_8_101721705_G/T PABPC1 8 101721705 G T 
PABPC1_8_101721709_T/A PABPC1 8 101721709 T A 
PABPC3_13_25671015_A/G PABPC3 13 25671015 A G 
PAK2_3_196529982_A/G PAK2 3 196529982 A G 
PANK3_5_167988433_T/A PANK3 5 167988433 T A 
PAPPA2_1_176679244_G/T PAPPA2 1 176679244 G T 
PCDHB8_5_140558628_T/C PCDHB8 5 140558628 T C 
PHACTR1_6_13283706_G/A PHACTR1 6 13283706 G A 
PIGT_20_44048972_A/C PIGT 20 44048972 A C 
PIK3C2G_12_18650667_A/T PIK3C2G 12 18650667 A T 
PKHD1L1_8_110457064_G/T PKHD1L1 8 110457064 G T 
PLCG2_16_81888178_C/T PLCG2 16 81888178 C T 
PPIAL4G_1_143767513_A/T PPIAL4G 1 143767513 A T 
PRSS1_7_142460744_G/C PRSS1 7 142460744 G C 
PRSS3_9_33797951_A/C PRSS3 9 33797951 A C 
PTCH1_9_98209594_G/A PTCH1 9 98209594 G A 
RIMS1_6_73016976_A/T RIMS1 6 73016976 A T 
RRAS_19_50140130_G/A RRAS 19 50140130 G A 
SCN2A_2_166245924_G/C SCN2A 2 166245924 G C 
SCN4A_17_62041068_T/C SCN4A 17 62041068 T C 
SDHA_5_236628_C/T SDHA 5 236628 C T 
SDR16C5_8_57228812_G/A SDR16C5 8 57228812 G A 
SIPA1L1_14_72054755_C/A SIPA1L1 14 72054755 C A 
SLC25A5_X_118604911_C/A SLC25A5 X 118604911 C A 
SLC25A5_X_118604935_T/C SLC25A5 X 118604935 T C 
SLC45A4_8_142228160_C/T SLC45A4 8 142228160 C T 
SLCO5A1_8_70617423_C/G SLCO5A1 8 70617423 C G 
SVIL_10_29779847_A/C SVIL 10 29779847 A C 
TAS2R31_12_11183066_A/T TAS2R31 12 11183066 A T 
TCF7_5_133451683_C/A TCF7 5 133451683 C A 
TIMM23_10_51623147_C/T TIMM23 10 51623147 C T 
TRPV5_7_142625304_C/T TRPV5 7 142625304 C T 
TSPAN31_12_58139552_G/T TSPAN31 12 58139552 G T 
TTPAL_20_43117986_C/T TTPAL 20 43117986 C T 
VANGL2_1_160388913_G/A VANGL2 1 160388913 G A 
WDR62_19_36577616_G/C WDR62 19 36577616 G C 
WNK2_9_96021312_G/A WNK2 9 96021312 G A 
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Table 4 – Single nucleotide variants exclusive to the responders  
 
Annotation Gene Chromosome Location 
Substituted 
Amino Acid 
New Amino 
Acid 
A2M_12_9262564_G/T A2M 12 9262564 G T 
ABCA7_19_1045173_G/A ABCA7 19 1045173 G A 
ABCA9_17_67017930_T/C ABCA9 17 67017930 T C 
ABCB5_7_20762646_G/T ABCB5 7 20762646 G T 
ABCC9_12_22017410_C/T ABCC9 12 22017410 C T 
ACTN2_1_236911005_G/A ACTN2 1 236911005 G A 
ACTR1A_10_104241913_C/T ACTR1A 10 104241913 C T 
ADCY2_5_7789872_C/A ADCY2 5 7789872 C A 
ADD1_4_2916762_C/G ADD1 4 2916762 C G 
ALDH3B2_11_67433662_C/T ALDH3B2 11 67433662 C T 
ANKK1_11_113269792_C/A ANKK1 11 113269792 C A 
APOB_2_21250914_G/A APOB 2 21250914 G A 
ARHGEF19_1_16532498_G/A ARHGEF19 1 16532498 G A 
ARHGEF19_1_16534255_C/G ARHGEF19 1 16534255 C G 
ARSD_X_2836002_C/T ARSD X 2836002 C T 
ASPM_1_197070442_G/T ASPM 1 197070442 G T 
ATP11A_13_113530199_G/A ATP11A 13 113530199 G A 
ATP13A4_3_193209178_T/C ATP13A4 3 193209178 T C 
ATXN1_6_16306751_G/A ATXN1 6 16306751 G A 
AZU1_19_830841_G/A AZU1 19 830841 G A 
BAIAP3_16_1394822_C/T BAIAP3 16 1394822 C T 
BCHE_3_165491184_A/C BCHE 3 165491184 A C 
BMP3_4_81967150_G/A BMP3 4 81967150 G A 
BPI_20_36954670_G/A BPI 20 36954670 G A 
BRAF_7_140453136_A/T BRAF 7 140453136 A T 
C16orf96_16_4625938_A/T C16orf96 16 4625938 A T 
C1orf109_1_38151996_A/C C1orf109 1 38151996 A C 
C5orf22_5_31532534_G/C C5orf22 5 31532534 G C 
CACNA1B_9_140777306_C/G CACNA1B 9 140777306 C G 
CACNA1H_16_1268376_G/A CACNA1H 16 1268376 G A 
CADM4_19_44130960_A/G CADM4 19 44130960 A G 
CALCA_11_14991511_A/G CALCA 11 14991511 A G 
CCDC136_7_128454762_G/A CCDC136 7 128454762 G A 
CCDC138_2_109408208_G/A CCDC138 2 109408208 G A 
CCDC78_16_774760_T/C CCDC78 16 774760 T C 
CCT6B_17_33269648_C/G CCT6B 17 33269648 C G 
CCT8_21_30439894_C/A CCT8 21 30439894 C A 
CD1A_1_158226621_G/T CD1A 1 158226621 G T 
CD93_20_23065209_G/A CD93 20 23065209 G A 
314 
 
CDAN1_15_43020983_G/A CDAN1 15 43020983 G A 
CDC27_17_45214606_G/T CDC27 17 45214606 G T 
CDC27_17_45214648_G/C CDC27 17 45214648 G C 
CDC27_17_45214654_C/T CDC27 17 45214654 C T 
CDC27_17_45214690_G/A CDC27 17 45214690 G A 
CDC27_17_45214699_T/C CDC27 17 45214699 T C 
CELA1_12_51740416_C/G CELA1 12 51740416 C G 
CHAT_10_50835687_C/T CHAT 10 50835687 C T 
CHRNA3_15_78894026_C/T CHRNA3 15 78894026 C T 
CHRNA5_15_78880752_G/A CHRNA5 15 78880752 G A 
CHRND_2_233398698_C/T CHRND 2 233398698 C T 
CLCNKA_1_16356501_G/A CLCNKA 1 16356501 G A 
CLDN3_7_73183979_G/A CLDN3 7 73183979 G A 
CLEC18C_16_70211379_C/T CLEC18C 16 70211379 C T 
CNGB1_16_57996933_C/A CNGB1 16 57996933 C A 
CNN2_19_1037715_T/C CNN2 19 1037715 T C 
CNN2_19_1037716_G/A CNN2 19 1037716 G A 
CNN2_19_1037718_G/T CNN2 19 1037718 G T 
CNN2_19_1037756_G/A CNN2 19 1037756 G A 
CNN2_19_1037766_G/A CNN2 19 1037766 G A 
COL24A1_1_86512536_C/T COL24A1 1 86512536 C T 
COL4A3_2_228135631_C/T COL4A3 2 228135631 C T 
COL5A3_19_10071347_C/T COL5A3 19 10071347 C T 
CORO1C_12_109094907_A/G CORO1C 12 109094907 A G 
CP_3_148916235_T/A CP 3 148916235 T A 
CPAMD8_19_17025292_G/A CPAMD8 19 17025292 G A 
CTBP2_10_126683058_T/G CTBP2 10 126683058 T G 
CTBP2_10_126683099_G/A CTBP2 10 126683099 G A 
CTBP2_10_126683111_C/T CTBP2 10 126683111 C T 
CTBP2_10_126683132_A/T CTBP2 10 126683132 A T 
CTBP2_10_126683244_C/G CTBP2 10 126683244 C G 
CTBP2_10_126686629_G/A CTBP2 10 126686629 G A 
CTBP2_10_126691979_C/G CTBP2 10 126691979 C G 
CTDSP2_12_58220784_A/T CTDSP2 12 58220784 A T 
CTDSP2_12_58220811_G/T CTDSP2 12 58220811 G T 
CX3CR1_3_39307162_G/A CX3CR1 3 39307162 G A 
CYP21A2_6_32006387_A/T CYP21A2 6 32006387 A T 
CYP2C8_10_96818119_G/C CYP2C8 10 96818119 G C 
CYP2D6_22_42526694_G/A CYP2D6 22 42526694 G A 
CYP4F12_19_15784377_C/T CYP4F12 19 15784377 C T 
D2HGDH_2_242690675_G/A D2HGDH 2 242690675 G A 
DCLK1_13_36686139_G/C DCLK1 13 36686139 G C 
DHTKD1_10_12143122_C/T DHTKD1 10 12143122 C T 
DIS3L2_2_233127938_C/G DIS3L2 2 233127938 C G 
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DLAT_11_111916647_G/A DLAT 11 111916647 G A 
DNAH9_17_11651057_A/G DNAH9 17 11651057 A G 
EFCAB8_20_31480028_A/T EFCAB8 20 31480028 A T 
EHBP1_2_63176139_A/C EHBP1 2 63176139 A C 
ELP2_18_33736498_C/T ELP2 18 33736498 C T 
EP400_12_132445675_G/A EP400 12 132445675 G A 
EPB41L3_18_5398020_C/G EPB41L3 18 5398020 C G 
EPPK1_8_144944226_G/A EPPK1 8 144944226 G A 
ESRRA_11_64083320_T/C ESRRA 11 64083320 T C 
ESRRA_11_64083328_C/T ESRRA 11 64083328 C T 
ESRRA_11_64083331_C/T ESRRA 11 64083331 C T 
FAM136A_2_70524515_T/A FAM136A 2 70524515 T A 
FAM136A_2_70524576_C/G FAM136A 2 70524576 C G 
FAM136A_2_70524606_G/A FAM136A 2 70524606 G A 
FAM65C_20_49209710_C/T FAM65C 20 49209710 C T 
FAM70B_13_114504663_G/A FAM70B 13 114504663 G A 
FCRLB_1_161697072_G/C FCRLB 1 161697072 G C 
FERMT1_20_6088265_G/A FERMT1 20 6088265 G A 
FLVCR1_1_213068595_C/T FLVCR1 1 213068595 C T 
FMN2_1_240370985_C/T FMN2 1 240370985 C T 
FRG1_4_190878563_C/A FRG1 4 190878563 C A 
FRG1_4_190878569_T/C FRG1 4 190878569 T C 
GALNT2_1_230391032_G/A GALNT2 1 230391032 G A 
GATA3_10_8100641_G/A GATA3 10 8100641 G A 
GGT1_22_25011031_C/T GGT1 22 25011031 C T 
GHR_5_42719239_A/C GHR 5 42719239 A C 
GNAQ_9_80537112_T/A GNAQ 9 80537112 T A 
GPRC6A_6_117130544_A/C GPRC6A 6 117130544 A C 
GZMM_19_548612_G/A GZMM 19 548612 G A 
HIP1R_12_123345509_G/T HIP1R 12 123345509 G T 
HMCN1_1_186101539_A/G HMCN1 1 186101539 A G 
HMCN2_9_133294224_C/T HMCN2 9 133294224 C T 
HMGXB3_5_149390148_G/A HMGXB3 5 149390148 G A 
HNF1A_12_121435427_G/A HNF1A 12 121435427 G A 
HSD17B11_4_88278497_C/T HSD17B11 4 88278497 C T 
HSPD1_2_198363406_C/T HSPD1 2 198363406 C T 
HSPG2_1_22179244_C/T HSPG2 1 22179244 C T 
IFI16_1_159024668_A/T IFI16 1 159024668 A T 
IFI30_19_18285944_G/A IFI30 19 18285944 G A 
INPP5B_1_38329999_C/G INPP5B 1 38329999 C G 
INS_11_2181060_T/G INS 11 2181060 T G 
ITIH1_3_52820981_A/T ITIH1 3 52820981 A T 
ITSN2_2_24435599_G/A ITSN2 2 24435599 G A 
KCNB1_20_47991468_G/A KCNB1 20 47991468 G A 
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KCNH8_3_19574945_A/G KCNH8 3 19574945 A G 
KCNJ16_17_68128332_G/A KCNJ16 17 68128332 G A 
KCNK13_14_90651135_G/T KCNK13 14 90651135 G T 
KCNV1_8_110984553_G/A KCNV1 8 110984553 G A 
KIAA0141_5_141309824_G/A KIAA0141 5 141309824 G A 
KIF19_17_72340981_G/A KIF19 17 72340981 G A 
KIF26B_1_245848798_C/T KIF26B 1 245848798 C T 
KLHL33_14_20897676_T/C KLHL33 14 20897676 T C 
KRAS_12_25398284_C/T KRAS 12 25398284 C T 
KRT14_17_39742807_C/T KRT14 17 39742807 C T 
KRT32_17_39616430_G/T KRT32 17 39616430 G T 
LAMA5_20_60889385_G/T LAMA5 20 60889385 G T 
LAMB1_7_107594098_C/A LAMB1 7 107594098 C A 
LGALS3_14_55604935_C/A LGALS3 14 55604935 C A 
MAP2K3_17_21207813_T/G MAP2K3 17 21207813 T G 
MAP2K3_17_21207834_C/T MAP2K3 17 21207834 C T 
MASP2_1_11090916_C/A MASP2 1 11090916 C A 
MBD1_18_47800179_G/C MBD1 18 47800179 G C 
MEOX2_7_15725874_C/G MEOX2 7 15725874 C G 
MKL2_16_14341144_A/G MKL2 16 14341144 A G 
MLL3_7_151935871_C/A MLL3 7 151935871 C A 
MOGAT1_2_223559089_T/C MOGAT1 2 223559089 T C 
MSH6_2_48027136_A/G MSH6 2 48027136 A G 
MTCH2_11_47640398_T/C MTCH2 11 47640398 T C 
MTCH2_11_47660334_C/T MTCH2 11 47660334 C T 
MTMR11_1_149906167_T/G MTMR11 1 149906167 T G 
MUC16_19_8999530_C/T MUC16 19 8999530 C T 
MUC16_19_9002597_C/T MUC16 19 9002597 C T 
MYO5A_15_52664445_C/T MYO5A 15 52664445 C T 
MYO9B_19_17213218_G/A MYO9B 19 17213218 G A 
NAGLU_17_40696233_C/G NAGLU 17 40696233 C G 
NAV1_1_201754444_G/C NAV1 1 201754444 G C 
NDUFS2_1_161183191_C/G NDUFS2 1 161183191 C G 
NOD1_7_30492237_C/T NOD1 7 30492237 C T 
NOS1_12_117669907_G/A NOS1 12 117669907 G A 
NOTCH1_9_139412350_G/A NOTCH1 9 139412350 G A 
NOTCH2NL_1_145281408_C/T NOTCH2NL 1 145281408 C T 
NOTCH4_6_32188383_T/C NOTCH4 6 32188383 T C 
NPEPPS_17_45669359_T/G NPEPPS 17 45669359 T G 
NRP2_2_206610510_G/A NRP2 2 206610510 G A 
NUP88_17_5289554_T/C NUP88 17 5289554 T C 
NUP98_11_3744435_C/G NUP98 11 3744435 C G 
OGDHL_10_50950976_G/A OGDHL 10 50950976 G A 
OLFM1_9_138011540_T/C OLFM1 9 138011540 T C 
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PABPC3_13_25670868_G/A PABPC3 13 25670868 G A 
PABPC3_13_25670877_G/A PABPC3 13 25670877 G A 
PABPC3_13_25670955_C/T PABPC3 13 25670955 C T 
PABPC3_13_25671015_A/G PABPC3 13 25671015 A G 
PABPC3_13_25671195_A/G PABPC3 13 25671195 A G 
PAK2_3_196529902_G/C PAK2 3 196529902 G C 
PANK3_5_167986134_T/C PANK3 5 167986134 T C 
PANK3_5_167988433_T/A PANK3 5 167988433 T A 
PAPPA2_1_176679244_G/T PAPPA2 1 176679244 G T 
PCDHA9_5_140228164_C/A PCDHA9 5 140228164 C A 
PEX6_6_42935117_G/A PEX6 6 42935117 G A 
PHACTR1_6_13283706_G/A PHACTR1 6 13283706 G A 
PHKB_16_47732476_C/T PHKB 16 47732476 C T 
PIEZO1_16_88787673_G/A PIEZO1 16 88787673 G A 
PIEZO2_18_10731428_C/T PIEZO2 18 10731428 C T 
PIK3C2G_12_18649057_C/T PIK3C2G 12 18649057 C T 
PIK3C2G_12_18650667_A/T PIK3C2G 12 18650667 A T 
PKHD1L1_8_110457064_G/T PKHD1L1 8 110457064 G T 
PLCG2_16_81888178_C/T PLCG2 16 81888178 C T 
PLEC_8_144995494_C/T PLEC 8 144995494 C T 
PLVAP_19_17471595_T/G PLVAP 19 17471595 T G 
POTED_21_14987871_G/T POTED 21 14987871 G T 
POU2F1_1_167343528_G/A POU2F1 1 167343528 G A 
PPIAL4G_1_143767513_A/T PPIAL4G 1 143767513 A T 
PPIAL4G_1_143767544_T/A PPIAL4G 1 143767544 T A 
PPIAL4G_1_143767547_G/A PPIAL4G 1 143767547 G A 
PPP1R2_3_195269788_T/C PPP1R2 3 195269788 T C 
PPP1R9A_7_94540527_G/A PPP1R9A 7 94540527 G A 
PRKRA_2_179300979_A/T PRKRA 2 179300979 A T 
PSAPL1_4_7435721_C/T PSAPL1 4 7435721 C T 
PSMD9_12_122353796_A/G PSMD9 12 122353796 A G 
RAB26_16_2203334_G/A RAB26 16 2203334 G A 
RAB40B_17_80615774_T/G RAB40B 17 80615774 T G 
RAG1_11_36597313_A/G RAG1 11 36597313 A G 
RC3H1_1_173952595_C/T RC3H1 1 173952595 C T 
RIMS1_6_73016976_A/T RIMS1 6 73016976 A T 
RNF123_3_49759490_G/A RNF123 3 49759490 G A 
RPL19_17_37360863_A/T RPL19 17 37360863 A T 
RRAS_19_50140130_G/A RRAS 19 50140130 G A 
RRN3_16_15162102_G/A RRN3 16 15162102 G A 
RSPH4A_6_116950734_G/A RSPH4A 6 116950734 G A 
RYR3_15_33954652_C/T RYR3 15 33954652 C T 
SACS_13_23905771_C/A SACS 13 23905771 C A 
SALL2_14_21991626_C/G SALL2 14 21991626 C G 
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SBNO1_12_123805023_C/A SBNO1 12 123805023 C A 
SCN2A_2_166245924_G/C SCN2A 2 166245924 G C 
SCN4A_17_62041068_T/C SCN4A 17 62041068 T C 
SDR16C5_8_57228812_G/A SDR16C5 8 57228812 G A 
SERPINB10_18_61600384_C/T SERPINB10 18 61600384 C T 
SERPINB8_18_61654463_A/G SERPINB8 18 61654463 A G 
SETD8_12_123889492_A/C SETD8 12 123889492 A C 
SLC25A5_X_118604006_A/G SLC25A5 X 118604006 A G 
SLC25A5_X_118604467_C/T SLC25A5 X 118604467 C T 
SLC25A5_X_118604911_C/A SLC25A5 X 118604911 C A 
SLC25A5_X_118604935_T/C SLC25A5 X 118604935 T C 
SLC25A5_X_118605017_C/T SLC25A5 X 118605017 C T 
SLC35E2_1_1666175_C/T SLC35E2 1 1666175 C T 
SLC39A12_10_18270341_A/G SLC39A12 10 18270341 A G 
SLCO5A1_8_70617423_C/G SLCO5A1 8 70617423 C G 
SNCAIP_5_121761114_C/T SNCAIP 5 121761114 C T 
STAB2_12_104048454_C/A STAB2 12 104048454 C A 
SYT6_1_114641758_A/G SYT6 1 114641758 A G 
SYT8_11_1857751_C/G SYT8 11 1857751 C G 
TAS2R31_12_11183066_A/T TAS2R31 12 11183066 A T 
TAS2R46_12_11214025_A/T TAS2R46 12 11214025 A T 
TCF3_19_1650228_A/G TCF3 19 1650228 A G 
TEKT4_2_95541427_G/T TEKT4 2 95541427 G T 
TEKT4_2_95541447_C/T TEKT4 2 95541447 C T 
TGM1_14_24729863_G/A TGM1 14 24729863 G A 
TH_11_2190951_C/T TH 11 2190951 C T 
TIAM2_6_155561796_C/T TIAM2 6 155561796 C T 
TIMM23_10_51620361_G/C TIMM23 10 51620361 G C 
TIMM23_10_51623147_C/T TIMM23 10 51623147 C T 
TLR2_4_154625951_C/A TLR2 4 154625951 C A 
TMEM74_8_109796955_G/A TMEM74 8 109796955 G A 
TMPRSS13_11_117789345_G/C TMPRSS13 11 117789345 G C 
TP53_17_7577139_G/A TP53 17 7577139 G A 
TP53_17_7579472_G/C TP53 17 7579472 G C 
TPD52L3_9_6328947_T/C TPD52L3 9 6328947 T C 
TPTE_21_10943003_C/T TPTE 21 10943003 C T 
TSPAN31_12_58139552_G/T TSPAN31 12 58139552 G T 
TSTA3_8_144697051_T/C TSTA3 8 144697051 T C 
TTPAL_20_43117986_C/T TTPAL 20 43117986 C T 
TXNRD2_22_19907099_C/A TXNRD2 22 19907099 C A 
TYR_11_89017961_G/A TYR 11 89017961 G A 
USP32_17_58285542_G/A USP32 17 58285542 G A 
VANGL2_1_160388913_G/A VANGL2 1 160388913 G A 
WDR62_19_36577616_G/C WDR62 19 36577616 G C 
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WDR72_15_53907948_G/A WDR72 15 53907948 G A 
WNK2_9_96021312_G/A WNK2 9 96021312 G A 
WNT16_7_120969745_G/T WNT16 7 120969745 G T 
YLPM1_14_75248652_C/G YLPM1 14 75248652 C G 
ZCWPW1_7_100017260_T/C ZCWPW1 7 100017260 T C 
ZNF404_19_44377669_G/A ZNF404 19 44377669 G A 
ZNF544_19_58774094_C/T ZNF544 19 58774094 C T 
ZNF880_19_52888071_G/T ZNF880 19 52888071 G T 
ZP3_7_76071228_A/G ZP3 7 76071228 A G 
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Table 5 – Single nucleotide variants exclusive to the non-responders  
 
Annotation Gene Chromosome Location 
Substituted 
Amino Acid 
New Amino 
Acid 
A4GALT_22_43089654_C/T A4GALT 22 43089654 C T 
ABCA13_7_48390326_G/A ABCA13 7 48390326 G A 
ABCC3_17_48761053_G/A ABCC3 17 48761053 G A 
ACAA1_3_38167095_A/G ACAA1 3 38167095 A G 
ACACB_12_109650663_A/G ACACB 12 109650663 A G 
ACAD11_3_132338346_T/G ACAD11 3 132338346 T G 
ACADL_2_211060050_T/G ACADL 2 211060050 T G 
ACE_17_61568577_C/T ACE 17 61568577 C T 
ACTN2_1_236902618_G/A ACTN2 1 236902618 G A 
ADAMTS1_21_28212761_G/A ADAMTS1 21 28212761 G A 
ADNP2_18_77895325_T/G ADNP2 18 77895325 T G 
AGXT_2_241808314_C/T AGXT 2 241808314 C T 
AK2_1_33478931_G/C AK2 1 33478931 G C 
ALG1_16_5128817_G/A ALG1 16 5128817 G A 
ALPP_2_233243586_C/T ALPP 2 233243586 C T 
ALPPL2_2_233271669_C/T ALPPL2 2 233271669 C T 
AMY2A_1_104163266_G/A AMY2A 1 104163266 G A 
ANKRD36_2_97860487_T/C ANKRD36 2 97860487 T C 
APOBEC3G_22_39482396_C/A APOBEC3G 22 39482396 C A 
ATP6V0D2_8_87151837_A/T ATP6V0D2 8 87151837 A T 
BMP2K_4_79832411_A/G BMP2K 4 79832411 A G 
C18orf25_18_43796346_G/C C18orf25 18 43796346 G C 
C1QTNF9_13_24895805_G/A C1QTNF9 13 24895805 G A 
C2orf43_2_20974689_C/T C2orf43 2 20974689 C T 
C3orf39_3_43121884_G/C C3orf39 3 43121884 G C 
CACNA1H_16_1254369_C/T CACNA1H 16 1254369 C T 
CCBL2_1_89448608_G/A CCBL2 1 89448608 G A 
CDC27_17_45214523_A/C CDC27 17 45214523 A C 
CDC27_17_45214531_G/A CDC27 17 45214531 G A 
CDC27_17_45214551_G/A CDC27 17 45214551 G A 
CDC27_17_45214615_G/C CDC27 17 45214615 G C 
CDC27_17_45214617_G/C CDC27 17 45214617 G C 
CDC27_17_45214623_G/A CDC27 17 45214623 G A 
CDC27_17_45219296_G/C CDC27 17 45219296 G C 
CDC27_17_45219332_T/G CDC27 17 45219332 T G 
CDC27_17_45247298_A/G CDC27 17 45247298 A G 
CDC27_17_45247301_A/G CDC27 17 45247301 A G 
CDC27_17_45258951_A/G CDC27 17 45258951 A G 
CDC27_17_45258954_A/G CDC27 17 45258954 A G 
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CDH8_16_61859047_T/C CDH8 16 61859047 T C 
CEP135_4_56819375_A/G CEP135 4 56819375 A G 
CFTR_7_117188750_C/T CFTR 7 117188750 C T 
CHRNE_17_4806020_G/A CHRNE 17 4806020 G A 
CHST15_10_125769672_G/A CHST15 10 125769672 G A 
CLCN4_X_10176599_T/C CLCN4 X 10176599 T C 
CLCNKB_1_16371067_G/T CLCNKB 1 16371067 G T 
CNGA4_11_6265242_G/C CNGA4 11 6265242 G C 
CNN2_19_1036211_C/T CNN2 19 1036211 C T 
COL15A1_9_101778346_C/G COL15A1 9 101778346 C G 
COL18A1_21_46911188_C/G COL18A1 21 46911188 C G 
COL6A2_21_47551942_G/A COL6A2 21 47551942 G A 
COSM45060_17_7577581_A/G COSM45060 17 7577581 A G 
CTBP2_10_126681824_G/A CTBP2 10 126681824 G A 
CTBP2_10_126681831_C/G CTBP2 10 126681831 C G 
CTBP2_10_126681838_C/G CTBP2 10 126681838 C G 
CTBP2_10_126681848_T/A CTBP2 10 126681848 T A 
CTBP2_10_126683235_C/A CTBP2 10 126683235 C A 
CTBP2_10_126691552_T/G CTBP2 10 126691552 T G 
CTDSP2_12_58217698_G/T CTDSP2 12 58217698 G T 
CTDSP2_12_58217770_G/T CTDSP2 12 58217770 G T 
CYP4F2_19_15989696_G/C CYP4F2 19 15989696 G C 
DISP1_1_223116472_G/A DISP1 1 223116472 G A 
DNA2_10_70191724_C/G DNA2 10 70191724 C G 
DNAH17_17_76456017_C/G DNAH17 17 76456017 C G 
DOCK7_1_62993881_T/C DOCK7 1 62993881 T C 
DROSHA_5_31508739_C/T DROSHA 5 31508739 C T 
DSG1_18_28909921_G/T DSG1 18 28909921 G T 
DUOX2_15_45392075_G/A DUOX2 15 45392075 G A 
DUOX2_15_45393014_G/C DUOX2 15 45393014 G C 
EME1_17_48457758_C/G EME1 17 48457758 C G 
EMR2_19_14875388_G/A EMR2 19 14875388 G A 
ENOX2_X_129837156_G/A ENOX2 X 129837156 G A 
ESPNL_2_239039981_A/G ESPNL 2 239039981 A G 
EXTL3_8_28575417_T/C EXTL3 8 28575417 T C 
FAM126A_7_23016393_C/G FAM126A 7 23016393 C G 
FAM8A1_6_17606159_C/A FAM8A1 6 17606159 C A 
FANCA_16_89857935_G/A FANCA 16 89857935 G A 
FCGBP_19_40376675_G/A FCGBP 19 40376675 G A 
FES_15_91433090_A/G FES 15 91433090 A G 
FGFR3_4_1806629_C/T FGFR3 4 1806629 C T 
FNDC1_6_159655103_T/G FNDC1 6 159655103 T G 
FOXN4_12_109725707_G/A FOXN4 12 109725707 G A 
FRG1_4_190876196_G/A FRG1 4 190876196 G A 
FRG1_4_190876293_C/A FRG1 4 190876293 C A 
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FRG1_4_190883039_T/C FRG1 4 190883039 T C 
FUT3_19_5843784_A/T FUT3 19 5843784 A T 
GDNF_5_37816112_G/A GDNF 5 37816112 G A 
GLB1_3_33138549_G/A GLB1 3 33138549 G A 
GLIS2_16_4385158_A/G GLIS2 16 4385158 A G 
GLOD4_17_685752_G/A GLOD4 17 685752 G A 
GPATCH2_1_217604654_T/C GPATCH2 1 217604654 T C 
GSTT1_22_24379402_T/G GSTT1 22 24379402 T G 
HEXDC_17_80391684_A/G HEXDC 17 80391684 A G 
HRAS_11_533880_G/A HRAS 11 533880 G A 
IL3RA_X_1471083_C/G IL3RA X 1471083 C G 
INF2_14_105180785_C/T INF2 14 105180785 C T 
IQSEC3_12_247544_C/T IQSEC3 12 247544 C T 
IRX4_5_1878325_C/T IRX4 5 1878325 C T 
IRX6_16_55362942_T/C IRX6 16 55362942 T C 
KCNG4_16_84256410_C/T KCNG4 16 84256410 C T 
KCNH6_17_61615545_A/G KCNH6 17 61615545 A G 
KCNJ12_17_21319087_G/A KCNJ12 17 21319087 G A 
KCNJ12_17_21319523_C/T KCNJ12 17 21319523 C T 
KCNJ12_17_21319786_G/A KCNJ12 17 21319786 G A 
KIAA0753_17_6513329_G/A KIAA0753 17 6513329 G A 
KIAA1958_9_115422069_G/A KIAA1958 9 115422069 G A 
KIF24_9_34254413_G/C KIF24 9 34254413 G C 
KLK10_19_51519365_C/G KLK10 19 51519365 C G 
KRAS_12_25398284_C/A KRAS 12 25398284 C A 
KRT18_12_53343209_G/A KRT18 12 53343209 G A 
KRT18_12_53343225_C/T KRT18 12 53343225 C T 
KRT18_12_53343231_G/C KRT18 12 53343231 G C 
KRT32_17_39619115_G/A KRT32 17 39619115 G A 
KRT36_17_39643340_T/G KRT36 17 39643340 T G 
KRT40_17_39135089_G/A KRT40 17 39135089 G A 
KRT40_17_39137154_C/G KRT40 17 39137154 C G 
KRT40_17_39137387_C/T KRT40 17 39137387 C T 
LDHAL6B_15_59500180_C/G LDHAL6B 15 59500180 C G 
LRP1B_2_141459344_C/T LRP1B 2 141459344 C T 
LRRC17_7_102574920_G/C LRRC17 7 102574920 G C 
LYPD2_8_143833856_C/T LYPD2 8 143833856 C T 
MATN2_8_98943447_G/C MATN2 8 98943447 G C 
MDGA2_14_47770622_G/A MDGA2 14 47770622 G A 
MGAT2_14_50089014_A/C MGAT2 14 50089014 A C 
MINK1_17_4797305_G/A MINK1 17 4797305 G A 
MLL2_12_49430947_T/C MLL2 12 49430947 T C 
MLL3_7_151927021_C/A MLL3 7 151927021 C A 
MLL3_7_151927067_T/C MLL3 7 151927067 T C 
MLL3_7_151935910_C/T MLL3 7 151935910 C T 
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MLL5_7_104717522_A/G MLL5 7 104717522 A G 
MPPED1_22_43831057_G/T MPPED1 22 43831057 G T 
MSR1_8_16026181_T/C MSR1 8 16026181 T C 
MTCH2_11_47663948_C/T MTCH2 11 47663948 C T 
MTCH2_11_47663951_A/G MTCH2 11 47663951 A G 
MUC4_3_195495916_G/C MUC4 3 195495916 G C 
MUC6_11_1027811_C/T MUC6 11 1027811 C T 
MYH3_17_10542257_A/G MYH3 17 10542257 A G 
MYH4_17_10355371_C/T MYH4 17 10355371 C T 
MYO1H_12_109872909_C/T MYO1H 12 109872909 C T 
MYOM3_1_24409191_C/T MYOM3 1 24409191 C T 
MZT2B_2_130948087_C/T MZT2B 2 130948087 C T 
NCOA1_2_24888632_G/A NCOA1 2 24888632 G A 
NCOR1_17_16097870_C/A NCOR1 17 16097870 C A 
NHLRC1_6_18122258_C/T NHLRC1 6 18122258 C T 
NIN_14_51202311_G/C NIN 14 51202311 G C 
NPBWR1_8_53852871_A/T NPBWR1 8 53852871 A T 
OR51G1_11_4945199_C/T OR51G1 11 4945199 C T 
PABPC1_8_101725003_C/A PABPC1 8 101725003 C A 
PABPC1_8_101727714_G/A PABPC1 8 101727714 G A 
PABPC1_8_101727716_C/T PABPC1 8 101727716 C T 
PABPC1_8_101730043_G/C PABPC1 8 101730043 G C 
PABPC1_8_101730064_G/A PABPC1 8 101730064 G A 
PABPC1_8_101730110_A/C PABPC1 8 101730110 A C 
PAK2_3_196509577_C/G PAK2 3 196509577 C G 
PARN_16_14576574_A/C PARN 16 14576574 A C 
PCDHB3_5_140480852_G/A PCDHB3 5 140480852 G A 
PCDHB4_5_140502343_C/T PCDHB4 5 140502343 C T 
PCDHB4_5_140502344_C/T PCDHB4 5 140502344 C T 
PCDHB8_5_140558628_T/C PCDHB8 5 140558628 T C 
PCDHGB6_5_140788491_T/G PCDHGB6 5 140788491 T G 
PHF11_13_50095041_A/G PHF11 13 50095041 A G 
PIEZO1_16_88791458_G/A PIEZO1 16 88791458 G A 
PIGT_20_44048972_A/C PIGT 20 44048972 A C 
PLEKHG2_19_39913519_C/G PLEKHG2 19 39913519 C G 
POU4F2_4_147561758_C/T POU4F2 4 147561758 C T 
PPL_16_4935985_C/G PPL 16 4935985 C G 
PRDM7_16_90126993_A/G PRDM7 16 90126993 A G 
PRKRA_2_179309165_G/A PRKRA 2 179309165 G A 
PRR23C_3_138762854_G/T PRR23C 3 138762854 G T 
PRSS3_9_33797951_A/C PRSS3 9 33797951 A C 
PRUNE2_9_79320847_G/C PRUNE2 9 79320847 G C 
PTPRS_19_5258067_C/T PTPRS 19 5258067 C T 
RANBP2_2_109382348_T/C RANBP2 2 109382348 T C 
RASA4_7_102235769_T/C RASA4 7 102235769 T C 
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RBBP5_1_205068225_T/C RBBP5 1 205068225 T C 
RBMX_X_135958704_G/C RBMX X 135958704 G C 
SDK2_17_71426656_G/T SDK2 17 71426656 G T 
SEC14L3_22_30864610_A/G SEC14L3 22 30864610 A G 
SERPINB10_18_61582751_T/G SERPINB10 18 61582751 T G 
SETD8_12_123892186_T/C SETD8 12 123892186 T C 
SIGLEC11_19_50463982_T/G SIGLEC11 19 50463982 T G 
SIPA1L1_14_72054755_C/A SIPA1L1 14 72054755 C A 
SKIV2L_6_31931747_G/A SKIV2L 6 31931747 G A 
SLC15A1_13_99337138_A/G SLC15A1 13 99337138 A G 
SLC25A5_X_118603958_G/A SLC25A5 X 118603958 G A 
SLC25A5_X_118604030_T/C SLC25A5 X 118604030 T C 
SLC25A5_X_118604399_C/G SLC25A5 X 118604399 C G 
SLC25A5_X_118604428_T/C SLC25A5 X 118604428 T C 
SLC2A1_1_43393457_T/C SLC2A1 1 43393457 T C 
SLC44A4_6_31846741_C/A SLC44A4 6 31846741 C A 
SLC45A4_8_142228160_C/T SLC45A4 8 142228160 C T 
SLC46A3_13_29292117_C/T SLC46A3 13 29292117 C T 
SLC6A7_5_149578877_C/T SLC6A7 5 149578877 C T 
SMPD4_2_130930380_A/G SMPD4 2 130930380 A G 
SOX7_8_10683685_A/G SOX7 8 10683685 A G 
SPNS1_16_28990588_G/A SPNS1 16 28990588 G A 
SREK1IP1_5_64020269_T/C SREK1IP1 5 64020269 T C 
SRMS_20_62174830_C/T SRMS 20 62174830 C T 
SRPK3_X_153047251_A/G SRPK3 X 153047251 A G 
STK17A_7_43659260_T/C STK17A 7 43659260 T C 
TAS2R46_12_11214080_G/A TAS2R46 12 11214080 G A 
TBX10_11_67402362_T/G TBX10 11 67402362 T G 
TCF7_5_133451683_C/A TCF7 5 133451683 C A 
TFAP2A_6_10410556_C/T TFAP2A 6 10410556 C T 
TGM4_3_44929287_G/C TGM4 3 44929287 G C 
TMEM41B_11_9308058_A/G TMEM41B 11 9308058 A G 
TNFRSF14_1_2488153_A/G TNFRSF14 1 2488153 A G 
TNRC6A_16_24834859_T/C TNRC6A 16 24834859 T C 
TNS1_2_218713282_G/A TNS1 2 218713282 G A 
TNXB_6_32010272_T/A TNXB 6 32010272 T A 
TPSD1_16_1306986_C/T TPSD1 16 1306986 C T 
TROAP_12_49724370_G/A TROAP 12 49724370 G A 
TRPM2_21_45825813_G/C TRPM2 21 45825813 G C 
TRPV5_7_142625304_C/T TRPV5 7 142625304 C T 
TSPAN32_11_2325427_T/C TSPAN32 11 2325427 T C 
USP40_2_234394477_A/G USP40 2 234394477 A G 
VWA3B_2_98928429_C/G VWA3B 2 98928429 C G 
VWF_12_6128067_G/A VWF 12 6128067 G A 
WDR33_2_128525866_A/G WDR33 2 128525866 A G 
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WNT10B_12_49364239_C/T WNT10B 12 49364239 C T 
WWC3_X_10090689_G/T WWC3 X 10090689 G T 
ZBTB9_6_33423004_C/G ZBTB9 6 33423004 C G 
ZNF717_3_75790837_C/A ZNF717 3 75790837 C A 
ZNF717_3_75790880_A/G ZNF717 3 75790880 A G 
ZNF730_19_23329194_A/G ZNF730 19 23329194 A G 
ZNF813_19_53995266_C/T ZNF813 19 53995266 C T 
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Table 6 – Single nucleotide variants present in paired samples and exclusive to the 
responders 
 
Annotation Gene Chromosome Location 
Substituted 
Amino Acid 
New Amino 
Acid 
A2M_12_9262564_G/T A2M 12 9262564 G T 
ABCA7_19_1045173_G/A ABCA7 19 1045173 G A 
ACTN2_1_236911005_G/A ACTN2 1 236911005 G A 
ADCY2_5_7789872_C/A ADCY2 5 7789872 C A 
BRAF_7_140453136_A/T BRAF 7 140453136 A T 
C1orf109_1_38151996_A/C C1orf109 1 38151996 A C 
CDAN1_15_43020983_G/A CDAN1 15 43020983 G A 
CDC27_17_45214648_G/C CDC27 17 45214648 G C 
CDC27_17_45214654_C/T CDC27 17 45214654 C T 
CTDSP2_12_58220784_A/T CTDSP2 12 58220784 A T 
CTDSP2_12_58220811_G/T CTDSP2 12 58220811 G T 
EPB41L3_18_5398020_C/G EPB41L3 18 5398020 C G 
KRAS_12_25398284_C/T KRAS 12 25398284 C T 
LAMB1_7_107594098_C/A LAMB1 7 107594098 C A 
LGALS3_14_55604935_C/A LGALS3 14 55604935 C A 
MAP2K3_17_21207834_C/T MAP2K3 17 21207834 C T 
MEOX2_7_15725874_C/G MEOX2 7 15725874 C G 
MYO5A_15_52664445_C/T MYO5A 15 52664445 C T 
NOS1_12_117669907_G/A NOS1 12 117669907 G A 
NRP2_2_206610510_G/A NRP2 2 206610510 G A 
PABPC3_13_25671015_A/G PABPC3 13 25671015 A G 
PANK3_5_167988433_T/A PANK3 5 167988433 T A 
PAPPA2_1_176679244_G/T PAPPA2 1 176679244 G T 
PHACTR1_6_13283706_G/A PHACTR1 6 13283706 G A 
PIK3C2G_12_18650667_A/T PIK3C2G 12 18650667 A T 
PKHD1L1_8_110457064_G/T PKHD1L1 8 110457064 G T 
PLCG2_16_81888178_C/T PLCG2 16 81888178 C T 
PPIAL4G_1_143767513_A/T PPIAL4G 1 143767513 A T 
RIMS1_6_73016976_A/T RIMS1 6 73016976 A T 
RRAS_19_50140130_G/A RRAS 19 50140130 G A 
SCN2A_2_166245924_G/C SCN2A 2 166245924 G C 
SCN4A_17_62041068_T/C SCN4A 17 62041068 T C 
SDR16C5_8_57228812_G/A SDR16C5 8 57228812 G A 
SLC25A5_X_118604911_C/A SLC25A5 X 118604911 C A 
SLC25A5_X_118604935_T/C SLC25A5 X 118604935 T C 
SLCO5A1_8_70617423_C/G SLCO5A1 8 70617423 C G 
TAS2R31_12_11183066_A/T TAS2R31 12 11183066 A T 
TIMM23_10_51623147_C/T TIMM23 10 51623147 C T 
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TSPAN31_12_58139552_G/T TSPAN31 12 58139552 G T 
TTPAL_20_43117986_C/T TTPAL 20 43117986 C T 
VANGL2_1_160388913_G/A VANGL2 1 160388913 G A 
WDR62_19_36577616_G/C WDR62 19 36577616 G C 
WNK2_9_96021312_G/A WNK2 9 96021312 G A 
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Table 7 – Single nucleotide variants present in paired samples and exclusive to the non-
responders 
 
Gene Chromosome Location 
Substituted 
Amino Acid 
New 
Amino Acid 
ABCA13_7_48390326_G/A 7 48390326 G A 
ACAA1_3_38167095_A/G 3 38167095 A G 
C1QTNF9_13_24895805_G/A 13 24895805 G A 
CDC27_17_45214551_G/A 17 45214551 G A 
CDC27_17_45258951_A/G 17 45258951 A G 
CDC27_17_45258954_A/G 17 45258954 A G 
COL18A1_21_46911188_C/G 21 46911188 C G 
CTDSP2_12_58217698_G/T 12 58217698 G T 
KRAS_12_25398284_C/A 12 25398284 C A 
KRT18_12_53343209_G/A 12 53343209 G A 
KRT32_17_39619115_G/A 17 39619115 G A 
KRT40_17_39137387_C/T 17 39137387 C T 
MDGA2_14_47770622_G/A 14 47770622 G A 
MINK1_17_4797305_G/A 17 4797305 G A 
MTCH2_11_47663948_C/T 11 47663948 C T 
NCOA1_2_24888632_G/A 2 24888632 G A 
PCDHB8_5_140558628_T/C 5 140558628 T C 
PIGT_20_44048972_A/C 20 44048972 A C 
PRSS3_9_33797951_A/C 9 33797951 A C 
SIPA1L1_14_72054755_C/A 14 72054755 C A 
SLC45A4_8_142228160_C/T 8 142228160 C T 
TCF7_5_133451683_C/A 5 133451683 C A 
TRPV5_7_142625304_C/T 7 142625304 C T 
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Appendix 2 
Genetic variants in colorectal cancer identified by next generation sequencing studies
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Paper Number of 
Patients 
Comparing Identified Variants Summary 
The Cancer Genome 
Atlas Network 
 
Nature, 2012 
276 Tumour and 
normal 
mucosa 
ACVR2A, APC, TGFBR2, BRAF, MSH3, MSH6, MYO1B, TCF7L2, 
CASP8, CDC27, FZD3, MIER3, TCERG1, MAP7, PTPN12, P53, KRAS, 
TTN, PIK3CA, FBXW7, SMAD4, NRAS, FAM123B, SMAD2, 
CTNNB1, KIAA1804, SOX9, ACVR1B, GPC6, EDNRB 
Implicated pathways included 
WNT, RAS-MAPK, PI3K, TGF-B, 
P53, and DNA mismatch 
repair. 
The consensus coding 
sequences of human 
breast and colorectal 
cancers 
 
Science, 2006 
11 Tumour and 
normal 
mucosa 
ABCA1, ACSL5, ADAM29, ADAMTS15, ADAMTS18, ADAMTSL3, 
APC, C10orf137, C15orf2, C6orf29, CD109, CD248, CHL1, CNTN4, 
CSMD3, EPHA3, EPHB6, ERCC6, EVL, EYA4, FBXW7, GALNS, GNAS, 
GUCY1A2, HAPLN1, HIST1H1B, K6IRS3, KCNQ5, KIAA1409, KRAS, 
LGR6, LMO7, LOC157697, LRP2, MAP2, MCP, MGC33407, 
MKRN3, MLL3, MMP2, NF1, OBSCN, P2RX7, P2RY14, PHIP, 
PKHD1, PKNOX1, PRKD1, PTPRD, PTPRU, RET, RUNX1T1, SCN3B, 
SDBCAG84, SEC8L1, SFRS6, SLC29A1, SMAD2, SMAD3, SMAD4, 
SYNE1, TBX22, TCF7L2, TGFBR2, TP53, TTLL3, UHRF2, UQCRC2, 
ZNF442 
Sanger sequencing study 
identifying 189 genes, most of 
which not known to be 
implicated in carcinogenesis 
Patterns of somatic 
mutation in human 
cancer genomes 
 
Nature, 2007 
28 Tumour and 
normal 
mucosa 
TTN, BRAF, ATM, TAF1L, ERN1, MAP2K4, SHUK, FGFR2, NTRK3, 
MGC42105, TGFBR2, EPHA6, FLJ23074, ITK, DCAMKL3, STK11, 
PAK7, STK6, BRD2, RPS6KA2 
44 mutations identified, many 
of which were protein kinases 
Somatic mutation 
profiles of MSI and MSS 
colorectal cancer 
identified by whole 
exome next generation 
sequencing and 
bioinformatics analysis 
 
PLOS One, 2010 
2 (1 MSI-S, 1 
MSI-H) 
Tumour and 
normal 
mucosa 
FRAP1, FAM5B, RGS16, RCOR3, ATF3, C1orf201, C1orf91, RLF, 
ZNF691, ALX3, COPA, TRIM17, CNR2, WDTC1, FOXJ3, PTPRF, 
GATAD2B, USP21, IPO9, MTR, CSMD2, DNALI1, MYCL1, SYT6, 
CD2, PRCC, NR1I3, FCGR2A, KIF14, PLXNA2, PTPN14, CDC42BPA, 
ZMYM4, STK40, HPS1, TACC2, ITIH2, CEP55, RRP12, FAM171A1, 
PTER, SVIL, PFKP, LRRTM3, HERC4, TCF7L2, C10orf119, FGFR2, 
BICC1, IDE, PNLIPRP1, TIAL1, FRMD4A, BMPR1A, SORBS1, PGR, 
CUL5, RBM7, UBE4A, NCAPD3, NAV2, PAX6, DDB1, NRXN2, 
MTMR2, BUD13, HYOU1, HINFP, MADD, CTR9, POU2AF1, TECTA, 
NUP160, SF1, ATG2A, NUMA1, CWF19L2, VWA5A, COPB1, 
AHNAK, RAB6A, FBXW8, ERC1, RECQL, CPNE8, MFSD5, IPO8, 
SFRS2IP, MAP3K12, DDX23, GPR84, ITGA7, LRP1, UBE3B, 
MSI List: 359 significant 
mutations for the MSI tumour 
and 45 for the MSS, all with 
predicted altered protein 
function 
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MED13L, DHX37, SLC39A5, ALG5, CARS2, WASF3, UBL3, RAB2B, 
EXDL2, PCNX, KCNK10, C14orf102, ADCY4, NIN, PTPN21, TDP1, 
CPSF2, CTSG, CDKN3, SIX6, SLC10A1, FLVCR2, SSTR1, ACTR10, 
RDH12, MLH3, SPG11, GLDN, SNX1, OCA2, GJD2, ALDH1A2, 
MYO1E, KIAA1024, C15orf29, INO80, DMXL2, RORA, ARNT2, 
DNAJA3, LONP2, GRIN2A, NUP93, GAN, ZNF597, C16orf62, 
SEZ6L2, RBL2, RFWD3, BCAR1, TLK2, ALDH3A1, OR1A1, ZNF403, 
ETV4, CA10, MTMR4, APPBP2, ELAC2, PRPF8, FBXL20, CACNG4, 
TMEM104, DRG2, PIGS, PLXDC1, SPAG9, COIL, KCTD2, DOK6, 
TXNL1, ROCK1, WDR7, ZADH2, ANGPTL6, CREB3L3, ZNF569, 
LENG8, ARHGEF18, COPE, STXBP2, RNASEH2A, TSSK6, C19orf47, 
HAS1, SF4, IL1A, DHRS9, ITGAV, TRAK2, MAP2, HDAC4, AGXT, 
MAPRE3, EHD3, FSHR, MGAT4A, GLI2, MBD5, SCN3A, SSFA2, 
NRP2, GALNT14, WDR33, UGCGL1, ACVR2A, LRP2, RBM45, DYSF, 
CNNM4, CHRNA1, MARCH4, SPHKAP, SPTBN1, SMEK2, C20orf6, 
TNNC2, SLC2A10, TSHZ2, NCOA6, GMEB2, ACSS1, JAG1, FLRT3, 
SEC23B, CSE1L, DSCR3, DYRK1A, ERG, FAM3B, PCNT, USP25, 
KIAA0179, HMGXB4, TMPRSS6, SULT4A1, CYTSA, RBM5, ALAS1, 
CCDC37, SUCNR1, FNDC3B, OSBPL10, CTNNB1, C3orf23, HYAL2, 
TBC1D23, HRH1, TIPARP, LARS2, WDR6, NFKBIZ, UROC1, 
SLC25A38, CXCR6, PRKCD, PHF17, GRIA2, KDR, PCDH18, CCRN4L, 
GABRB1, COX18, MTTP, MANBA, MFSD8, GALNT7, IRF2, WDFY3, 
LMNB1, PCDHB3, LARP1, GABRA6, PCDH24, ADAMTS12, 
DMGDH, CSPG2, MAN2A1, TRIM36, SIL1, GRM6, PARP8, WDR55, 
POU4F3, C5orf42, ACOT12, ALDH7A1, LAMA4, ROS1, ENPP3, 
TAAR2, TAAR1, IL20RA, CNPY3, PLA2G7, POPDC3, TULP4, 
ZNF318, RP3-337H4.1, CDC2L6, AIG1, ITPR3, ZFAND3, FRS3, 
MEP1A, IGF2R, TFAP2B, SLC17A5, PRSS35, MAP3K7, PLOD3, 
BRAF, PDIA4, TRA2A, AEBP1, GRM3, MCM7, STAG3, RELN, 
LAMB4, GLI3, DDX56, PCOLCE, SMURF1, C8orf41, CNGB3, HTRA4, 
ASPH, SULF1, ANXA13, RB1CC1, ARFGEF1, CSMD3, NOV, PPM2C, 
LAPTM4B, UGCG, UNC13B, RORB, KIF12, GLE1, NUP214, DBC1, 
ENDOG, ADAMTS13, SNAPC3, EXOSC2, SLC24A2, L1CAM, KIF4A, 
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ABCB7, GPR174, GABRE, NHS, PRICKLE3, DMD 
Somatic mutation 
profiles of MSI and MSS 
colorectal cancer 
identified by whole 
exome next generation 
sequencing and 
bioinformatics analysis 
 
PLOS One, 2010 
2 (1 MSI-S, 1 
MSI-H) 
Tumour and 
normal 
mucosa 
PLA2G2D, MEF2D, AKR7A3, WDTC1, IL12RB2, ARHGAP21, 
SUPV3L1, BMPR1A, CTR9, MLL, DAGLA, MICAL2, TNKS1BP1, 
RCOR2, PRICKLE1, KRAS, MTERFD3, DAO, FREM2, UGCGL2, 
SETDB2, RBBP6, TP53, KCNJ12, ADNP2, CD22, NUP62, STAT1, 
PNPT1, GPR45, EHD3, ATP9A, USP13, PLD1, ITGA9, DNAH5, 
SNX18, TNFRSF21, ASCC3, THEM2, HCRTR2, SRRT, CREB3L2, 
HOXA1, ABRA 
MSS List: 359 significant 
mutations for the MSI tumour 
and 45 for the MSS, all with 
predicted altered protein 
function 
Exome capture 
sequencing of adenoma 
reveals genetic 
alterations in multiple 
cellular pathways at the 
early stage of colorectal 
tumorigenesis 
 
PLOS One, 2013 
1 Tumour, 
adenoma 
and normal 
mucosa 
OR6X1, SLC15A3, KRTHB4, RBFOX1, LAMA3, CDH20, BIRC6, APC, 
NMBR, GLCCI1, EFR3A, FTHL17, , PGM1, DTL, PPP1R3C, OR51E2, 
RRP8, NARS2, FAM109A, FAM181A, NRXN3, KIAA1409, TGM7, 
CORO1A, KRTHA1, GNAL, PPAP2C, FLJ37549, RYR1, GSK3A, ATF2, 
AFP36L2, NFATC2, ZFP64, GRIK1, KRTAP19-7, DESK1, KLHL22, 
ALPK1, FBXW7, APC, POU4F3, FLT4, FAM54A, KIF25, SDK1, TRF2, 
CUX1, NRG1, OR13J1, COL4A6, WDR44 
12 variants were identified in 
the adenoma and 42 in the 
adenocarcinoma 
Chromothripsis is a 
common mechanism 
driving genomic 
rearrangements in 
primary and metastatic 
colorectal cancer 
 
Genome Biology, 2011 
4 Primary 
tumour, 
normal 
mucosa, 
liver 
metastasis 
and liver 
parenchyma 
APC, DDR2, KRAS, PTPRF, SMAD2, SMAD4, TP53, MLL3, PART14, 
PIK3CA, KDR, PRKCD, RFC1, EXOC4, TSC1, FGFR2, NUP98, ERBB3, 
RASA3, DNAH9, TAOK1, ATRX, TTN, EPHA4 
24 genes suggesting the 
relevance of chromothripsis 
to metastagenesis 
Genomic sequencing of 
colorectal 
adenocarcinomas 
identifies a recurrent 
VTI1A-TCF7L2 fusion 
 
9 Tumour and 
normal 
mucosa 
TARDBP, INADL, CFH, CYS1, RASGRP3, CCDC88A, C2orf78, 
FER1L5, TTN, IGFBP5, RAF1, LTF, PPP2R3A, PCCB, KLHL6, PAK2, 
SLC10A7, ACSL1, CMYA5, FAM81B, APC, APC, PCDHGC3, DHX16, 
SYNGAP1, C6orf204, POT1, GRM8, DMRT1, KIAA1539, ECM2, 
BAAT, ABL1, SEC16A, ITIH5, ITPRIP, IRF7, TRIM6-TRIM34, IPO7, 
ANO3, OR8H2, CEP164, CASC1, KRAS, DDX11, PUS7L, PAN2, 
Eleven rearrangements 
encode predicted in-frame 
fusion proteins, including a 
fusion of TVI1A and TCF7L2 
found in 3 out of 9 patients 
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Nature Genetics, 2011 ZFP106, BBS4, UBFD1, TP53, MAP2K3, TOP2A, TRIM47, FAM38B, 
ROCK1, NFATC1, OR10H3, TMEM147, SAE1, PPP2R1A, GZF1, 
PTPRT, CASS4, GTPBP5, CHAF1B, LCA5L, CHEK2, FAM47A, 
FAM123B, CACNA1S, C1orf107, TAF5L, C2orf78, FIGN, COBLL1, 
GLB1, TOPBP1, KCNAB1, TMPRSS11F, RGMB, APC, APC, OPRM1, 
PCLO, AKAP9, PRKAR2B, PLXNA4, FOXD4, C9orf95, CYLC2, TAF3, 
C10orf82, OR51B4, C11orf65, WNK1, KRAS, MDM1, CLLU1, 
DNAH10, DHX37, KIAA1409, RYR3, PLIN1, OR4F15, NSMCE1, 
HYDIN, ZNF521, EMR1, OR7E24, KIAA1683, ZNF761, EYA2, 
UBASH3A, MXRA5, FAM47C, TBC1D8B, CHD5, CSMD2, PODN, 
NTNG1, HAO2, SEMA6C, SLC27A3, DHX9, HHIPL2, SUSD4, ABCG8, 
SCN1A, TTN, TTN, MYO1B, COL6A3, FLNB, STXBP5L, PCOLCE2, 
P2RY12, MED12L, DCAF4L1, FAM13A, DCHS2, CYP4V2, FYB, 
PCDHGA6, CSF1R, SNCB, TBC1D9B, HIST1H1D, ZNF323, NKAIN2, 
PLG, SP4, RABGEF1, CYP3A43, DGKI, OR2A5, TM7SF4, CSMD3, 
TG, DMRT3, PDCD1LG2, GABBR2, JMJD1C, ANXA11, GRID1, 
SORCS1, PRMT3, RAG1, ATG2A, GPR83, NCAM1, DSCAML1, 
OR8D1, NDUFA9, ADAMTS20, KRT76, NBEA, SIAH3, ATP7B, SCEL, 
RTN1, ALDH6A1, NRXN3, SERPINA1, DICER1, RYR3, CYP1A2, 
DNAH3, SCNN1G, MYH3, ATPAF2, PNMT, ASB16, USH1G, ASXL3, 
SMAD4, ABCA7, SEMA6B, EMR1, SYDE1, PSG3, LILRB3, CYP2D6, 
FLJ44635, MAGEE2, MAGEA11, SYTL1, PHACTR4, KIAA0467, C8A, 
PTPRC, CAPN2, PLB1, CTNNA2, SNRNP200, LRP2, HAT1, TTN, 
HECW2, CADPS, CADPS, PVRL3, UROC1, NFXL1, RNF150, C5orf44, 
SLCO6A1, APC, PCDHA3, PCDHGA7, FAT2, TBC1D9B, TRIM26, 
MUC21, BAT2, PI16, MDGA1, TCTE1, PGK2, ASCC3, RBM16, 
IGF2R, C6orf118, C6orf118, ISPD, ADCY1, IMMP2L, ZNF425, 
ADRA1A, MMP16, DEPDC6, EPPK1, AK3, TAF1L, FANCG, DAPK1, 
DBC1, CDK5RAP2, LRIT2, CSRP3, PDHX, OR4D9, HSPA8, WNK1, 
C3AR1, PHC1, PDZRN4, C12orf56, TMCC3, CUX2, FLT1, FARP1, 
HDC, TMOD3, IREB2, ACAN, RBBP6, TAT, PHF23, TP53, EFCAB5, 
BPTF, TCEB3CL, ARHGEF18, CACNA1A, LAIR1, HM13, B4GALT5, 
SLC9A8, KRTAP6-2, PRAME, MYO18B, RANGAP1, ATP6AP2, 
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USP9X, UBE4B, NRAS, USH2A, OBSCN, XDH, VRK2, ANKRD36B, 
LIPT1, TTN, TTN, ICA1L, SCN10A, PCBP4, DZIP3, PIK3CA, HTT, 
ANK2, PRSS48, CDH12, IL31RA, TNPO1, APC, SLC27A6, 
HIST1H2AJ, BRD2, COL12A1, EPM2A, SYNE1, MRPS17, PTPN12, 
AKAP9, SSPO, DLC1, SLC7A2, PREX2, FLJ43860, EPPK1, GLT6D1, 
NEBL, PTCHD3, ANK3, C10orf4, TCF7L2, TUB, BTBD10, LDHA, 
OR4C13, OR8K3, OR1S2, TMEM218, CACNA1C, PIK3C2G, LRRK2, 
PDZRN4, ZFC3H1, ZNF84, PCDH17, SIPA1L1, SPTLC2, EFTUD1, 
C15orf32, SYNM, TP53, ABCA10, OTOP2, ZNF750, CXXC1, 
CPAMD8, ZNF568, ZNF569, SYNGR4, ZNF578, KIR2DL1, TSHZ2, 
ADAMTS5, COL4A5, KIAA1210, EIF4G3, SFRS4, HDAC1, LPHN2, 
LCE4A, GREB1, SCLT1, APC, SRA1, CRIP3, HCRTR2, AKD1, RP1L1, 
TRPA1, ZFHX4, OR1L4, KCNT1, PNPLA7, CNTN5, KRAS, FLT3, 
DCLK1, ADPRHL1, WWP2, CDC27, SCN4A, SMAD4, MUC16, 
GPR32, MAGEC1, SLITRK2, VPS13D, NRAS, DDR2, PRG4, SRBD1, 
UXS1, PTPN4, LRP1B, GAD1, TTN, ITGAV, NOP58, DNAJB2, 
PDCD6IP, DCLK3, SCN11A, BOC, STXBP5L, ENOPH1, C4orf31, 
FBXW7, PPWD1, APC, APC, RBM27, PEG10, PSMC2, BCAP29, 
PLXNA4, CSMD3, CSMD3, FLJ46321, BAT2L, C9orf96, CARD9, 
FRMD4A, PTER, CUBN, CACNB2, SVIL, PCBD1, EXOC6, DMBT1, 
GRIK4, KRT1, DNAJC14, ESYT1, KCNMB4, PPP1R12A, ANKS1B, 
ACACB, PDS5B, SLITRK5, HECTD1, RHOJ, SFRS5, FAM181A, 
HERC1, MFGE8, NLRC5, COG4, TP53, SLFN5, GAS2L2, FBXO47, 
NPEPPS, TXNDC2, SMAD2, MBD1, GRWD1, FPR2, NLRP9, NLRP4, 
FRMPD4, TRO, FAM70A, HSPG2, GMEB1, TNNI3K, EPS8L3, ARNT, 
SHC1, KIF14, BTG2, ANGEL2, TARBP1, APOB, USP34, FAM136A, 
TBR1, COL6A3, MYRIP, CD200R1L, C4orf49, GALNTL6, SORBS2, 
MTRR, FBXL7, OSMR, C7, RASA1, MEP1A, PTP4A1, PHIP, HTR1E, 
C6orf167, FAM184A, GRM1, VSTM2A, C7orf42, CCDC146, 
DOCK4, ST7, UBE2H, MGAM, DLC1, KIAA1967, NRG1, UBR5, 
MTSS1, COL22A1, DNTT, GSTO2, MUC2, FOLH1, NUMA1, PCF11, 
FAT3, CUL5, OR10G7, PRMT8, KCNA6, KCNA1, KRAS, OVCH1, 
SFRS2IP, DDX23, ANKRD33, HELB, NAV3, C12orf51, RPL6, SACS, 
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FNDC3A, KPNA3, TDRD3, FAM155A, OR4K14, PNN, FBN1, 
SLC27A2, VPS13C, TP53, KCNJ12, RAB11FIP4, NFE2L1, TLK2, 
ABCA9, PTPRM, HNRNPM, ZNF667, ZNF329, ITCH, ELFN2, 
SAMM50, ESPN, MTHFR, PPT1, ZCCHC11, DPT, FAM129A, 
HMCN1, HMCN1, NFASC, CENPF, PRSS38, ARID4B, RYR2, 
OR14C36, C2orf71, EHBP1, TEX261, FER1L5, CNTNAP5, TLK1, 
ALS2CR11, CXCR2, TMBIM1, COL4A4, COL6A3, OR6B2, USP19, 
TOPBP1, EPHB1, LEKR1, APBB2, REST, RAPGEF2, WDR17, CDH9, 
ZFYVE16, ST8SIA4, APC, APC, KIF3A, ATP10B, C5orf41, CAPN11, 
GABRR2, WBSCR17, SEMA3C, STAG3, TFR2, LRRN3, CPA5, 
MGAM, GIMAP8, PXDNL, RP1, NCOA2, CA2, FBXO43, RANBP6, 
ACO1, FAM189A2, GABBR2, OR13D1, FAM129B, NTNG2, 
MAMDC4, C10orf18, PRKCQ, USP6NL, C10orf140, KIAA1462, 
GJD4, CSGALNACT2, RTKN2, CHUK, PKD2L1, SHOC2, ATRNL1, 
BNIP3, OR52A5, CCKBR, DENND5A, SAA2, NAV2, C11orf49, 
OR4C11, GLYATL1, FAM111B, FAT3, BCL9L, FLI1, GLB1L2, AKAP3, 
NOP2, A2M, DUSP16, RERGL, KRAS, KRT75, KRT2, OR6C2, 
TIMELESS, APAF1, CKAP4, RNFT2, CLIP1, FLJ10357, ZNF219, SPTB, 
NDN, RTF1, PML, SNX33, UNC45A, C16orf38, DCI, STX1B, CHD9, 
CCDC135, TSNAXIP1, SLC12A4, DHX38, CBFA2T3, ZNF778, SHBG, 
KRT12, GPATCH8, SPATA20, TEX14, C18orf34, MYO9B, WDR88, 
HRC, C20orf12, RALGAPA2, WFDC3, C20orf108, UCKL1, PRPF6, 
IGSF5, CCT8L2, GAB4, MCAT, CELSR1, ARSH, TLR8, PHEX, TCEAL3, 
COL4A5 
Exome sequencing 
reveals frequent 
inactivating mutations in 
ARID1A, ARID1B, ARID2 
and ARID4 in 
microsatellite unstable 
colorectal cancer 
 
International Journal of 
21 Tumour and 
normal 
mucosa 
ARID1A, ARID1B, ARID2, ARID3A, ARID4A, ARID4B, ARID5A, 
JARID2, KDM5A, KDM5B, KDM5C, KDM5D 
Analysis focussed to ARID 
genes only which were 
frequently mutated (13-39%) 
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Comprehensive genomic 
analysis of a metastatic 
colon cancer to the lung 
by whole exome 
sequencing and gene 
expression analysis 
 
International Journal of 
Oncology, 2014 
1 Metastatic 
lung tumour 
and normal 
lung 
ADCY2, ADCY9, APC, GNB5, KRAS, LRP6, HDAC6, ARHGEF17 8 of the 71 variants identified 
pertain to the ‘metastatic 
colorectal cancer signalling’ or 
‘phospholipase C signalling’ 
pathways 
Targeted sequencing of 
cancer related genes in 
colorectal cancer using 
next generation 
sequencing 
 
PLOS One, 2013 
60 Tumour and 
normal 
mucosa 
AATK, ABL1, ABL2, ACVR2A, AKT1, AKT2, ALK, APC, ATM, AXIN2, 
BCL2, BCL9, BLM, BMPR1A, BRCA1, BRAF, BRCA2, BUB1B, BCL10, 
BRIP1, CARD11, CBL, CCND1, CDH1, CDK4, CDK6, CDKN1B, 
CDKN2A, CDX2, CEBPA, CHEK2, CREB1, CREBBP, CSF1, CSF1R, 
CSMD3, CTNNB1, CYLD, DCC, EGFR, ELK1, ELN, ENG, EP300, 
EPHA1, EPHB1, EPM2A, ERBB2, ERCC1, ERCC2, ERCC3, ERCC4, 
ERCC5, EWSR1, EXT1, EXT2, EZH2, FANCA, FANCC, FANCE, FANCF, 
FGFR1, FGFR3, FGFR2, FLI1, FLT3, FBXW7, FOXN1, FOXL2, GATA1, 
GATA2, GATA3, GNAS, GPC3, HIP1, HNF1A, HRAS, IDH1, IL21R, 
IL6ST, ITK, JAK1, JAK2, JAK3, KIT, KRAS, LCK, MAF, MAFB, 
MAP2K4, MDM2, MEN1, MET, MLH1, MLH3, MLL, MMP14, MPL, 
MSH2, MSH6, MUTYH, MUSK, MYC, MYCN, MYH11, MYH9, 
NEK11, NF1, NF2, NFKB2, NOTCH1, NPM1, NRAS, NTRK1, NTRK3, 
OBSCN, PALB2, PARP1, PDGFRA, PDGFRB, PHOX2B, PIK3CA, 
PIK3R1, PIM1, PLAG1, PML, PMS1, PMS2, PRDM16, PRKAR1A, 
PTGS2, PTEN, PTPN11, PTK7, RAD51L1, RAF1, RARA, RASSF1, 
RB1, RECQL4, REL, RET, ROR1, ROS1, RUNX1, RYR1, SH3GL1, 
SMAD2, SMAD4, SMARCB1, SMO, SPP1, SPTAN1, SRC, STAT1, 
STAT3, STK11, STK11IP, SUFU, SYK, TAF15, TAF1L, TEK, TGFBR1, 
TGFBR2, TGFA, TLX1, TLX3, TOP1, TOP2A, TP53, TRRAP, TSC1, 
TSC2, TTN, VHL, VEGFA, WAS, WHSC1, WRN, WT1, XPA, XPC 
183 genes selected for 
analysis from COSMIC 
database (study designed to 
validate new platform) 
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Proteomic comparison of metastatic tumour and normal adjacent liver parenchyma 
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Accession Number Name p Value Log2 Fold Change 
(Metastasis/Parenchyma) 
P09210 Glutathione S-transferase A2 3.92E-09 -5.472 
P23141 Liver carboxylesterase 1 5.38E-09 -5.215 
Q68CK6 Acyl-coenzyme A synthetase 
ACSM2B, mitochondrial 
1.10E-10 -5.201 
P11509 Cytochrome P450 2A6 9.30E-08 -5.094 
Q93088 Betaine--homocysteine S-
methyltransferase 1 
6.84E-10 -5.021 
P09110 3-ketoacyl-CoA thiolase, 
peroxisomal 
1.19E-10 -4.897 
P10632 Cytochrome P450 2C8 2.59E-08 -4.883 
P00367 Glutamate dehydroge0se 1, 
mitochondrial 
6.38E-11 -4.759 
P16662 UDP-glucuronosyltransferase 
2B7 
4.67E-08 -4.733 
P45954 Short/branched chain specific 
acyl-CoA dehydroge0se, 
mitochondrial 
8.59E-12 -4.690 
Q16822 Phosphoenolpyruvate 
carboxyki0se [GTP], 
mitochondrial 
8.59E-11 -4.683 
P30039 Phe0zine biosynthesis-like 
domain-containing protein 
1.44E-07 -4.662 
Q9UJM8 Hydroxyacid oxidase 1 1.46E-09 -4.651 
P50440 Glycine amidinotransferase, 
mitochondrial 
5.74E-10 -4.582 
P28845 Corticosteroid 11-beta-
dehydroge0se isozyme 1 
2.94E-11 -4.552 
P05091 Aldehyde dehydroge0se, 
mitochondrial 
2.66E-11 -4.547 
P11712 Cytochrome P450 2C9 7.21E-08 -4.523 
P21549 Serine--pyruvate 
aminotransferase 
6.46E-10 -4.497 
Q3LXA3 Bifunctio0l ATP-dependent 
dihydroxyacetone ki0se/FAD-
AMP lyase (cyclizing) 
4.01E-08 -4.489 
Q00796 Sorbitol dehydroge0se 9.97E-09 -4.479 
Q08426 Peroxisomal bifunctio0l 
enzyme 
5.57E-10 -4.474 
P00352 Reti0l dehydroge0se 1 4.66E-09 -4.468 
O95954 Formimidoyltransferase-
cyclodeami0se 
2.03E-09 -4.437 
P00325 Alcohol dehydroge0se 1B 2.72E-07 -4.425 
P07099 Epoxide hydrolase 1 1.68E-09 -4.398 
P55157 Microsomal triglyceride 
transfer protein large subunit 
1.45E-09 -4.386 
P00480 Ornithine 
carbamoyltransferase, 
mitochondrial 
1.55E-11 -4.383 
P30084 Enoyl-CoA hydratase, 1.00E-09 -4.341 
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mitochondrial 
P08684 Cytochrome P450 3A4 9.61E-09 -4.333 
P24752 Acetyl-CoA acetyltransferase, 
mitochondrial 
2.54E-10 -4.315 
P42765 3-ketoacyl-CoA thiolase, 
mitochondrial 
7.98E-11 -4.304 
P54868 Hydroxymethylglutaryl-CoA 
synthase, mitochondrial 
8.37E-09 -4.299 
P33121 Long-chain-fatty-acid--CoA 
ligase 1 
9.84E-10 -4.269 
P07327 Alcohol dehydroge0se 1A 5.89E-07 -4.240 
P00966 Argininosucci0te synthase 2.59E-09 -4.227 
Q14749 Glycine N-methyltransferase 1.88E-08 -4.213 
P05089 Argi0se-1 1.88E-10 -4.202 
P16152 Carbonyl reductase [0DPH] 1 8.85E-11 -4.163 
Q9P0Z9 Peroxisomal sarcosine oxidase 9.10E-10 -4.145 
P10620 Microsomal glutathione S-
transferase 1 
9.58E-08 -4.141 
P30046 D-dopachrome decarboxylase 2.87E-07 -4.117 
P80404 4-aminobutyrate 
aminotransferase, 
mitochondrial 
4.38E-11 -4.083 
P04040 Catalase 1.11E-09 -4.064 
P52895 Aldo-keto reductase family 1 
member C2 
7.97E-06 -4.055 
P30038 Delta-1-pyrroline-5-carboxylate 
dehydroge0se, mitochondrial 
9.86E-10 -4.039 
P05062 Fructose-bisphosphate aldolase 
B 
7.22E-09 -4.038 
P00326 Alcohol dehydroge0se 1C 2.73E-07 -4.016 
O75521 Enoyl-CoA delta isomerase 2, 
mitochondrial 
7.57E-10 -4.013 
P00505 Aspartate aminotransferase, 
mitochondrial 
1.50E-10 -4.004 
Q9UBQ7 Glyoxylate 
reductase/hydroxypyruvate 
reductase 
3.57E-09 -4.004 
Q7Z4W1 L-xylulose reductase 2.61E-08 -3.962 
Q9UI17 Dimethylglycine dehydroge0se, 
mitochondrial 
1.26E-08 -3.958 
P23378 Glycine dehydroge0se 
[decarboxylating], 
mitochondrial 
4.07E-06 -3.956 
P20132 L-serine dehydratase/L-
threonine deami0se 
3.70E-03 -3.955 
P16930 Fumarylacetoacetase 3.06E-09 -3.899 
Q14032 Bile acid-CoA:amino acid N-
acyltransferase 
5.92E-07 -3.896 
P21695 Glycerol-3-phosphate 
dehydroge0se [0D+], 
cytoplasmic 
2.35E-06 -3.893 
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P16219 Short-chain specific acyl-CoA 
dehydroge0se, mitochondrial 
1.07E-08 -3.877 
P35914 Hydroxymethylglutaryl-CoA 
lyase, mitochondrial 
1.89E-09 -3.849 
O75452 Retinol dehydroge0se 16 4.42E-08 -3.837 
O75891 Cytosolic 10-
formyltetrahydrofolate 
dehydroge0se 
3.31E-09 -3.825 
P05181 Cytochrome P450 2E1 1.95E-06 -3.820 
P30042 ES1 protein homolog, 
mitochondrial 
3.84E-08 -3.818 
P00167 Cytochrome b5 5.81E-10 -3.811 
P32754 4-hydroxyphenylpyruvate 
dioxyge0se 
2.86E-09 -3.800 
P34896 Serine 
hydroxymethyltransferase, 
cytosolic 
9.55E-09 -3.796 
P22307 Non-specific lipid-transfer 
protein 
5.34E-11 -3.769 
P11310 Medium-chain specific acyl-CoA 
dehydroge0se, mitochondrial 
2.06E-07 -3.769 
P30086 Phosphatidylethanolamine-
binding protein 1 
8.69E-09 -3.766 
P52758 Ribonuclease UK114 1.92E-09 -3.762 
P22310 UDP-glucuronosyltransferase 1-
4 
1.07E-08 -3.762 
P51648 Fatty aldehyde dehydroge0se 1.15E-08 -3.756 
P49419 Alpha-aminoadipic 
semialdehyde dehydroge0se 
1.78E-10 -3.721 
P49189 4-
trimethylaminobutyraldehyde 
dehydroge0se 
2.60E-09 -3.702 
P27338 Amine oxidase [flavin-
containing] B 
4.97E-09 -3.685 
P30613 Pyruvate ki0se isozymes R/L 1.47E-06 -3.670 
P51857 3-oxo-5-beta-steroid 4-
dehydroge0se 
3.04E-06 -3.654 
P54855 UDP-glucuronosyltransferase 
2B15 
8.05E-07 -3.630 
P04424 Argininosucci0te lyase 2.90E-10 -3.624 
Q06520 Bile salt sulfotransferase 3.44E-07 -3.615 
P40939 Trifunctio0l enzyme subunit 
alpha, mitochondrial 
3.25E-09 -3.612 
P34913 Epoxide hydrolase 2 3.16E-08 -3.610 
P48735 Isocitrate dehydroge0se [0DP], 
mitochondrial 
1.57E-07 -3.600 
P28332 Alcohol dehydroge0se 6 9.97E-07 -3.599 
A6NLP5 Tetratricopeptide repeat 
protein 36 
2.67E-08 -3.599 
Q02252 Methylmalo0te-semialdehyde 
dehydroge0se [acylating], 
mitochondrial 
1.62E-08 -3.590 
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Q16851 UTP--glucose-1-phosphate 
uridylyltransferase 
1.76E-09 -3.589 
Q9H8H3 Methyltransferase-like protein 
7A 
1.19E-08 -3.582 
P31513 Dimethylaniline monooxyge0se 
[N-oxide-forming] 3 
1.08E-06 -3.581 
Q6YN16 Hydroxysteroid dehydroge0se-
like protein 2 
6.56E-09 -3.578 
Q00266 S-adenosylmethionine synthase 
isoform type-1 
3.32E-07 -3.550 
Q14117 Dihydropyrimidi0se 2.73E-09 -3.527 
Q9H2M3 Betaine--homocysteine S-
methyltransferase 2 
2.25E-07 -3.521 
Q02928 Cytochrome P450 4A11 9.11E-08 -3.515 
P11498 Pyruvate carboxylase, 
mitochondrial 
9.27E-07 -3.513 
P11182 Lipoamide acyltransferase 
component of branched-chain 
alpha-keto acid dehydroge0se 
complex, mitochondrial 
7.68E-09 -3.512 
P25705 ATP synthase subunit alpha, 
mitochondrial 
3.70E-08 -3.508 
Q16762 Thiosulfate sulfurtransferase 5.35E-09 -3.500 
Q13228 Selenium-binding protein 1 3.18E-10 -3.499 
Q16698 2,4-dienoyl-CoA reductase, 
mitochondrial 
2.60E-08 -3.484 
Q13011 Delta(3,5)-Delta(2,4)-dienoyl-
CoA isomerase, mitochondrial 
1.34E-10 -3.483 
P36871 Phosphoglucomutase-1 1.80E-08 -3.462 
P23786 Carnitine O-
palmitoyltransferase 2, 
mitochondrial 
8.17E-08 -3.457 
Q6IB77 Glycine N-acyltransferase 2.04E-07 -3.439 
P38117 Electron transfer flavoprotein 
subunit beta 
4.54E-09 -3.429 
Q9Y2P5 Bile acyl-CoA synthetase 3.49E-08 -3.426 
P06737 Glycogen phosphorylase, liver 
form 
2.48E-08 -3.421 
P35573 Glycogen debranching enzyme 1.53E-08 -3.418 
Q93099 Homogentisate 1,2-dioxyge0se 4.25E-07 -3.413 
P26440 Isovaleryl-CoA dehydroge0se, 
mitochondrial 
2.95E-09 -3.412 
Q02338 D-beta-hydroxybutyrate 
dehydroge0se, mitochondrial 
1.37E-08 -3.400 
Q9H2X3 C-type lectin domain family 4 
member M 
7.42E-06 -3.400 
P46952 3-hydroxyanthranilate 3,4-
dioxyge0se 
8.79E-08 -3.373 
P51649 Succi0te-semialdehyde 
dehydroge0se, mitochondrial 
3.03E-08 -3.371 
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Q9H2A2 Aldehyde dehydroge0se family 
8 member A1 
3.59E-07 -3.368 
Q96HR9 Receptor expression-enhancing 
protein 6 
3.51E-08 -3.360 
Q16836 Hydroxyacyl-coenzyme A 
dehydroge0se, mitochondrial 
1.24E-09 -3.341 
P13804 Electron transfer flavoprotein 
subunit alpha, mitochondrial 
1.98E-09 -3.335 
Q9UNU6 7-alpha-hydroxycholest-4-en-3-
one 12-alpha-hydroxylase 
1.27E-07 -3.332 
Q9BRX8 Redox-regulatory protein 
PAMM 
7.44E-10 -3.311 
O14975 Very long-chain acyl-CoA 
synthetase 
1.38E-07 -3.304 
Q7Z5P4 17-beta-hydroxysteroid 
dehydroge0se 13 
8.32E-07 -3.299 
P49327 Fatty acid synthase 5.55E-06 -3.286 
P22033 Methylmalonyl-CoA mutase, 
mitochondrial 
1.53E-07 -3.279 
Q6UX53 Methyltransferase-like protein 
7B 
7.92E-08 -3.274 
A2VDF0 Fucose mutarotase 1.39E-06 -3.257 
O95563 Brain protein 44 2.57E-07 -3.254 
P36537 UDP-glucuronosyltransferase 
2B10 
4.92E-06 -3.249 
P30041 Peroxiredoxin-6 9.49E-08 -3.246 
Q9UBR1 Beta-ureidopropio0se 1.38E-06 -3.237 
Q9UJS0 Calcium-binding mitochondrial 
carrier protein Aralar2 
1.86E-07 -3.236 
P13929 Beta-enolase 1.04E-03 -3.232 
Q9NR77 Peroxisomal membrane protein 
2 
9.39E-07 -3.229 
P09467 Fructose-1,6-bisphosphatase 1 6.65E-06 -3.215 
P24298 Alanine aminotransferase 1 3.13E-08 -3.204 
P21399 Cytoplasmic aconitate 
hydratase 
1.49E-07 -3.193 
Q06278 Aldehyde oxidase 2.66E-07 -3.173 
Q96DG6 Carboxymethylenebutenolidase 
homolog 
4.86E-09 -3.161 
O75874 Isocitrate dehydroge0se [0DP] 
cytoplasmic 
9.23E-08 -3.159 
P00918 Carbonic anhydrase 2 2.26E-07 -3.148 
P47989 Xanthine 
dehydroge0se/oxidase 
2.52E-07 -3.139 
O14756 17-beta-hydroxysteroid 
dehydroge0se type 6 
1.23E-06 -3.129 
P11168 Solute carrier family 2, 
facilitated glucose transporter 
member 2 
9.98E-07 -3.126 
P42330 Aldo-keto reductase family 1 2.49E-04 -3.116 
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member C3 
P13716 Delta-aminolevulinic acid 
dehydratase 
3.83E-08 -3.114 
P07954 Fumarate hydratase, 
mitochondrial 
1.87E-09 -3.112 
Q14914 Prostaglandin reductase 1 7.04E-07 -3.111 
P50226 Sulfotransferase 1A2 1.56E-03 -3.104 
P11586 C-1-tetrahydrofolate synthase, 
cytoplasmic 
1.85E-07 -3.080 
Q96I99 Succinyl-CoA ligase [GDP-
forming] subunit beta, 
mitochondrial 
9.26E-10 -3.064 
O95154 Aflatoxin B1 aldehyde 
reductase member 3 
5.86E-07 -3.061 
P07237 Protein disulfide-isomerase 2.25E-08 -3.053 
Q9BWD1 Acetyl-CoA acetyltransferase, 
cytosolic 
1.03E-06 -3.042 
P50053 Ketohexoki0se 7.29E-07 -3.031 
Q86WU2 Probable D-lactate 
dehydroge0se, mitochondrial 
3.30E-05 -3.020 
Q86WA6 Valacyclovir hydrolase 2.42E-06 -3.020 
O60701 UDP-glucose 6-dehydroge0se 9.44E-08 -3.008 
Q96DC8 Enoyl-CoA hydratase domain-
containing protein 3, 
mitochondrial 
1.88E-05 -2.983 
O76054 SEC14-like protein 2 4.38E-07 -2.948 
Q9BPW8 Protein NipS0p homolog 1 1.57E-07 -2.911 
P32929 Cystathionine gamma-lyase 1.46E-05 -2.905 
P55084 Trifunctio0l enzyme subunit 
beta, mitochondrial 
7.96E-09 -2.898 
Q9BY49 Peroxisomal trans-2-enoyl-CoA 
reductase 
3.21E-07 -2.897 
P31937 3-hydroxyisobutyrate 
dehydroge0se, mitochondrial 
1.10E-05 -2.895 
O43175 D-3-phosphoglycerate 
dehydroge0se 
1.09E-07 -2.884 
O95831 Apoptosis-inducing factor 1, 
mitochondrial 
1.39E-09 -2.882 
Q86TX2 Acyl-coenzyme A thioesterase 1 3.06E-08 -2.867 
O00264 Membrane-associated 
progesterone receptor 
component 1 
2.65E-07 -2.864 
Q96AB3 Isochorismatase domain-
containing protein 2, 
mitochondrial 
3.75E-07 -2.856 
P25325 3-mercaptopyruvate 
sulfurtransferase 
1.71E-07 -2.852 
Q9H0W9 Ester hydrolase C11orf54 1.90E-06 -2.847 
Q15166 Serum paraoxo0se/lacto0se 3 9.24E-06 -2.843 
Q9UI32 Glutami0se liver isoform, 
mitochondrial 
6.92E-04 -2.832 
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Q96EY8 Cob(I)yrinic acid a,c-diamide 
adenosyltransferase, 
mitochondrial 
2.64E-07 -2.822 
Q4G0N4 0D ki0se domain-containing 
protein 1 
3.97E-08 -2.822 
Q9Y281 Cofilin-2 3.80E-08 -2.820 
Q16134 Electron transfer flavoprotein-
ubiquinone oxidoreductase, 
mitochondrial 
6.80E-07 -2.818 
P51659 Peroxisomal multifunctio0l 
enzyme type 2 
1.58E-10 -2.813 
P35520 Cystathionine beta-synthase 1.72E-07 -2.807 
Q92947 Glutaryl-CoA dehydroge0se, 
mitochondrial 
2.16E-07 -2.805 
Q9Y2Q3 Glutathione S-transferase 
kappa 1 
1.13E-06 -2.800 
P49638 Alpha-tocopherol transfer 
protein 
1.58E-06 -2.782 
Q9UL12 Sarcosine dehydroge0se, 
mitochondrial 
4.04E-08 -2.781 
P30048 Thioredoxin-dependent 
peroxide reductase, 
mitochondrial 
2.83E-08 -2.781 
Q15067 Peroxisomal acyl-coenzyme A 
oxidase 1 
7.92E-06 -2.780 
P37059 Estradiol 17-beta-
dehydroge0se 2 
1.62E-04 -2.769 
Q08AH3 Acyl-coenzyme A synthetase 
ACSM2A, mitochondrial 
6.28E-05 -2.761 
Q6NVY1 3-hydroxyisobutyryl-CoA 
hydrolase, mitochondrial 
1.23E-05 -2.760 
P06576 ATP synthase subunit beta, 
mitochondrial 
2.78E-06 -2.759 
Q13576 Ras GTPase-activating-like 
protein IQGAP2 
1.09E-06 -2.759 
P27144 Adenylate ki0se isoenzyme 4, 
mitochondrial 
1.33E-07 -2.752 
Q86VD7 Solute carrier family 25 
member 42 
3.76E-05 -2.748 
Q53FZ2 Acyl-coenzyme A synthetase 
ACSM3, mitochondrial 
5.86E-07 -2.716 
O43708 Maleylacetoacetate isomerase 3.64E-04 -2.702 
P22760 Arylacetamide deacetylase 2.37E-04 -2.700 
Q99424 Peroxisomal acyl-coenzyme A 
oxidase 2 
1.17E-06 -2.687 
P48449 Lanosterol synthase 8.01E-08 -2.687 
Q86YB7 Enoyl-CoA hydratase domain-
containing protein 2, 
mitochondrial 
1.96E-06 -2.677 
O15229 Kynurenine 3-monooxyge0se 1.52E-05 -2.674 
Q99714 3-hydroxyacyl-CoA 
dehydroge0se type-2 
5.39E-10 -2.664 
Q9ULD0 2-oxoglutarate dehydroge0se- 9.73E-07 -2.649 
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like, mitochondrial 
P54840 Glycogen [starch] synthase, 
liver 
2.50E-06 -2.625 
Q9BX68 Histidine triad nucleotide-
binding protein 2, 
mitochondrial 
3.45E-07 -2.622 
P42126 Enoyl-CoA delta isomerase 1, 
mitochondrial 
2.11E-10 -2.598 
Q08257 Quinone oxidoreductase 3.53E-06 -2.590 
P34897 Serine 
hydroxymethyltransferase, 
mitochondrial 
5.12E-10 -2.588 
Q9NQR4 Omega-amidase NIT2 1.53E-06 -2.581 
O00748 Cocaine esterase 2.83E-06 -2.574 
P06133 UDP-glucuronosyltransferase 
2B4 
7.26E-08 -2.570 
P20815 Cytochrome P450 3A5 2.61E-02 -2.565 
P05177 Cytochrome P450 1A2 1.09E-04 -2.564 
Q13423 0D(P) transhydroge0se, 
mitochondrial 
4.39E-07 -2.561 
Q96CN7 Isochorismatase domain-
containing protein 1 
1.50E-08 -2.558 
P28288 ATP-binding cassette sub-
family D member 3 
1.46E-05 -2.557 
P17174 Aspartate aminotransferase, 
cytoplasmic 
1.91E-05 -2.536 
Q96LJ7 Dehydroge0se/reductase SDR 
family member 1 
8.40E-06 -2.527 
Q9NQ94 APOBEC1 complementation 
factor 
8.17E-06 -2.491 
Q969Z3 MOSC domain-containing 
protein 2, mitochondrial 
3.12E-05 -2.468 
P14550 Alcohol dehydroge0se [0DP+] 1.42E-06 -2.466 
Q709F0 Acyl-CoA dehydroge0se family 
member 11 
2.26E-04 -2.458 
P43155 Carnitine O-acetyltransferase 1.14E-05 -2.433 
Q9NPJ3 Acyl-coenzyme A thioesterase 
13 
5.53E-06 -2.428 
P17516 Aldo-keto reductase family 1 
member C4 
1.52E-05 -2.420 
P31040 Succi0te dehydroge0se 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
7.73E-08 -2.395 
Q03154 Aminoacylase-1 1.15E-05 -2.393 
Q96GK7 Fumarylacetoacetate hydrolase 
domain-containing protein 2A 
1.34E-06 -2.388 
O14832 Phytanoyl-CoA dioxyge0se, 
peroxisomal 
4.37E-06 -2.369 
P30043 Flavin reductase (0DPH) 1.32E-05 -2.355 
Q8NBX0 Saccharopine dehydroge0se-
like oxidoreductase 
1.46E-06 -2.351 
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Q9NPD5 Solute carrier organic anion 
transporter family member 1B3 
1.02E-03 -2.336 
Q9Y6B6 GTP-binding protein SAR1b 5.38E-07 -2.335 
Q96I15 Selenocysteine lyase 5.78E-06 -2.327 
P49326 Dimethylaniline monooxyge0se 
[N-oxide-forming] 5 
1.57E-05 -2.322 
P54819 Adenylate ki0se 2, 
mitochondrial 
7.53E-06 -2.321 
Q8WW59 SPRY domain-containing 
protein 4 
8.13E-07 -2.319 
P16083 Ribosyldihydronicoti0mide 
dehydroge0se [quinone] 
8.43E-04 -2.314 
Q15493 Regucalcin 1.13E-05 -2.314 
Q96KP4 Cytosolic non-specific 
dipeptidase 
8.57E-07 -2.312 
O75356 Ectonucleoside triphosphate 
diphosphohydrolase 5 
3.11E-07 -2.310 
Q9Y2S2 Lambda-crystallin homolog 3.52E-06 -2.310 
P21953 2-oxoisovalerate dehydroge0se 
subunit beta, mitochondrial 
6.02E-05 -2.308 
P09417 Dihydropteridine reductase 1.09E-04 -2.307 
Q96EK6 Glucosamine 6-phosphate N-
acetyltransferase 
7.81E-05 -2.300 
P11766 Alcohol dehydroge0se class-3 2.22E-06 -2.297 
P49748 Very long-chain specific acyl-
CoA dehydroge0se, 
mitochondrial 
1.59E-06 -2.296 
Q96NU7 Probable imidazolonepropio0se 1.04E-05 -2.294 
Q9UBM7 7-dehydrocholesterol 
reductase 
6.33E-06 -2.288 
Q9H9B4 Sideroflexin-1 3.37E-05 -2.285 
P05166 Propionyl-CoA carboxylase beta 
chain, mitochondrial 
7.36E-07 -2.285 
Q969I3 Glycine N-acyltransferase-like 
protein 1 
5.84E-04 -2.275 
P48047 ATP synthase subunit O, 
mitochondrial 
4.80E-06 -2.266 
P21397 Amine oxidase [flavin-
containing] A 
1.57E-04 -2.264 
P23434 Glycine cleavage system H 
protein, mitochondrial 
1.11E-04 -2.259 
Q8N0X4 Citrate lyase subunit beta-like 
protein, mitochondrial 
1.73E-08 -2.257 
P16435 0DPH--cytochrome P450 
reductase 
1.95E-07 -2.245 
Q9UP52 Transferrin receptor protein 2 1.63E-04 -2.236 
Q9NUI1 Peroxisomal 2,4-dienoyl-CoA 
reductase 
4.41E-06 -2.225 
Q6NUM9 All-trans-retinol 13,14- 7.29E-05 -2.223 
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reductase 
Q7L5Y1 Mitochondrial enolase 
superfamily member 1 
1.18E-02 -2.221 
Q96IU4 Abhydrolase domain-
containing protein 14B 
1.64E-05 -2.208 
O95479 GDH/6PGL endoplasmic 
bifunctio0l protein 
5.60E-04 -2.205 
O75964 ATP synthase subunit g, 
mitochondrial 
2.24E-05 -2.201 
Q96RQ3 Methylcrotonoyl-CoA 
carboxylase subunit alpha, 
mitochondrial 
2.07E-05 -2.183 
Q9Y2T3 Guanine deami0se 6.65E-07 -2.178 
P78417 Glutathione S-transferase 
omega-1 
4.80E-05 -2.177 
Q6NUN0 Acyl-coenzyme A synthetase 
ACSM5, mitochondrial 
3.48E-05 -2.177 
P04179 Superoxide dismutase [Mn], 
mitochondrial 
9.69E-04 -2.176 
P30040 Endoplasmic reticulum resident 
protein 29 
3.30E-08 -2.153 
P00441 Superoxide dismutase [Cu-Zn] 3.61E-04 -2.150 
P07306 Asialoglycoprotein receptor 1 1.11E-03 -2.137 
P78329 Leukotriene-B(4) omega-
hydroxylase 1 
3.44E-06 -2.128 
P51570 Galactoki0se 5.10E-06 -2.123 
P21964 Catechol O-methyltransferase 1.93E-04 -2.110 
P21912 Succi0te dehydroge0se 
[ubiquinone] iron-sulfur 
subunit, mitochondrial 
4.42E-07 -2.105 
O43772 Mitochondrial 
carnitine/acylcarnitine carrier 
protein 
2.43E-04 -2.092 
Q5R3I4 Tetratricopeptide repeat 
protein 38 
1.13E-05 -2.053 
Q9NRV9 Heme-binding protein 1 3.48E-06 -2.029 
P40925 Malate dehydroge0se, 
cytoplasmic 
3.88E-06 -2.019 
Q16719 Kynureni0se 1.50E-05 -2.019 
P36269 Gamma-glutamyltransferase 5 2.46E-04 -2.005 
P04208 Ig lambda chain V-I region WAH 1.44E-03 2.013 
P24158 Myeloblastin 9.71E-03 2.019 
P60903 Protein S100-A10 8.84E-04 2.022 
P35555 Fibrillin-1 3.19E-03 2.029 
P55011 Solute carrier family 12 
member 2 
2.51E-03 2.050 
Q96PD5 N-acetylmuramoyl-L-alanine 
amidase 
2.83E-03 2.060 
P02647 Apolipoprotein A-I 9.89E-04 2.107 
P05546 Heparin cofactor 2 3.09E-02 2.109 
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P07195 L-lactate dehydroge0se B chain 1.01E-03 2.132 
P05155 Plasma protease C1 inhibitor 1.77E-03 2.148 
Q01105 Protein SET 3.17E-03 2.151 
P30740 Leukocyte elastase inhibitor 1.57E-04 2.155 
P68032 Actin, alpha cardiac muscle 1 1.06E-02 2.171 
P98095 Fibulin-2 2.33E-05 2.204 
P00751 Complement factor B 3.50E-04 2.208 
P62328 Thymosin beta-4 1.40E-02 2.211 
P01766 Ig heavy chain V-III region BRO 5.99E-04 2.213 
P37802 Transgelin-2 3.13E-05 2.214 
Q14126 Desmoglein-2 7.40E-06 2.233 
P00736 Complement C1r 
subcomponent 
7.20E-03 2.247 
Q12805 EGF-containing fibulin-like 
extracellular matrix protein 1 
2.55E-04 2.254 
P25311 Zinc-alpha-2-glycoprotein 9.84E-04 2.260 
P63104 14-3-3 protein zeta/delta 1.35E-05 2.262 
P23528 Cofilin-1 1.79E-05 2.267 
P43652 Afamin 1.74E-03 2.297 
O14791 Apolipoprotein L1 5.69E-03 2.308 
P06331 Ig heavy chain V-II region ARH-
77 
2.62E-03 2.309 
P04003 C4b-binding protein alpha 
chain 
2.59E-03 2.357 
P04217 Alpha-1B-glycoprotein 3.39E-02 2.364 
Q9H299 SH3 domain-binding glutamic 
acid-rich-like protein 3 
1.44E-04 2.376 
P01023 Alpha-2-macroglobulin 4.31E-03 2.378 
P16070 CD44 antigen 2.35E-04 2.379 
Q16363 Laminin subunit alpha-4 3.26E-07 2.395 
Q16819 Meprin A subunit alpha 2.64E-02 2.424 
P01024 Complement C3 1.76E-03 2.443 
Q9UM07 Protein-arginine deimi0se type-
4 
1.04E-02 2.454 
P21333 Filamin-A 4.40E-06 2.457 
Q9UGI8 Testin 4.34E-03 2.459 
P19827 Inter-alpha-trypsin inhibitor 
heavy chain H1 
1.84E-04 2.469 
P01591 Immunoglobulin J chain 9.02E-04 2.470 
P16402 Histone H1.3 3.73E-03 2.473 
P02786 Transferrin receptor protein 1 1.93E-03 2.499 
P01717 Ig lambda chain V-IV region Hil 5.64E-03 2.507 
P07585 Decorin 4.01E-04 2.535 
P01859 Ig gamma-2 chain C region 2.23E-03 2.553 
P35749 Myosin-11 9.25E-05 2.590 
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P13671 Complement component C6 3.09E-02 2.609 
P01008 Antithrombin-III 3.76E-02 2.619 
P00734 Prothrombin 4.60E-03 2.623 
P50454 Serpin H1 3.39E-06 2.629 
P01876 Ig alpha-1 chain C region 3.84E-04 2.672 
P04114 Apolipoprotein B-100 1.99E-03 2.688 
P16401 Histone H1.5 2.34E-03 2.690 
Q9BXN1 Asporin 2.88E-03 2.728 
P08670 Vimentin 2.57E-04 2.763 
P01011 Alpha-1-antichymotrypsin 4.90E-03 2.766 
P0CG05 Ig lambda-2 chain C regions 4.52E-05 2.785 
P01033 Metalloprotei0se inhibitor 1 7.08E-04 2.804 
P02763 Alpha-1-acid glycoprotein 1 4.18E-03 2.805 
P02749 Beta-2-glycoprotein 1 5.44E-04 2.808 
P80188 Neutrophil gelati0se-associated 
lipocalin 
5.35E-03 2.827 
P07355 Annexin A2 3.16E-05 2.829 
P05452 Tetranectin 5.28E-05 2.829 
P51888 Prolargin 2.00E-04 2.836 
P12429 Annexin A3 2.65E-05 2.841 
P01833 Polymeric immunoglobulin 
receptor 
1.50E-02 2.847 
Q15113 Procollagen C-endopeptidase 
enhancer 1 
3.66E-03 2.847 
O00560 Syntenin-1 1.32E-02 2.848 
Q01995 Transgelin 4.97E-04 2.854 
P01042 Kininogen-1 2.29E-04 2.860 
Q08380 Galectin-3-binding protein 9.63E-06 2.868 
P02750 Leucine-rich alpha-2-
glycoprotein 
1.27E-02 2.869 
P02790 Hemopexin 9.56E-04 2.890 
P01743 Ig heavy chain V-I region HG3 4.13E-04 2.909 
P12532 Creatine ki0se U-type, 
mitochondrial 
2.69E-03 2.928 
P07358 Complement component C8 
beta chain 
7.16E-04 2.933 
P04075 Fructose-bisphosphate aldolase 
A 
7.57E-08 2.947 
P01764 Ig heavy chain V-III region VH26 1.02E-03 2.962 
P17096 High mobility group protein 
HMG-I/HMG-Y 
2.03E-03 3.007 
B9A064 Immunoglobulin lambda-like 
polypeptide 5 
1.83E-04 3.007 
P80511 Protein S100-A12 9.60E-04 3.013 
P04083 Annexin A1 1.85E-05 3.045 
P35900 Keratin, type I cytoskeletal 20 2.34E-05 3.045 
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P54709 Sodium/potassium-
transporting ATPase subunit 
beta-3 
1.76E-05 3.057 
P35858 Insulin-like growth factor-
binding protein complex acid 
labile subunit 
8.85E-03 3.082 
P06396 Gelsolin 4.81E-06 3.084 
P00747 Plasminogen 3.27E-04 3.100 
Q12864 Cadherin-17 6.88E-04 3.109 
P02649 Apolipoprotein E 1.21E-03 3.120 
P08603 Complement factor H 2.60E-05 3.129 
P06454 Prothymosin alpha 2.30E-02 3.130 
P17931 Galectin-3 1.88E-05 3.130 
P36955 Pigment epithelium-derived 
factor 
1.94E-06 3.146 
Q8WVV4 Protein POF1B 2.45E-04 3.166 
P16444 Dipeptidase 1 5.43E-05 3.169 
Q7Z406 Myosin-14 6.83E-06 3.177 
P02452 Collagen alpha-1(I) chain 1.33E-04 3.178 
P00450 Ceruloplasmin 3.16E-04 3.191 
O15551 Claudin-3 7.97E-03 3.200 
P07357 Complement component C8 
alpha chain 
4.67E-03 3.209 
P02743 Serum amyloid P-component 4.14E-04 3.246 
P02671 Fibrinogen alpha chain 9.40E-04 3.256 
P10643 Complement component C7 6.01E-03 3.263 
P26447 Protein S100-A4 6.37E-05 3.265 
O00299 Chloride intracellular channel 
protein 1 
9.57E-06 3.304 
P07996 Thrombospondin-1 2.81E-06 3.327 
Q92598 Heat shock protein 105 kDa 2.91E-06 3.337 
P19823 Inter-alpha-trypsin inhibitor 
heavy chain H2 
6.42E-05 3.346 
P02788 Lactotransferrin 1.15E-03 3.377 
P02787 Serotransferrin 8.27E-05 3.408 
P09211 Glutathione S-transferase P 4.77E-08 3.439 
P06314 Ig kappa chain V-IV region B17 5.25E-05 3.485 
P21810 Biglycan 5.67E-06 3.547 
P02774 Vitamin D-binding protein 1.07E-05 3.566 
P55058 Phospholipid transfer protein 5.77E-05 3.571 
P01857 Ig gamma-1 chain C region 2.10E-05 3.574 
P01871 Ig mu chain C region 1.55E-04 3.600 
P40121 Macrophage-capping protein 3.63E-08 3.651 
P08123 Collagen alpha-2(I) chain 3.43E-05 3.656 
P02766 Transthyretin 2.21E-03 3.669 
P02765 Alpha-2-HS-glycoprotein 2.16E-05 3.674 
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P01861 Ig gamma-4 chain C region 1.69E-02 3.679 
P13688 Carcinoembryonic antigen-
related cell adhesion molecule 
1 
6.13E-03 3.681 
P02679 Fibrinogen gamma chain 1.02E-03 3.710 
Q8NFJ5 Retinoic acid-induced protein 3 5.13E-04 3.712 
Q14764 Major vault protein 3.73E-09 3.752 
P06727 Apolipoprotein A-IV 2.88E-05 3.799 
P02652 Apolipoprotein A-II 5.84E-05 3.813 
P31949 Protein S100-A11 3.50E-08 3.869 
Q15582 Transforming growth factor-
beta-induced protein ig-h3 
7.34E-06 3.893 
P24821 Te0scin 1.54E-07 3.927 
P14618 Pyruvate ki0se isozymes 
M1/M2 
5.51E-09 3.927 
Q9H444 Charged multivesicular body 
protein 4b 
4.25E-06 3.937 
P31947 14-3-3 protein sigma 9.06E-04 3.946 
P07360 Complement component C8 
gamma chain 
1.04E-03 3.970 
P06702 Protein S100-A9 8.84E-05 3.971 
P06703 Protein S100-A6 6.13E-06 3.993 
P11166 Solute carrier family 2, 
facilitated glucose transporter 
member 1 
5.16E-03 3.995 
P05107 Integrin beta-2 2.63E-03 4.036 
P02751 Fibronectin 1.68E-08 4.059 
P59665 Neutrophil defensin 1 1.22E-03 4.069 
P08727 Keratin, type I cytoskeletal 19 2.77E-06 4.077 
P51884 Lumican 7.04E-06 4.097 
P25815 Protein S100-P 1.36E-04 4.127 
P02675 Fibrinogen beta chain 1.20E-04 4.128 
P05109 Protein S100-A8 4.42E-04 4.202 
P01009 Alpha-1-antitrypsin 6.42E-04 4.293 
P02748 Complement component C9 1.66E-04 4.363 
P11215 Integrin alpha-M 6.70E-04 4.400 
P05164 Myeloperoxidase 5.23E-04 4.425 
Q8IUX7 Adipocyte enhancer-binding 
protein 1 
6.98E-08 4.429 
P35442 Thrombospondin-2 5.61E-08 4.620 
O95994 Anterior gradient protein 2 
homolog 
9.84E-06 4.621 
Q6UX06 Olfactomedin-4 4.59E-05 4.640 
Q9H3R2 Mucin-13 5.42E-07 4.643 
P01031 Complement C5 8.03E-05 4.708 
P16422 Epithelial cell adhesion 
molecule 
3.64E-06 4.751 
352 
 
P04004 Vitronectin 3.43E-05 4.790 
P10909 Clusterin 8.79E-05 4.928 
P19075 Tetraspanin-8 1.49E-03 4.960 
P06731 Carcinoembryonic antigen-
related cell adhesion molecule 
5 
5.12E-07 5.132 
Q99715 Collagen alpha-1(XII) chain 9.58E-09 5.181 
Q15063 Periostin 2.53E-08 5.322 
P21926 CD9 antigen 7.72E-06 5.684 
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Accession Number Name P Value 
Log2 Fold Change 
(Responder/Non-Responder) 
Q04695 Keratin, type I cytoskeletal 17 3.71E-02 -165.421 
O95831 
Apoptosis-inducing factor 1, 
mitochondrial 1.37E-04 -13.086 
O00217 
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
8, mitochondrial 2.13E-03 -12.553 
P13804 
Electron transfer flavoprotein 
subunit alpha, mitochondrial 1.72E-03 -12.381 
Q07812 Apoptosis regulator BAX 2.07E-03 -11.959 
P08729 Keratin, type II cytoskeletal 7 1.25E-02 -11.876 
Q08426 Peroxisomal bifunctional enzyme 2.33E-04 -9.918 
P15559 
NAD(P)H dehydrogenase 
[quinone] 1 2.64E-04 -9.918 
O75494 
Serine/arginine-rich splicing 
factor 10 1.50E-05 -9.448 
P30101 Protein disulfide-isomerase A3 2.10E-03 -9.063 
P05091 
Aldehyde dehydrogenase, 
mitochondrial 1.18E-02 -9.063 
P50225 Sulfotransferase 1A1 1.29E-02 -7.781 
P05783 Keratin, type I cytoskeletal 18 2.35E-02 -7.727 
P36952 Serpin B5 1.58E-02 -7.111 
Q9HCY8 Protein S100-A14 1.70E-03 -6.916 
Q12788 Transducin beta-like protein 3 3.30E-03 -6.727 
P58107 Epiplakin 4.30E-05 -6.277 
O43704 
Sulfotransferase family cytosolic 
1B member 1 4.09E-02 -6.233 
P08727 Keratin, type I cytoskeletal 19 1.41E-02 -5.856 
P36776 
Lon protease homolog, 
mitochondrial 1.72E-03 -5.657 
Q9NUV9 GTPase IMAP family member 4 3.06E-03 -5.579 
Q00266 
S-adenosylmethionine synthase 
isoform type-1 2.19E-02 -5.426 
Q9Y6N5 
Sulfide:quinone oxidoreductase, 
mitochondrial 4.74E-04 -5.278 
P22695 
Cytochrome b-c1 complex 
subunit 2, mitochondrial 4.27E-03 -5.098 
P49411 
Elongation factor Tu, 
mitochondrial 1.18E-02 -5.098 
Q15084 Protein disulfide-isomerase A6 1.62E-02 -5.063 
O00515 Ladinin-1 2.93E-02 -5.028 
Q9BW92 
Threonyl-tRNA synthetase, 
mitochondrial 4.75E-03 -4.724 
Q15477 Helicase SKI2W 2.09E-02 -4.691 
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P63151 
Serine/threonine-protein 
phosphatase 2A 55 kDa 
regulatory subunit B alpha 
isoform 9.31E-03 -4.659 
P09327 Villin-1 2.32E-02 -4.659 
P49748 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 1.25E-02 -4.595 
P35900 Keratin, type I cytoskeletal 20 2.16E-02 -4.469 
P20339 Ras-related protein Rab-5A 3.00E-02 -4.469 
P42765 
3-ketoacyl-CoA thiolase, 
mitochondrial 1.81E-03 -4.438 
P41240 Tyrosine-protein kinase CSK 2.84E-04 -4.228 
Q56VL3 
OCIA domain-containing protein 
2 1.39E-02 -4.170 
P30039 
Phenazine biosynthesis-like 
domain-containing protein 7.25E-04 -4.141 
P05026 
Sodium/potassium-transporting 
ATPase subunit beta-1 4.09E-04 -4.056 
Q9NX46 
Poly(ADP-ribose) glycohydrolase 
ARH3 5.11E-04 -4.028 
P24666 
Low molecular weight 
phosphotyrosine protein 
phosphatase 2.93E-02 -4.000 
P12532 
Creatine kinase U-type, 
mitochondrial 8.75E-03 -3.945 
O15438 
Canalicular multispecific organic 
anion transporter 2 4.04E-05 -3.918 
Q16836 
Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial 1.96E-03 -3.681 
P09110 
3-ketoacyl-CoA thiolase, 
peroxisomal 2.84E-03 -3.605 
P13667 Protein disulfide-isomerase A4 2.07E-02 -3.555 
Q99959 Plakophilin-2 2.05E-02 -3.506 
Q99623 Prohibitin-2 1.07E-03 -3.482 
P62424 60S ribosomal protein L7a 1.52E-02 -3.482 
Q6UX53 Methyltransferase-like protein 7B 2.86E-02 -3.434 
P26373 60S ribosomal protein L13 1.46E-03 -3.411 
Q9BRX8 Redox-regulatory protein PAMM 2.12E-02 -3.411 
P20810 Calpastatin 2.48E-02 -3.364 
P15924 Desmoplakin 8.44E-04 -3.340 
Q6YN16 
Hydroxysteroid dehydrogenase-
like protein 2 4.58E-03 -3.294 
Q15067 
Peroxisomal acyl-coenzyme A 
oxidase 1 2.15E-02 -3.294 
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Q27J81 Inverted formin-2 8.85E-03 -3.249 
Q13523 
Serine/threonine-protein kinase 
PRP4 homolog 2.10E-04 -3.204 
P16219 
Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial 1.41E-02 -3.182 
Q8NE62 
Choline dehydrogenase, 
mitochondrial 3.82E-04 -3.010 
O60218 
Aldo-keto reductase family 1 
member B10 1.08E-03 -2.928 
P14324 Farnesyl pyrophosphate synthase 3.17E-02 -2.908 
Q9NYK5 
39S ribosomal protein L39, 
mitochondrial 1.48E-02 -2.888 
Q9UM54 Myosin-VI 2.04E-02 -2.888 
P07332 Tyrosine-protein kinase Fes/Fps 1.07E-03 -2.868 
O95487 Protein transport protein Sec24B 8.33E-04 -2.848 
Q7Z406 Myosin-14 1.95E-02 -2.848 
P98170 
Baculoviral IAP repeat-containing 
protein 4 1.44E-02 -2.828 
P56134 
ATP synthase subunit f, 
mitochondrial 1.79E-02 -2.789 
P21912 
Succinate dehydrogenase 
[ubiquinone] iron-sulfur subunit, 
mitochondrial 1.84E-02 -2.789 
Q9H4G0 Band 4.1-like protein 1 7.41E-03 -2.770 
Q9UHG3 Prenylcysteine oxidase 1 3.59E-02 -2.770 
Q9NX40 
OCIA domain-containing protein 
1 2.18E-03 -2.676 
Q99523 Sortilin 1.34E-02 -2.676 
Q9Y394 
Dehydrogenase/reductase SDR 
family member 7 1.65E-04 -2.639 
O14936 
Peripheral plasma membrane 
protein CASK 7.48E-04 -2.621 
Q9BRP8 Partner of Y14 and mago 3.54E-02 -2.621 
O95571 Protein ETHE1, mitochondrial 3.68E-04 -2.567 
P07355 Annexin A2 4.91E-02 -2.567 
Q9UBF2 Coatomer subunit gamma-2 2.16E-02 -2.532 
O75795 
UDP-glucuronosyltransferase 
2B17 1.86E-04 -2.497 
Q9Y446 Plakophilin-3 8.78E-03 -2.497 
Q15149 Plectin 1.33E-02 -2.497 
Q6NUK1 
Calcium-binding mitochondrial 
carrier protein SCaMC-1 1.94E-02 -2.445 
P06753 Tropomyosin alpha-3 chain 3.27E-02 -2.412 
P07954 Fumarate hydratase, 1.04E-02 -2.395 
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mitochondrial 
O14896 Interferon regulatory factor 6 1.79E-02 -2.395 
Q9NVS9 Pyridoxine-5'-phosphate oxidase 2.00E-02 -2.395 
Q00610 Clathrin heavy chain 1 2.75E-02 -2.378 
P30153 
Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A alpha 
isoform 3.68E-03 -2.362 
Q14764 Major vault protein 7.77E-03 -2.362 
Q8N1S5 Zinc transporter ZIP11 2.24E-02 -2.282 
P45880 
Voltage-dependent anion-
selective channel protein 2 4.92E-02 -2.282 
Q12962 
Transcription initiation factor 
TFIID subunit 10 5.44E-03 -2.250 
Q16718 
NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
subunit 5 2.06E-03 -2.219 
O43491 Band 4.1-like protein 2 1.81E-02 -2.204 
P05141 ADP/ATP translocase 2 2.20E-02 -2.204 
Q8WUM4 
Programmed cell death 6-
interacting protein 4.71E-03 -2.173 
P24539 
ATP synthase subunit b, 
mitochondrial 8.16E-03 -2.158 
P38117 
Electron transfer flavoprotein 
subunit beta 1.29E-02 -2.158 
Q9BTZ2 
Dehydrogenase/reductase SDR 
family member 4 1.77E-02 -2.144 
A5YKK6 
CCR4-NOT transcription complex 
subunit 1 6.41E-03 -2.114 
Q02318 
Sterol 26-hydroxylase, 
mitochondrial 6.70E-03 -2.114 
P35232 Prohibitin 3.53E-03 -2.099 
P30040 
Endoplasmic reticulum resident 
protein 29 2.40E-02 -2.099 
Q9Y2S2 Lambda-crystallin homolog 3.25E-03 -2.085 
Q6NUM9 All-trans-retinol 13,14-reductase 4.99E-02 -2.085 
P45974 
Ubiquitin carboxyl-terminal 
hydrolase 5 6.28E-03 -2.056 
O95168 
NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex 
subunit 4 4.86E-02 -2.056 
P51659 
Peroxisomal multifunctional 
enzyme type 2 2.65E-02 -2.042 
Q9UNZ2 NSFL1 cofactor p47 2.50E-02 -2.028 
Q9NPJ3 Acyl-coenzyme A thioesterase 13 1.40E-03 2.014 
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Q9BVP2 
Guanine nucleotide-binding 
protein-like 3 1.15E-03 2.042 
P63208 
S-phase kinase-associated protein 
1 4.18E-02 2.071 
Q13451 
Peptidyl-prolyl cis-trans 
isomerase FKBP5 2.86E-02 2.085 
Q6NYC8 Phostensin 2.41E-02 2.114 
Q4VC31 
Coiled-coil domain-containing 
protein 58 7.64E-03 2.129 
Q9ULC4 
Malignant T cell-amplified 
sequence 1 3.02E-02 2.173 
P17931 Galectin-3 5.40E-03 2.219 
P49591 
Seryl-tRNA synthetase, 
cytoplasmic 1.51E-02 2.362 
P42345 
Serine/threonine-protein kinase 
mTOR 3.09E-03 2.395 
Q96IJ6 
Mannose-1-phosphate 
guanyltransferase alpha 4.98E-03 2.428 
Q13315 Serine-protein kinase ATM 1.55E-02 2.462 
Q15181 Inorganic pyrophosphatase 4.43E-02 2.479 
Q08945 FACT complex subunit SSRP1 4.70E-02 2.532 
P61970 Nuclear transport factor 2 6.29E-03 2.657 
P04003 C4b-binding protein alpha chain 4.76E-02 2.676 
O00505 Importin subunit alpha-3 2.00E-04 2.751 
O43708 Maleylacetoacetate isomerase 2.73E-02 2.751 
Q96CW1 AP-2 complex subunit mu 4.68E-03 2.828 
P07686 
Beta-hexosaminidase subunit 
beta 2.26E-02 2.828 
P29622 Kallistatin 2.85E-02 2.888 
Q5SSJ5 
Heterochromatin protein 1-
binding protein 3 4.86E-02 2.928 
P04083 Annexin A1 2.96E-02 2.969 
P48643 
T-complex protein 1 subunit 
epsilon 1.20E-02 3.010 
P27169 
Serum paraoxonase/arylesterase 
1 6.80E-03 3.031 
P01903 
HLA class II histocompatibility 
antigen, DR alpha chain 1.33E-02 3.117 
P28845 
Corticosteroid 11-beta-
dehydrogenase isozyme 1 8.77E-04 3.182 
Q06323 
Proteasome activator complex 
subunit 1 3.88E-04 3.272 
P04899 
Guanine nucleotide-binding 
protein G(i) subunit alpha-2 1.92E-03 3.411 
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P62917 60S ribosomal protein L8 8.21E-04 3.434 
P56199 Integrin alpha-1 1.04E-03 3.458 
Q14019 Coactosin-like protein 2.49E-02 3.458 
P05388 60S acidic ribosomal protein P0 4.43E-02 3.555 
P62701 
40S ribosomal protein S4, X 
isoform 1.94E-02 3.655 
P11387 DNA topoisomerase 1 4.28E-02 3.811 
P04216 Thy-1 membrane glycoprotein 1.52E-02 3.837 
P31513 
Dimethylaniline monooxygenase 
[N-oxide-forming] 3 2.00E-02 3.864 
Q12805 
EGF-containing fibulin-like 
extracellular matrix protein 1 1.30E-03 3.891 
Q9C005 Protein dpy-30 homolog 2.71E-02 4.028 
O75874 
Isocitrate dehydrogenase [NADP] 
cytoplasmic 3.10E-03 4.347 
P21953 
2-oxoisovalerate dehydrogenase 
subunit beta, mitochondrial 1.32E-03 4.563 
P21980 
Protein-glutamine gamma-
glutamyltransferase 2 2.99E-03 4.595 
Q9Y6D6 
Brefeldin A-inhibited guanine 
nucleotide-exchange protein 1 7.37E-03 4.595 
O94826 
Mitochondrial import receptor 
subunit TOM70 3.15E-03 4.857 
P40227 T-complex protein 1 subunit zeta 1.93E-02 5.063 
P50135 Histamine N-methyltransferase 1.82E-04 5.618 
P07339 Cathepsin D 6.55E-04 5.657 
P16662 UDP-glucuronosyltransferase 2B7 2.29E-02 5.657 
Q8TEX9 Importin-4 5.29E-03 5.816 
Q99536 
Synaptic vesicle membrane 
protein VAT-1 homolog 1.85E-02 5.856 
P09417 Dihydropteridine reductase 1.40E-02 6.021 
Q9H1E5 
Thioredoxin-related 
transmembrane protein 4 3.43E-02 6.190 
P12111 Collagen alpha-3(VI) chain 4.77E-02 6.409 
P24752 
Acetyl-CoA acetyltransferase, 
mitochondrial 9.73E-03 8.282 
Q05707 Collagen alpha-1(XIV) chain 2.32E-02 8.694 
P06733 Alpha-enolase 7.48E-03 8.754 
P11586 
C-1-tetrahydrofolate synthase, 
cytoplasmic 1.73E-05 15.242 
P13760 
HLA class II histocompatibility 
antigen, DRB1-4 beta chain 5.91E-03 88.035 
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Q16822 
Phosphoenolpyruvate 
carboxykinase [GTP], 
mitochondrial 3.11E-05 194.012 
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